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Abstract 
Asthma is an incapacitating disease of the respiratory system, which causes 
extensive morbidity and mortality worldwide. Asthma affects more than 300 million 
people globally(Masoli et al. 2004). In Australia, it affects 10.2% of the population 
(Masoli et al. 2004) and causes 60,000 people to be hospitalised annually. Health 
care expenditure due to asthma in Australia was $606 million in 2004–2005. There 
are four primary biological factors that function in the initiation and exacerbation of 
asthma. Airway inflammation is important as it is often the first response to an 
airway insult, initiating the three other components: bronchoconstriction, mucus 
hyper-secretion and hyper-reactivity. The mediators involved in asthma are still not 
well understood, and current anti-inflammatory corticosteroid treatments are not 
effective with all asthmatics. As there is currently no cure for asthma, and airway 
inflammation is the primary component of the disease, it is important that we 
understand and investigate the mediators of airway inflammation to look for a 
potential cure and to produce better therapeutics to treat the inflammation. 
Trefoil factors (TFFs) and secretoglobins (SCGBs) are small secreted proteins 
involved in the mediation of inflammation and epithelial restitution. TFFs are pro-
inflammatory and SCGBs anti-inflammatory by nature. The hypothesis of this study 
is that in response to induced acute airway inflammation, the expression of TFF1 and 
TFF3 will increase and expression of SCGB1A1 and SCGB3A2 will decrease in non-
asthmatics (N-A), asthmatics medicating with bronchodilators (A-BD) and 
asthmatics medicating with corticosteroids (A-ST). When comparing the three 
groups, we expect to see higher expression of the TFFs in the A-BD group compared 
to the N-A and A-ST groups, indicating that inflammation is mediated by TFFs in 
asthma and that corticosteroid medication controls their expression as part of the 
control of inflammation. We expect to see the opposite with SCGBs, with a greater 
decrease in the A-BD group compared to the other two groups, suggesting that the A-
BD group has the least anti-inflammatory activity in response to inflammatory insult. 
Epigenetic modification plays a role in the regulation of genes that initiate 
disease states such as inflammatory conditions and cancers. Histone acetylation is 
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one such modification, which involves the acetylation of histones in chromatin by 
histone acetyltransferases (HATs). This increases the transcription of genes involved 
with inflammation or enrols histone deacetylases (HDACs) to down-regulate the 
transcription of inflammatory genes. These HATs and HDACs work in a homeostatic 
fashion; however, in the event of inflammation, increased HAT activity can stimulate 
further inflammation, which is believed to be the mechanism involved in some 
inflammatory diseases. This study hypothesises that in response to inflammation, the 
expression of HDACs (HDAC1-5) will decrease and the expression of HATs 
(NCOA1-3, HAT-1 and CREBBP) will increase in all groups. When comparing the 
expression between the groups, it was expected that a greater decrease in HDACs and 
a greater increase in HATs will be seen in the A-BD group compared to the other two 
groups. This would identify histone acetylation as a mechanism involved in the 
inflammatory condition of asthma and indicate that corticosteroids may treat the 
inflammation in asthma at least in part by controlling histone acetylation. 
The aim of the project was to compare the expression of inflammatory genes 
TFF1, TFF3, SCGB1A1 and SCGB3A2, as well as to compare the gene expression of 
HDAC1-5, NCOA1-3, HAT-1 and CREBBP within and between N-A (n=15), A-BD 
(n=15) and A-ST (n=15) groups in response to inflammation. This was performed by 
collecting airway cells and proteins by sputum induction in three sessions. The 
sessions were coordinated into an initial baseline collection (SI-1), followed by a 
second session at least one week later (SI-2) and a third session, six hours after SI-2 
to collect a sample containing the resultant acute inflammation caused in SI-2 (SI-3). 
Analysis of the SI-1 and SI-2 samples in all three groups had high amounts of 
variability between samples. The samples were taken at least one weak apart and the 
environmental stimuli on each participant outside of the testing sessions could not be 
controlled. For this reason, the SI-1 samples were not used for analysis; instead SI-2 
and SI-3 samples were compared as they were same-day collections, reducing the 
probability of differences being due to anything other than the sputum induction.  
The gene expressions of the TFFs, SCGBs, HDACs and HATs were analysed 
using real-time PCR. Western blot analysis was performed to analyse the protein 
concentrations of the TFFs and SCGBs in secreted fractions of the sputum collection. 
Both the secreted and intracellular protein fractions collected from the sputum 
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inductions for pre- and post-inflammation (SI-2, SI-3) samples of the N-A and A-BD 
groups were analysed using a proteomic method called iTRAQ. This allowed the 
comparison of the change in protein expression as a result of airway inflammation in 
each group. This technique was used as a discovery method to identify novel proteins 
that are modulated by induced acute airway inflammation. Any proteins of interest 
would then be further validated and used for future research. 
Inflammation was achieved in the SI-3 samples of the N-A group with a 21% 
unit increase in % neutrophils compared to SI-2 (p=0.01). The N-A group had a 
marked 5.5-fold decrease in HDAC1 gene expression in SI-3 compared to SI-2 
(p=0.03). No differences were seen in any of the TFFs, SCGBs or any of the rest of 
the HDACs and HATs. Western blot data did not display any significant changes in 
the protein levels of the TFFs and SCGBs analysed. However, non-significant 
analysis of the data displayed increases in TFF1 and TFF3, and decreases in 
SCGB1A1 and SCGB3A2 for the majority of SI-3 samples compared to SI-2.  
The A-BD group also presented a marked increase in neutrophils in the SI-3 
samples compared to SI-2 (27% unit increase, p=0.04). The A-BD group had a 
significant increase in TFF3 and SCGB1A1 gene expression concomitant with 
induced acute airway inflammation. A 7.3-fold increase in TFF3 (p=0.05) in SI-3 
indicated that TFF3 is linked to inflammation in asthmatics. A 2.8-fold increase in 
SCGB1A1 (p=0.03) indicated that this gene is also up-regulated, suggesting that this 
SCGB is expressed to try to combat induced acute airway inflammation. No 
significant changes were seen in any of the other genes analysed. Western blot data 
did not display any significant changes in the protein levels of the TFFs and SCGBs 
analysed. However, non-significant analysis of the data displayed an increase in 
TFF1 and TFF3, and a decrease in SCGB1A1 and SCGB3A2 in SI-3, similar to that 
seen in the N-A group.   
The A-ST group was different from the A-BD group, characterised by the use 
of inhaled corticosteroid medication to treat asthma symptoms. Inhaled 
corticosteroids are known to treat asthma symptoms through the control of 
inflammation. Therefore, it was expected that corticosteroid medication would also 
control the expression of TFFs, SCGBs, HATs and HDACs. Gene expression results 
only identified a 7.6-fold decrease in HDAC2 expression in SI-3 (p=0.001), which is 
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proposed to be due to the up-regulation of HDAC2 protein that is known to be a 
function of corticosteroid use. Western blot data did not display any significant 
changes in the protein levels of the TFFs and SCGBs analysed. 
The gene expression in SI-2 and SI-3 in each group was compared. When 
comparing the A-BD group to the N-A group, a 9-fold increase in TFF3 (p=0.008) 
and a 34-fold increase in SCGB1A1 (p=0.03) were seen in the SI-3 samples. 
Comparisons of the A-ST group to the N-A group had an increased expression in SI-
2 samples for HDAC5 (3.6-fold, p=0.04), NCOA2 (8.5-fold, p=0.04), NCOA3 (17-
fold, p=0.01), HAT-1 (36-fold, p=0.003) and CREBBP (13-fold, p=0.001). The SI-3 
samples in the A-ST group compared to the N-A group had increased expression for 
HDAC1 (6.4-fold, p=0.04), HDAC5 (5.2-fold, p=0.008), NCOA2 (9.6-fold, p=0.03), 
NCOA3 (16-fold, p=0.06), HAT-1 (41-fold, p<0.001) and CREBBP (31-fold, 
p=0.001). Comparisons of the A-ST group to the A-BD group had SI-2 increases in 
HDAC1 (3.8-fold, p=0.03), NCOA3 (4.5-fold, p=0.03), HAT-1 (5.3-fold, p=0.01) and 
CREBBP (23-fold, p=0.001), while SI-3 comparisons saw a decrease in HDAC2 (41-
fold, p=0.008) and increases in HAT-1 (4.3-fold, p=0.003) and CREBBP (40-fold, 
p=0.001). Results showed that TFF3 and SCGB1A1 expression is higher in 
asthmatics than non-asthmatics and that histone acetylation is more active in the A-
ST group than either the N-A or A-BD group, which suggests that histone acetylation 
activity may be positively correlated with asthma severity. 
The iTRAQ proteomic analysis of the secreted protein samples identified the 
SCGB1A1 protein and found it to be decreased in both the N-A and A-BD groups 
post-inflammation, but significantly so only in the A-BD group. Although no 
significant results were obtained from the western blot data, both groups displayed a 
decrease in SCGB1A1 concentration in SI-3 samples, suggesting a correlation with 
the proteomic data. Only 31 peptides were identified from the secreted samples. The 
intracellular iTRAQ analysis successfully identified 664 peptides, eight of which had 
differential expression in association with induced acute airway inflammation. 
Significant increases were seen in the A-BD group in SI-3 compared to SI-2 than in 
the N-A group in chloride intracellular channel protein 1, keratin-19, eosinophil 
cationic protein, calnexin, peroxiredoxin-5, and ATP-synthase delta subunit, while 
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decreases were seen in cystatin-A and mucin-5AC. The iTRAQ analysis was only a 
discovery measure and further validation must be performed. 
In summary, the expression of TFFs and SCGBs differed between non-
asthmatics and asthmatics. It is clear that TFF3 is active in the airway inflammation 
associated with asthma as indicated by an increase associated with inflammation in 
the A-BD group compared to the N-A group. Results for HDAC and HAT genes 
showed high HAT expression in the A-ST group compared to the N-A and A-BD 
groups, suggesting that histone acetyltransferases may be responsible for the 
characteristic unregulated inflammatory symptoms of asthmatics taking 
corticosteroids. Interestingly, corticosteroid medication did not seem to silence the 
expression of the analysed HAT genes, which indicates that corticosteroids may not 
control inflammation by direct regulation of HATs, but instead by competition, most 
probably with HDAC2 protein. As a discovery tool, iTRAQ is a potent method to 
both identify and compare the concentration of proteins between samples. The 
method is a powerful first step into the identification of novel proteins that are 
regulated in response to different treatments. 
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Chapter 1: Literature Review 
1.1 INTRODUCTION: ASTHMA 
Asthma is an incapacitating disease of the respiratory system, causing 
extensive morbidity and mortality worldwide. Asthma affects more than 300 million 
people globally (Masoli et al. 2004). In Australia, asthma affects 10.2% of the 
population (Masoli et al. 2004), of these, 60,000 people are hospitalised annually. 
Asthma is more prevalent in boys than girls under the age of 14, but more prevalent 
in females than males 15 years and over, suggesting a hormone component to the 
disease (Australian Institute of Health and Welfare 2008). Australian statistics show 
that 402 deaths in 2006 had asthma as the underlying cause, representing 0.3% of all 
deaths in that year. This mortality rate is considered high on an international scale 
(Australian Institute of Health and Welfare 2008). Health care expenditure on asthma 
in Australia was $606 million in 2004–2005. The proportion of total deaths per year 
due to asthma has declined over the past 10 years from 0.4% (1997) to 0.3% (2006), 
possibly due to better disease management by inhaled corticosteroid use; however, 
there was a spike in deaths in 2006 in people aged 65 years and over who succumbed 
to symptoms of their asthma. Current therapies for the treatment of asthma are not 
effective in all individuals, and can have adverse health impacts and decreased 
effectiveness due to necessary chronic use (Fahy and Boushey 1995; Martin et al. 
2007). Hence, more effective therapies with minimal detrimental side effects are 
required to treat this highly prevalent and debilitating disease. 
Genetic and environmental factors may contribute to the initiation and 
exacerbation of asthma. These factors include atopy, airborne toxins and allergens, 
exercise, airway cooling or drying, bacterial and viral infection of the lungs, and 
psychological stress. There are four primary biological factors that function in the 
initiation and exacerbation of asthma (Figure 1.1).  
1. Airway inflammation, which is described as the influx of 
leukocytes into the airway walls, causing swelling in response to allergens 
and infections in the airways. 
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2. Mucus hyper-secretion, which is the production of excess 
mucus in the airways causing obstruction (Moreno et al. 1986; James and 
Carroll 1995). 
3. Bronchoconstriction, which is the tightening of the smooth 
muscle surrounding the airways, causing coughing, wheezing and 
shortness of breath; it is known to be both exercise and allergen induced. 
4. Airway hyper-reactivity, which is the extreme sensitivity to 
environmental stimuli, ultimately resulting in bronchoconstriction 
(Bousquet et al. 2000).  
5. The inflammation process is an important mechanism in this 
study and is proposed to be the primary component of asthma, controlling 
the other factors including bronchoconstriction and hyper-reactivity. The 
primary physiological response to these factors is the overt wheezing that 
is a function of bronchoconstriction, due to the contraction of airway 
smooth muscle, and airway inflammation. The bronchoconstriction 
response is characterised by a decrease in the forced expiratory volume in 
1 second (FEV1), forced vital capacity (FVC) and the FEV1/FVC ratio. 
Pulmonary function is an important tool for both the diagnosis and assessment 
of asthma. Asthma is commonly diagnosed by measuring the reversibility of a 
patient’s airways in response to treatment with a bronchodilator. An increase in FEV1 
of 12% and 200 mL is considered the benchmark qualifier for asthma according to 
the American Thoracic Society (ATS 1991). A FEV1/FVC ratio less than 80% is also 
considered a restriction of the airways that could be explained by asthma (Bateman et 
al. 2008). These changes in pulmonary function in asthma are due to 
bronchoconstriction, which is at least in part due to airway inflammation. 
There are currently four recognised sub-types within the general term ‘asthma’, 
based on the cellular distribution in the airway secretion. These are known as 
neutrophilic asthma (increased neutrophils), eosinophilic asthma (increased 
eosinophils), mixed granulocytic asthma (increased neutrophils and eosinophils) and 
paucigranulocytic asthma (normal levels of neutrophils and eosinophils) (Simpson et 
al. 2006). The participants in this study were not recruited on the basis of their type 
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of asthma. The induced acute airway inflammation technique used in this thesis was 
designed to induce an epithelial-based (not allergy-based), neutrophil-associated 
inflammation. 
Irrespective of asthma type, there are two main forms of treatment for 
symptoms, which are chosen based on symptom severity: rescue medication and 
controller medication. Ventolin, a commonly used bronchodilator, is an example of 
rescue medication as it is taken when the sufferer feels the symptoms of asthma. 
Inhaled corticosteroids (ICS) are controller medications as they are taken either 
morning, night or both to prevent the symptoms of asthma occurring. The use of ICS 
is generally very effective at controlling inflammation in the asthmatic airways. 
However, this treatment is not effective for all sufferers as a sub-group of steroid-
insensitive asthmatics don’t respond to ICS. There is currently a lack of complete 
understanding of the biological mechanisms of airway inflammation in asthma, and 
there is more to be learned about the effectiveness of asthma*a treatments.   
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Figure 1.1.  Four primary biological factors that function in asthma. (A) is a non-
asthmatic airway; (B) is an inflamed asthmatic airway, showing mucus hyper-
secretion and bronchoconstriction/airway hyper-reactivity.  
 
  
  
Chapter 1: Literature Review 5 
 
 
1.2 AIRWAY INFLAMMATION IN ASTHMA 
Airway inflammation is a primary component of asthma and can contribute to 
the mediation of the bronchoconstriction, hyper-reactivity and mucus hyper-secretion 
associated with the disease. Airway inflammation in asthma is the result of mediators 
at the gene, protein and cellular level producing a coordinated response that 
ultimately results in an influx of leukocytes into the airway. These leukocytes can, in 
turn, secrete further pro-inflammatory mediators to continue the cycle until the 
source of the inflammation is removed. 
Within the process of airway inflammation, there are specific mediators at the 
cellular (neutrophils), systemic protein (cytokines), epithelial (TFFs, SCGBs) and 
gene expression (histone acetylation) levels that are involved in the control of the 
epithelial-based inflammatory response specific to the airway and are potentially 
further modulated in asthma. 
1.2.1 Cellular Responses in Airway Inflammation 
In an allergic response, a large part is played by mast cells secreting histamine, 
prostaglandin and leukotriene, which are capable of inducing bronchoconstriction 
and mucus hyper-secretion. Mast cells also secrete a large number of pro-
inflammatory cytokines, all of which contribute to the exacerbation of asthma 
(Bradding et al. 2006). Mast cells are not seen in non-allergic airway inflammation in 
asthma, instead varying proportions of macrophages, neutrophils, lymphocytes and 
eosinophils are released.  
The influx of neutrophils is an important factor in the exacerbation of airway 
inflammation. A study by Fahy et al. (1995) found prominent neutrophilic 
inflammation in sputum from subjects with asthma exacerbation. The study found 
that neutrophils accounted for more than 75% of airway cells in the sputum of the 
majority of asthmatic participants. Other studies have also shown that the process of 
sputum induction to collect airway samples causes neutrophilic inflammation. 
Studies by Holz et al. (1998) and Nightingale et al. (1998) looking at the effect of 
sputum induction on the inflammatory cell composition of sputum showed marked 
increases in neutrophil numbers 24 hours and eight hours after initial sputum 
induction in healthy non-asthmatic individuals and asthmatics. So it is known that the 
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distribution of leukocytes changes in response to induced acute airway inflammation. 
These cells, along with the airway epithelial cells, release protein mediators to 
control and stimulate the inflammatory functions of the airways.  
This project is solely focused on airway inflammation that is mediated by an 
exogenous disruption to the airway epithelial surface, which can stimulate an 
increase in neutrophils. This is a non-allergic process.  
1.2.2 Protein Mediators of Inflammation 
Cytokines 
Specific inflammatory mediators (cytokines) play an integral role in the 
coordination and persistence of chronic inflammation. Cytokines determine the 
nature of the inflammatory response by directing the selective recruitment and 
activation of inflammatory cells. Pro-inflammatory mediators such as TNF-α, 
interleukin-8 (IL-8) and NF-κB (Ohmori et al. 1997; Striz et al. 1999; Lee et al. 2006; 
Keslacy et al. 2007), and anti-inflammatory mediators such as IL-10 (Daftarian et al. 
1996) and TGF-β (Bissonnette et al. 1997) are important cytokines commonly 
implicated in airway inflammation of humans. By studying the levels of pro- and 
anti-inflammatory cytokines in correlation with differential airway leukocyte counts, 
the inflammatory status of the airways can be assessed. Comparisons can be made 
for differentiation in other peptides of interest and conclusions may be made about 
whether an increase in the concentration of a protein is attributed to airway 
inflammation and/or asthma status.  
Several studies have looked at the difference in cytokine production of the 
airways of asthmatics and non-asthmatics. A study by Matsunaga et al.  determined 
the level of airway cytokine expression by measuring the mean concentrations in 
exhaled breath condensate samples using protein arrays (Matsunaga et al. 2006). The 
group looked at expression levels of 40 cytokines in the airways of 16 non-smoking 
non-steroid-using asthmatics and 10 non-smoking non-asthmatics. They also 
correlated the results with physiological properties in the asthma patients such as 
airway responsiveness and airway hyper-reactivity. The group concluded that IL-8, 
TNF-α, and TGF-β among others were all significantly increased in asthmatic 
airways when compared to non-asthmatic values, and that TNF-α and TGF-β values 
significantly correlated with the degree of airway hyper-responsiveness. This study 
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suggested that TNF-α, TGF-β and IL-8 would be adequate markers for gauging 
inflammation in the airways and do distinguish between inflammation in asthmatics 
and non-asthmatics.  
NF-κB is a significant transcription factor controlling the expression of 
numerous genes involved in inflammation, immune response and cellular 
proliferation in the human airways (Ohmori et al. 1997). NF-κB is important in 
asthmatic inflammation as it is activated by a number of stimuli, including cytokines 
such as TNF-α and IL-1β. Cytokine IL-10 inhibits macrophage function by 
suppressing the production of a number of pro-inflammatory cytokines such as TNF-
α and IL-8 (de Waal Malefyt et al. 1991; Fiorentino et al. 1991; Seitz et al. 1995). 
Studies show that there is significantly less IL-10 mRNA and protein in alveolar 
macrophages of asthmatic subjects than non-asthmatic individuals (Borish et al. 
1996; John et al. 1998).  
Trefoil Factors 
Trefoil factor family proteins (TFF) consist of three peptides known as TFF1 
(gastrointestinal trefoil protein pS2), TFF2 (spasmolytic protein) and TFF3 
(intestinal trefoil factor). They are small mucin-associated molecules involved in 
inflammation. In mammals, TFFs are well known to be expressed in specific 
epithelial cells of the gastrointestinal tract, breast, uterus, brain and lungs (Kindon et 
al. 1995; Baus-Loncar and Giraud 2005), and are known to initiate inflammation in 
these areas (Hoffmann 2004). TFF1 is commonly expressed in carcinomas of several 
organs (Baus-Loncar and Giraud 2005). TFF2 is well documented for its presence in 
the stomach, pancreas and bowel (Sands and Podolsky 1996); and TFF3 is 
implicated in the gastrointestinal tract and has also been documented in small lung 
cell carcinomas (Sands and Podolsky 1996).  
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Structure 
Trefoil factors (TFFs) are characterised as peptides containing one to two 
trefoil domains (Madsen et al. 2007). Each trefoil domain consists of 42–43 amino 
acid residues with six cysteine residues forming three disulfide bonds and creating a 
three-leafed structure (Thim 1997). Trefoil factor 1 (TFF1) is a 60 amino acid mature 
peptide containing one trefoil domain and one acidic C-terminal domain (Sands and 
Podolsky 1996). Trefoil factor 2 (TFF2) is a mature peptide of 106 amino acids and 
contains two trefoil domains and one acidic C-terminal domain  (Sands and Podolsky 
1996). Trefoil factor 3 (TFF3) is a 51 amino acid mature peptide containing one 
trefoil domain and one acidic C-terminal domain (Sands and Podolsky 1996). All 
three of these trefoil factors share homology and the genes encoding them are found 
on chromosome 21q22.3 in humans (Sands and Podolsky 1996). 
Function 
Results from several in vitro and in vivo studies have demonstrated that TFFs 
protect epithelia against induced mucosal damage (Alison et al. 1995; Kindon et al. 
1995) and are involved in stimulating cellular motility (Dignass et al. 1994). 
Therefore, part of the function of TFFs in the airways is thought to be to repair and 
protect the airway by stimulating epithelial cell motility, to repair the lining of the 
airways subsequent to disruption of the epithelium, and to initiate an inflammatory 
process when necessary.  
Trefoil factors in the gastrointestinal tract in humans are well described 
(Kindon et al. 1995). Trefoil factor 1 is found mainly in the stomach, while TFF2 is 
found in the stomach and the duodenum, and TFF3 in the small and large intestines 
(Wright et al. 1997). Masiakowski et al. (1982) first described TFF1 in MCF-7 breast 
cancer cell lines, while TFF2 expression has not been reported in normal tissues 
outside the gastrointestinal tract. In gastrointestinal cells, each TFF is known to 
enhance cell migration in vitro, and epithelial restitution and mucosal repair after 
induction of injury in vivo (Podolsky 1997; Wong et al. 1999). Trefoil peptides have 
been shown to be expressed in high concentrations in ulcer-cell-associated stem cell 
lineages at sites of mucosal ulceration in the stomach, and therefore are thought to 
play a role in repair of ulceration (Marchbank et al. 1998).  
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Another known function of the TFFs is their role in tissue protection and 
repair. They are also believed to be involved in cell proliferation and differentiation 
(Lefebvre et al. 1996). TFF3 over-expression is observed in human cancers such as 
gastric cancer (Leung et al. 2002), papillary-mucinous tumours in the pancreas 
(Terris et al. 2002), skin carcinoma (Hanby et al. 1998) and breast cancer (May and 
Westley 1997), and is thought to play a role in the induction of cancer cell growth. 
Okada et al. (2005) showed that the over-expression of TFF3 in hepatocellular 
carcinomas was associated with an epigenetic change: hypomethylation of a cytosine 
5’ to guanosine (CpG island) in the promoter region of its gene. 
It is now known that trefoil factors can be localised to the normal airway 
epithelium and may have a functional role similar to that seen in the gastrointestinal 
tract. There is currently little research comparing the expression of TFFs in 
asthmatics and normal individuals. No studies have researched the effect that 
induced acute airway inflammation has on TFF expression. One study by Hallstrand 
et al. (2010) performed a gene microarray study on asthmatics with and without 
exercise-induced bronchoconstriction (EIB) and found TFF3 to be up-regulated in 
EIB+ participants after the induction of EIB. Dos Santos Silva et al. (2000) found 
that TFF3 was expressed at higher concentrations in the lungs of cystic fibrosis (CF) 
sufferers than in normal lungs. This indicates that TFFs may play a part in the 
inflammatory process of airway disease; however, CF is different to asthma, so the 
role of TFFs cannot be assumed to be similar in the two disease states. A study by 
Weide et al. (1999) localised TFF3 in the human lower airways and found it to be a 
significant constituent of airway mucus of patients with chronic bronchitis. 
Bronchitis is an inflammatory disease of the airways much like asthma, and this is 
further evidence that these peptides are involved in an inflammatory process of the 
airways. The Wiede group also noted that, in comparison to TFF3 expression, TFF1 
and TFF2 transcripts were unable to be detected when samples were subjected to 
RT-PCR (Wiede et al. 1999).  
A study by Thim et al. (1997) found that TFFs promote migration of bronchial 
epithelial cells. This study looked at the effect of TFF2 and TFF3 on restitution of 
BEAS-2B cells in vitro. The addition of hTFF2 peptides was found to be the most 
effective at stimulating the migration of epithelial cells. The main TFFs expressed in 
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the airways of humans are TFF1 and TFF3. TFF2 is not known to be expressed in 
the lungs. The Thim study effectively deduced that TFF2 may have potential as a 
therapeutic agent to stimulate restitution of the airways. However, this study may not 
reflect the conditions inside the human airways which may not correlate with the in-
vitro approach. 
A dos Santos Silva et al. (2000) study reported the presence of TFFs in the 
human respiratory tract. They believed that TFFs were involved with mucin proteins. 
Mucins are secreted throughout the respiratory tract and are part of the mucocilliary 
clearance and defence system. Using immunohistochemistry of the upper respiratory 
tract of CF patients, they found that TFF1 and TFF3 were expressed in nasal polyps 
and in ciliated and goblet cells in the cilia, whereas TFF2 was not. Analysis of the 
lower respiratory tract of CF patients showed TFF1 and TFF3 to be abundant in 
epithelial ciliated cells and goblet cells, and TFF2 was not detected. Through qPCR 
analysis of RNA isolates of respiratory tissues, they found that when comparing the 
results of each TFF gene to GAPDH in the tissues, TFF1 expression was lower and 
TFF3 expression higher in the CF airways compared to normal airways. TFF2 once 
again was not detected. This study compared the expression of TFFs between normal 
and CF lungs. The expression of TFFs in asthmatics compared to non-asthmatics is 
unknown and therefore is a logical step in the identification of the molecular 
mechanisms of asthma. 
Nikolaidis et al. (2003) employed transcript expression profile analysis to 
define a set of ‘asthma signature’ genes in an asthma mouse model. They found a 
marked ectopic expression of TFF2, but not of TFF1 or TFF3, in allergic lung 
inflammation triggered by diverse allergens. They concluded that TFF2 played a 
major role in the inflammatory process of asthma. Mouse TFF2 is more conserved 
with human TFF3. This indicates that mouse and human TFF expression profiles are 
different and that mouse models are inappropriate for studying the involvement of 
TFFs in asthma.  
Secretoglobins  
Secretoglobins (SCGBs) are a group of 12 anti-inflammatory peptides secreted 
by epithelial Clara cells, which are found in the primary bronchioles of the airways 
of humans and are expressed abundantly within the airway epithelia (Reynolds et al. 
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2002). SCGBs that are of interest for their potential role in airway disease include 
secretoglobin 1A1 (SCGB1A1), secretoglobin 3A1 (SCGB3A1) and secretoglobin 
3A2 (SCGB3A2). SCGB1A1 is also known as Clara cell protein 10/16 (CC10/16) and 
is expressed in high levels in the respiratory system by epithelial Clara cells (Yoneda 
1978), which are non-ciliated columnar cells of the small and large bronchi and 
bronchioles (van Vyve et al. 1995), and by nasal mucosal epithelial cells (Benson et 
al. 2005). SCGB1A1 is expressed in much lower levels in the male urogenital tract 
(Bernard et al. 1997), the endometrium, foetal lung and kidney (Hermans and 
Bernard 1999), amniotic fluid (Bernard et al. 1994) and in the female urogenital tract 
(Laing et al. 1998). SCGB3A1, also known as high in normal 1 (HIN1), has been 
detected in high levels in the human lung, but has also been detected in lower levels 
in the stomach, heart, small intestine, uterine and mammary glands (Porter et al. 
2002). SCGB3A2 has been shown to be expressed in high levels in the human 
airways and exhibits an amino acid sequence similar to SCGB1A1 (Yamada et al. 
2005). 
Structure 
SCGB1A1 is a 10kDa peptide found on human chromosome 11 between q12.3-
13.1. SCGB3A1 is an 11kDa peptide positioned on human chromosome 5q35. 
SCGB3A2 is found on chromosome 5q31-34. It is now thought that the difference in 
expression between SCGB1A1 and SCGB3A2 can in some cases be due to a 
functional polymorphism in their respective gene sequences (Ohchi et al. 2004). A 
study by Ohchi et al. (2004) investigated an A38G variant in the SCGB1A1 gene in 
Japanese patients with sarcoidosis. The study found an increased occurrence of 38A 
carriers in the patients when compared to the control subjects. A study by Jansen et 
al. (2004) aimed to validate this in clinically well-defined groups and found that 
there was no correlation between the polymorphism and sarcoidosis.  
A polymorphism in the SCGB3A2 gene promoter has been linked to asthma. A 
study by Niimi et al. (2002) found a polymorphism G-A -112bp into the promoter 
region of human SCGB3A2. They found that the -112A allele was responsible for a 
24% reduction in promoter activity in relation to -112G allele. These results were 
compared to a case study performed using 169 Japanese individuals, and it was 
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found that those with the -112A allele were 4.1 times more likely to have asthma 
than those with the wild type allele. 
Function 
Secretoglobin 1A1 (SCGB1A1) is known to decrease chemotaxis and 
phagocytosis of some leukocytes, inhibit phospholipase activity, and stimulate anti-
inflammatory activity (Levin et al. 1986; Miele et al. 1988; Mukherjee et al. 1988; 
Camussi et al. 1990; Zhong et al. 2006). Secretoglobin 3A1 (SCGB3A1) is well 
documented for its expression in normal breast tissue, exhibits phospholipase 
inhibition, and suppresses both the influx of neutrophils and chemotaxis response 
(Yamada et al. 2005). The function of secretoglobin 3A2 (SCGB3A2) is unclear, but 
it is expressed in high levels in the airways of healthy humans and, due to its 
sequence similarity with SCGB1A1, it is thought to function as an anti-inflammatory 
mediator (Niimi et al. 2002). 
A study by de Burbure et al. (2007) found differential expression in SCGB3A2 
protein and a non-significant yet positive correlation of SCGB1A1 protein 
concentrations in patients with asthma and rhinitis compared to normal subjects. The 
study looked at the induced sputum samples from patients with asthma or rhinitis and 
from non-smoking non-atopic individuals. There were issues with the treatment 
conditions within the asthma group, where 19 of the 32 were medicating with inhaled 
corticosteroids. Corticosteroids are an anti-inflammatory treatment for asthma and 
may affect the expression of genes involved with airway inflammation initiation and 
regulation. In fact, SCGB1A1 has previously been shown to be up-regulated by 
corticosteroid treatment (Zhang et al. 1997). To assess the true in-vivo expression of 
SCGBs in the airways of asthmatics, groups must be clearly defined and contain 
either non-treating asthmatics, corticosteroid-treating asthmatics or a group of each 
so comparison can be made between the treatment types. Thirteen of the asthmatics 
in the de Burbure study were smokers. A study by Chari et al. (2007) showed that 
tobacco smoke caused a decrease in SCGB1A1 expression in human airways. Both 
the lack of defined treatment within the asthma group and the smoking status of the 
participants more than likely contributed to the lack of significance in the difference 
in SCGB1A1 expression between asthmatics and non-asthmatics.  
  
Chapter 1: Literature Review 13 
 
 
SCGB1A1 has been assessed for a role as a potential biomarker of asthma 
(Bernard et al. 1993; Shijubo et al. 1997; Broeckaert and Bernard 2000; Bernard et 
al. 2005; Calvo et al. 2009). Although SCGB1A1 is secreted from epithelial Clara 
cells, its protein size is small enough to diffuse from the airways into serum along a 
concentration gradient (Bernard et al. 2005). Serum SCGB1A1 levels are much lower 
than airway SCGB1A1 levels; however, they are sufficient to measure using enzyme-
linked immuno-sorbent assays (ELISA) (Bernard et al. 1993; Shijubo et al. 1997; 
Broeckaert and Bernard 2000). Shijubo et al. saw a significant correlation between 
BALF and serum SCGB1A1 levels, which is supporting evidence that even though 
SCGB1A1 is expressed by other organs, serum levels reflect airway levels and are 
not influenced by release from other organs. A conflicting study by Halatek et al. 
(1998) found no correlation between BALF and serum SCGB1A1 levels in rodents 
(Halatek et al. 1998). This discrepancy may be due to the different hosts being 
analysed as Shijubo studied humans and Halatek studied rodents. However, the 
results highlight that for SCGB1A1 to be an appropriate biomarker, it needs to be 
collected from the airways and not the blood. Calvo et al. (2009) adopted a 
proteomic approach using whole lung tissue from a mouse model and SELDI-TOF-
MS to identify proteins that are up-regulated in the asthma model. They found that 
SCGB1A1 was up-regulated in allergen-exposed mice compared to non-exposed 
mice. This again indicates the potential of SCGB1A1 as a biomarker of airway 
inflammation and asthma; however, when applied to a clinical setting, less invasive 
sampling measures must be used when applying this to humans.  
1.3 EPIGENETICS 
Epigenetics is the study of heritable changes in gene expression that are not 
encoded in the underlying DNA sequence (Cheung and Lau 2005). It refers to 
functionally relevant modifications to the genome that do not involve a change in 
nucleotide sequence. Epigenetic modifications include DNA methylation and 
chromatin remodelling.  
DNA methylation refers to the addition of methyl groups to DNA, often in 
CpG sites located in the promoter regions of genes, and converts cytosine to 5-
methylcytosine. In highly methylated areas of the genome, the effect is 
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transcriptional inactivity. This modification persists from the germ cell of either 
parent into the zygote, presenting inheritance known as genetic imprinting. Genetic 
imprinting is the cause of human disorders such as Angelman syndrome and Prader-
Willi syndrome (Dagli and Williams 1993). DNA methylation has also been 
associated with a number of malignancies. In the majority of cases, hypermethylation 
(silencing) of genes involved with cell cycle regulation, DNA repair, apoptosis, 
angiogenesis and metastasis lead to the production of cancers. One example is the 
GSTP1 gene, which is hypermethylated in the majority of prostate cancers (Lee et al. 
1994). Hypomethylation of genes contributes to oncogenesis via the activation of 
oncogenes such as cMYC and H-RAS, by the activation of retrotransposons or by 
chromosome instability that leads to transcriptional activation found in many cancer 
types (Feinberg and Vogelstein 1983; Singer et al. 1993; Alves et al. 1996; Tuck-
Muller et al. 2000). Initial research by our group looked into the possible effect of 
DNA methylation on trefoil factor and secretoglobin genes from airway cells 
collected from asthmatics and non-asthmatics. There were no significant changes 
found in the methylation status of the promoter regions of the genes between 
asthmatics and non-asthmatics, indicating that methylation is not involved with these 
genes (Solomon and Hadaway, data unpublished). 
Chromatin remodelling is the post-translational modification of the amino 
acids that comprise histone proteins. Histone proteins make up nucleosomes that act 
as molecular ‘spindles’ around which DNA is wound, constituting chromatin. The 
post-translational modification of these histones changes their affinity to the DNA, 
which in turn changes the expression of the genes within the remodelled chromatin. 
Although these modifications can occur throughout the histone sequence, and to any 
protein for that matter, the N-termini of the histones are particularly targeted. Histone 
methylation is one modification which involves enzymes that target arginine and 
lysine amino acids, methylating them and causing repression of gene transcription 
(Chen et al. 1999; Ng et al. 2002).  Recent asthma research has discovered that  tri-
methylation of histone H3 at lysine 9 is responsible for the lower vascular endothelial 
growth factor (VEGF) in airway smooth muscle cells from non-asthmatics compared 
with celss derived from asthmatics (Clifford et al. 2012).  Phosphorylation is another 
modification that incorporates the addition of a phosphate group to serine, threonine 
or tyrosine amino acids, and has been linked with the rapid but transient induction of 
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gene expression (Nowak and Corces 2004; Ciesla et al. 2011). Histone ubiquitination 
is a modification involving the attachment of ubiquitin molecules to lysine-119 on 
H2A and lysine-120 on H2B histones in humans, which are known to cause 
transcriptional activation in many cases (Thorne et al. 1987; Nickel and Davie 1989). 
Histone sumoylation is a modification similar to ubiquitination, involving enzymes 
known as small ubiquitin-related modifier (SUMO) family proteins that bind 
predominantly to the N-terminus of the H4 histone and are linked to transcriptional 
repression (Wotton and Merrill 2007). Lastly, histone acetylation is the post-
translational modification of histones by a group of enzymes called histone 
acetyltransferases and histone deacetylases, which activate or repress transcription 
respectively. Histone acetylation is highly studied, and is certainly a popular 
explanation for a lot of airway diseases, including asthma. However, little solid 
research has been done to confirm the role of histone acetylation in asthma.  
1.3.1 Histone Acetylation 
Histone acetylation is a mode of modification that affects gene transcription 
and is controlled by enzymes known as histone acetyltransferases (HATs) (Barnes et 
al. 2005). A nucleosome is formed by 146 base pairs of DNA wrapped around an 
octamer of core histone proteins (two molecules of H2A, H2B, H3 and H4), forming 
the basic structure of chromatin (Arents et al. 1991; Luger et al. 1997) (Figure 1.2). 
In a resting cell, DNA is tightly wound around the core histones, making it 
impenetrable to transcription factors and other large protein complexes. HATs 
produce hyperacetylation of specific lysine residues in the N-terminal tails of H3 and 
H4 histones (Figure 1.3(b)), forming a molecular tag for the recruitment of 
chromatin remodelling enzymes such as Brg1 (Keslacy et al. 2007), which allows 
local chromatin unwinding and the recruitment of other transcriptional factors – the 
basal transcriptional complex and RNA polymerase II (Bilodeau et al. 2006). This 
process leads to the increased transcription of the gene affected. Transcriptional co-
activators such as cyclic adenosine monophosphate response element binding protein 
(CREBBP), histone acetyltranferase-1 (HAT-1) and nuclear receptor co-activators 1-3 
(NCOA1-3) have intrinsic HAT activity (Bilodeau et al. 2006). Many stimuli can 
activate histone acetylation through induction of pro-inflammatory transcription 
factors such as activator protein 1 (AP1) and NF-κB (Bilodeau et al. 2006). 
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Acetylation is associated with gene induction and is catalysed by HATs; the reverse 
is catalysed by histone deacetylases (HDACs) and is explained in Section 1.3.1.  
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Figure 1.2  Chromatin structure showing a nucleosome consisting of a pair of H2A, 
H2B, H3 and H4 histones, wrapped by 146 base pairs of DNA. 
 
 
  
 
Figure 1.3.  (A) Histone deacetylation: Acetyl groups are removed from lysines on 
the N-terminal tails of H3 and H4 histones making the chromatin permissive. (B) 
Histone hyperacetylation: Acetyl groups are added to the lysine residues on N-
terminal tails of H3 and H4 histones allowing transcriptional machinery to activate 
gene transcription.  
18 Chapter 1: Literature Review 
 
1.3.2 Histone Deacetylation  
Histone deacetylation is the process where HDAC enzymes remove acetyl 
groups from the lysines on the N-terminal tails of H3 and H4 histones (Figure 
1.3(a)). HDACs can be divided into four classes. Class I consists of HDAC1, 2, 3 and 
8; class II consists of HDAC4, 5, 6, 7, 9 and 10; class III consists of sirtuins (Sirt) 1–
7; and class IV includes HDAC11. Class I HDACs are predominantly localised to the 
nucleus but have been found in the cytoplasm, whereas class II HDACs shuttle 
between the nucleus and the cytoplasm. Class III HDACs are all unique, present as 
NAD+-dependent deacetylases and include all known sirtuins, which all bestow 
intrinsic transcriptional repression (North and Verdin 2004). There is only one class 
IV HDAC: HDAC11. This HDAC is in its own class as it has the characteristics of 
class I and class II HDACs. 
1.3.3 HATs and HDACs 
Histone acetylase and deacetylase expression are thought to play a functional 
role in lung inflammation. With regards to asthma, preliminary data from bronchial 
biopsies show a marked increase in HAT activity and a small reduction in HDAC 
activity compared to normal airways (Ito et al. 2002). A study by Cosio et al. (2004) 
looking at histone acetylation activity in alveolar macrophages in asthma found an 
increase in HAT activity and a decrease in HDAC activity in asthmatics compared to 
non-asthmatics. These results highlighted an association between airway 
inflammatory cells and mediators of histone acetylation. In the same study, 
peripheral blood mononuclear cells appeared to have normal HAT and HDAC 
activity. This indicated that the HAT and HDAC changes were localised to the 
airways. Ito et al. (2004) reported no change in HAT activity but a reduction in 
HDAC activity in patients with chronic obstructive pulmonary disorder (COPD) and 
that this decrease was correlated with disease severity. This demonstrated that 
different airway diseases have different regulation patterns of histone acetylation, 
which therefore may be an appropriate marker to differentiate between airway 
diseases. A study by Su et al (2009) compared the activity of HATs and HDACs in 
bronchial biopsies of children with varying asthma status.  In this study it was found 
that HDAC activity was significantly decreased in the mild and severe asthmatics 
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compared to the non-atopic non-asthmatic control group, and HAT activity was 
significantly increased in the allergic asthmatics. 
Trefoil factors have been previously described as regulated by acetylation. 
TFF1 gene expression has been studied in oestrogen-responsive breast cancer cells 
(Sun et al. 2005). A Sp1/Sp3 binding site has been identified in the TFF1 promoter 
region. The addition of oestradiol resulted in a reduction of Sp1 and an increase in 
the steady state levels of acetylated H3 and H4 histones bound to the TFF1 promoter, 
while Sp3, HDAC1 and HDAC2 remained bound (Sun et al. 2005). It may be 
proposed that Sp1 or Sp3 recruit HATs and HDACs to the TFF1 promoter, catalysing 
dynamic histone acetylation and placing the TFF1 promoter in a ready state to 
respond to events upon oestrogen administration to the cell. This shows that 
acetylation is involved in the control of a TFF and therefore could occur in other 
TFF expressing cells such as those involved in the airways. 
The Ito et al. (2002) study found reductions in the level of protein expression 
of HDAC1 and HDAC2 in bronchial biopsies obtained from subjects with mild 
asthma compared with normal control subjects. Asthma status, however, did not 
appear to affect the distribution of HDAC1-6 expression in the airways (Ito et al. 
2002). The study also observed higher HDAC activity and less HAT activity in the 
biopsy samples obtained from asthmatics taking inhaled corticosteroids (ICS); in 
fact, HAT expression mirrored levels seen in the non-asthmatic control group. This 
suggests that the effectiveness of ICS may be linked to histone acetylation.  
1.4 CORTICOSTEROIDS 
Corticosteroids are the most effective anti-inflammatory drug used in the 
treatment of asthma. Their effectiveness since their introduction in 2000 is shown by 
the decrease in emergency department visits in Australia due to asthma from 41,000 
in 2001–2 to 37,461 in 2004–5 and the reduction in the use of bronchodilator 
medication (Australian Institute of Health and Welfare 2003; Australian Bureau of 
Statistics 2006).  
Corticosteroids are administered as an inhaled medication when needed. 
Although corticosteroids are the predominant medication for asthma, the molecular 
mechanisms of their effect are not well understood. Corticosteroids are known to 
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bind to a specific glucocorticoid receptor (GR) that is predominantly localised to the 
cytoplasm of target cells. Upon activation, the GR translocates to the nucleus and, 
through unknown mechanisms, either increases (transactivates) or decreases 
(transrepresses) the expression of genes involved with airway inflammation (Figure 
1.4) (Barnes and Adcock 2003). GRs are expressed in almost every cell type, 
including human lung where there is a high level of expression in airway epithelium 
and the endothelium of bronchial vessels (Adcock et al. 1996). Separate studies by 
Adcock et al. (1996) and Vachier et al. (1998) have shown that GR mRNA and 
protein expression in bronchial biopsies and epithelial cell brushings are unchanged 
in asthmatic and COPD patients compared with normal subjects.  
It is thought that the major action of corticosteroids is the inhibition of pro-
inflammatory transcription factors such as activator protein (AP)-1, signal 
transducers and activators of transcription (STATs), nuclear factor of activated T-
cells (NFAT) and NF-κB (Barnes and Adcock 1998). It is also thought that 
corticosteroids can switch on the expression of anti-inflammatory genes such as 
lipocortin-1 (Karin 1998). All of the aforementioned transcription factors are known 
to be involved in airway inflammation, and corticosteroids control their function 
directly or indirectly, hence controlling inflammation.  
Studies looking at the effect of corticosteroids on rat airways have shown an 
increase in SCGB1A1 expression in both foetal rat airways and adult rat lungs. A 
study by Karin et al. (1998), which looked at the SCGB1A1 expression after acute 
lung inflammation induced by intratracheal lipopolysaccharide (LPS) administration, 
found that SCGB1A1 decreased with LPS-induced inflammation, and pre-treatment 
with dexamethasone, a corticosteroid, failed to increase the permeability of 
SCGB1A1.  To date, the expression of SCGB1A1 as a result of corticosteroid use has 
not been studied and is therefore one of the aims of this project 
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Figure 1.4.  Cellular response to corticosteroids. Corticosteroids bind to 
glucocorticoid receptors (GR) in the cell membrane, which are then internalised and 
participate in transactivation or transrepression of transcription of genes. This 
activates or represses the gene accordingly.   
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There are a small portion of asthmatics that are corticosteroid resistant. This 
means they fail to respond to even a high dosage of corticosteroids (Barnes and 
Adcock 1995). Corticosteroid resistance is defined as a failure to improve lung 
function by more than 15% after treatment with high doses of prednisolone 
(30−40 mg daily for two weeks) (Barnes 2004). There are several proposed 
mechanisms for corticosteroid resistance, including long-term cigarette smoke 
inhalation (Walters et al. 2005) and genetic predispositions (Sousa et al. 2000).  
Corticosteroid treatment has been linked to the control of histone acetylation. A 
study by Cosio et al. (2004) found an increase in HDAC activity in prednisone-
treated mild asthmatics. There is evidence of an interaction between corticosteroid 
treatment and HAT and HDAC expression; however, more precise research is needed 
to compare the expression levels of individual HATs and HDACs, not only between 
non-asthmatics and asthmatics medicating with corticosteroids, but also with 
asthmatics medicating with bronchodilators. 
1.5 NOVEL SPUTUM ANALYSIS TOOLS 
1.5.1 Proteomics 
Proteomics is a broad term given to the large-scale study of proteins, in 
particular their structures and functions. Proteomics is quite complicated as the 
proteome of an organism can differ from cell to cell and from time to time, and 
proteins can be affected by post-translational modifications. Proteomics is a powerful 
analysis tool for comparing the effect of different states or treatments on protein 
expression within any cell or biological fluid. Samples containing proteins are 
processed and cleaved with trypsin or similar enzymes to create peptides. The 
peptides are usually either fractionated using column high-performance liquid 
chromatography (HPLC) or kept as a neat sample. The samples are then analysed 
with mass spectrometry, which identifies the amino acid sequence of the peptides by 
mass. The amino acid sequence is then scanned through a database to find the protein 
belonging to the identified peptide. This approach identifies the protein constituents 
of the original sample.  
Proteomic techniques have recently become very popular due to the ability to 
analyse mixed samples and build a list of the sample’s constituents. This is extremely 
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effective for clinical samples where, with the right preparation, the sample can be 
interrogated for its entire protein make-up. However, there are also downsides 
associated with some proteomic approaches, including protein masking when highly 
abundant, high molecular weight proteins are present, and the equipment and 
techniques can be quite expensive.  
Proteomics has been used to analyse sputum samples in asthma studies with 
marked success. To date, the majority of studies using proteomics in airway research 
have been discovery projects. The identification of a biomarker for asthma has been 
the main drive for using proteomics due to the relative speed and ease of the 
procedure from obtaining a sample to receiving a result. Secretoglobin 1A1 has been 
implicated with many asthma proteome studies. Research by Calvo et al. (2009), 
Gray et al. (2008) and Gharib et al. (2011) has identified SCGB1A1 in asthmatic 
sputum through the use of shotgun proteomics. The Gray et al. study used SELDI-
TOF-MS to pick peaks that were different between non-asthmatics and asthmatics, 
and found a down-regulation in the SCGB1A1 protein in the asthmatic samples. The 
Gharib et al. study used a spectral count method to assess relative concentrations and 
also found SCGB1A1 to be down-regulated in the asthmatic group. These studies 
demonstrate the ability to identify proteins in the sputum samples, to quantify levels 
of a particular protein, and to compare different groups or treatments. 
Isobaric Tag for Relative and Absolute Quantification (iTRAQ) 
The iTRAQ is a proteomic approach that allows the quantification of proteins 
within a sample. iTRAQ is available as a kit that allows either relative or absolute 
quantity analysis of samples. When dealing with an unknown entity (sample with 
unknown proteins), the relative quantification approach is used. The technique works 
by covalent labelling of the N-terminus of the peptides from the protein digest of the 
sample. The iTRAQ kit comes in two forms: a 4-plex and an 8-plex, which allow 
individual labelling of four or eight samples, respectively.  
The 8-plex kit utilizes eight isobaric reagents for the labelling of peptides 
within a sample, and each is named by the mass of the reporter group in its structure 
(113, 114, 115,116, 117, 118, 119 and 121). This kit allows the user to label eight 
individual digests for mass spectrometry analysis. Once the eight samples have been 
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labelled with one of the iTRAQ reagents the samples are combined for analysis.  The 
combined mixture is analysed using LC-MS/MS for both identification and 
quantification. The sequence of the peptides within the samples is determined from 
the product ions generated from cleavage about inter-residue bonds, and the relative 
quantity of a peptide among the samples is measured by the intensity of the reporter 
ion signal in the MS/MS scan data.  This effectively allows the user to determine out 
of a total of eight samples at a time, what proteins are within the samples, and 
compare the quantity in each sample compared to the others.  This is very useful in 
studies trying to identify changes in protein levels due to different treatments.  
However, to compare the quantity of a protein between samples, all samples must 
contain the protein.This procedure has not been used to analyse the protein 
constituent of induced sputum.  This project is designed to compare samples by 
group (asthmatic/ non-asthmatic), and pre- and post- induction of acute airway 
inflammation.  For this reason it is believed that iTRAQ is a potent analysis tool for 
both secreted protein and intracellular protein extracted from sputum of non-
asthmatics and asthmatics. 
1.6 SYNOPSIS OF CURRENT LITERATURE AND KNOWLEDGE 
It is understood that inflammation is a key component to the exacerbation of 
asthma in humans. The molecular mediators involved in the aberrant inflammation of 
the disease are not well understood. Furthermore, there is little research into the 
expression of genes in response to the controlled induction of airway inflammation. 
This review has outlined various instances whereby TFFs, SCGBs, HATs and 
HDACs are involved in the process or outcome of inflammation. As part of this 
project, a proteomics approach will be used as a discovery tool to identify other 
proteins that may be involved with inflammation in the airways and to provide a 
relative quantification of the expression of the identified proteins in association with 
induced acute airway inflammation. Understanding the expression of these mediators 
will build on the knowledge base regarding inflammation in the human airway and 
may aid in the development of therapeutic targets for treating asthma symptoms. 
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1.7 GENERAL HYPOTHESIS 
It is proposed that the primary cellular and protein components of airway 
inflammation are mediated, in part, by TFFs and SCGBs, and that these mediators 
are controlled by histone acetylation. 
It is hypothesised that trefoil factors 1 and 3 will be over-expressed and that 
SCGB1A1 and 3A2 will be under-expressed as a function of asthma status and 
induced acute airway inflammation, and that changes in the expression of TFFs and 
SCGBs will be associated with over-expression of histone acetyltransferases and 
under-expression of histone deacetylases.   
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1.7.1 Aims 
The aims of this project are: 
 to investigate the expression of TFFs, SCGBs, HATs and HDACs in 
sputum samples of non-asthmatics, asthmatics medicating with 
bronchodilators and asthmatics medicating with corticosteroids before the 
induction of airway inflammation; 
 to investigate the effect of induced acute airway inflammation on the 
expression of TFFs, SCGBs, HATs and HDACs in non-asthmatics, 
asthmatics medicating with bronchodilators and asthmatics medicating 
with corticosteroids through the use of hypertonic saline challenge; 
 to investigate whether there is a correlation between neutrophil percent and 
expression of TFFs, SCGBs, HATs and HDACs, and whether there is a 
correlation between TFF and SCGB expression, and HAT and HDAC 
expression; 
 to investigate the expression of proteins in both the secreted and 
intracellular component of sputum using iTRAQ proteomics. 
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Chapter 2: Materials and Methods 
2.1 INTRODUCTION 
All of the materials and methods referred to in the subsequent chapters are 
included in this chapter. 
2.2 DESIGN  
This thesis project consisted of a series of three independent but associated 
experiments. Each of the three experiments used a one-group, repeated measures 
design. The participant groups consisted of 15 healthy non-asthmatics (N-A), 15 
asthmatics medicating with bronchodilators (A-BD) and 15 asthmatics medicating 
with corticosteroids (A-ST). Each participant undertook three testing sessions in 
which sputum was collected for measurement of gene expression using qPCR, 
differential cell counts to gauge inflammation, and protein expression using 
proteomic analysis. Session 1 (SI-1) and session 2 (SI-2) were performed at least one 
week apart and were treated as repeated baseline samples. The purpose of the week 
between sputum inductions was to allow complete restoration of the airway. The 
third session (SI-3) was performed six hours after SI-2 to collect a sample containing 
all the inflammatory cells and mediators released due to the insult caused during SI-2 
(Figure 2.1). 
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Figure 2.1.  Testing session diagram for the three participant groups. All volunteers 
participated in a single sputum induction session. To allow the participants’ airways 
to recover from the initial sputum induction, at least one week later they returned to 
participate in a further sputum induction, followed by a final session six hours later 
to collect any inflammation caused by the earlier induction.  
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2.3 ETHICS 
This project was conducted using a protocol approved by the Queensland 
University of Technology University Human Research Ethics Committee UHREC 
#0800000179. 
2.4 PARTICIPANTS 
2.4.1 Participant Recruitment 
All participants were recruited through email lists through QUT’s staff and 
student sectors, as well as through external sources including newspapers, flyers and 
electronically through Facebook. All participants were between the ages of 18 and 
50, were non-smokers and were not pregnant or breastfeeding at the time of 
participation. Three cohorts were included in this study: 15 non-asthmatics (N-A), 15 
asthmatics using bronchodilator medication (A-BD) and 15 asthmatics using 
corticosteroid medication (A-ST). All participants provided informed consent and 
participated in a medical health questionnaire, spirometry and sputum induction.  
Recruitment Logistics 
This project had a high participant dropout rate. In the N-A group, 18 
participants came in for the first session and opted out of further participation. In the 
A-BD group, seven participants didn’t progress past the first session. In the A-ST 
group, only two participants dropped out after the first session. These results show 
that to collect three samples from 45 participants, a total of 72 participants agreed to 
participate in the initial testing session, which equates to a 32% dropout rate. A total 
of 37 initial respondents didn’t participate fully in the study. Recruitment involved 
correspondence with over 100 people to collect 45 participants for the three groups. 
We successfully collected three session samples from 17 N-A, 19 A-BD and 16 A-
ST participants. However, not all the participants provided enough sample, resulting 
in an inability to perform all gene and protein tests for all participant samples. 
2.4.2 Screening 
To assess participants for suitability, each participant completed a medical 
health questionnaire. Participants were accepted only if they were between 18 and 50 
30 Chapter 2: Materials and Methods 
years of age, non-smokers, and currently not suffering from any inflammatory 
conditions including respiratory infections such as cold or flu.  
2.4.3 Spirometric Pulmonary Function 
Spirometric pulmonary function tests to determine pulmonary volumes and 
airflow rates were performed for subject characterisation and for safety during 
sputum induction. Measurements were taken at baseline, 15 mins post-treatment with 
400 µg salbutamol, every 2 mins during sputum induction, and post-sputum 
induction. The tests were conducted using a COSMED Pony FX spirometer 
(COSMED, Rome, Italy) and standard testing procedures (Miller 2005).  
2.4.4 Sputum Induction 
Sputum inductions (SI) were conducted on subjects at the Institute of Health 
and Biomedical Innovation, Queensland University of Technology (IHBI, Kelvin 
Grove, Qld) to collect lower airway secretions (cells and proteins) using a modified 
version of a standardised procedure (Djukanovic et al. 2002; Witten et al. 2005). All 
subjects completed spirometry to ascertain a baseline FEV1 reading, and then were 
pre-treated with 400 µg of salbutamol 15 mins prior to sputum induction to minimise 
the chance of bronchoconstriction. Subjects inhaled nebulised 3% saline through an 
ultrasonic nebuliser (Suchatzki, Rennerod, Germany) for 20 mins, with the 
instruction to take two large breaths of nebulised saline every two mins, clear the 
mouth of saliva, forcefully cough from the chest and expurgate the airway secretion 
into a specimen container kept on ice. After completion of sputum induction, the 
sample was transported to the wet laboratory at the IHBI for processing, which 
commenced within 30 mins of completion of collection. 
2.5 SPECIMEN PROCESSING 
2.5.1 Isolation of Airway Cells and Extracellular Protein 
Airway cells were isolated from sputum samples for use in gene and protein 
expression studies (Figure 2.2). To collect airway cells from sputum samples, the 
samples were first homogenised using an ‘in house’ mixed solution called sputasol. 
Sputasol is a liquefying agent that helps release airway cells from the airway mucus 
and consists of 60 mM dithiothreitol, 1.33 M sodium chloride, 78 mM disodium 
hydrogen phosphate and 14 mM potassium dihydrogen phosphate. Equal amounts of 
sputasol were added to the volume of sputum and the mix was incubated at room 
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temperature on a shaker for 15 mins. The sample was then passed through a 19-
gauge needle with a syringe 10 times to help break the mucus. From the sample, 
300 µL was taken for total and differential cell counts (Section 2.6) and the rest of 
the sample was distributed evenly between two 15 mL Falcon tubes. The divided 
samples were then centrifuged at 280xg for 15 mins. The supernatant was removed 
and collected in a fresh 15 mL Falcon tube. One of the remaining cell pellets was re-
constituted in 1 mL of TRI Reagent (Sigma-Aldrich, Castle Hill, Aus) and 
subsequently stored at −80°C while the other cell pellet was processed immediately 
to collect total cellular protein (Section 2.9.1). The collected supernatant was then 
centrifuged at 1060xg for 15 mins to spin out cellular debris and was divided into 
1.5 mL aliquots and stored at −80°C for later use in secreted protein analysis studies. 
 
 
 
 
Figure 2.2.  The project design for all three participant groups.   
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2.6 CELL COUNTS 
2.6.1 Total Cell Counts 
To assess the quality of the sputum sample collected, total cell counts were 
performed to count the number of leukocytes, erythrocytes, columnar epithelial cells 
and squamous epithelial cells. The counts were performed by loading 20 µL of 
sputum/sputasol mix into each chamber of a haemocytometer (Neuber double net 
ruling, ProSciTech, Qld) and reading two large squares (1 mm
2
 area) in each 
chamber. The average of the four counts was taken and multiplied by 10
4
 for a value 
of total number of cells per mL. If the total number of squamous epithelial cells in a 
sample exceeded 80% of the combined total of the other counted cells, the sample 
was deemed contaminated with too much saliva and considered unusable.  
2.6.2  Differential Cell Counts 
To examine the types of leukocytes in the participants’ sputum samples, 
differential cell counts were performed using a Rapid Diff stain kit (Australian 
Biostain, Traralgon, Victoria) following the manufacturer’s instructions. Briefly, two 
slides were made for each sample, one with two drops and the other with three drops 
of the sample. The drops were added to cytocentrifuge carriage consisting of a slide 
and cytocentrifuge funnel. The slides were centrifuged at 700xg for 3 mins. The 
slides were allowed to air dry. Staining consisted of five 1 sec dips into Rapid Diff 
fixative solution, five 1 sec dips into Rapid Diff stain 1 and five 1 sec dips into Rapid 
Diff stain 2, followed by a wash step. When dry, a cover slip was fixed for long-term 
storage. The sample slides were allocated a number randomly to blind the reader 
from the asthma status and sample session of each slide. Each slide was read four 
times, counting to 100 leucocytes/ columnar epithelial cells in total.  The mean of the 
four counts was taken and a percentage (%) of each cell type was calculated.  
Squamous epithelial cells were counted separately and were not included in the 100 
cell cut-off in each count. The counts allowed the calculation of the percentage of the 
different leukocytes and therefore the ability to judge the change in inflammation 
between SI-2 and SI-3 sample collections. 
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2.7 GENE EXPRESSION ANALYSIS USING QUANTITATIVE REAL-
TIME PCR (QPCR)  
2.7.1 RNA Extraction 
To perform gene expression analysis on sputum samples, first total RNA was 
extracted from the airway cells in TRI Reagent that were stored at −80°C. The 
extraction was performed using a combination of Sigma-Aldrich’s RNA extraction 
protocol and the standard protocol for RNA clean-up using RNeasy Mini Kit 
(QIAGEN, Doncaster, Victoria). Briefly, 200 µL of isopropanol was added to 1 mL 
of sample in TRI Reagent, mixed thoroughly and allowed to sit at room temperature 
for 10 mins. The sample was then centrifuged at 12,000xg for 10 mins. The clear 
supernatant was then collected into a fresh 2 mL microcentrifuge tube where 350 µL 
of buffer RLT and 250 µL of chilled 100% ethanol were added and the sample 
inverted to mix. The sample was then transferred to an RNeasy mini spin column 
(700 µL at a time) and centrifuged at 8,000xg for 15 sec. The flow-through was 
discarded and 500 µL of buffer RPE was added to the spin column and centrifuged at 
8,000xg for 15 sec. The flow-through was discarded and a further 500 µL of buffer 
RPE was added and then centrifuged at 8,000xg for 2 mins. The RNeasy mini 
column was then placed into a fresh 1.5 mL microcentrifuge tube and 30 µL of 
RNase-free water was added to the column and incubated at room temperature for 
1 min. The column was then centrifuged at 8,000xg for 1 min to elute the RNA. The 
resulting clean RNA was assessed for quantity and quality using a NanoDrop 
spectrometer (Thermo Scientific, Massachusetts, USA).   
2.7.2 First-Strand cDNA Synthesis 
Pure isolated RNA from each sample was converted to cDNA using 
SuperScript III First-Strand Synthesis SuperMix following the manufacturer’s 
protocol (Invitrogen, Mulgrave, Victoria). Briefly, 500 ng of each RNA sample was 
combined with 1 µL of random hexamers and 1 µL of annealing buffer and made up 
to 8 µL in RNase/DNase free H2O in 0.2 mL PCR tubes. The samples were then 
incubated in DNA engine PTC-200 RT-PCR machine (MJ-Research/Biorad, 
Gladesville, New South Wales) at 65°C for 5 mins; then immediately placed on ice 
for 1 minute. To each sample, 10 µL of 2X First-Strand reaction mix, 2 µL of 
Superscript III and 2 µL RNaseOUT enzyme (Invitrogen) were added, the sample 
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was vortexed and collected by brief centrifugation, and then incubated for 10 mins at 
25°C, 50 mins at 50°C and then the reaction was terminated at 85°C for 5 mins. To 
each sample, 2 µL of RNase H (Invitrogen) was added and incubated at 37°C for 
20 mins. The samples were then chilled on ice and stored at −80°C for real-time 
PCR.  
2.7.3 Standard RT-PCR Conditions 
All RT-PCR reactions were performed using a Platinum Taq PCR kit 
(Invitrogen). For each reaction, 15.5 µL DEPC H2O, 2 µL 10x PCR buffer, 0.6 µL 
50 mM MgCl2, 0.2 µL Platinum TAQ, 0.2 µL dNTPs 10 mM and 0.25 µL of forward 
and reverse primer (Table 2.1) were used for each gene interrogated, and 1 µL of 
sample cDNA. A two-step PCR reaction was used as it is the same as the reaction 
conditions of the standard ABI Prism real-time machines. The conditions consisted 
of a single denaturation at 94°C for 3 mins, followed by 35 repeats of denaturation at 
94°C for 15 sec, and combined annealing and extension at 68°C for 12 sec. This was 
then held at 4°C. Standard RT-PCR was performed to check the validity of the 
primers used to interrogate the genes of interest and also to make gene standards 
from the PCR product to be used in real-time PCR experiments. 
2.7.4 Real-time PCR Standard Creation 
To quantify genes of interest in participant samples, gene standards were 
prepared using the method described in Section 2.7.3. Total PCR reactions were 
mixed with 6x loading buffer (30% glycerol, 0.25% bromophenol blue in H2O) and 
electrophoresed on a 2% agarose gel set containing 0.01% ethidium bromide at 
110 V for 45 mins. The agarose gel was then visualised in a G:BOX gel imaging 
system (Syngene, Cambridge, United Kingdom). This was to confirm specific 
amplification of product. The gel was then visualised again on a 3UV bench top 
transilluminator (UVP, California, USA) and the bands were excised and transferred 
to individual 2 mL microcentrifuge tubes. The PCR products were then eluted from 
the gel pieces using Wizard SV Gel and PCR Clean-Up System (Promega, 
Wisconsin, USA). Briefly, 1 µg of membrane binding buffer was added for each mg 
of gel/product. The mixture was vortexed and incubated at 65°C for 10 mins or until 
the agarose was dissolved. The samples were then transferred to SV minicolumns 
and incubated at room temperature for 1 min and then centrifuged at 16,000xg for 
1 min. The flow-through was discarded and 700 µL of membrane wash solution was 
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added to the column and centrifuged at 16,000xg for 1 min. The flow-through was 
discarded and then another 500 µL of membrane wash solution was added and 
centrifuged at 16,000xg for 5 mins. The flow-through was discarded and the column 
was re-centrifuged for 1 min with the microcentrifuge lid off to allow residual 
evaporation. The minicolumn was then transferred to a clean microcentrifuge tube. 
To the minicolumn, 50 µL of nuclease-free water was added and incubated at room 
temperature for 1 min and then centrifuged at 16,000xg for 1 min. 
The product from the gel and PCR clean-up was then quantified using a 
NanoDrop spectrometer.   
Standard calculations 
To have accurate PCR standards, the following calculation was used to work 
out the appropriate dilutions of eluted PCR product: 
Number of copies = (ng x number/mole) / (bp x ng/g x g/mole of bp) 
ng   concentration of PCR product 
number/mole  Avogadro’s number 
bp  length of PCR product 
g/mole  1x10
9
 
mole of bp 660 (avg. mW of a bp) 
 
The sample was diluted to 10
8
 using the following calculation: 
10
8 
x (Final Vol µL)/Number of copies 
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Table 2.1.  Real-time PCR Primers    
Gene Symbol Primer (F-forward, R-Reverse) GenBank Accession # 
Trefoil Factors   
TFF1 F-CGACACCGTTCGTGGGGTCC NM_003225.2 
 R-AGGTGTCCGGTGGAGGTGGC  
TFF3 F-GCGAGTCCTGAGCTGCGTCC NM_003226.3 
 R-CCCTGTCCTTGGCTGGCACG  
Secretoglobins   
SCGB1A1 F-AGGCCAGAGCATCCCCCTCC NM_003357.3 
 R-ACACGCTGAAAGCTCGGGCA  
SCGB3A2 F-AGTGGAACCACTGGCTTGGTGGA NM_054023.4 
 R-GCCAACTTGTCAACAGGAAGGGGC  
Histone Deacetylases  
HDAC1 F-AGCAAGATGGCGCAGACGCA NM_004964.2 
 R-GCTTTGTGAGGGCGATAGATTTCCA  
HDAC2 F-AGTCAAGGAGGCGGCAAAA NM_001527.3 
 R-TGCGGATTCTATGAGGCTTCA  
HDAC3 F-TTCCAGCCGGTTATCAACCA NM_003883.3 
 R-GTTAAAGCAGCCCAATCGATCA  
HDAC4 F-TGTACATGTCCCTCCACCGCTA NM_006037.3 
 R-CATGTTGACGTTGAAACCCACG  
HDAC5 F-TCGGCAGATGGGATGTCAGGTCG NM_001015053.1 
 R-GGGCCCAGGCAAAGGCAGTT  
Histone 
Acetyltransferases 
 
NCOA1 F-GATGGAACCCAGCAGGTGCAACA NM_003743.4 
 R-AGGTAAGGGTCCCCGCCTACC  
NCOA2 F-CGTGACCGACCCGAGCCGAT NM_006540.2 
 R-GTTCCTTTTGGGGCTGGGTCCA  
NCOA3 F-AGCTCCCAGGGTTTTCTTAATGCTC NM_001174087 
 R-GCCACCCTCTGTTGTCGGAA  
CREBBP F-AGCAAACGGAGAGGTTCGGGC NM_001079846.1 
 R-CCAGGATGGCTTGGCAGGCTTTC  
HAT-1 F-GGGGATGATGAAACTGCTTTTGGT NM_003642.3 
 R-TGCCCTCAACATCATCTGCCTCT  
Normalising Gene   
18S rRNA F-TTCGGAACTGAGGCCATGAT NC_002753.1 
 R-CGAACCTCCGACTTTCGTTC  
This table includes the forward (F-) and reverse (R-) primers designed for use in real-time PCR. All 
primer sequences are arranged in 5’–3’ direction. The GenBank accession numbers correspond to the 
mRNA sequence for each gene.  
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2.7.5 Gene Analysis Using Real-time PCR 
Real-time PCR was performed using the ABI Prism 7300 real-time PCR 
machine (Applied Biosystems). Sample reactions were performed in Axygen PCR 
microplates (Axygen Scientific, California. USA). Prior to real-time PCR analysis, 
each cDNA sample was diluted 1:5 in TE buffer, and 2 µL of diluted cDNA was 
added in triplicate to individual PCR reaction mixtures containing 10 µL SYBR 
green 2x buffer, 0.1 µL of forward and reverse primer pertaining to the gene of 
interest (Table 2.1), and ddH2O to a final volume of 20 µL per well. The PCR 
microplates were then pulse centrifuged and loaded into the ABI Prism 7300 real-
time PCR machine and subjected to the following PCR cycle protocol: 50°C for 
2 min, 95°C for 10 min, then 40 cycles of 95°C for 15 sec, 60°C for 20 sec and 95°C 
for 15 sec. Sample triplicates were analysed for variation using the ABI 7300 
software and only triplicate results within 1 cycle were accepted. 
2.7.6 Real-time PCR Calculations 
Raw data was exported to a Microsoft Excel file and analysed using the 
standard curve method, normalising to 18S rRNA. Due to the high variability of 
other common housekeeping genes such as GAPDH in asthma, 18S rRNA was 
considered the most stable gene to use to normalise the data. The test samples were 
run against a standard curve of the target gene so a concentration result could be 
achieved for each sample and for each gene. The gene results for each sample were 
normalised to 18S rRNA, expressing results in concentrations. The asthmatic 
samples were then compared to the non-asthmatic samples for each gene, resulting in 
a fold change in expression in the asthma group compared to the non-asthmatic 
group.  
2.8 SECRETED PROTEIN PREPARATION, SDS-POLYACRYLAMIDE 
GEL ELECTROPHORESIS (SDS-PAGE), WESTERN 
IMMUNOBLOTTING AND PROTEOMICS 
2.8.1 Secreted Protein Preparation 
Supernatants from specimen processing were kept at −80°C for secreted 
protein analysis.  
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2.8.2 SDS-PAGE  
SDS-PAGE gels were prepared using a gel casting apparatus (Bio-Rad). The 
SDS-PAGE gels contain a 10% resolving layer combined with a 4% stacking gel 
layer to improve band resolution. Protein samples were mixed 1:2 with a Laemmli 
sample buffer (Bio-Rad) with the addition of 100 mM DTT for reducing conditions. 
The gels were then placed into Tris-glycine buffer (25 mM Tris, 0.2 M glycine, 0.1% 
SDS) and the samples loaded into their appropriate wells. The samples were then 
submitted to electrophoresis at 90 V until they left the stacking gel and then at 120 V 
for 1–2 hr through the 10% resolving gel depending on the size of the protein target. 
With each gel, a dual colour, Precision plus protein standard (Bio-Rad) was included 
to monitor run time and to estimate size of secreted proteins. 
2.8.3 Western Blotting 
Protein samples were resolved by SDS-PAGE and transferred to nitrocellulose 
membranes at 4°C in 25 mM Tris, 40 mM glycine and 10% methanol for 2 hr at 
200 mA. Presence of the pre-stained marker on the nitrocellulose membrane 
confirmed successful transfer. The membranes were then blocked using Licor 
blocking buffer and 1x PBS in a 1:1 mixture with 0.1% Tween-20 for 1 hr at room 
temperature. The blocked membranes were then incubated with Anti-hTFF1 (rabbit), 
Anti-hTFF3 (sheep), Anti-hSCGB3A1 (goat), Anti-hSCGB3A2 (goat) polyclonal 
antibodies or Anti-hSCGB1A1 (mouse) monoclonal antibodies overnight at 4°C in 
blocking buffer and 0.1% Tween-20. The membranes were washed four times for 
5 mins each in PBS-Tween before incubation in either IRDye 800CW donkey anti-
goat or Alexa Fluor® 680 donkey anti-sheep secondary antibodies. Following a 
further four 5 min washes with PBS-Tween and two 5 min washes with PBS only, 
the membrane was analysed by densitometry using the Licor Odyssey infra-red 
scanner using the appropriate channels to visualise the immunoreactive bands. Equal 
concentration of total protein for each sample was standardised by volume. Equal 
loading was compared by coomassie staining SDS-PAGE gels after resolving equal 
concentrations of each sample by electrophoresis, to determine whether the same 
amount of each sample was in fact loaded. 
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2.8.4 Proteomics 
Blue Albumin and IgG Depletion 
Extracellular protein samples were subjected to depletion of albumin and IgG 
to clear the samples of the high molecular weight, high abundance proteins and limit 
the masking effect they may have on the smaller proteins in the samples. The 
depletion was carried out using Proteoprep
®
 Blue Albumin and IgG Depletion kit 
(Sigma-Aldrich) following the manufacturer’s instructions. This kit incorporates a 
spin column method with a packed bead medium bed that specifically binds human 
serum albumin and IgG. Two hundred microlitres of sample was added to the top of 
the packed medium bed and was incubated at room temperature for 10 mins. The 
column was then centrifuged at 12,000xg for 60 secs. The eluate was then re-added 
to the top of the medium bed and incubated for another 5 mins and centrifuged at 
12,000xg for 60 secs. The eluate was retained in the collection tube and 100 µL of 
equilibration buffer was added to the medium bed and then centrifuged at 12,000xg 
for 60 secs. The collected fluid contained the depleted sample. 
Acetone Precipitation of Protein Samples 
Samples were precipitated using acetone to concentrate. Firstly, 10x the sample 
volume of cold acetone (−20°C) were added to each sample. The samples were then 
vortexed to mix and incubated at −20°C overnight. The samples were then 
centrifuged for 20 mins at 15,000xg at 4°C. The supernatant was then disposed, 
followed by a repeat addition of acetone with an incubation of 60 mins at −20°C. 
Again, the sample was centrifuged for 20 mins at 15,000xg at 4°C followed by the 
disposal of the supernatant. The tube was then uncapped and incubated at room 
temperature for 5 mins to dry the pellet. The sample pellets were then redissolved in 
50 µL of 0.5 M triethyl ammonium bicarbonate (TEAB). 
Removal of Mucins Using HiTrap Desalt Column 
The HiTrap desalt column was used to separate digested peptides from the 
mucin proteins in the sample. This works by size, with the mucins eluting first, 
followed by the peptides. Both were collected as fractions off the column, and the 
peptide fractions were pooled for the next step of processing. 
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Reduction and Cysteine Blocking of Protein 
Protein samples were reduced and cysteine blocking was performed using the 
iTRAQ instructions. To each sample, 20 µL of dissolution buffer and 1 µL of 
denaturant were added and vortexed to mix. To each sample tube, 4 µL of reducing 
reagent was added and then vortexed. Samples were incubated for 1 hr at 60°C. To 
each tube, 2 µL of cysteine blocking reagent was added, vortex mixed and incubated 
at room temperature for 10 mins. 
Trypsin Digest of Protein Samples 
Reduced and cysteine blocked protein samples were digested into peptides 
using trypsin, following the iTRAQ protocol. To each sample, 3 µL of trypsin 
solution was added and vortexed to mix. The samples were then incubated at 37°C 
overnight. A second digest was performed by adding a further 1 µL trypsin and 
incubation for 3 hrs at 37°C.  
Labelling of Digest with iTRAQ Reagent – 8-plex 
Treatment 
Samples were labelled with iTRAQ 8-plex reagents using the manufacturer’s 
protocol. Briefly, the iTRAQ labels were reconstituted in 50 µL isopropanol and 
vortexed to mix. Contents of one label reagent were added to one sample and 
vortexed to mix. To adjust the pH of the mix to above 7.5, 5–10 µL of 500 mM 
TEAB was added. The mix was then incubated at room temperature for 1 hr and 
samples were pooled. The pooled samples were cleaned using C18 SepPak cartridges 
with the procedure of activation with 1 mL 100% methanol followed by 1 mL 80% 
acetonitrile (ACN)/0.1% trifluoroacetic acid (TFA), equilibrated with 3 mL of 0.1% 
TFA. The sample was loaded, washed with 3 mL 0.1% TFA and eluted with 0.5 mL 
80% ACN/0.1% TFA. The samples were then dried using a rotary evaporator 
(SpeedyVac) and resuspended in 100 µL formic acid to a final concentration of 
1 µg/µL.  
Analysis 
For each sample, 25 µL was sent to the Institute for Molecular Bioscience at 
the University of Queensland to be run on the QStar Elite for ID-LC-MS-MS on a 
shallow gradient in duplicate. Results were analysed using ProteinPilot for individual 
and duplicate runs. 
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2.9  INTRACELLULAR PROTEIN ANALYSIS 
2.9.1 Nuclear and Cytoplasmic Protein Extraction 
Nuclear and cytoplasmic protein fractions were extracted from airway cells 
using G-Biosciences Nuclear and Cytoplasmic Extraction kit following the 
manufacturer’s protocol (G-Biosciences, Missouri, USA). Briefly, the cell pellet 
from sample processing was resuspended in 500 µL of SubCell Buffer-I and 
incubated on ice for 10 mins. Using a 19-gauge syringe needle, the suspension was 
gently pulled up and down 20 times. To the sample, 250 µL of 3x SubCell Buffer-II 
was added and mixed by inversion. The sample was then centrifuged at 700xg for 
10 mins to pellet the nuclei. The supernatant (cytoplasmic protein) was then 
transferred to a fresh 1.5 mL microcentrifuge tube. To the pellet, 100 µL of Nuclear 
Protein Extraction Buffer-I and 100 µL of Nuclear Protein Extraction Buffer-II were 
added and incubated in ice for 60 mins, mixing the content every 10 mins. The 
sample was then centrifuged at 30,000xg for 30 mins. The supernatant (nuclear 
protein) was then transferred to a fresh 0.5 mL tube and both the cytoplasmic and 
nuclear protein fractions were stored at −80°C. 
2.9.2 Proteomics 
iTRAQ 8-plex 
Treatment 
The nuclear fraction from the nuclear and cytoplasmic protein extraction 
protocol was used for the iTRAQ protocol. The protocol up to and including 
labelling was the same as used for the extracellular protein protocol (Section 2.8.4) 
with the exception that no depletion was performed. Briefly, to improve the 
effectiveness of picking up peptide hits, each sample was first fractionated using a 
Luna SCX column (Phenomenex) and HPLC. Only fractions with detected peaks 
were used. This meant that each 8-plex iTRAQ kit analysed eight pooled samples, 
but these were fractionated, which resulted in a total of 128 samples. The samples 
were dried down and reconstituted in 250 µL of 0.1% TFA and then cleaned using 
C18 SepPak cartridges (Waters) and the same protocol outlined in the extracellular 
proteomics procedure (Section 2.8.4). All the samples were again dried down and 
resuspended in 20 µL 5% formic acid. 
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Analysis 
Each sample was sent to the Institute for Molecular Bioscience to be run on the 
QStar Elite on a normal gradient for ID-LC-MS-MS. All fractions for each kit were 
pooled for analysis using ProteinPilot.   
2.10 STATISTICAL ANALYSIS AND DATA CALCULATION 
2.10.1 Statistical Analysis 
All data analyses were performed using one-way ANOVA to compare across 
each session with the groups and across the groups using Tukey’s post-hoc test 
unless otherwise stated. Statistically significant differences were considered present 
at p<0.05. Correlation analysis was performed to compare gene expression to 
neutrophil count and TFF or SCGB to HAT or HDAC expression across the sessions 
using Pearson’s product moment correlation analysis. All data analyses were 
performed using IBM SPSS statistical program, version 19. 
2.10.2 Data Calculation 
The original project design was to compare SI-1 and SI-2 data sets to assess the 
ability to collect representative baseline samples. Inspection saw large variability 
between the two sessions. The large variability was attributed to the large, 
unobserved break between the two sessions (≥ 1 week). Therefore SI-2 and SI-3 only 
have been compared, given the short time between the sessions (6 hrs), which limited 
the time for external factors to cause inflammation. 
2.10.3 Sample Size Calculation 
Currently, there is no published research, structured in the exact same manner 
as the studies performed in this thesis.  For this reason it was not possible to directly 
calculate the exact sample size for the studies.  A study by Fahy (1995), investigating 
prominent neutrophilic inflammation in the sputum of subjects with asthma 
exacerbation, used 18 acute severe asthma sufferers to measure a significant effect 
size. In terms of repeat sputum induction research, Nightingale et al. (1998), detected 
significant neutrophil increases from a sample size of eight, and Holz (1998), in a 
sample size of ten.  Given the number of participants and results of these 
experiments, an n of 15 was chosen for each of the three participant groups (N-A, A-
BD, A-ST) in this project.  A post hoc power calculation (G*Power version 3 online 
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free software) was performed.  The difference between two dependent means, using 
real-time PCR data collected in this study, using a sample size of 15, resulted in a 
power of 0.86 (86%), which is considered a large effect, and confirms that n=15 is 
appropriate. 
Chapter 3: Results 45 
Chapter 3: Expression of Trefoil Factors, 
Secretoglobins and Histone 
Acetylation in Non-Asthmatic 
Individuals 
3.1 INTRODUCTION 
Airway inflammation is an essential part of the normal workings of the human 
airways. Inflammation occurs regularly in order to fight off insult by bacteria, viruses 
and pollutants. During an inflammatory event in the human airways, varying 
proportions of macrophages, neutrophils, lymphocytes and eosinophils are released. 
It is common in asthmatic airways to have an increase in neutrophils and eosinophils 
during inflammation. In asthmatics this inflammation cannot always be controlled, 
which results in the symptoms of asthma. In non-asthmatics this inflammation 
usually is not a problem; therefore, the difference between an asthmatic and a non-
asthmatic can be put down to the production and control of mediators of 
inflammation. 
This study used sputum induction to collect both airway cells and proteins for 
all analyses. This method was chosen for its low invasiveness and cost effectiveness. 
Sputum induction, however, is not without its shortfalls as sample quality is 
dependent on the amount of effort the participant puts in and the method can be 
dangerous for chronic asthmatics.  This project did not incorporate cell enrichment 
techniques as this was not within the scope of the project.  This effectively made 
associating genetic differences due to one cell type unattainable.  Instead, the sample 
is considered a representative collection of multiple cell types of the airways, and 
changes may be attributed to the stimulus or treatment of the airways as a whole. 
A study by Nightingale et al. (1998) looking at the effect of sputum induction 
on inflammatory cell distribution over time in non-asthmatics showed that eight 
hours post initial sputum induction, neutrophils increased significantly from 22% to 
57%, and further increased in the 24 hr collection (76%). Knowing this effect, this 
study used the process of sputum induction itself to create acute inflammation in the 
airways of participants while also collecting the resultant inflammation.  In this 
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study, a six hour gap between sputum inductions was used to induce and 
subsequently collect airway inflammation. Six hours was a good compromise for the 
majority of participants who maintained full-time jobs as they were able to do an 
early morning session followed by a ‘lunchbreak’ session, resulting in little 
interruption to their jobs. It was also thought that if a 35% increase in neutrophil 
count was seen in eight hours, the inflammatory reaction to the sputum induction 
would have occurred earlier and should be seen at six hours also.  
The levels of TFF, SCGB, HAT and HDAC expression have not been compared 
within non-asthmatics in response to induced acute airway inflammation. Studies 
involving TFFs and SCGBs, HATs and HDACs have compared non-asthmatic levels 
to asthmatic levels. One study has compared the expression of TFF3 in asthmatics 
with and without exercise-induced bronchoconstriction (EIB) and non-asthmatics in 
response to an exercise protocol (Hallstrand et al. 2010). The study found that TFF3 
gene expression was higher in both asthma phenotypes and further increased in the 
EIB-sensitive asthmatics. The Hallstrand et al. results do not reflect the actual change 
of expression in response to inflammation in non-asthmatics as the exercise protocol 
should not affect the airways of that cohort. In the current study, sputum induction 
was used as a mechanical stimulation of inflammation, which was expected to cause 
inflammation in the non-asthmatic cohort. Secretoglobins have previously been 
compared in non-asthmatics and asthmatics. 
3.2 HYPOTHESIS 
This project hypothesised that in non-asthmatic individuals in response to acute 
induced airway inflammation: 
 the expression of TFF1 and TFF3 would be increased, the expression of 
SCGB1A1 and SCGB3A2 would be decreased, the expression of HATs 
would be increased and the expression of HDACs would be decreased; 
 the changes in TFF expression would be positively correlated with 
changes in neutrophil percentage, and that the changes in SCGB 
expression would be negatively correlated with changes in neutrophil 
percentage; 
 the changes in HAT expression would be positively correlated with 
changes in TFF expression and negatively correlated with changes in 
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SCGB expression, and that the changes in HDAC expression would be 
negatively correlated with changes in TFF expression and positively 
correlated with changes in SCGB expression. 
3.3 DESIGN 
This study used a single group, repeated measures design to measure the 
inflammatory response in the N-A group. The study recruited and screened 15 
healthy, non-smoking N-A participants. Each participant undertook three testing 
sessions from which sputum was collected for measurement of gene expression using 
qPCR, differential cell counts to gauge inflammation of each sample, and protein 
expression using immunological and proteomic analysis. Samples from non-
asthmatics were collected to access the gene and protein expression of TFFs, SCGBs, 
HATs and HDACs to compare to the expression of these targets in both A-BD and A-
ST groups. 
3.4 MATERIALS AND METHODS 
Materials and methods used for this chapter are outlined in Chapter 2. 
3.4.1 Participants 
The following table (Table 3.1) outlines the physical characteristics for the N-
A group. Participant health characteristics are outlined in Table 3.2. Participants 
were chosen for their smoking status (non-smoker or ex-smoker for at least one year) 
and asthma status (non-asthmatic). Participants had to be healthy and free of cold and 
flu for a minimum of two weeks prior to testing. Female participants must not have 
been pregnant or breast feeding at the time of participation. 
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Table 3.1.  N-A physical characteristics.   
n Gender Age (yrs) Height (cm) Weight (kg) Predicted FEV1 (L) FEV1(L) 
1 M 20 174 76 4.53 5.19 
2 F 24 159 72 3.25 2.86 
3 M 43 177 65 4.09 3.94 
4 M 26 190 77 5.04 5.92 
5 M 45 172 85 3.83 3.17 
6 F 21 163 55 3.46 3.55 
7 M 31 174 87 4.26 4.92 
8 F 18 156 46 3.3 2.39 
9 F 24 168 57 3.56 3.26 
10 F 21 168 62 3.63 2.51 
11 F 30 164 58 3.28 3.62 
12 F 19 170 62 3.75 2.88 
13 F 18 165 63 3.61 3.5 
14 F 24 158 58 3.21 2.94 
15 M 23 188 88 5.03 4.15 
Avg. M=6 
F=9 
26 170 68 3.86 3.65 
Std Dev.  8.34 9.93 12.75 0.61 1.02 
Data include predicted forced expiratory volume in 1 second (FEV1) based on gender (M=male, F=female), age (years) and height (centimetres), and initial FEV1 
(litres) for each participant (n). Averages (Avg.) and standard deviations (Std Dev.) are shown for all numerical data.  
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Table 3.2  N-A participant health characteristics. 
n Diagnosed 
asthma 
Family 
history 
Allergic 
rhinitis 
Allergies Eczema Medication Other 
medication 
Smoking Other 
medical 
1 no no no  no no no no no 
2 no no no  no no no no no 
3 no no no  no no no no no 
4 no no no  no no no no no 
5 no sister no  no no no no no 
6 no no no  no no no no no 
7 no no no  no no no ex no 
8 no no no  no no no no no 
9 no no no  no no no no no 
10 no father no  no no no no no 
11 no no yes cats no no lexapro ex no 
     pollen      
12 no no no  no no eleva no no 
13 no no yes dogs yes no no no no 
14 no no no  yes no no no no 
15 no no no  no no no no no 
Participants (n) were asked to reveal details of their medical health. Details included whether they had ever been diagnosed with asthma, if they had a family history 
of asthma, whether they suffer from allergic rhinitis and what stimulates their symptoms (allergies). Participants were asked whether they suffer from eczema and 
whether they were taking any unrelated prescription medication. The smoking status of the participants was important with only non-smokers or ex-smokers who 
had quit for a minimum of 1 year selected for the study. Lastly, participants were asked if they had any other medical problems in case they had a condition that 
could affect results or harm the participant. 
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3.5 RESULTS 
3.5.1 Airway Function 
Pulmonary function of the N-A group is shown in Table 3.3. On average in 
each session, the N-A group reached over 90% of their predicted FEV1 and exceeded 
80% FEV1/FVC both pre- and post-salbutamol treatment. Statistical analysis 
comparing FEV1 pre- and post-salbutamol treatment had significant change in SI-2 
and SI-3, but not in SI-1. 
3.5.2 Airway Inflammation 
Differential cell count results for all three sessions for the N-A group are 
shown in Table 3.4. Due to unviable samples, only 14 participants had cell counts for 
all three sessions. Due to this, the same 14 participants were used for all further 
analysis, and therefore the cell count data of the individuals may be compared with 
their corresponding gene expression results (Section 3.4.3). Due to the high 
variability of gene expression between SI-1 and SI-2 samples throughout the project, 
comparisons were not made between these two sessions. All comparisons were made 
between SI-2 and SI-3 collections. 
There were no significant changes in any of the cell types between the three 
sessions. However, the neutrophil count in SI-3 was 21% units above that in SI-2. 
The pattern in the neutrophil data was reversed in the corresponding macrophage 
data. It was noted that there was conserved concentration of macrophages and 
neutrophils in SI-1 and SI-2. Concentrations of lymphocytes and eosinophils did not 
change significantly between the three groups. Squamous epithelial counts were low, 
contributing to fewer than 35% of all non-squamous cells in each session. Individual 
data for the differential leukocyte counts (Figure 3.1) show varying increases in 
neutrophil count in SI-3 from SI-2 in all participants except N-A participants 1 and 6. 
In fact, a t-test performed discounting N-A1 and N-A6 revealed a p-value of 0.01, 
indicating a significant increase in neutrophils in response to the inflammation 
induction procedure. 
 
  
Chapter 3: Results 
 51 
Table 3.3.  Spirometry data for N-A group, representing lung function pre- and post-salbutamol treatment. 
Session FEV1 (L) 
(Pre) 
FVC (L) 
(Pre) 
FEV1/FVC % 
(Pre) 
FEV1  
% 
Pred. 
FEV1 (L) 
(Post) 
FVC (L) 
(Post) 
FEV1/FVC % 
(Post) 
Rev. % 
(FEV1) 
Pre/Post 
FEV1 
sig. (p) 
SI-1 3.57 
(0.9) 
4.26 
(1.1) 
84.2  
(5) 
92.7  
(4) 
3.61  
(0.9) 
4.11  
(1.1) 
88.0  
(6) 
1.1 
 (0.9) 
0.424 
 
SI-2 3.54 
(0.2) 
4.21 
(0.3) 
85.2  
(8) 
91.1  
(3) 
3.66  
(0.2) 
4.22  
(0.2) 
87.4  
(6) 
3.4  
(0.8) 
0.003 
SI-3 3.51 
(0.2) 
4.18  
(0.3) 
84.7  
(7) 
90  
(4) 
3.62  
(0.2) 
4.19  
(0.3) 
87.0  
(6) 
3.1  
(0.9) 
0.013 
          
p  
(SI-1 v SI-2) 
1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.82  
p  
(SI-2 v SI-3) 
1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00  
p  
(SI-1 v SI-3) 
1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.85  
Data are expressed as means ± SEM (in brackets). FEV1 (pre), FVC (pre), FEV1 (post) and FVC (post) represent forced expiratory volume in 1 second and forced 
vital capacity in litres both pre- and post-salbutamol treatment respectively. Rev. corresponds to airway reversibility due to salbutamol use and is measured as the 
difference between FEV1 (pre) and FEV1 (post). Statistical analysis was performed using ANOVA and Tukey’s post-hoc analysis with a p<0.05 accepted as 
significant. 
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Table 3.4.  Cell count data for sputum samples of N-A group. 
 Session TCC (x 10
5
/mL) Mac (%) Lymp (%) Neut (%) Eos (%) *Col Epi (%) *Squam Epi (%) 
SI-1 10.10 (0.7) 51.63 (4.6) 0.91 (0.2) 46.86 (4.7) 0.58 (0.3) 7.9 (1.7) 34 (11.2) 
SI-2 8.40 (1.7) 52.48 (5.4) 0.92 (0.2) 46.12 (5.3) 0.46 (0.1) 11.1 (2.9) 32.4 (4.3) 
SI-3 11.30 (2.2) 34.22 (4.9) 1.05 (0.2) 67.22 (4.9) 0.25 (0.3) 6.6 (1.7) 30.6 (5.7) 
 
p (SI-1 ν SI-2) 0.34 1.00 1.00 1.00 1.00 0.67 0.94 
p (SI-1 ν SI-3) 0.34 0.20 0.99 0.31 1.00 0.72 0.33 
p (SI-2 ν SI-3) 0.99 0.18 0.99 0.27 1.00 0.39 0.39 
Data expressed as means ± SEM. Values represent total cell count x 105/mL (TCC), Macrophages (Mac), Lymphocytes (Lymp), Neutrophils (Neut) and 
Eosinophils (Eos) as a percentage of total leukocytes. Columnar epithelial cells (*Col Epi) and squamous epithelial cells (*Squam Epi) are represented as a 
percentage of all non-squamous cells. 
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Figure 3.1.  Non-asthmatic (N-A) individual leukocyte counts. Data is represented as a percentage of total leukocytes. 
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3.5.3 qRT-PCR of TFFs, SCGBs, HATs and HDACs 
Due to the high variability of gene expression between SI-1 and SI-2 samples, 
comparisons were not made between these two sessions. All comparisons were made between 
SI-2 and SI-3 collections for all the following genes. 
Trefoil Factors (TFF1 and TFF3) 
Gene expression results for TFF1 and TFF3 over the three sputum induction sessions 
are presented in Figure 3.2. There were no significant differences in either TFF1 or TFF3 
between the three sessions.   
Secretoglobins (SCGB1A1 and SCGB3A2) 
Gene expression results for SCGB1A1 and SCGB3A2 over the three sputum induction 
sessions are shown in Figure 3.3.  Results showed no significant changes between SI-2 and 
SI-3 for SCGB1A1 and SCGB3A2. 
Histone Deacetylases (HDAC1-5) 
The mRNA expressions of HDAC1-3 are presented in Figure 3.4 and HDAC4-5 is 
presented in Figure 3.5. HDAC1 expression showed a 5.5-fold decrease from SI-2 to SI-3 
(p=0.03), which is particularly evident in the individual data with five participants showing 
large decreases in SI-3 compared to SI-2 (Figure 3.4 A.1). There were no significant changes 
in response to induced acute airway inflammation (SI-2: SI-3) in HDAC2-5.   
Histone Acetyltransferases (NCOA1-3, HAT1, CREBBP) 
The mRNA expressions of NCOA1-3 are presented in Figure 3.6, and HAT-1 and 
CREBBP are presented in Figure 3.7. There were no significant changes in response to airway 
inflammation in any of the HAT genes analysed. 
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Figure 3.2.  A.1 and B.1 represent the individual non-asthmatic (N-A) participant gene 
expression results for TFF1 and TFF3 respectively over the three sputum induction sessions. 
A.2 and B.2 represent the mean gene expression ± SEM for TFF1 and TFF3 respectively. All 
values are represented as a copy number relative to 18S rRNA gene expression. 
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Figure 3.3.  A.1 and B.1 represent the individual non-asthmatic (N-A) participant gene 
expression results for SCGB1A1 and SCGB3A2 respectively over the three sputum induction 
sessions. A.2 and B.2 represent the mean gene expression ± SEM for SCGB1A1 and 
SCGB3A2 respectively. All values are represented as a copy number relative to 18S rRNA 
gene expression. 
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Figure 3.4.  A.1, B.1 and C.1 represent the individual non-asthmatic (N-A) participant gene expression results for HDAC1, HDAC2 and HDAC3 
respectively over the three sputum induction sessions. A.2, B.2 and C.2 represent the mean gene expression ± SEM for HDAC1, HDAC2 and 
HDAC3 respectively. All values are represented as a copy number relative to 18S rRNA gene expression. *p≤0.05. 
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Figure 3.5.  A.1 and B.1 represent the individual non-asthmatic (N-A) participant 
gene expression results for HDAC4 and HDAC5 respectively over the three sputum 
induction sessions. A.2 and B.2 represent the mean gene expression ± SEM for 
HDAC4 and HDAC5 respectively. All values are represented as a copy number, 
relative to 18S rRNA gene expression. 
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Figure 3.6.  A.1, B.1 and C.1 represent the individual non-asthmatic (N-A) participant gene expression results for NCOA1, NCOA2 and NCOA3 
respectively over the three sputum induction sessions. A.2, B.2 and C.2 represent the mean gene expression ± SEM for NCOA1, NCOA2 and 
NCOA3 respectively. All values are represented as a copy number relative to 18S rRNA gene expression. 
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Figure 3.7.  A.1 and B.1 represent the individual non-asthmatic (N-A) participant 
gene expression results for HAT-1 and CREBBP respectively over the three sputum 
induction sessions. A.2 and B.2 represent the mean gene expression ± SEM for HAT-
1 and CREBBP respectively. All values are represented as a copy number relative to 
18S rRNA gene expression. 
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3.5.4 Correlation Analysis 
Correlation analysis comparing neutrophil concentration (%) to the expression 
of the genes in SI-2 and SI-3 as well as the change in gene expression between SI-2 
and SI-3 is presented in Table 3.5. A significant positive correlation between NCOA2 
gene expression and neutrophil concentration in SI-3 was seen. Comparisons of the 
difference between SI-3 and SI-2 showed a negative correlation between HDAC2 
gene expression and neutrophil concentration. The HAT-1 gene also presented a 
negative correlation with neutrophil concentration. 
To assess any gene expression changes associated with the amount of columnar 
epithelial cells, Pearson correlations were performed (Table 3.6). A negative 
correlation was seen between epithelial cell count and the change in NCOA3 
expression between SI-2 and SI-3. 
Correlations comparing the expression of TFFs and SCGBs to HATs and 
HDACs in the N-A group are presented in Table 3.7. Analysis showed positive 
correlation between SCGB1A1 and HDAC1, HDAC4 and NCOA3 in SI-2, and 
HDAC1 in SI-3. The SCGB3A2 gene expression presented positive correlations with 
HDAC5 in SI-2 and NCOA3 in SI-3. 
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Table 3.5.  Correlations between gene expression and neutrophil conc. (%) in non-
asthmatics (N-A). 
 
SI-2 SI-3 ∆ (SI-3)-(SI-2) 
Gene Pearson Sig. Pearson Sig. Pearson Sig. 
TFF1 -0.087 0.789 0.267 0.336 -0.042 0.892 
TFF3 0.003 0.992 0.421 0.118 -0.042 0.892 
SCGB1A1 0.565 0.056 0.176 0.530 0.511 0.108 
SCGB3A2 -0.237 0.482 0.193 0.491 0.432 0.160 
HDAC1 -0.005 0.987 0.155 0.580 0.373 0.209 
HDAC2 -0.134 0.693 0.005 0.986 -0.577* 0.039 
HDAC3 -0.288 0.390 -0.302 0.273 -0.056 0.855 
HDAC4 0.034 0.920 -0.078 0.783 0.117 0.704 
HDAC5 -0.357 0.282 0.137 0.627 0.066 0.831 
NCOA1 -0.129 0.704 0.485 0.067 0.408 0.187 
NCOA2 0.460 0.154 0.542* 0.037 -0.155 0.613 
NCOA3 -0.020 0.954 0.222 0.426 0.581 0.061 
HAT-1 -0.003 0.992 0.260 0.350 -0.593* 0.042 
CREBBP -0.008 0.980 0.058 0.838 0.030 0.930 
The data represent the correlation between copy numbers of each sample for each gene compared to 
the neutrophil concentration (%) of that sample. Pearson correlation scores with * represent a 
significant relation between the two factors (p<0.05).  
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Table 3.6.  Correlation between NCOA3 and columnar epithelial count (%) in non-
asthmatics (N-A). 
Gene ∆ (SI-3) − (SI-2) 
Pearson Sig. 
NCOA3 -6.57* 0.02 
The data represent the correlation between copy numbers for each sample for each gene compared to 
the columnar epithelial count (%) of that sample. Pearson correlation score with * represents a 
significant relation between the two factors (p<0.05). 
 
Table 3.7.  Correlations between TFF or SCGB expression, and HAT or HDAC 
expression in non-asthmatics (N-A). 
Gene 1 Gene 2 Session Pearson  Sig. (p-value) 
SCGB1A1 HDAC1 SI-2 .688* .019 
  
SI-3 .603* .038 
 
HDAC4 SI-2 .761** .006 
 
NCOA3 SI-2 .839** .001 
SCGB3A2 HDAC5 SI-2 .590* .034 
 
NCOA3 SI-3 .778** .003 
The data represent the correlation between TFF or SCGB expression and HAT or HDAC expression. 
Pearson correlation scores with * represent significance of p<0.05 and **p <0.01. 
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3.5.5 Extracellular Protein Analysis 
Western Blotting of TFF1 and 3, and SCGB1A1 and 3A2 
Due to high variability in SI-1 and SI-2 data, no comparisons were made 
between the two groups. All following data analysed are from SI-2 and SI-3 of the 
N-A group.  The following figures depicting the protein concentrations for TFF1, 
TFF3, SCGB1A1 and SCGB3A2 all have different y-axis scales. 
TFF1 
Densitometry data of western blot analysis of TFF1 protein in the N-A group 
are presented in Figure 3.8. The mean density (OD) for each session was 0.22 (SI-1), 
0.36 (SI-2) and 0.54 (SI-3). No significant changes were seen in association with 
induced acute airway inflammation. However, 9 of the 12 samples interrogated 
displayed varying increases in SI-3 compared to SI-2, with only participants N-A1, 3, 
9 and 13 not displaying an increase. 
TFF3 
Densitometry data of western blot analysis of TFF3 protein in the N-A group 
are presented in Figure 3.9. The mean density for each session was 0.61 (SI-1), 1.33 
(SI-2) and 2.31 (SI-3). No significant changes were seen in association with induced 
acute airway inflammation. However, 10 of the 12 samples interrogated displayed 
varying increases in SI-3 compared to SI-2, with N-A1 and N-A6 being the only 
exceptions.  
SCGB1A1 
Densitometry data of western blot analysis of SCGB1A1 protein in the N-A 
group are presented in Figure 3.10. The mean density for each session was 1.92 (SI-
1), 2.58 (SI-2) and 2.00 (SI-3). No significant changes were seen in association with 
induced acute airway inflammation. However, 9 of the 12 samples displayed varying 
decreases in SI-3 compared to SI-2, with the exception of N-A3, 4 and 9. 
SCGB3A2 
Densitometry data of western blot analysis of SCGB3A2 protein in the N-A 
group are presented in Figure 3.11. The mean density for each session was 0.28 (SI-
1), 0.8 (SI-2) and 1.13 (SI-3). No significant changes were seen in association with 
induced acute airway inflammation. However, 8 of the 11 samples interrogated 
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displayed varying increases in SI-3 compared to SI-2, with decreases only seen in N-
A6, 7 and 11. 
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Figure 3.8.  Expression of TFF1 protein of non-asthmatics (N-A) in all three sessions. Extracellular protein collected from sputum 
samples was quantified using BCA protein assay. Samples were evenly loaded and subjected to SDS-polyacrylamide gel electrophoresis 
and immunoblot analysis for the TFF1 protein. The graph represents the integrated intensity of the band as determined by LICOR 
Odyssey densitometry function. 
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Figure 3.9.  Expression of TFF3 protein for the non-asthmatics (N-A) in all three sessions. Extracellular protein collected from sputum 
samples was quantified using BCA protein assay. Samples were evenly loaded and subjected to SDS-polyacrylamide gel electrophoresis 
and immunoblot analysis for the TFF3 protein. The graph represents the integrated intensity of the band as determined by LICOR 
Odyssey densitometry function. 
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Figure 3.10.  Expression of SCGB1A1 protein for the non-asthmatics (N-A) in all three sessions. Extracellular protein collected from 
sputum samples was quantified using BCA protein assay. Samples were evenly loaded and subjected to SDS-polyacrylamide gel 
electrophoresis and immunoblot analysis for the SCGB1A1 protein. The graph represents the integrated intensity of the band as 
determined by LICOR Odyssey densitometry function. 
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Figure 3.11.  Expression of SCGB3A2 protein for the non-asthmatics (N-A) in all three sessions. Extracellular protein collected from 
sputum samples was quantified using BCA protein assay. Samples were evenly loaded and subjected to SDS-polyacrylamide gel 
electrophoresis and immunoblot analysis for the SCGB3A2 protein. The graph represents the integrated intensity of the band as 
determined by LICOR Odyssey densitometry function 
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3.6 DISCUSSION 
The aim of this study was to identify the expression of TFFs, SCGBs, HATs 
and HDACs in association with induced acute airway inflammation in sputum 
samples from non-asthmatic (N-A) individuals. Differential leukocyte counts saw an 
increase in neutrophil counts in SI-3 compared to SI-2, signifying an acute induction 
of inflammation. The primary result seen in this study was a decrease in HDAC1 
expression in SI-3 compared to SI-2, which did not support the original hypothesis. 
There were no major significant changes in any of the other experimental targets in 
association with induced acute airway inflammation.   
3.6.1 Airway Function 
The airway function of the N-A group was expected to follow normal 
pulmonary function criteria. Important milestones in terms of airway function of 
normal airways include a FEV1/FVC% greater than 80% and an initial FEV1 greater 
than 90% of the predicted FEV1. The N-A group presented mean FEV1/FVC% of 
85.2% in SI-2 and 84.7% in SI-3. Initial FEV1 reached 91.1% in SI-2 and 90% in SI-
3 of the mean predicted values for the N-A group. These results confirmed that the 
participants in the N-A group had no airway function characteristic of asthma or any 
other airway disease.  
The N-A group was expected to show negligible airway reversibility. 
Reversibility measurements in the three testing sessions were 0.4%, 3.4% and 3.3% 
respectively. Statistical analysis showed the difference in FEV1 pre- and post-
salbutamol treatment in SI-2 and SI-3 to be significant (p<0.05). It is possible that a 
learning effect may confound the reversibility data, although the level of airway 
reversibility is low (<4%) and does not portray reversible airway obstruction. The 
entire N-A group had no change in pre-salbutamol FEV1 across the three sessions, 
suggesting that a learning effect is not at fault. A learning effect has been discussed 
in the literature but tends to be excluded due to the effect being minor (Araujo et al. 
2011). The American Thoracic Society (ATS) and European Respiratory Society 
(ERS) agree with the definition of airway reversibility in asthmatics as an increase in 
FEV1 post-bronchodilator treatment of at least 12% from baseline and at least 200 
mL (ATS 1991). The N-A group did not reach this threshold in any of the sessions. 
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The N-A participants in this study are a satisfactory cohort to be used as a 
control group. They surpass FEV1/FVC% (>80%) and % predicted FEV1 (>90%) 
thresholds and have low airway reversibility in response to salbutamol. 
3.6.2 Airway Inflammation 
It was hypothesised that the use of sputum induction would induce airway 
inflammation, allowing the collection of pre- and post-inflammation samples for 
comparison of the targets of experimentation. Comparisons of the leukocyte 
distribution in SI-1 and SI-2 showed little difference, indicating strong repeatability 
of baseline samples in terms of the cellular component. Due to the high variability 
seen in the gene expression of SI-1 and SI-2 samples, no comparisons were made 
between the two collections. Instead comparisons were made between SI-2 and SI-3 
only, as they were same day collections, narrowing the opportunity for external 
stimuli to affect airway inflammation. The goal of the inflammation induction 
procedure was to create a statistically significant increase in neutrophil count in the 
SI-3 collect. Due to insufficient sample from one participant, the N-A cohort 
consisted of 14 participants. Pooled mean data of SI-3 differential cell counts did not 
show a significant change in the distribution of leukocytes when analysing the full 
cohort (Table 3.3). A 21% unit increase in neutrophils in SI-3 compared to SI-2 was 
seen, but it was non-significant (p=0.27). Analysis of the individuals (Figure 3.1) 
showed that N-A1 displayed a decrease in neutrophil count in SI-3 and N-A6 had no 
change in SI-3 compared to SI-2. Out of interest, further analysis of the neutrophil 
counts in SI-2 and SI-3 with participant 1 and 6 excluded displayed a significant 
increase in neutrophil count in SI-3 (p=0.01) with all 12 participants demonstrating 
neutrophilic increase in response to the inflammation induction protocol. 
Total cell counts were conserved between the three testing sessions. The 
present study followed the exclusion criteria for saliva contamination used by other 
studies (van der Vaart et al. 2006). Samples with squamous epithelial cell counts 
>80% of total non-squamous cells were excluded. All samples used fell within this 
threshold. Lymphocyte and eosinophil counts were low and conserved between the 
three sessions. This was as expected and indicated no underlying airway disease. 
Sputum induction is a low invasive measure for obtaining a viable mixed cell 
type, airway sample. The procedure has previously been shown to induce 
inflammation as seen by neutrophilic influx, which is the intended use in this project. 
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A study by Holz et al. (1998) researched the effect of sputum induction on 
inflammatory cell composition of sputum and found marked increases in neutrophil 
numbers (17.4% units, p<0.01) 24 hours post initial sputum induction in healthy, 
non-asthmatic individuals. A corresponding decrease in macrophages was seen, 
while no significant differences were seen in eosinophil or lymphocyte 
concentrations. Another study by Nightingale et al. (1998) showed increased sputum 
neutrophil counts eight hours after the initial induction. There are a multitude of 
sputum induction protocols in existence. For this study, six hours was chosen as the 
time after initial induction to take a second sample. Six hours was expected to be 
long enough to observe neutrophil increase and was chosen for the convenience of 
participants. It was hard to entice participants for this study, so six hours was chosen 
so a participant had the option of an early morning participation followed by a 
lunchbreak participation, or a lunchbreak participation followed by a post-work 
participation. This made the project more participant friendly for full-time workers.  
Comparing the full cohort, no increase in neutrophils was seen in association 
with the inflammation induction protocol. With outliers excluded, a significant 
increase was identified. Considering the Holz and Nightingale studies, six hours 
between collections may not have been long enough to allow sufficient influx of 
inflammatory cells into the airways of all participants. This study has tried to assess 
cellular inflammation, gene expression and protein expression from single 
collections. It is known that all three processes work on different timelines. 
Therefore, it is highly likely that due to waiting for inflammation to be identified by 
a cellular increase in the airways, gene and protein fluctuation may be missed. No 
previous study has compared the expression of the target genes in association with 
induced acute airway inflammation. This study is the first known to use sputum and 
induced inflammation to analyse any changes. 
This study used clinical samples whose quality was directly dependent on the 
effort put in by the participant. Some samples were low in all cells. This made 
counting and all further processing and analysis much more difficult. Sputum 
induction went for a fixed time limit (20 mins) and not every participant was able to 
produce a significant amount of sputum in this time. A better alternative may have 
been to extend the period of time where the participant would exclusively breathe the 
nebulised saline (i.e. 10 min) and then proceed with the normal sputum induction 
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procedure (breathe for 20 min, expectorating sputum every two min). This would 
have given the saline more time to initiate irritation and stimulate secretion, in turn 
producing a more satisfactory sample. Six hours was given between SI-2 and SI-3; 
however, this was not long enough to see a neutrophil influx in all participants. With 
the exclusion of two participants, significant increase in neutrophils in SI-3 
compared to SI-2 was seen. Longer incubation time between the inductions may have 
resulted in higher neutrophil increases, but would have changed the gene and protein 
expression in the samples also. This fact highlights the highly variable nature of the 
clinical sample and shows that the best must be made with what is collected. 
3.6.3 qRT-PCR 
For many of the genes analysed, the SI-1 and SI-2 results were highly variable. 
These samples were meant to be representative of baseline conditions. It was decided 
that there was too much time between SI-1 and SI-2 (1 week), which could allow for 
environmental factors to influence the samples. Environmental factors may include 
any outside stimulators of inflammation including dust, pollution, weather, exercise 
or even any psychological stress the participant may have encountered.  It is also 
most likely that there is just an inherent variability in clinical samples collected on 
different days. Therefore, it was decided that only SI-2 and SI-3 would be analysed 
to reduce the effect of a long interlude between sampling. 
Trefoil Factors (TFF1 and TFF3) 
TFF1 and TFF3 expression was expected to be up-regulated in response to the 
induction of airway inflammation. With all participants included, no significant 
inflammatory increase was seen in the samples. Results indicated that no change 
occurred in either TFF1 or TFF3 expression in SI-3 compared to SI-2 
Trefoil factors are implicated in many airway diseases such as chronic 
obstructive pulmonary disease (COPD), cystic fibrosis, chronic bronchitis and 
asthma (dos Santos Silva et al. 2000). In asthma specifically, TFFs play a major role 
in the restitution process, acting as motogens in the airway epithelium triggering 
rapid repair of the damaged mucosa (Oertel et al. 2001). A study by Hallstrand et al. 
(2010) using gene microarray and qPCR identified the gene expression profile of 
asthmatics with and without exercise-induced bronchoconstriction (EIB), and non-
asthmatics, in association with induced airway inflammation (Hallstrand et al. 2010). 
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The study indicates that trefoil factor gene expression is not impacted by the 
induction of inflammation in non-asthmatics  
 
Secretoglobins (SCGB1A1 and SCGB3A2) 
It was hypothesised that with induced acute airway inflammation in the N-A 
group, an increase in SCGBs would occur in an effort to control the inflammation. 
No significant differences were seen between the three sessions for SCGB1A1 and 
SCGB3A2 in samples from non-asthmatics, which does not follow our initial 
hypothesis. It is possible that the induced acute airway inflammation was not 
significant enough to stimulate an SCGB mediated anti-inflammatory response. 
Most studies exploring the expression of SCGBs in the airways have compared 
their expression in disease state to that of a normal state. It is not known whether 
inflammation in N-A airways causes regulation of SCGB1A1 or SCGB3A2. This 
study endeavoured to answer this by inducing acute inflammation in the airway and 
assessing the resultant changes in mediators involved. Studies have shown that 
SCGBs are regulated by cytokines and therefore are involved in many inflammatory 
diseases of the airways including chronic rhino-sinusitis, bronchitis and asthma 
(Inoue et al. 2008). A study by Lu et al. (2011) looking at the cytokine driven 
regulation of SCGBs in normal human airways showed that SCGB3A2 mRNA 
expression was induced by Th1 cytokines but suppressed by pro-inflammatory Th2 
cytokines. 
When comparing SI-2 and SI-3 results for SCGB1A1 and SCGB3A2, the 
expression levels appeared to be unchanged. Secretoglobins are anti-inflammatory 
genes. Unchanged gene expression may indicate that SCGBs do not play a role in the 
control of the inflammation caused by the sputum induction in this study. It is also 
highly possible that changes have occurred in the gene expression of SCGBs, but 
have been missed due to the six hour lag time between initiation and collection of the 
inflamed sample. 
Histone Deacetylases (HDACs) 
Histone acetylation is a form of epigenetic modification that most likely acts in 
a homeostatic manner unless it causes or plays a role in a disease state. Overabundant 
histone acetyltransferase (HAT) activity generally causes increased gene transcription 
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and is responsible for the increased transcription of genes involved in inflammatory 
activity. The HDACs have the opposing effect, silencing gene expression. This gene 
silencing mechanism occurs through HDACs removing acetyl groups from the N-
terminal tails of histone proteins, which allows tighter packaging on the genome, 
limiting the ability for transcriptional machinery to access and transcribe genes in the 
affected area. In this study, induced inflammation was expected to increase HAT 
gene expression and decrease HDAC expression, contributing to the inflammatory 
process. It was thought that this effect would be minimal in the N-A group because 
the group is much less sensitive to inflammatory stimuli than asthmatics.  
In regard to HDAC expression, the only change identified was a marked 
decrease in HDAC1 expression in SI-3 compared to SI-2. This was as hypothesised, 
but as the HDAC1 protein levels were not known, this result may actually indicate an 
up-regulation of the protein, resulting in a decrease in mRNA abundance. It is 
possible that HDAC1 plays a role in the control of airway inflammation in response 
to inflammatory stimulus. Histone acetylation is well known as at least a partial 
contributor to the symptoms of asthma. Even so, there is little solid data on the gene 
expression of HDACs in asthmatics and non-asthmatics. A study by Ito et al. (2002) 
into the expression of HDACs in asthmatics using bronchial biopsy showed that in a 
non-asthmatic population, there is higher protein expression of HDAC1 and HDAC2, 
but no change in gene expression compared to asthmatics medicating with 
bronchodilators. The Ito et al. (2002) results do provide evidence for the 
aforementioned theory for the decrease in HDAC1 gene in SI-3. To confirm this, the 
HDAC1 protein expression must be identified in the N-A group.  
Histone acetylation activity has been reported by Su et al (2009) in bronchial 
biopsies taken from children with and without asthma. The study found that HDAC 
activity was significantly decreased in the mild and severe asthmatics relative to the 
non-atopic non-asthmatic control group.  The HDAC activity analysis does not 
characterise the activity of the individual HDACs and therefore does not allow the 
detection of which HDACs are actively involved in asthma 
Histone Acetyltransferases (HATs) 
Histone acetyltransferase genes were expected to be up-regulated in the N-A 
group in association with airway inflammation. Histone acetyltransferases bind to 
histones causing the unwinding of DNA, which allows the entrance of transcriptional 
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machinery and increased gene transcription. This process is involved in the increase 
of inflammatory gene transcription. Due to the more robust nature of non-asthmatic 
lungs, it was thought that the reaction would be less apparent than that seen in 
asthmatic airways. In this study, comparisons between SI-2 and SI-3 in the N-A 
group saw no changes in HAT expression. The lack of inflammation caused in the 
procedure may be the key to the lack of differential expression. 
Using bronchial biopsies, there is preliminary data to suggest that there is a 
marked increase in HAT activity in asthmatics compared to non-asthmatics (Ito et al. 
2002). Similar changes were found in a study that used alveolar macrophages 
obtained by broncho-alveolar lavage of asthmatics and non-asthmatics (Cosio et al. 
2004). Su et al (2009) saw HAT activity was significantly increased in bronchial 
biopsy samples taken from children with allergic asthma compared to non-
asthmatics. Although no changes were seen in association with the inflammation 
induction protocol, it is highly possible that differences will be identified when the 
N-A group is compared with the asthmatic groups. 
General 
As described in Section 3.4.2, two N-A participants did not show an increase in 
neutrophil counts in association with the induced sputum, airway inflammation 
protocol. This suggests that these two participants did not respond to the 
inflammation protocol. Participant N-A1 had a 10% units decrease in neutrophils in 
SI-3, concomitant with decreases in TFF1, SCGB1A1, HDAC1, HDAC4, NCOA1, 
NCOA3 and CREBBP gene expression, and increases in TFF3, SCGB3A2, HDAC2, 
HDAC3, HDAC5, NCOA2 and HAT-1 gene expression. Participant N-A6 had no 
change in neutrophil count; however, gene expression decreases were seen in all 
genes analysed with the exception of HDAC4, which had an increase in SI-3 
compared to SI-2. These very different results identified the variability due to 
differential reactions to the inflammation induction protocol, and as a result the 
changes seen in the genes in SI-3 for the participants are possibly random and 
possibly irrelevant to the induction of inflammation in asthma. 
Correlation Analysis 
Pearson’s product moment correlation coefficient was calculated to assess any 
association between inflammatory gene expression (TFFs, SCGBs) and histone 
acetylation gene expression (HDACs and HATs), as well as any association between 
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neutrophil increase and TFF, SCGB, HAT or HDAC expression. To assess whether 
the concentration of columnar epithelial cells in a sample affected the expression of 
TFF, SCGB, HDAC or HAT genes, correlation analysis was performed.  
There was a positive correlation between neutrophil count and gene expression 
for NCOA2 in SI-3, which indicated an increase in NCOA2 gene expression with 
increased neutrophil concentration. This result is due to seven of the participants 
showing increased NCOA2 gene expression and 12 showing increased neutrophil 
concentration. However, not all participants showed increases in both, with N-A1 
showing a neutrophil decrease but an increase in NCOA2, and N-A3, 4, 5, 10, 13 and 
14 showing decreased NCOA2 expression and increased neutrophil concentration. 
This draws attention to a problem with grouping clinical data for correlations, as the 
amount of change shown by certain participants contributed to this result rather than 
the number of participants who demonstrated the change. The correlation between 
the change between SI-3 and SI-2 for both gene and neutrophil count was compared 
to rectify this issue. This resulted in negative correlations between HDAC2 and HAT-
1 when compared to neutrophils. The negative correlation involving HDAC2 is 
interesting as the mean gene expression shows no significant change when 
comparing SI-2 and SI-3 (Figure 3.4 B.2). However, analysis of the individual 
samples showed that 11 of the participants had a decrease in HDAC2 expression 
(Figure 3.4 B.1). The data look to be skewed predominantly by N-A1, who showed a 
decrease in neutrophil concentration. Examination of the individual data for HAT-1 
also revealed that 10 of the participants had a decrease in expression in SI-3 
compared to SI-2, explaining the negative correlation with neutrophil increase. 
Again, the real-time data suggested no significant change in association with the 
inflammation induction protocol, due to the increase seen in N-A1, as well as N-A5, 
9 and 10.  
Correlations were made between gene expression and columnar epithelial cell 
concentration. The concentrations of these cells were quite variable between 
participants and samples. If the cell concentrations had an effect on the gene 
concentrations in the samples, they could contribute to high variability and in turn 
cause us to miss possible significant changes between the testing sessions. 
Correlation analysis revealed a negative correlation between the difference of SI-3 
and SI-2 for NCOA3 and columnar epithelial count. Only five of the participants 
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showed a decrease in NCOA3 expression, and the mean expression was higher in SI-
3 than SI-2. The higher mean was due to N-A7 and N-A11, who had a much higher 
expression than the rest of the SI-3 data.  
The SCGB1A1 gene showed positive correlation with HDAC1 and HDAC4 in 
SI-2, which indicates that with increased SCGB1A1 expression, there was higher 
histone deacetylase activity. This indicates an association between active anti-
inflammatory activity (SCGB1A1) and the silencing of pro-inflammatory genes 
(HDAC activity). The SCGB3A2 gene showed positive correlation with NCOA3 in 
SI-3. Justification for this is difficult; however, no significant change was seen in the 
expression of either gene in SI-3, which suggests that this correlation is of no 
biological relevance. 
3.6.4 Western Blotting of TFFs and SCGBs 
The change in the expression of TFF1 and TFF3, and SCGB1A1 and SCGB3A2 
proteins was assessed using western immunoblot analysis of extracellular protein 
collections of the N-A participant sputum samples. Due to the make-up of the sample 
and the conditions being analysed, no standardised loading control could be chosen 
to assure equal loading of the participant samples. Both ponceau red membrane 
staining and coomassie blue gel staining were performed; assessment of equal 
loading was not possible with the coomassie staining (Appendix C). However, trends 
were noticed when comparing western densitometry data. It must be stressed that due 
to the nature of the induced sputum sample, only finite amounts of protein were 
collected, so western blots could not be performed for all samples, resulting in 
smaller cohorts for some of the western blots. Densitometry results for TFF1 and 
TFF3 showed an increase in SI-3 compared to SI-2 in 9 and 10 participants out of 12 
respectively. SCGB1A1 showed a decrease in 9 of 12 SI-3 samples compared to SI-2, 
and SCGB3A2 showed an increase in 8 of 11 samples. It was hypothesised that in 
association with induced acute airway inflammation, TFF protein expression would 
be up-regulated and SCGB protein expression down-regulated, suggesting that 
inflammation is stimulated by up-regulated TFF1 and TFF3 expression. 
It has previously been shown that sputum induction causes airway 
inflammation (Holz et al. 1998; van der Vaart et al. 2006). This study is the first to 
compare the expression of TFF and SCGB proteins within an N-A group in 
association with induced acute airway inflammation. The western blot data does not 
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provide any statistically significant results.  However, an increase in SI-3 for TFF1 
and TFF3 proteins within the samples was seen. A decreases was seen in SCGB1A1 . 
With regard to SCGB3A2, an increase was seen in the majority of SI-3 samples.. 
Pearson’s product moment correlation comparing the change in gene and protein 
expression in SI-3 and SI-2 showed no statistical correlations. This stresses a very 
prominent point: that the sputum samples collected are only a ‘snapshot’ in time, and 
therefore it is highly possible that the window for observing both gene and protein 
change may have been missed. 
Due to the nature of the secreted protein samples, it was hard to select a 
loading control or indicate equal loading by other methods. Extracellular samples 
contain no cell structure proteins or evenly expressed protein that can be used as a 
loading control, so choosing such a protein was impossible. Coomassie blot was used 
as an alternative to show equal loading (Appendix C). Multiple Bradford 
quantification assays were performed on each sample to assure equal loading. Even 
so, the coomassie blots suggested differential distribution of proteins in each sample. 
There are multiple possible reasons for this. One reason is the differential dilutions 
involved as a consequence of saliva contamination. Each participant and each session 
resulted in varying amounts of saliva contamination in the samples.  To prevent this 
problem, the sputum plug selection method (Pin et al. 1992) could have been used as 
other studies using this method have had more success with cleaner samples with less 
saliva contamination; however, this method also loses a substantial amount of the 
secreted proteins collected, which would raise major problems for the secreted 
protein analysis 
The second possibility for the variability is the differential expression of 
proteins due to the inflammation caused by sputum induction. Sputum induction was 
used to create acute airway inflammation. This inflammation causes a myriad of 
expressional changes and therefore makes the protein concentration profile in the 
coomassie stains appear different. This also highlights the day-to-day variability of 
the samples, with SI-1 and SI-2 samples having different band concentrations, which 
makes comparison of the baseline samples inappropriate.  
The sputum sample is a mixed cell type collection and can be made up of 
varying concentrations of all of the airway cells. The sample represents the secreted 
proteins collected from the airways and hence the protein make-up of each sample 
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can be very different. No enzyme activity blocking was used during the processing or 
storing of the samples. The samples were stored at −80ºC with haste, and freeze–
thaw was kept to an absolute minimum to limit degradation. It is highly possible that 
all of these issues contributed to the varying complexity of the protein constituents in 
each sample. 
In summary, with the exclusion of N-A1 and N-A6, we were able to prove a 
significant neutrophilic influx stimulated by the sputum induction protocol, resulting 
in a significant 21% units increase in neutrophils seen in SI-3 compared to SI-2. A 
marked decrease in HDAC1 expression was found in SI-3 compared to SI-2, which 
was consistent with the initial hypothesis; however, it has previously been shown that 
HDAC1 protein is increased in non-asthmatics and this may mean that the HDAC1 
gene has been used for HDAC1 protein production. Correlation analysis identified an 
interesting positive correlation between NCOA2 gene expression and neutrophil 
concentration in SI-3. This indicates that inflammation may be present in the SI-3 
samples. Positive correlations were seen between TFF3, HAT-1 and CREBBP, and 
SCGB1A1, HDAC1 and HDAC4, indicating that increased inflammation is linked to 
increases in HATs, while competition with anti-inflammatory activity (SCGB1A1, 
HDAC1 and HDAC4) is present in association with increased inflammation. Results 
from this part of the study are to be compared with the A-BD and A-ST groups to 
ascertain the differences in expression not only in association with inflammation, but 
also between disease types. 
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Chapter 4: Expression of Trefoil Factors, 
Secretoglobins and Histone 
Acetylation in Asthmatics 
Medicating with 
Bronchodilators 
4.1 INTRODUCTION 
Asthma is a disease of the lower respiratory tract in which bronchoconstriction, 
airway inflammation and mucus hyper-secretion occur in response to a stimulus. 
Many different types of stimulus can bring on asthma attack including exercise, 
allergens, pollutants and even food. Asthma is primarily treated with corticosteroids 
for moderate to chronic sufferers, but there is a sub-group of mild intermittent 
asthmatics who are usually able to control their symptoms through the use of short-
acting beta-agonists (SABA), such as salbutamol, which are known as bronchodilator 
medication. This medication is not a preventative, but is used during the onset of 
asthma symptoms such as shortness of breath.  
This study used sputum induction to collect both airway cells and proteins for 
all analyses. This method was chosen for its low invasiveness and cost effectiveness. 
Sputum, however, is not without its disadvantages as sample quality is dependent on 
the amount of effort the participant puts in and the method can be dangerous for 
chronic asthmatics. Also, the sample is a representative collection of multiple cell 
types of the airways, making it impossible to attribute molecular differences to one 
cell type only. 
A study by Holz et al. (1998) looking at the effect of sputum induction on 
inflammatory cell composition of sputum showed marked increases in neutrophil 
numbers (14.6% units, p<0.05) 24 hours post initial sputum induction in mild 
bronchial asthmatics. A study by Nightingale et al. (1998) looking at the effect of 
sputum induction on inflammatory cell distribution over time in non-asthmatics 
showed that eight hours post initial sputum induction, neutrophils increased 
significantly from 22% to 57%, and further increased in the 24 hour collection 
(76%). Knowing this effect, this study used the process of sputum induction itself to 
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create acute inflammation in the airways of participants while also collecting the 
resultant inflammation. In this study, a six hour gap between sputum inductions was 
used to induce and subsequently collect airway inflammation. Six hours was a good 
compromise for the majority of participants who maintained full-time jobs as they 
were able to do an early morning session followed by a ‘lunchbreak’ session, 
resulting in little interruption to their jobs. It was also thought that if a 35% increase 
in neutrophil count could be seen in eight hours, the inflammatory reaction to the 
sputum induction would have occurred earlier and should be seen at six hours also.  
The expression levels of TFFs, SCGBs, HDACs and HATs have not previously 
been compared within asthmatics medicating with bronchodilators in association 
with induced acute airway inflammation. One study has compared the expression of 
TFF3 in asthmatics with and without exercise-induced bronchoconstriction (EIB) 
and non-asthmatics in response to an exercise protocol (Hallstrand et al. 2010). The 
study found that TFF3 gene expression was higher in both asthma phenotypes and 
further increased in the EIB-sensitive asthmatics. A study by de Burbure et al. (2007) 
found differential expression in SCGB3A2 protein and a non-significant increase in 
SCGB1A1 protein concentrations in patients with asthma and rhinitis compared to 
normal subjects. The study looked at the induced sputum samples from patients with 
asthma or rhinitis and from non-smoking, non-atopic individuals. However, there 
were issues with the treatment conditions within the asthma group, where 19 of the 
32 were taking inhaled corticosteroids. Corticosteroids are an anti-inflammatory 
treatment for asthma and may affect the expression of genes involved with airway 
inflammation initiation and regulation. This study will compare the change in 
SCGB1A1 and SCGB3A2 in association with induced acute airway inflammation in a 
more conserved asthma group who are only medicating with bronchodilators.  
A study by Cosio et al. (2004) looking at histone acetylation activity in alveolar 
macrophages in asthma found an increase in HAT activity and a decrease in HDAC 
activity in asthmatics compared to non-asthmatics. These results highlight an 
association between airway inflammatory cells and mediators of histone acetylation. 
The present study has compared HAT and HDAC gene expression within the A-BD 
group in association with induced acute airway inflammation. 
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4.2 HYPOTHESIS 
This project hypothesised that in asthmatic individuals medicating with 
bronchodilators in response to acute induced acute airway inflammation: 
 the expression of TFF1 and TFF3 would be increased, the expression of 
SCGB1A1 and SCGB3A2 would be decreased, the expression of HATs 
would be increased and the expression of HDACs would be decreased; 
 the changes in TFF expression would be positively correlated with 
changes in neutrophil percentage, and that the changes in SCGB 
expression would be negatively correlated with changes in neutrophil 
percentage; 
 the changes in HAT expression would be positively correlated with 
changes in TFF expression and negatively correlated with changes in 
SCGB expression, and that the changes in HDAC expression would be 
negatively correlated with changes in TFF expression and positively 
correlated with changes in SCGB expression.  
4.3 DESIGN 
This study used a single group, repeated measures design to measure the 
inflammatory response in bronchodilator-treated asthmatics (A-BD). The study 
recruited and screened 15 healthy, non-smoking asthmatics that were treating their 
symptoms with salbutamol only. All participants were asked to abstain from using 
their salbutamol from the night before the sputum induction, unless needed. Each 
participant undertook three testing sessions (SI-1, SI-2 and SI-3) from which sputum 
was collected for measurement of gene expression using qPCR, differential cell 
counts to gauge inflammation of each sample, and protein expression using 
immunological analysis. Samples were collected to analyse the gene and protein 
expression of TFFs, SCGBs, HATs and HDACs, so as to compare to the expression 
of these targets in both non-asthmatic and asthmatics medicating with 
corticosteroids. 
4.4 MATERIALS AND METHODS 
Materials and methods used for this chapter are outlined in Chapter 2. 
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4.4.1 Participants 
The following table (Table 4.1) outlines the physiology data for the 
bronchodilator asthmatic group. Participant health characteristics are outlined in 
Table 4.2. Participants were chosen for their smoking status (non-smoker or ex-
smoker) and asthma status (A-BD). All asthmatics were treating their asthma with 
ventolin if at all, with the exception of one participant (A-BD9) who used bricanyl, a  
short-acting β2-agonist similar to ventolin. One participant (A-BD10) had previously 
used symbicort, a corticosteroid, to treat their asthma. However, they had not used 
the medication for more than a year. Triggers for the onset of asthma symptoms for 
the participants included allergens, pollutants, weather events and exercise.  
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Table 4.1.  A-BD physical characteristics. 
n Gender Age (yrs) Height (cm) Weight (kg) Predicted FEV1 (L) FEV1 (L) 
1 M 27 176 72 4.44 2.44 
2 M 25 181 81 4.69 4.25 
3 F 23 164 74 3.44 2.83 
4 F 34 173 65 3.45 3.51 
5 M 19 177 65 4.67 3.6 
6 M 23 188 88 5.03 3.95 
7 M 20 183 74 4.9 3.88 
8 M 20 180 109 4.77 3.65 
9 M 22 185 83 4.93 5.24 
10 F 18 167 67 3.67 2.66 
11 F 22 156 53 3.2 3.03 
12 F 23 173 69 3.75 3.8 
13 F 26 171 52 3.61 2.53 
14 M 22 180 73 4.73 4.86 
15 M 18 172 58 4.49 2.44 
Avg. M=9 F=6 22.8 175 72 4.25 3.51 
Std Dev.   4.11 8.47 14.47 0.65 0.86 
Data include predicted forced expiratory volume in 1 second (FEV1) based on gender (M=male, F=female), age (years) and height (centimetres), and initial FEV1 
(litres) for each participant (n). Averages (Avg.) and standard deviations (Std Dev.) are shown for all numerical data.  
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Table 4.2.  A-BD health characteristics. 
n Diagnosed 
asthma 
Visit  
hosp. 
Onset Family  
history 
Allergic 
rhinitis 
Allergies Eczema Medication Other  
medication 
Smoking Other  
medical 
1 yes yes mould both parents yes pollen no ventolin no no   
      pollen     dust           
      animals                 
      weather                 
2 yes yes flu brother yes cats no ventolin proscar no   
3 yes yes exercise mother no   no ventolin no no   
      flu brother       becotide 
(past) 
      
4 yes no sulphur sister no   yes no no no   
      smoke father               
5 yes no exercise sister no   no no no no   
      cold father               
6 yes yes exercise 2 brothers yes cats no ventolin no no   
            dust           
            pollen           
7 yes no cat father yes dust dk ventolin no no   
      dust brother   pets           
      pollen                 
8 yes yes cold no no   no ventolin no no   
      dust                 
9 yes yes dust sister yes pollen yes ventolin no no   
      pollution     grass   bricanyl       
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Table 4.2.  cont. A-BD health characteristics. 
n Asthma Visit  
hosp. 
Onset Family  
history 
Allergic 
 rhinitis 
Allergies Eczema Medication Other  
medication 
Smoking Other  
medical 
10 yes yes exercise no yes dust no ventolin no no  
      weather     grass   symbicort      
                (past)      
11 yes yes exercise sister no    no ventolin no no  
      pollen                
      dust                
12 yes yes allergens no no     No ventolin no no  
      exercise                
13 yes no exercise no  no    no ventolin no no  
      dust                
14 yes no exercise no no   yes ventolin no no  
15 yes no exercise no no   no ventolin doxycyclin no  
Data include the participant number (n), whether the participant has been hospitalised for asthma (visit hosp.), whether they have a family history of asthma, 
whether they have allergic rhinitis and the stimulus for their allergies. The type of asthma medication each participant was on including relevant past medication 
and other non-asthma related medications are included. Participants were asked about their smoking status as well as any other medical conditions.
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4.5 RESULTS 
4.5.1 Airway Function 
Airway function data for the A-BD group are shown in Table 4.3. Participant 
pre-salbutamol FEV1/FVC ratio was less than 80% in all three sessions. Post-
salbutamol treatment saw a rise in FEV1/FVC ratio to over 80%. The initial FEV1 
values fell under 80% of their predicted value in SI-2 and SI-3. Airway reversibility 
results showed increases greater than 7% in all three sessions. Statistical analysis 
showed the difference between pre- and post-salbutamol FEV1 to be highly 
significant in all three sessions (p<0.001).  
4.5.2 Airway Inflammation 
Differential leukocyte counts (DLC) are shown in Table 4.4 and Figure 4.1. 
Comparison of SI-1 and SI-2 counts showed conserved distribution of all leukocytes. 
Neutrophil increase was noticed in SI-3 with a 27% units increase compared to SI-2 
(p=0.04). A corresponding decrease was seen in the macrophage counts of SI-3 with 
a 22% units decrease compared to SI-2. Eosinophil mean counts were higher in SI-2 
than SI-3. It would seem that A-BD7 was suffering from airway eosinophilia in SI-2 
and SI-3. The participant had an SI-2 neutrophil concentration of 24% and an 
eosinophil concentration of 54%. The SI-3 concentrations were 14% neutrophils and 
72% eosinophils. This participant wasn’t omitted from any of the further analysis, 
though the participant’s results were examined for any differences compared to the 
rest of the cohort. The mean eosinophil counts showed a large decrease in SI-3 
compared to SI-2 that was not statistically significant. The high SI-2 eosinophil 
concentration was driven by A-BD1, 7, 10 and 11 displaying high eosinophil counts. 
SI-3 results showed large decreases for A-BD1 and A-BD11, resulting in a low 
average eosinophil count. Squamous epithelial counts were less than 80% of total 
non-squamous cells for all participants, and therefore the samples were deemed 
appropriate for the study 
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Table 4.3.  Spirometry data for A-BD group, representing lung function pre- and post-salbutamol treatment.  
Session FEV1 (L) 
(Pre) 
FVC (L) 
(Pre) 
FEV1/FVC %  
(Pre) 
FEV1 % 
Pred. 
FEV1 (L) 
(Post) 
FVC (L) 
(Post) 
FEV1/FVC % 
(Post) 
Rev. 
(%) 
Pre/Post 
FEV1 
sig. (p) 
SI-1 3.64  
(0.8) 
4.67  
(1.1) 
78.6  
(10) 
81.9  
(6) 
3.95  
(0.9) 
4.89  
(1.2) 
81.1  
(7) 
7.1  
(1.5) 
<0.001 
SI-2 3.61  
(0.9) 
4.83  
(1.1) 
74.8  
(9) 
77.3  
(4) 
3.95  
(1.0) 
4.91  
(1.1) 
80.3  
(7) 
7.2  
(1.7) 
<0.001 
 
SI-3 3.5  
(0.9) 
4.58  
(1.1) 
77  
(8) 
77.7  
(4) 
3.87  
(0.9) 
4.75  
(1.1) 
82.2  
(6) 
9.5  
(2.2) 
<0.001 
          
p 
(SI-1 v SI-2) 
0.99 1.00 0.99 0.98 0.99 0.99 1.00 1.00  
p 
(SI-2 v SI-3) 
1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00  
p 
(SI-1 v SI-3) 
1.00 1.00 1.00 0.99 1.00 0.99 0.99 0.98  
Data are expressed as means ± SEM (in brackets). FEV1 (pre), FVC (pre), FEV1 (post) and FVC (post) represent forced expiratory volume in 1 second and forced 
vital capacity in litres both pre- and post-salbutamol treatment respectively. Rev. corresponds to airway reversibility due to salbutamol use and is measured as the 
difference between FEV1 (pre) and FEV1 (post). Statistical analysis was performed using ANOVA and Tukey’s post-hoc analysis. 
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Table 4.4.  Cell count data of sputum samples from the A-BD group. 
 Session TCC (x 10
5
/mL) Mac (%) Lymp (%) Neut (%) Eos (%) *Col Epi (%) *Squam Epi (%) 
SI-1 10.50 (0.9) 51.06 (4.5) 0.68 (0.2) 41.05 (3.7) 7.19 (7.2) 4.3 (1.4) 29 (9.1) 
SI-2 8.80 (2.1) 47.17 (5.8) 1.75 (0.7) 43.62 (5.3) 7.43 (3.6) 5.5 (1.0) 31 (4.3) 
SI-3 7.80 (3.0) 25 (3.8) 0.38 (0.2) 70.73 (6.0) 0.25 (5.0) 6.3 (1.4) 40.1 (4.8) 
 
p (SI-1 ν SI-2) 0.18 1.00 0.45 1.00 1.00 0.10 0.98 
p (SI-1 ν SI-3) 0.09 0.008 1.00 0.01 1.00 0.43 0.13 
p (SI-2 ν SI-3) 0.92 0.04 0.69 0.04 1.00 0.36 0.09 
Data expressed as means ± SEM. Values represent total cell count x 105/mL (TCC), macrophages (Mac), lymphocytes (Lymp), neutrophils (Neut) and eosinophils 
(Eos) as a percentage of total leukocytes. Columnar epithelial cells (*Col Epi) and squamous epithelial cells (*Squam Epi) are represented as a percentage of all 
non-squamous cells. A p≤0.05 was considered significant. 
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Figure 4.1.  Asthmatics medicating with bronchodilator (A-BD) individual leukocyte counts. Data is represented as a percentage 
of total leukocytes. 
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4.5.3 qRT-PCR of TFFs, SCGBs, HATs and HDACs 
Due to the high variability of gene expression between SI-1 and SI-2 samples, 
comparisons were not made between these two sessions. All comparisons were made 
between SI-2 and SI-3 collections for all the following genes. 
Trefoil Factors (TFF1 and TFF3) 
TFF1 and TFF3 mRNA expression results are presented in Figure 4.2. TFF3 
expression (B.1/B.2) showed a 7.3-fold increase in SI-3 compared to SI-2 (p=0.05). 
This result was due to gene increases in SI-3 for 12 of the 14 participants (Figure 4.2 
B.1). 
Secretoglobins (SCGB1A1 and SCGB3A2) 
Gene expression data of SCGB1A1 and SCGB3A2 are presented in Figure 4.3. 
A 2.8-fold increase in SCGB1A1 in SI-3 compared to SI-2 was seen (p=0.03). The 
mean increase was due to an increase seen in 13 of the A-BD individuals. No change 
was seen with regard to SCGB3A2 expression. 
Histone Deacetylases (HDAC1-5) 
Gene expression data of HDAC1-3 are presented in Figure 4.4, and HDAC4-5 
are presented in Figure 4.5. No changes were seen when comparing SI-2 and SI-3 for 
any of the genes. 
Histone Acetyltransferases (NCOA1-3, HAT-1 and CREBBP)  
Gene expression data of NCOA1-3 are presented in Figure 4.6, and HAT-1 and 
CREBBP in Figure 4.7. No changes were seen when comparing SI-2 and SI-3 for 
any of the genes.  
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Figure 4.2.  A.1 and B.1 represent the individual asthmatic medicating with 
bronchodilators (A-BD) participants’ gene expression results for TFF1 and TFF3 
respectively over the three sputum induction sessions. A.2 and B.2 represent the 
mean gene expression ± SEM for TFF1 and TFF3 respectively. All values are 
represented as a copy number relative to 18S rRNA gene expression. *p≤0.05.
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Figure 4.3.  A.1 and B.1 represent the individual asthmatic medicating with 
bronchodilators (A-BD) participants’ gene expression results for SCGB1A1 and 
SCGB3A2 respectively over the three sputum induction sessions. A.2 and B.2 
represent the mean gene expression ± SEM for SCGB1A1 and SCGB3A2 
respectively. All values are represented as a copy number relative to 18S rRNA gene 
expression. *p≤0.05. 
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Figure 4.4.  A.1, B.1 and C.1 represent the individual participant gene expression results for HDAC1, HDAC2 and HDAC3 respectively over the 
three sputum induction sessions. A.2, B.2 and C.2 represent the mean gene expression ± SEM for HDAC1, HDAC2 and HDAC3 respectively. All 
values are represented as a copy number relative to 18S rRNA gene expression. 
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Figure 4.5.  A.1 and B.1 represent the individual asthmatic medicating with 
bronchodilators (A-BD) participants’ gene expression results for HDAC4 and 
HDAC5 respectively over the three sputum induction sessions. A.2 and B.2 represent 
the mean gene expression ± SEM for HDAC4 and HDAC5 respectively. All values 
are represented as a copy number relative to 18S rRNA gene expression. 
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Figure 4.6.  A.1, B.1 and C.1 represent the individual asthmatic medicating with bronchodilators (A-BD) participants gene expression results for 
NCOA1, NCOA2 and NCOA3 respectively over the three sputum induction sessions. A.2, B.2 and C.2 represent the mean gene expression ± SEM 
for NCOA1, NCOA2 and NCOA3 respectively. All values are represented as a copy number relative to 18S rRNA gene expression
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Figure 4.7.  A.1 and B.1 represent the individual asthmatic medicating with 
bronchodilators (A-BD) participants’ gene expression results for HAT-1 and 
CREBBP respectively over the three sputum induction sessions. A.2 and B.2 
represent the mean gene expression ± SEM for HAT-1 and CREBBP respectively. All 
values are represented as a copy number relative to 18S rRNA gene expression. 
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4.5.4 Correlation Analysis 
Correlations comparing gene expression to neutrophil concentration (%) are 
presented in Table 4.5. Significant negative correlations between gene expression 
and neutrophil concentration were seen in HAT-1 SI-1 and NCOA2 SI-3. 
Gene expression and columnar epithelial cell concentration (%) correlations 
were performed and are shown in Table 4.6. A positive correlation was noted for 
HDAC1 and for HDAC3 when comparing the change in columnar epithelial counts 
and gene expression in SI-2 and SI-3.  
Correlations comparing the expression of TFFs and SCGBs to HATs and 
HDACs in the A-BD group are presented in Table 4.7. Analysis showed a positive 
correlation between TFF1 increase and HDAC2, NCOA2 and NCOA3 in SI-2, and 
HDAC3 in SI-3. Positive correlations were seen between SCGB3A2 and HDAC3, 
NCOA1 and HAT-1 in SI-1, CREBBP in SI-2 and HDAC4 in SI-3. 
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Table 4.5.  Correlations between gene expression and neutrophil conc. (%) for 
asthmatics medicating with bronchodilators (A-BD). 
 SI-2 SI-3 ∆ (SI-3) − (SI-2) 
Gene Pearson  Sig. Pearson  Sig. Pearson  Sig. 
TFF1 0.048 0.876 -0.292 0.311 0.110 0.721 
TFF3 -0.065 0.824 0.295 0.305 0.110 0.721 
SCGB1A1 -0.163 0.577 0.126 0.668 -0.132 0.652 
SCGB3A2 -0.273 0.367 -0.378 0.183 0.406 0.215 
HDAC1 0.120 0.696 0.024 0.934 0.525 0.080 
HDAC2 -0.038 0.903 0.073 0.805 0.110 0.719 
HDAC3 -0.403 0.153 0.117 0.690 0.571 0.052 
HDAC4 0.051 0.862 0.193 0.509 0.009 0.978 
HDAC5 -0.043 0.885 -0.257 0.375 -0.045 0.885 
NCOA1 -0.504 0.066 0.477 0.085 0.185 0.546 
NCOA2 -0.001 0.999 -0.554* 0.040 0.030 0.925 
NCOA3 -0.139 0.651 -0.470 0.090 0.042 0.897 
HAT-1 -0.513 0.073 -0.504 0.066 0.177 0.583 
CREBBP -0.361 0.226 -0.322 0.261 0.411 0.185 
The data represent the correlation between copy numbers of each sample for each gene compared to 
the neutrophil count (%) of that sample. Pearson correlation scores with * represent a significant 
relation between the two factors (p<0.05).  
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Table 4.6.  Correlations between gene expression and columnar epithelial cell conc. 
(%) for asthmatics medicating with bronchodilators (A-BD). 
Gene Session Pearson Sig. (p-value) 
HDAC1 SI-3 0.779** 0.006 
HDAC3 ∆ (SI-3) – (SI-2) -0.604* 0.029 
The data represent the correlation between copy numbers of each sample for each gene compared to 
the columnar epithelial cell count (%) of that sample. Pearson correlation scores with * represent a 
significant relation between the two factors (p<0.05); ** represents p <0.01. 
 
 
Table 4.7.  Correlations between TFF or SCGB expression and HAT or HDAC 
expression for asthmatics medicating with bronchodilators (A-BD). 
Gene 1 Gene 2 Session Pearson Sig. (p-value) 
TFF1 HDAC2 SI-2 0.761** 0.003 
 NCOA2 SI-2 0.925** <0.001 
 NCOA3 SI-2 0.658* 0.015 
 HDAC3 SI-3 0.641* 0.018 
SCGB3A2 CREBBP SI-2 0.946** <0.001 
 HDAC4 SI-3 0.883** <0.001 
The data represent the correlation between TFF or SCGB expression and HAT or HDAC expression. 
Pearson correlation scores with * represent significance of p<0.05 and ** p<0.01. 
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4.5.5 Extracellular Protein Analysis 
Western Blotting of TFF1 and 3, and SCGB1A1 and 3A2 
As in the real-time PCR data, no comparisons were made between SI-1 and SI-
2 or SI-3. High amounts of variability in SI-1 and SI-2 led to the decision to compare 
only SI-2 and SI-3 as they are same day collects and limit the environmental effect 
that one week between collections can have on the airways and hence sputum 
samples. The following figures depicting the protein concentrations for TFF1, TFF3, 
SCGB1A1 and SCGB3A2 all have different y-axis scales. 
TFF1 
Densitometry data of western blot analysis of TFF1 protein in the A-BD group 
are presented in Figure 4.8. The mean density (OD) for each session was 0.37 (SI-1), 
0.41 (SI-2) and 0.44 (SI-3). No significant changes were seen in association with 
induced acute airway inflammation. However, 8 of the 14 samples interrogated 
displayed varying increases in SI-3 compared to SI-2, signifying an increase in 
association with airway inflammation.  
TFF3 
Densitometry data of western blot analysis of TFF3 protein in the A-BD group 
are presented in Figure 4.9. The mean density for each session was 1.45 (SI-1), 0.86 
(SI-2) and 0.97 (SI-3). No significant changes were seen in association with induced 
acute airway inflammation. Individual sample analysis showed that 8 of the 14 
samples interrogated displayed varying increases in SI-3 compared to SI-2, 
signifying an increase in association with airway inflammation. Seven participants 
showed increases in both TFF3 and TFF1 (A-BD3, 5, 7, 8, 10, 12 and 13). 
SCGB1A1 
Densitometry data of western blot analysis of SCGB1A1 protein in the A-BD 
group are presented in Figure 4.10. The mean density for each session was 1.78 (SI-
1), 1.62 (SI-2) and 1.07 (SI-3). No significant changes were seen in association with 
induced acute airway inflammation. However, 11 of the 14 samples interrogated 
displayed varying decreases in SI-3 compared to SI-2, signifying a decrease in 
association with airway inflammation.   
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SCGB3A2 
Densitometry data of western blot analysis of SCGB3A2 protein in the A-BD 
group are presented in Figure 4.11. The mean density for each session was 0.21 (SI-
1), 0.16 (SI-2) and 0.16 (SI-3). No significant changes were seen in association with 
induced acute airway inflammation. However, 8 of the 14 samples interrogated 
displayed varying decreases in SI-3 compared to SI-2, signifying a decrease in 
association with airway inflammation.   
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Figure 4.8.  Expression of TFF1 protein for asthmatics medicating with bronchodilators (A-BD) in all three sessions. Extracellular 
protein collected from sputum samples was quantified using BCA protein assay. Samples were evenly loaded and subjected to SDS-
polyacrylamide gel electrophoresis and immunoblot analysis for the TFF1 protein. The graph represents the integrated intensity of the 
band as determined by LICOR Odyssey densitometry function. 
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Figure 4.9.  Expression of TFF3 protein for asthmatics medicating with bronchodilators (A-BD) in all three sessions. Extracellular 
protein collected from sputum samples was quantified using BCA protein assay. Samples were evenly loaded and subjected to SDS-
polyacrylamide gel electrophoresis and immunoblot analysis for the TFF3 protein. The graph represents the integrated intensity of the 
band as determined by LICOR Odyssey densitometry function. 
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Figure 4.10.  Expression of SCGB1A1 protein for asthmatics medicating with bronchodilators (A-BD) in all three sessions. Extracellular 
protein collected from sputum samples was quantified using BCA protein assay. Samples were evenly loaded and subjected to SDS-
polyacrylamide gel electrophoresis and immunoblot analysis for the SCGB1A1 protein. The graph represents the integrated intensity of 
the band as determined by LICOR Odyssey densitometry function. 
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Figure 4.11.  Expression of SCGB3A2 protein for asthmatics medicating with bronchodilators (A-BD) in all three sessions. Extracellular 
protein collected from sputum samples was quantified using BCA protein assay. Samples were evenly loaded and subjected to SDS-
polyacrylamide gel electrophoresis and immunoblot analysis for the SCGB3A2 protein. The graph represents the integrated intensity of 
the band as determined by LICOR Odyssey densitometry function. 
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4.6 DISCUSSION 
The aim of this study was to measure the expression of TFFs, SCGBs, HATs 
and HDACs in response to induced acute airway inflammation in sputum samples of 
the A-BD group. The significant increase in neutrophils seen in SI-3 compared to SI-
2 clearly indicated that our experimental design induced acute airway inflammation. 
The primary result of this study was that this inflammation was accompanied by an 
increase in TFF3 gene expression, which supports our original hypothesis.  
An increase in SCGB1A1 expression in SI-3 compared to SI-2 was also seen. 
This was not as initially hypothesised but indicates that SCGB1A1 may be implicated 
in the resistance against inflammation. An increase in HDAC4 expression occurred in 
association to inflammation, again indicating some sort of reciprocal anti-
inflammatory effect of induced acute airway inflammation.  
Correlation analysis showed a negative correlation between NCOA2 gene 
expression and neutrophil concentration, a positive correlation between HDAC1 and 
columnar epithelial concentration, and a negative correlation between the change in 
HDAC3 expression and columnar epithelial counts in SI-3 compared to SI-2. Gene to 
gene comparisons had positive correlations between TFF1 and HDAC2, NCOA2 and 
NCOA3 in SI-2, and HDAC3 in SI-3, while SCGB3A2 had positive correlations with 
CREBBP in SI-2 and HDAC4 in SI-3.  
4.6.1 Airway Function 
Using salbutamol, we measured the reversibility of the airways of the A-BD 
group. Airway reversibility for the A-BD group showed an increase of 7.1%, 7.2% 
and 9.5% in SI-1, SI-2 and SI-3 respectively. These values represent significant 
improvements in airway function, which is a prominent clinical feature of asthma.  
Pre-salbutamol treatment FEV1 mean results for all three sessions fell short of 
80% of their predicted values (Table 4.3), which was expected of the asthmatics and 
demonstrated airway obstruction. Post-salbutamol FEV1 means surpassed 80% 
indicating that the airway obstruction was reversible, a characteristic of asthma. 
Paired t-tests comparing pre- and post-bronchodilator FEV1 data for each session 
deemed the increases significant (p<0.001). These results further indicate reversible 
airway obstruction, which is a common feature of mild intermittent asthmatics. 
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There is general consensus between the European Respiratory Society (ERS) 
and the American Thoracic Society (ATS) on the definition of airway reversibility: 
in asthmatics it is an increase in FEV1 post-bronchodilator treatment of at least 12% 
from baseline and at least 200 mL (ATS 1991). This classification is still disputed as 
studies have shown this threshold to be too high, especially in mild intermittent 
asthmatics like those portrayed in this study. Although mean reversibility scores in 
this study did not reach 12%, the results did surpass 200 mL, which qualifies as a 
significant increase in airway function.  
As explained in Chapter 3, spirometry is an effort-based test where the results 
are directly dependent on correct technique. Most asthmatics in this cohort had 
performed spirometry with clinicians before and so had above average technique, 
leading to more accurate results. This also meant that there was less chance of a 
learning effect skewing the data, as the participants had pre-training. Airway function 
of the asthmatics medicating with bronchodilators closely followed the expected lung 
function of a typical asthmatic. All participants demonstrated airway reversibility and 
had sub-normal preliminary FEV1/FVC% (<80%).  
4.6.2 Airway Inflammation 
It was hypothesised that the use of sputum induction would cause airway 
inflammation as evidenced by an increase in neutrophil concentration in the SI-3 
samples compared to the SI-2 samples. A significant neutrophil increase to 70.7% in 
SI-3 from 43.6% (p=0.04) in SI-2 was seen. As expected, a corresponding decrease 
in macrophages was seen in the SI-3 sample. These results signify a significant 
inflammatory process in the A-BD airways in response to sputum induction, which 
was expected. 
Eosinophil counts were higher in SI-2 (7.43%) than SI-3 (0.25%). The majority 
of participants had low eosinophil counts in both SI-2 and SI-3 (Figure 4.1). The 
high SI-2 concentration was driven by A-BD1, 7, 10 and 11. The SI-3 results showed 
a large decrease in A-BD1 and A-BD11 eosinophil counts, which were responsible 
for the drop in the mean. Participant A-BD7 demonstrated significantly high sputum 
eosinophilia, with an SI-2 concentration of 54% and SI-3 concentration of 72%. A 
corresponding decrease in neutrophils in SI-3 was seen. Although A-BD7 did not 
show a neutrophil increase, the participant was not omitted from the study, only 
observed for disparity. 
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Consensus for diagnosing sputum eosinophilia is when eosinophils consist of 
>2% of the total inflammatory cells in a sample. The raw participant data saw seven 
participants in SI-2 and four participants in SI-3 present with sputum eosinophilia 
under this classification. Asthma was classically described by an influx of 
eosinophils to the airways. There is increasing evidence that inflammatory 
mechanisms other than eosinophilic inflammation are involved in the bronchial 
reactivity and reversibility that are characteristic of asthma (Fahy et al. 1995; Wenzel 
et al. 1997; Lamblin et al. 1998; Shaw et al. 2007). Review of the literature showed 
that at most only 50% of asthma cases in studies are attributed to eosinophilic 
inflammation and it is proposed that neutrophilic airway inflammation composes a 
large percentage also (Douwes et al. 2002). Considering the eosinophil counts of the 
A-BD group, the participants reflect the literature, with 13 participants not presenting 
with sputum eosinophilia, instead having neutrophilic increases in association with 
induced acute airway inflammation.  
Neutrophilic influx due to induced acute airway inflammation has previously 
been shown. A study by Nightingale et al. (1998) into airway inflammation after 
controlled exposure to diesel exhaust particles showed a small increase in neutrophil 
concentration in normal volunteers. Studies using ozone to cause an airway 
inflammatory response have also shown neutrophilic influx as a result, especially in 
asthmatics (Nightingale et al. 1999). We have shown that it is possible to cause a 
neutrophil increase with nebulised 3% saline and sputum induction alone. This 
mechanism of inflammation induction is much less invasive on the participants than 
the aforementioned studies’ protocols. 
The increase of neutrophils seen in SI-3 indicates that sputum induction is an 
adequate technique to induce inflammation in the airways of asthmatics. It also 
shows that the inflammatory effect is detectable at least six hours post sputum 
induction. A study by Holz et al. (1998) looking at the effect of sputum induction on 
inflammatory cell composition of sputum showed marked increases in neutrophil 
numbers (14.6% units, p<0.05) 24 hours post initial sputum induction in mild 
bronchial asthmatics. A corresponding decrease in macrophages was seen, while no 
significant differences were seen in eosinophil or lymphocyte concentrations. 
Another study by Nightingale et al. (1998) showed sputum neutrophil counts 
increase as early as eight hours after the initial induction.  
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This study was able to demonstrate the power of sputum induction alone as a 
method of inducing acute airway inflammation in the A-BD group, as displayed by a 
significant increase in neutrophil counts. This allows the comparison of the target 
gene expressions in SI-2 and SI-3 to be associated with induced acute airway 
inflammation.  
4.6.3 qRT-PCR 
For many of the genes analysed, the SI-1 and SI-2 results were highly variable. 
These samples were meant to be baseline representatives. It was decided that there 
was too much time between SI-1 and SI-2 (one week), which allowed environmental 
factors to influence the samples. Environmental factors may include any outside 
stimulators of inflammation including dust, pollution, weather, exercise or even any 
psychological stress the participant may have encountered.  It is also most likely that 
there is just an inherent variability in clinical samples collected on different days. 
Therefore, it was decided that only SI-2 and SI-3 would be analysed to reduce the 
effect of a long interlude between sampling. 
Trefoil Factors (TFF1 and TFF3) 
TFF gene expression was expected to increase due to induced acute airway 
inflammation in the A-BD group, as the TFFs are associated with the up-regulation 
of inflammation. TFF3 demonstrated a mean 7.3-fold increase in SI-3 compared to 
SI-2 (Figure 4.2 B.2), which was due to large increases in 12 of the 15 A-BD 
participants (Figure 4.2 B.1). This confirmed the original hypothesis that TFF3 
expression would increase in association with induced acute airway inflammation. 
It was expected that TFF1 would also exhibit an increase in gene expression in 
association with inflammation. However, no change was seen between SI-2 and SI-3. 
Analysis of the individuals showed an increase in SI-3 for seven participants and a 
decrease for eight participants. Results showed no real tendency for the hypothesised 
increase in the A-BD group.  
A recent study by Hallstrand et al. (2010) showed an increase in TFF3 mRNA 
levels in asthmatics with exercise-induced bronchoconstriction (EIB). Hallstrand 
showed that in response to exercise, EIB-sensitive asthmatics had a marked increase 
in TFF3 expression. The Hallstrand study used sputum induction to collect the 
samples. The study also demonstrated a smaller increase in TFF3 in EIB-insensitive 
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asthmatics. It is possible that this subset of asthmatics displayed an increase due to 
the sputum induction rather than to the exercise protocol. This also raises concerns 
for the EIB-sensitive group as the TFF3 increase may not solely be due to the 
exercise protocol. To our knowledge, the present study is the first time this increase 
in TFF3 mRNA has been demonstrated using sputum induction alone to create the 
inflammation. Sputum induction is a low invasive technique and is less time 
consuming than using exercise procedures to cause inflammation. Only EIB-
sensitive asthmatics would have a reaction to an exercise protocol, and therefore it 
would not be suitable for broader experimentation.  
Secretoglobins (SCGB1A1 and SCGB3A2) 
It was hypothesised that the increase in inflammation in the A-BD group 
airways would result in a decrease in SCGB expression, indicating that SCGB 
expression is retarded in asthmatics, contributing to the inflammation associated with 
the disease. Analysis of the SCGB1A1 gene showed a significant 2.8-fold increase in 
association with induced acute airway inflammation (p=0.03). This result was driven 
by increases in SI-3 in 12 of the 15 A-BD participants and indicates that SCGB1A1 
may be functioning as it should in the airways of asthmatics, increasing production to 
help fight the inflammation. Results of the SCGB3A2 expression saw no significant 
changes in expression in SI-3 compared to SI-2. Individual data showed increases in 
11 participants in SI-3; however, increases were small with the exception of A-BD7 
and A-BD11, and large decreases were seen in A-BD5 and A-BD6, all of which 
contributed to the lack of significant change in association with induced acute airway 
inflammation. 
SCGB1A1 inhibits the chemotaxis of neutrophils and monocytes, and controls 
fibroblast proliferation and migration (Marsh et al. 1994). This indicates that 
SCGB1A1 may play a protective role against the pro-inflammatory response of the 
airway. Asthma is defined by its uncontrolled inflammation, so it is reasonable to 
hypothesise that SCGB1A1 would have decreased expression in the A-BD group in 
association with induced acute inflammation. The increase in SCGB1A1 may be 
working in a manner to resolve the inflammation of the airways.   
Secretoglobin 3A2 is also important as it shares significant sequence similarity 
to SCGB1A1 and exhibits similar characteristics in terms of function (Singh and 
Katyal 1997; Mukherjee and Chilton 2000). Most research into gene expression of 
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SCGBs has been performed in animals. The mRNA levels of SCGB3A2 have been 
shown to be down-regulated in inflamed mouse lungs, and IL-5, an important 
stimulator of inflammation, has been shown to have an inhibitory effect on the 
expression of SCGB3A2 (Niimi et al. 2001; Chiba et al. 2006). The main focus of 
previous SCGB1A1 research has been on gene polymorphisms, which were identified 
in certain asthmatic populations. The gene polymorphism has been linked to possible 
increased risk of developing airway inflammation and asthma. The polymorphism 
(A38G) has been studied in Japanese, Indian and Caucasian populations with little 
significant correlation between the populations or with asthma (Mao et al. 1998; 
Laing et al. 2000; Mansur et al. 2002; Sengler et al. 2003; Sharma and Ghosh 2004). 
This study is not interested in the SCGB1A1 polymorphism, rather the interest lies in 
the possible regulation of the SCGB1A1 and SCGB3A2 genes in association with 
acute airway inflammation.  
There are studies indicating the involvement of SCGB1A1 and 3A2 in immune 
responses that produce anti-inflammatory and immuno-modulatory effects, including 
in airway disease (Wang et al. 2003; Choi et al. 2004). Studies identifying their 
expression in asthmatics have traditionally only compared baseline expression of 
asthmatics and non-asthmatics. This study has attempted to identify a change in the 
SCGBs’ expression in association with acute airway inflammation and found a 
significant increase in SCGB1A1 gene expression. This result indicates that 
SCGB1A1 may play an important anti-inflammatory role in asthma.  
Histone Deacetylases (HDAC1-5) 
Histone deacetylases are known to down-regulate genes involved with 
inflammation. Knowing this, it was hypothesised that in the A-BD group, expression 
of HDACs would decrease in association with induced acute airway inflammation. 
However, no expression differences were identified for any HDAC genes in 
association with induced acute airway inflammation. 
Histone acetylation activity has been reported by Su et al (2009) in bronchial 
biopsies taken from children with and without asthma. The study found that HDAC 
activity was significantly decreased in the mild and severe asthmatics relative to the 
non-atopic non-asthmatic control group.  The HDAC activity analysis does not 
characterise the activity of the individual HDACs and therefore does not allow the 
detection of which HDACs are actively involved in asthma 
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To date, no studies have compared the expression of HDAC genes pre- and 
post-inflammation in asthmatics. A study comparing the baseline expression of 
HDACs showed lower protein expression of HDAC1 and HDAC2 in bronchodilator-
treated asthmatics compared to non-asthmatics, but no change in gene expression (Ito 
et al. 2002). The interesting findings in regards to HDAC gene expression may be in 
across-group comparisons.  
 
Histone Acetyltransferases (NCOA1-3, HAT1 and CREBBP) 
Histone acetyltransferases are known for their role in increasing the expression 
of genes involved in inflammatory pathways. An overabundance of HATs is related 
to inflammatory disease. It was hypothesised that in the A-BD group, HAT 
expression would be up-regulated in association with airway inflammation. No 
significant mRNA changes were seen between SI-2 and SI-3 for any of the HAT 
genes analysed. It was hypothesised that an increase in expression would be seen in 
SI-3, indicating an abundance of HATs and the possibility of histone hyper-
acetylation, which leads to the increased expression of inflammatory genes and in 
turn inflammation.  The results of this study do not support this hypothesis.  
NCOA1 showed a possible increase in expression in SI-3 when compared to SI-
2; however, due to decreases seen in A-BD5, 6, 7, 10 and 14, the mean change was 
not significant. Ten of the participants did exhibit an increase in NCOA1 in 
association with induced acute airway inflammation. All remaining HATs showed 
highly variable expression amongst the individuals over SI-2 and SI-3. This indicates 
that the HATs are not involved with the type of inflammatory process in the A-BD 
group. It cannot be discredited that participants could react to the sputum induction 
differently due to the samples being taken at single time points. It is highly possible 
that samples were collected at varying time points in the inflammatory process, 
causing the high variation between the participants.  
Very few research groups have studied histone acetylation in asthma 
experimentally, but many reviews discuss the possibility of this epigenetic 
modification and its possible role in asthma. Through the use of bronchial biopsy, 
there is preliminary data to suggest that in asthmatics there is a marked increase in 
HAT activity compared to non-asthmatics (Ito et al. 2002). Similar changes were 
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found in a study that used alveolar macrophages obtained by broncho-alveolar lavage 
of asthmatics and non-asthmatics (Cosio et al. 2004). Su et al (2009) saw HAT 
activity was significantly increased in bronchial biopsy samples taken from children 
with allergic asthma compared to non-asthmatics. We believe this is the first study to 
compare pre- and post-airway inflammation gene expression of HATs to analyse the 
possible regulation of these genes in association with airway inflammation. The 
literature suggests that the real interest in HAT and HDAC expression is the role 
corticosteroids may play in the modulation of their expression. 
Correlation Analysis 
Pearson’s product moment correlation coefficient was calculated to assess any 
association between inflammatory gene expression (TFFs and SCGBs) and histone 
acetylation gene expression (HDACs and HATs) (Table 4.7), as well as any 
association between neutrophil increase and TFF, SCGB, HAT or HDAC expression 
(Table 4.5). To assess whether the concentration of columnar epithelial cells in a 
sample affects the expression of TFF, SCGB, HDAC or HAT genes, correlation 
analysis was performed (Table 4.6). 
Comparisons between neutrophil count and gene expression uncovered a 
negative correlation for NCOA2 in SI-3, which indicates a decrease in NCOA2 gene 
expression with increased neutrophil concentration. This result was due to low gene 
expression accompanied by high neutrophil counts in A-BD11 and A-BD14, and 
higher gene expression accompanied by low neutrophil counts in A-BD5 and A-
BD10. Gene to columnar epithelial cell count comparisons had a positive correlation 
with the HDAC1 gene in SI-3 (0.77, p<0.001). This result shows that the amount of 
columnar epithelial cells counted in an A-BD SI-3 sample correlate with the 
expression of HDAC1. Gene expression of HDAC1 in the A-BD group was quite 
variable and no significant change was seen in association with induced acute airway 
inflammation. This may be due to the columnar epithelial cell count correlation with 
HDAC1. The change in columnar epithelial cell count in SI-3 from SI-2 was 
compared to the difference for each gene, finding the HDAC3 gene negatively 
correlated with columnar epithelial cell counts. This was driven by 10 of the 
participants who showed higher columnar epithelial cell counts in SI-3, and 12 of the 
participants who showed a decrease in HDAC3 expression. 
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Comparisons between inflammatory genes and histone acetylation genes 
identified multiple positive correlations. The TFF1 gene was positively correlated 
with HDAC2, NCOA2 and NCOA3 in SI-2, and HDAC3 in SI-3. This result indicates 
that both HAT and HDAC expression are involved with TFF1 expression. This 
demonstrates that histone acetylation is not necessarily a case of ‘all or nothing’, and 
it is more likely a homeostatic process that is over-balanced in certain disease states. 
The SCGB3A2 gene had positive correlations with CREBBP in SI-2 and HDAC4 in 
SI-3. This again shows that both HATs and HDACs are involved. This result suggests 
that in the A-BD group, HDAC4 and SCGB3A2 genes are up-regulated during an 
inflammatory event to combat inflammation. 
4.6.4 Western Blotting of TFFs and SCGBs 
Through the use of western blot analysis, we endeavoured to semi-quantify the 
protein expression of TFFs and SCGBs between the three sessions, within each 
participant in the A-BD group.  Unfortunately, the inability to choose an appropriate 
loading control inhibited the extraction of significant data. Both ponceau red 
membrane staining and coomassie blue gel staining were performed,  but assessment 
of equal loading was not possible with the coomassie staining (Appendix C).  
Trends that reflect our original hypothesis were found. From the A-BD group, 
14 participant samples had sufficient protein for immunoblot analysis. From those 
14, eight showed an increase in TFF1 expression in SI-3 compared to SI-2. Trefoil 
factor 3 had eight samples with an increase in SI-3 compared to SI-2. These samples 
reflected the hypothesised result for TFF expression in association with induced 
acute airway inflammation. These data represent the influx of pro-inflammatory 
TFFs that drive inflammation.  
Results for SCGB1A1 showed 10 samples with a decrease in expression in SI-3 
compared to SI-2, and SCGB3A2 showed a decrease in eight samples. The majority 
of samples reflected the hypothesis of a decrease in SCGBs in association with 
airway inflammation, demonstrating their down-regulation, which resulted in an 
inability to provide anti-inflammatory processes to the inflamed airway. 
This study is the first to our knowledge to compare the protein expression of 
TFFs and SCGBs in association with induced acute airway inflammation in 
asthmatics. It has previously been shown that sputum induction causes airway 
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inflammation (Holz et al. 1998; van der Vaart et al. 2006), and this study is the first 
to take advantage of this to compare the expression of genes and proteins. The 
presence of TFF1 and TFF3 proteins has been previously described in the asthmatic 
airway (Wiede et al. 1999; dos Santos Silva et al. 2000). Secretoglobin expression 
has previously been identified in asthmatics, and SCGB3A2 expression has been 
found to be increased in asthmatics compared to non-asthmatics, while SCGB1A1 did 
not change significantly but was correlated positively with SCGB3A2 expression (de 
Burbure et al. 2007). Our data indicated that a further increase in TFF1 and TFF3 
expression and a decrease in SCGB1A1 expression occur in the event of airway 
inflammation. Pearson’s product moment correlation analysis was performed to 
compare gene to protein expression in SI-2, SI-3 and the difference between the two 
sessions. No significant correlations were noted, stressing a very prominent point that 
the sputum samples collected are only a ‘snapshot’ in time. As gene and protein 
expression occur at different speeds, it is highly possible that the collection time 
wasn’t appropriate to analyse both gene and protein change in response to induced 
acute airway inflammation. 
Due to the nature of the secreted protein samples, it was hard to select a 
loading control or indicate equal loading by other methods. As extracellular samples 
contain no cell structure proteins or evenly expressed protein that can easily be used 
as a loading control, choosing such a protein was impossible. Coomassie and 
ponceau staining were used as alternatives to show equal loading, as well as 
Bradford assays to quantify protein concentration. Unfortunately, the secreted protein 
samples were very difficult to process as each sample contained a variable volume of 
saliva contamination. This changed the protein composition of each sample 
dramatically, which can be seen in the coomassie blots performed for the 
bronchodilator asthmatic samples (Appendix C). Multiple Bradford quantification 
assays were performed on each sample to assure equal loading; therefore, it is 
believed that the differences in the appearance of some bands between the samples in 
the coomassie stain can be attributed to the dilution effect as a consequence of 
variable saliva contamination. To prevent this problem, the sputum plug selection 
method (Pin et al. 1992) could have been used as other studies using this method 
have had more success with cleaner samples with less saliva contamination; 
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however, this method also loses a substantial amount of the secreted proteins 
collected, which would raise major problems for the secreted protein analysis  
Another possibility for the variability we have seen is differential expression of 
proteins due to the sputum induction itself. Sputum induction was used to create 
acute airway inflammation, which causes a myriad of expressional changes and 
therefore makes the protein concentration profile in the coomassie stains look 
different. This also highlights the day-to-day variability of the samples, with SI-1 and 
SI-2 samples having different band concentrations even though they both represent a 
baseline sample. 
In summary, results indicated that sputum induction induces airway 
inflammation with a significant increase in neutrophils in SI-3 compared to SI-2. 
Gene expression data indicated that TFF3 expression was increased in association 
with induced acute airway inflammation. This indicates that TFF3 is directly 
involved with airway inflammation. The western blots showed increases in the TFF 
proteins and decreases in the SCGB proteins in association with airway 
inflammation. This confirmed our hypothesis and indicates uncontrolled 
inflammation in the airways of the A-BD group. Correlation analysis provided an 
insight into the dependence of HATs and HDACs in airway inflammation and 
suggested that histone acetylation is not a clear cut case of all HATs increased and all 
HDACs decreased in an inflammatory condition. It is probable that not all the HATs 
and HDACs chosen play a role in asthma or control/exacerbation of inflammation. 
To get a better idea of the differences of expression in the A-BD group, comparisons 
must be made with other cohorts. The following chapter describes the same 
experimentation performed in this chapter for asthmatics medicating with 
corticosteroids (A-ST). 
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Chapter 5: Expression of TFFs, SCGBs, 
HATs and HDACs in Asthmatics 
Medicating with Corticosteroids  
5.1 INTRODUCTION 
Asthma is a disease of the lower respiratory tract in which bronchoconstriction, 
airway inflammation and mucus hyper-secretion occur in response to a stimulus. The 
majority of moderate to severe asthma sufferers treat their disease with inhaled 
corticosteroids. Doctors presently prescribe these medications to mild asthmatics 
also. The class of corticosteroids used for asthma are termed glucocorticoids, which 
are known for their anti-inflammatory effect in the airways. They are the most 
effective anti-inflammatory drug used in the treatment of asthma. Their effectiveness 
since their introduction in 2000 is shown by the decrease in emergency department 
visits in Australia due to asthma from 41,000 in 2001–2 to 37,461 in 2004–5 and the 
reduction in the use of bronchodilator medication (Australian Institute of Health and 
Welfare 2003; Australian Bureau of Statistics 2006).  
Corticosteroids are administered as an inhaled medication when needed. 
Although corticosteroids are well known in the treatment of asthma, the molecular 
mechanisms of their effect are not well understood. Corticosteroids are known to 
bind to a specific glucocorticoid receptor (GR) that is predominantly localised in the 
cytoplasm of airway macrophages, neutrophils, lymphocytes, eosinophils and 
epithelial cells (Adcock et al. 1996). Upon activation, the GR translocates to the 
nucleus and, through unknown mechanisms, either increases (transactivates) or 
decreases (transrepresses) gene expression (Barnes & Adcock. 2003). The GRs are 
expressed in almost every cell type, including human lung where there is a high level 
of expression in airway epithelium and the endothelium of bronchial vessels (Adcock 
et al. 1996).  
The major action of corticosteroids is thought to be the inhibition of pro-
inflammatory transcription factors such as activator protein (AP)-1, signal 
transducers and activators of transcription (STATs), nuclear factor of activated T-
cells (NFAT) and nuclear factor-kappa β (NF-κB) (Barnes & Adcock. 1998). It is 
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also thought that corticosteroids can switch on the expression of anti-inflammatory 
genes, such as lipocortin-1 (Karin 1998). All of the aforementioned transcription 
factors are known to be involved in airway inflammation, and corticosteroids control 
their function directly or indirectly, hence controlling inflammation.  
Knowing the effect corticosteroids can have on airway inflammation, it is of 
great interest to assess the expression of TFFs, SCGBs, HATs and HDACs in 
response to induced acute airway inflammation in asthmatics medicating with 
corticosteroids. A de Burbure et al. (2007) study found differential expression in 
SCGB3A2 protein and a non-significant SCGB1A1 increase which correlated 
positively with SCGB3A2, in patients with asthma compared to normal subjects. In 
the study, 19 of the 32 asthmatic participants medicated with inhaled corticosteroids. 
The differences in medication of the group may have had a critical effect on the 
results. In this study, all participants were medicated with inhaled corticosteroids. A 
study by Cosio et al. (2004) found an increase in HDAC activity in prednisone-
treated mild asthmatics. The current study focused on the gene expression of HATs 
and HDACs in association with induced acute airway inflammation in asthmatics 
medicating with inhaled corticosteroids, not a potent oral corticosteroid. 
5.2 HYPOTHESIS 
This project hypothesised that in asthmatic individuals medicating with 
corticosteroids in response to acute induced airway inflammation: 
6. the expression of TFF1 and TFF3 would be increased, the expression of 
SCGB1A1 and SCGB3A2 would be decreased, the expression of HATs 
would be increased and the expression of HDACs would be decreased; 
7. the changes in TFF expression would be positively correlated with 
changes in neutrophil numbers percentage, and that the changes in SCGB 
expression would be negatively correlated with changes in neutrophil 
percentage; 
8. the changes in HAT expression would be positively correlated with 
changes in TFF expression, and negatively correlated with changes in 
SCGB expression, and that the changes in HDAC expression would be 
negatively correlated with changes in TFF expression, and positively 
correlated with changes in SCGB expression. 
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5.3 DESIGN 
This study used a single group, repeated measures design to measure the 
inflammatory response in asthmatics medicating with corticosteroids (A-ST). The 
study recruited and screened 15 healthy, non-smoking asthmatics that were treating 
their symptoms regularly with corticosteroid medications. Each participant undertook 
three testing sessions from which sputum was collected for measurement of gene 
expression using qPCR, differential cell counts to gauge inflammation of each 
sample, and protein expression using immunological analysis. The samples from the 
A-ST group were collected to analyse the gene and protein expression of TFFs and 
SCGBs, and HAT and HDAC gene expression so as to later compare to the 
expression of these targets in both N-A and A-BD groups. 
5.4 MATERIALS AND METHODS 
Materials and methods used for this chapter are outlined in Chapter 2. 
5.4.1 Participants 
Table 5.1 outlines the physical characteristics of the corticosteroid asthmatic 
group. The health characteristics of the A-ST group are outlined in Table 5.2. 
Participants were chosen for their smoking status (non- or ex-smoker) and treatment 
of asthma (A-ST). All asthmatics were currently treating their asthma with inhaled 
corticosteroids including seretide, pulmicort, symbicort and flixotide. Some 
participants still used bronchodilator medication for symptom relief throughout the 
day. Participant A-ST8 had suffered a pneumothorax nine months before testing, but 
was considered healthy and able to participate. 
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Table 5.1  A-ST physical characteristics.  
n Gender Age (yrs) Height (cm) Weight (kg) Predicted FEV1 (L) FEV1 (L) 
1 F 41 161 60 2.88 3.13 
2 F 39 172 59 3.31 2.94 
3 M 23 175 64 4.49 4.45 
4 F 24 160 52 3.28 2.78 
5 M 19 179 69 4.76 3.82 
6 M 40 161 72 3.50 3.17 
7 F 30 163 52 3.23 3.16 
8 M 18 186 62 5.07 4.41 
9 M 21 187 83 5.04 5.68 
10 F 24 174 59 3.76 3.79 
11 M 20 184 77 4.94 4.57 
12 F 20 162 58 3.45 2.56 
13 F 25 163 60 3.36 3.24 
14 M 23 188 69.4 5.03 3.97 
15 F 37 162 96 3.02 1.91 
Avg. M=7  F=8 26.93 171.80 66.16 3.94 3.57 
Std Dev.  8.24 10.79 11.99 0.83 0.95 
Data include predicted forced expiratory volume in 1 second (FEV1) based on gender (M=male, F=female), age (years) and height (centimetres), and initial FEV1 
(litres) for each participant (n). Averages (Avg.) and standard deviations (Std Dev.) are shown for all numerical data.  
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Table 5.2.  A-ST health characteristics. 
n Diagnosed 
asthma 
Visit 
hosp 
Onset Family 
history 
Allergic 
rhinitis 
Allergies Eczema Medication Other 
medication 
Smoking Other 
medical 
1 yes yes cold brother yes dust no pulmicort  
3x 180 µg/day 
claratyne no   
        mother   pollen   ventolin        
        daughter               
2 yes no night brother yes cat no current levelin no   
      exercise     dust mite   symbicort       
            pollen   ventolin       
            grass   past       
                seretide       
                intal       
3 yes yes allergens mother no eggs no seretide  
1x 250 µg/day 
no no   
      cold air sister   cats           
      dust                 
4 yes yes flu sister no no no seretide  
1x 250µg/day 
no no   
      seasons         atrovent  
2 x 22 µg/day 
      
5 yes yes flu no dk dairy   ventolin  no no   
      allergies     nuts   flixotide  
2x 1000µg/day 
      
      humidity                 
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Table 5.2 cont. A-ST health characteristics. 
n Diagnosed 
asthma 
Visit 
hosp 
Onset Family 
history 
Allergic 
rhinitis 
Allergies Eczema Medication Other 
medication 
Smoking Other 
medical 
6 yes no pollen no yes spring yes current tacrolimus  
ointment 
stopped 2002   
      flu     cat   symbicort  
2 x 84.5µg/day 
      
      pollution     dogs   bricanyl        
      cat     allergens   past       
      dog         ventolin       
      night         pulmicort       
                prednisone  
18 mnth before 
      
                intral       
7 yes yes weather mother yes dust no current phenergin no   
      exercise     pollen   seretide  
1x 250µg/day 
      
      food         ventolin  
2 x 100µg/day 
      
                past       
                becotide  
2 x 100µg/day 
      
                prednisone 2004       
8 yes yes weather no no season no seretide  
lx 250µg/day 
roaccutane no pneumothorax 
 9 months earlier 
      exercise         ventolin       
      flu                 
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Table 5.2 cont. A-ST health characteristics. 
n Diagnosed 
asthma 
Visit 
hosp 
Onset Family 
history 
Allergic 
rhinitis 
Allergies Eczema Medication Other 
medication 
Smoking Other 
medical 
9 yes yes stress no yes winter no current no no   
      dust     spring   symbicort  
2 x 84.5µg/day 
      
      cold         past       
      exercise         bricanyl       
                predinosolone 25 µg       
10 yes yes pollen 3 brothers yes animal hair no current levlen no   
      dust sister   pollens   seretide  
2x 250µg/day 
      
      smoke grandmother  
(mat) 
      ventolin        
      cats  uncle  
(pat) 
      past       
      dogs grandmother  
(pat) 
      bricanyl       
      horses         intal       
      exercise         singulair       
      cold         pulmicort       
                flixotide  
2 x 1000µg/day 
      
                serevent       
                prednisone       
11 yes no exercise no yes nuts no flixotide 
2 x 1000µg/day 
no no   
                ventolin       
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Table 5.2 cont. A-ST health characteristics. 
n Diagnosed 
asthma 
Visit 
hosp 
Onset Family 
history 
Allergic 
rhinitis 
Allergies Eczema Medication Other 
medication 
Smoking Other 
medical 
12 yes yes exercise no yes dust dk symbicort levlen no   
      pollen     pollen   ventolin       
      dust     dog           
      flu     cat           
      cold                 
13 yes yes exercise brother no   dk symbicort  
1x 84.5µg/day 
no no   
                ventolin as needed       
14 yes no night no no   no current no ex-1yr ago   
      dust         symbicort  
2 x 84.5µg/day 
      
                ventolin        
                past       
                seretide       
15 yes yes season sister no   no ventolin  no no   
      aircon. daughter       alvesco  
2x 80 µg/week 
      
        cousins       flixotide  
1 x 1000µg/day 
      
        great aunt               
Data include the participant number (n), whether the participant has been hospitalised for asthma (visit hosp.), whether they have a family history of asthma, 
whether they have allergic rhinitis and the stimulus for their allergies. The type of asthma medication each participant was on including relevant past medication 
and other non-asthma related medications are included. Participants were asked about their smoking status as well as any other medical conditions. 
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5.5 RESULTS 
5.5.1 Airway Function 
Airway function data for asthmatics medicating with corticosteroids (A-ST) are 
presented in Table 5.3. Initial FEV1 fell short of 90% of the predicted in all three 
sessions. Pre-salbutamol treatment, the FEV1/FVC% was sub-80% in all three 
sessions, and rose to above 80% post-salbutamol treatment. Mean reversibility was 
greater than 5% in each session. Statistical analysis of pre- and post-salbutamol FEV1 
confirmed statistical significance. 
5.5.2 Airway Inflammation 
Differential leukocyte counts are presented in Table 5.4. A neutrophil increase 
of 29% units was seen in SI-3 compared to SI-2. A corresponding decrease in 
macrophages was seen. No other significant differences in cell distribution were 
noted.   
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Table 5.3.  Spirometry data for A-ST group, representing lung function pre- and post-salbutamol treatment.   
Session FEV1 (L)  
(Pre) 
 
FVC (L) 
(Pre) 
 
FEV1/FVC % 
(Pre) 
FEV1 
% Pred.  
FEV1 (L) 
(Post) 
 
FVC (L) 
(Post) 
 
FEV1/FVC %  
(Post) 
Rev. 
(%) 
Pre/Post 
FEV1 
sig. (p) 
SI-1 3.3  
(0.8) 
4.2  
(0.9) 
77.7  
(2) 
84.8  
(3) 
3.4  
(0.7) 
4.2  
(0.7) 
80.7  
(2) 
5.4  
(2.3) 
0.049 
SI-2 3.4  
(0.9) 
4.3 
(1.0) 
78.8  
(2) 
86.4  
(3) 
3.6  
(0.9) 
4.3 
 (0.9) 
83.3  
(2) 
6.4 
(1.5) 
0.001 
SI-3 3.4  
(0.9) 
4.2  
(1.0) 
79.5  
(2) 
89.5  
(3) 
3.6  
(0.9) 
4.2 
 (0.9) 
83.8  
(2) 
5.0  
(1.4) 
0.002 
          
p 
(SI-1 v SI-2) 
1.00 1.00 1.00 1.00 1.00 1.00 0.98 1.00  
p 
(SI-2 v SI-3) 
1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00  
p 
(SI-1 v SI-3) 
1.00 1.00 1.00 1.00 1.00 1.00 0.96 1.00  
Data are expressed as means ± SEM (in brackets). FEV1 (pre), FVC (pre), FEV1 (post) and FVC (post) represent forced expiratory volume in 1 second and forced 
vital capacity in litres both pre- and post-salbutamol treatment respectively. Rev. corresponds to airway reversibility due to salbutamol use and is measured as the 
difference between FEV1 (pre) and FEV1 (post). Statistical analysis was performed using ANOVA and Tukey’s post-hoc analysis. 
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Table 5.4.  Cell count data for sputum samples of A-ST group. 
Data expressed as means ± SEM. Values represent total cell count x 105/mL (TCC), and macrophages (Mac), lymphocytes (Lymp), neutrophils (Neut) and 
eosinophils (Eos) as a percentage of total leukocytes. Columnar epithelial cells (*Col Epi) and squamous epithelial cells (*Squam Epi) are represented as a 
percentage of all non-squamous cells. A  p≤0.05 was considered significant. 
 
  
TCC (x 10
5
/mL) Mac (%) Lymp (%) Neut (%) Eos (%) *Col Epi *Squam Epi 
SI-1 8.90 (1.8) 31.4 (5.1) 0.3 (0.1) 64.4 (5.2) 3.7 (1.1) 4.9 (1.2) 38 (5.2) 
SI-2 13.40 (2.6) 38.9 (5.1) 1.1 (0.3) 56.3 (5.9) 3.5 (1.3) 5.3 (1.6) 44.8 (6.0) 
SI-3 12.10 (6.2) 19.1 (4.3) 0.6 (0.2) 85.5 (4.6) 0.7 (0.6) 3.5 (1.7) 28.6 (6.3) 
 
p (SI-1 ν SI-2) 0.47 0.97 0.68 0.96 1.00 0.67 0.39 
p (SI-1 ν SI-3) 0.42 0.44 1.00 0.33 1.00 0.40 0.18 
p (SI-2 ν SI-3) 0.88 0.03 0.81 0.01 1.00 0.93 0.07 
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Figure 5.1.  Asthmatics medicating with corticosteroid (A-ST) individual leukocyte counts. Data is represented as a percentage of total 
leukocytes.
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5.5.3 qRT-PCR of TFFs, SCGBs, HATs and HDACs 
Trefoil Factors (TFF1 and TFF3) 
The gene expression over three sessions for TFF1 and TFF3 are presented in 
Figure 5.2. No significant differences were noted in association with airway 
inflammation in either gene. Participant A-ST8 was responsible for the higher TFF3 
SI-2 expression, with the rest of the participants showing relatively similar 
expression between SI-2 and SI-3 (Figure 5.2 B.1). 
Secretoglobins (SCGB1A1 and SCGB3A2) 
The gene expression data of SCGB1A1 and SCGB3A2 are presented in Figure 
5.3. No significant expressional differences were detected between SI-2 and SI-3, 
with a lot of variability noticed in both genes. 
Histone Deacetylases (HDAC1-5) 
The expression data of the HDAC genes are presented in Figure 5.4 and Figure 
5.5. Histone deacetylase 2 expression showed a significant 7.6-fold decrease 
(p=0.001) in SI-3 compared to SI-2 (Figure 5.4 B.2). Out of the total 15 A-ST 
participants, 11 showed decreases in SI-3 compared to SI-2 (Figure 5.4 B.1). 
Histone Acetyltransferases (NCOA1-3, HAT-1 and CREBBP) 
The gene expression data of the HATs are presented in Figure 5.6 and Figure 
5.7. No significant changes in expression were noted in association with airway 
inflammation. 
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Figure 5.2.  A.1 and B.1 represent the individual asthmatic medicating with corticosteroids 
(A-ST) participant gene expression results for TFF1 and TFF3 respectively over the three 
sputum induction sessions. A.2 and B.2 represent the mean gene expression ± SEM for TFF1 
and TFF3 respectively. All values are represented as a copy number relative to 18S rRNA 
gene expression. 
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Figure 5.3.  A.1 and B.1 represent the individual asthmatic medicating with corticosteroids 
(A-ST) participant gene expression results for SCGB1A1 and SCGB3A2 respectively over the 
three sputum induction sessions. A.2 and B.2 represent the mean gene expression ± SEM for 
SCGB1A1 and SCGB3A2 respectively. All values are represented as a copy number relative to 
18S rRNA gene expression. 
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Figure 5.4.  A.1, B.1 and C.1 represent the individual asthmatic medicating with corticosteroids (A-ST) participant gene expression results for 
HDAC1, HDAC2 and HDAC3 respectively over the three sputum induction sessions. A.2, B.2 and C.2 represent the mean gene expression ±SEM 
for HDAC1, HDAC2 and HDAC3 respectively. All values are represented as a copy number relative to 18S rRNA gene expression. *p≤0.05.
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Figure 5.5.  A.1 and B.1 represent the individual asthmatic medicating with 
corticosteroids (A-ST) participant gene expression results for HDAC4 and HDAC5 
respectively over the three sputum induction sessions. A.2 and B.2 represent the 
mean gene expression ± SEM for HDAC4 and HDAC5 respectively. All values are 
represented as a copy number relative to 18S rRNA gene expression.
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Figure 5.6.  A.1, B.1 and C.1 represent the individual asthmatic medicating with corticosteroids (A-ST) participant gene expression results for 
NCOA1, NCOA2 and NCOA3 respectively over the three sputum induction sessions. A.2, B.2 and C.2 represent the mean gene expression ± SEM 
for NCOA1, NCOA2 and NCOA3 respectively. All values are represented as a copy number relative to 18S rRNA gene expression. 
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Figure 5.7.  A.1 and B.1 represent the individual asthmatic medicating with 
corticosteroids (A-ST) participant gene expression results for HAT-1 and CREBBP 
respectively over the three sputum induction sessions. A.2 and B.2 represent the 
mean gene expression ± SEM for HAT-1 and CREBBP respectively. All values are 
represented as a copy number relative to 18S rRNA gene expression. 
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5.5.4 Correlation of Gene Expression and Inflammation 
Correlations comparing gene expression to neutrophil concentration (%) are 
presented in Table 5.5. A significant negative correlation was seen between gene 
expression and neutrophil concentration in HDAC3 SI-3 and NCOA2 SI-3. A 
significant positive correlation was seen in the difference between SI-3 and SI-2 for 
HDAC4. 
Analysis of the correlations between gene expression and columnar epithelial 
cell concentration is presented in Table 4.6. Positive correlations were noted for 
HDAC1 in SI-3 and NCOA2 for SI-2 and SI-3. 
Correlations comparing the expression of TFFs and SCGBs to HATs and 
HDACs in the A-ST group are presented in Table 5.6. Analysis showed positive 
correlations between TFF1 increase and HDAC4 and NCOA3 in SI-1, HDAC5, 
NCOA2 and NCOA3 in SI-2, and NCOA3 in SI-3. Trefoil factor 3 showed positive 
correlations with NCOA1 in SI-1, HDAC3 and HDAC5 in SI-2, and HDAC3 and 
CREBBP in SI-3. Positive correlations were seen between SCGB1A1 and NCOA1 in 
SI-1, and HDAC3, HDAC5 and CREBBP in SI-2. Secretoglobin 3A2 showed 
positive correlations with HDAC1 in SI-1 and NCOA3 in SI-3. 
  
Chapter 5: Results 139 
Table 5.5.  Correlations between gene expression and neutrophil conc. (%) in 
asthmatics medicating with corticosteroids (A-ST). 
 SI-2 SI-3 ∆ (SI-3) − (SI-2) 
Gene Pearson  Sig.                     Pearson  Sig.                     Pearson  Sig.                     
TFF1 0.200 0.474 0.091 0.767 0.286 0.344 
TFF3 -0.397 0.179 0.188 0.540 0.286 0.344 
SCGB1A1 -0.543 0.055 0.197 0.519 -0.245 0.442 
SCGB3A2 -0.044 0.886 0.233 0.444 -0.193 0.527 
HDAC1 -0.033 0.914 -0.428 0.144 -0.081 0.791 
HDAC2 -0.048 0.877 -0.223 0.464 0.085 0.793 
HDAC3 -0.563* 0.045 0.305 0.311 0.217 0.498 
HDAC4 0.035 0.910 0.188 0.558 0.614* 0.044 
HDAC5 0.069 0.816 0.391 0.187 -0.144 0.654 
NCOA1 -0.025 0.935 0.375 0.206 0.109 0.736 
NCOA2 -0.009 0.977 -0.573* 0.041 0.447 0.145 
NCOA3 0.032 0.918 0.158 0.606 0.026 0.937 
HAT-1 -0.440 0.133 0.286 0.344 -0.384 0.218 
CREBBP 0.010 0.974 0.068 0.825 -0.140 0.664 
The data represent the correlation between copy numbers of each sample for each gene compared to 
the neutrophil count (%) of that sample. Pearson correlation scores with * represent a significant 
relation between the two factors (p<0.05).  
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Table 5.6.  Correlations between gene expression and columnar epithelial cell conc. 
(%) in asthmatics medicating with corticosteroids (A-ST). 
Gene Session Pearson Sig. (p-value) 
HDAC1 SI-3 0.715** <0.001 
NCOA2 SI-2 0.629* 0.016 
 SI-3 0.834** <0.001 
The data represent the correlation between copy numbers of each sample for each gene compared to 
the columnar epithelial cell count (%) of that sample. Pearson correlation scores with * represent a 
significant relation between the two factors (p<0.05); ** represent p<0.01. 
 
Table 5.7.  Correlations between TFF or SCGB expression and HAT or HDAC 
expression in asthmatics medicating with corticosteroids (A-ST). 
Gene 1 Gene 2 Session Pearson  Sig. 
TFF1 HDAC5 SI-2 0.586* 0.028 
 NCOA2 SI-2 0.720** 0.004 
 NCOA3 SI-2 0.601* 0.023 
 NCOA3 SI-3 0.805** 0.001 
 CREBBP SI-3 0.653* 0.015 
TFF3 HDAC3 SI-2 0.921** <0.001 
 HDAC5 SI-2 0.630* 0.016 
 HDAC3 SI-3 0.671* 0.012 
 CREBBP SI-3 0.602* 0.029 
SCGB1A1 HDAC3 SI-2 0.805** 0.001 
 HDAC5 SI-2 0.760** 0.002 
 CREBBP SI-2 0.758** 0.002 
SCGB3A2 NCOA3 SI-3 0.783** 0.002 
The data represent the correlation between TFF or SCGB expression and HAT or HDAC expression. 
Pearson correlation scores with * represent significance of p<0.05 and ** p<0.01. 
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5.5.5 Extracellular Protein Analysis 
Western Blotting of TFF1 and 3, and SCGB1A1 and 3A2 
Due to high variability in SI-1 and SI-2 data, no comparisons were made 
between the two groups. All following data analysed are from SI-2 and SI-3 of the 
N-A group.  The following figures depicting the protein concentrations for TFF1, 
TFF3, SCGB1A1 and SCGB3A2 all have different y-axis scales. 
TFF1 
Densitometry data of western blot analysis of TFF1 protein in the A-ST group 
are presented in Figure 5.8. The mean density (OD) for each session was 0.27 (SI-1), 
0.42 (SI-2) and 0.25 (SI-3). No significant changes were seen in association with 
induced acute airway inflammation. However, six of the nine samples interrogated 
displayed varying decreases in SI-3 compared to SI-2, signifying a decrease in 
association with airway inflammation.  
TFF3 
Densitometry data of western blot analysis of TFF3 protein in the A-ST group 
are presented in Figure 5.9. The mean density for each session was 0.59 (SI-1), 1.53 
(SI-2) and 0.92 (SI-3). No significant changes were seen in association with induced 
acute airway inflammation. Individual sample analysis showed that 10 of the 12 
samples interrogated displayed varying decreases in SI-3 compared to SI-2, 
signifying a decrease in association with airway inflammation.   
SCGB1A1 
Densitometry data of western blot analysis of SCGB1A1 protein in the A-ST 
group are presented in Figure 5.10. The mean density for each session was 5.74 (SI-
1), 9.29 (SI-2) and 3.61 (SI-3). No significant changes were seen in association with 
induced acute airway inflammation. However, 11 of the 13 samples interrogated 
displayed varying decreases in SI-3 compared to SI-2, signifying a decrease in 
association with airway inflammation.   
SCGB3A2 
Densitometry data of western blot analysis of SCGB3A2 protein in the A-ST 
group are presented in Figure 5.11 The mean density for each session was 0.09 (SI-
1), 0.25 (SI-2) and 0.16 (SI-3). No significant changes were seen in association with 
induced acute airway inflammation. However, six of the nine samples interrogated 
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displayed varying decreases in SI-3 compared to SI-2, signifying a decrease in 
association with airway inflammation. 
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Figure 5.8.  Expression of TFF1 protein for asthmatics medicating with corticosteroids (A-ST) in all three sessions. Extracellular protein 
collected from sputum samples was quantified using BCA protein assay. Samples were evenly loaded and subjected to SDS-
polyacrylamide gel electrophoresis and immunoblot analysis for the TFF1 protein. The graph represents the integrated intensity of the 
band as determined by LICOR Odyssey densitometry function. 
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Figure 5.9.  Expression of TFF3 protein for asthmatics medicating with corticosteroids (A-ST) in all three sessions. Extracellular protein 
collected from sputum samples was quantified using BCA protein assay. Samples were evenly loaded and subjected to SDS-
polyacrylamide gel electrophoresis and immunoblot analysis for the TFF3 protein. The graph represents the integrated intensity of the 
band as determined by LICOR Odyssey densitometry function. 
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Figure 5.10.  Expression of SCGB1A1 protein for asthmatics medicating with corticosteroids (A-ST) in all three sessions. Extracellular 
protein collected from sputum samples was quantified using BCA protein assay. Samples were evenly loaded and subjected to SDS-
polyacrylamide gel electrophoresis and immunoblot analysis for the SCGB1A1 protein. The graph represents the integrated intensity of 
the band as determined by LICOR Odyssey densitometry function. 
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Figure 5.11.  Expression of SCGB3A2 protein for asthmatics medicating with corticosteroids (A-ST) in all three sessions. Extracellular 
protein collected from sputum samples was quantified using BCA protein assay. Samples were evenly loaded and subjected to SDS-
polyacrylamide gel electrophoresis and immunoblot analysis for the SCGB3A2 protein. The graph represents the integrated intensity of 
the band as determined by LICOR Odyssey densitometry function. 
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5.6 DISCUSSION 
The aim of this study was to identify the expression of TFFs, SCGBs, HATs 
and HDACs in association with induced acute airway inflammation in sputum 
samples from the A-ST group. It was clear that our experiment design induced acute 
airway inflammation as indicated by a significant increase in neutrophils in SI-3 
compared to SI-2. The primary result of this study was that this inflammation was 
accompanied by a decrease in HDAC2 expression, which supports our original 
hypothesis. Negative correlations were observed between gene expression and 
neutrophil concentration pre-inflammation for the HDAC3 gene and post-
inflammation for the NCOA2 gene. There was a positive correlation in the difference 
between SI-3 and SI-2 (Δ(SI-3) − (SI-2)) for the HDAC4 gene. Positive correlations 
were identified between columnar epithelial counts and NCOA2 in SI-2 and SI-3, and 
HDAC1 in SI-3. Comparisons made between inflammatory genes and histone 
acetylation genes had correlations between all TFFs and SCGBs, and a number of 
HATs and HDACs for both SI-2 and SI-3. There were no major significant changes in 
the other experimental targets across the three conditions.   
5.6.1 Airway Function 
Due to the corticosteroid treatment of the A-ST group, it was expected that less 
reversible airway obstruction would be present, as the medication should have better 
control of asthma symptoms. Mean airway reversibility reached 6.46% at its highest 
(SI-2), which was lower than seen in the A-BD results (Table 4.3). It is evident that 
the corticosteroid treatment may indirectly control airway hyper-reactivity to an 
extent. However, the A-ST group still presented with significant airway reversibility. 
The group’s FEV1/FVC% was <80% pre-salbutamol treatment but improved to 
>80% post-treatment. Initial FEV1 fell short of 90% of predicted FEV1 in all three 
sessions. These results reflect the clinical symptoms of asthma. These results were 
not as low as the A-BD group, indicating that the corticosteroid medication was 
better at controlling the asthma symptoms. 
Corticosteroid use in both low and high doses has previously been found to 
cause a decrease in airway hyper-responsiveness and decrease the effect of 
salbutamol when testing for reversibility (Pedersen and Hansen 1995). Both the ERS 
and ATS define airway reversibility in asthmatics as an increase in FEV1 post-
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bronchodilator treatment of at least 12% from baseline or at least 200 mL (ATS 
1991). Most asthma studies using this method to classify their asthmatic cohort tend 
to fall short of this target with their mean reversibility data, which highlights how 
unnecessarily high the target is. The A-ST group did not exhibit the 12% increase; 
however, the mean increase in SI-2 and SI-3 was more than 200 mL. Therefore, this 
study has still classified the airway reversibility of the A-ST group as significant. 
5.6.2 Airway Inflammation 
The aim of this study was to induce airway inflammation using sputum 
induction, identified by increases in neutrophil counts. A significant neutrophil 
increase of 29% units from SI-2 to SI-3 was seen. This showed that the mechanical 
stimulation via sputum induction caused neutrophilic inflammation in the A-ST 
group, and further analysis of gene and protein changes can be associated with 
induced acute airway inflammation. A corresponding decrease in macrophage counts 
was seen in SI-3 compared to SI-2. This was expected as it correlates to the influx of 
neutrophils.  
Studies by Holz et al. (1998) and Nightingale et al. (1998) have previously 
described an increase in neutrophil counts 24 and 8 hours post initial sputum 
induction, respectively. The present study demonstrated inflammation six hours post 
initial sputum induction as qualified by neutrophil increase. Interestingly, the mean 
neutrophil count in SI-1 was higher than baseline counts in the N-A and A-BD 
groups. This demonstrates the high variability associated with working with clinical 
samples. A pitfall of using any clinical sample is the inherent variability of the 
sample population. This study used participants who were not hospitalised and were 
free to live their lives outside of the testing sessions. For this reason, participants 
may be subjected to stimuli that can cause inflammation, outside of the testing 
sessions.  
The A-ST group consisted of asthmatics whose symptoms may be worse than 
the average mild intermittent asthmatic, hence the use of corticosteroid medication. 
This means that the A-ST group were more sensitive to stimuli that can bring on 
asthma symptoms, including airway inflammation. Higher neutrophil counts seen in 
SI-1 were due to A-ST4, 5, 9, 10 and 12, indicating that they may have presented to 
SI-1 with acute inflammation. Participants A-ST5 and 10 showed high neutrophil 
counts throughout the three sessions, indicating that their medication schedule may 
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not have been effective at controlling their inflammatory symptoms. To limit the 
effect of different sample collection days on the inflammation in sputum, this study 
only compared changes seen between SI-2 and SI-3, so there would be less chance of 
changes due to external influences.  
5.6.3 qRT-PCR  
For many of the genes analysed, the SI-1 and SI-2 results were highly variable. 
These samples were meant to be baseline representatives. It was decided that there 
was too much time between SI-1 and SI-2 (one week) for environmental factors to 
influence the samples. Environmental factors may include any outside stimulators of 
inflammation including dust, pollution, weather, exercise or even any psychological 
stress the participant may have encountered.  It is also most likely that there is just an 
inherent variability in clinical samples collected on different days. Therefore, it was 
decided that only SI-2 and SI-3 would be analysed to reduce the effect of a long 
interlude between sampling. 
Trefoil Factors (TFF1 and TFF3) 
It was hypothesised that in the A-ST group, TFF1 and TFF3 expression would 
increase in response to inflammation. However, no differences were noted for either 
TFF1 or TFF3 gene expression. As TFF3 expression increased in association with 
induced acute airway inflammation in the A-BD group (Chapter 4), it is possible that 
corticosteroid medication plays a role in the control of TFF3 expression. This means 
that TFF3 may play a role in airway inflammation, which corticosteroids are known 
to control. 
To date, the only study to successfully identify the expression of the TFF3 
gene in association with induced acute airway inflammation is Hallstand et al. 
(2010). They compared the expression profile of exercise-induced 
bronchoconstriction sensitive (EIB+) and insensitive (EIB-) asthmatics and non-
asthmatics using gene microarray. Results showed a higher expression of TFF3 for 
both asthmatic groups and a significant increase in response to the exercise protocol 
in the EIB+ asthmatics. All the asthmatic participants were treated with β2-agonists 
only. No data previously existed pertaining to asthmatics medicating with 
corticosteroids. To our knowledge, this is the first study to analyse the gene 
expression of TFF1 and TFF3 in A-ST participants. 
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Secretoglobins (SCGB1A1 and SCGB3A2) 
It was hypothesised that the expression of the SCGBs in the A-ST group would 
be down-regulated in association with airway inflammation, indicating that anti-
inflammatory action by these mediators was being silenced, causing the increased 
inflammation seen in asthmatic airways. Secretoglobin 1A1 and 3A2 mRNA did not 
show any significant changes over the three sessions. Individual data showed high 
amounts of variability between the individuals in both SI-2 and SI-3, for both 
SCGB1A1 and SCGB3A2. The SCGB1A1 expression looked to be inhibited by 
corticosteroid treatment as compared to expression in the A-BD group. 
A study by Inoue et al. (2008) found that SCGB3A2 plasma levels decreased in 
correlation with asthma severity. However, when the severe asthma group was split 
into corticosteroid-treated and untreated groups, the treated group showed 
significantly higher expression. This project did not demonstrate this; however, as 
airway samples (sputum) were used, there was a lower probability of systemic 
influence affecting the findings, which is a common problem with using plasma. 
Secretoglobin 3A2 has previously been shown to have increased expression in 
asthmatics compared to non-asthmatics (de Burbure et al. 2007). In the de Burbure et 
al. study, SCGB1A1 did not show a significant increase; however, it was positively 
correlated with SCGB3A2 expression. Sixteen of the 32 asthma participants in the de 
Burbure et al. study were medicating with corticosteroids. The reason for the non-
significant change in SCGB1A1 in the de Burbure study was most probably the 
down-regulation by the corticosteroid users, as seen in this study’s A-ST group. 
In summary, results showed no significant differences in the expression of 
either gene in association with induced acute airway inflammation. However, it 
would seem that in regard to SCGB1A1, corticosteroid medication may have an 
inhibitory effect on expression, as compared to A-BD expression. 
Histone Deacetylases (HDAC1-5) 
In the A-ST group, it was hypothesised that HDAC expression would be 
decreased in association with airway inflammation. Histone deacetylase 2 showed a 
decrease in the post-inflammation (SI-3) samples compared to the pre-inflammation 
(SI-2) samples. The SI-2 mean expression was 7.6-fold higher than SI-3 (p=0.03) 
(Figure 5.4 B.1/B.2). This result indicates that HDAC2 gene expression was 
decreased in the A-ST group in association with airway inflammation. 
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HDAC1 is known to deacetylase histones and in turn suppress NF-κB-
dependent gene expression, which is responsible for stimulating inflammation in 
asthmatics (Zhong et al. 2002). Steroidal treatment in endometriosis has 
demonstrated an up-regulation of HDAC1 compared to untreated samples (Irizarry 
2009). In asthma, corticosteroids suppress inflammatory genes in part by recruiting 
HDAC2 to the NF-κB-activated inflammatory gene complex (Barnes 2009). Previous 
research has shown that HDAC2 protein expression is reduced in more severe 
asthmatics (Bhavsar et al. 2008) and that HDAC2 expression can be restored with 
corticosteroids in mild asthmatics, but not in moderate and severe asthmatics (Ito et 
al. 2002). Deficiency in HDAC2 protein has been linked with corticosteroid 
insensitivity in vitro (Hew et al. 2006). The lower HDAC2 expression in SI-3 may be 
due to the severity of the asthma disease in the participants as shown in the Bhavsar 
et al. study. Therefore, it is highly possible that for at least some of the A-ST group, 
the corticosteroid treatment is inefficient at controlling the inflammation in their 
airways due to deficient HDAC2 levels. It is more likely that the decrease in the 
HDAC2 gene is due to uptake for protein expression for use to combat the 
inflammation stimulated in the A-ST airways. This is likely as all the participants felt 
that their inhaled corticosteroids were controlling their asthma. 
Fischle et al. (2002) demonstrated a HDAC3 increase in non-eosinophilic 
asthmatics compared to the eosinophilic phenotype. The current study did not group 
the participants by inflammatory cell phenotype. No studies have looked at the gene 
expression of HDAC4 in asthmatics medicating with corticosteroids. A study has 
shown HDAC4 to be up-regulated in patients with COPD compared to normal 
healthy airways (Ito et al. 2002; Ito et al. 2005). A recent study comparing gene 
microarray data in resting neutrophils from eosinophilic and non-eosinophilic asthma 
phenotypes had a significant 2.7-fold increase in HDAC3 and 2.5-fold increase in 
HDAC5 in the non-eosinophilic asthma phenotype (Baines et al. 2010). This suggests 
that HDAC3 and HDAC5 play a role in asthma, at least in certain phenotypes. These 
results highlight that it may be important to further sub-classify asthma groups when 
performing histone acetylation studies. 
Histone Acetyltransferases (NCOA1-3, HAT-1 and CREBBP) 
In association with airway inflammation in the A-ST group, it was expected 
that HAT levels would increase. No significant changes occurred in association with 
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induced acute airway inflammation in this group. This did not agree with our initial 
hypothesis. 
Interestingly, all of the HAT genes were expressed in high levels in all three 
sessions. This suggests that there was higher HAT activity in the A-ST group. 
Kurihara et al. (2000) demonstrated a down-regulation of NCOA1 mRNA expression 
by dexamethasone treatment in rat tissues including liver, heart, kidney, stomach and 
cerebrum in vivo. Dexamethasone is a potent corticosteroid and is usually only 
prescribed to asthmatics with severe and chronic disease, and only in 1–2 week 
cycles. Prednisone and prednisolone are more common choices for oral 
corticosteroid treatment. All the participants in this study were using less potent 
inhaled corticosteroids and all reported having good control of their symptoms. Lack 
of research into the gene expression of HATs in humans and specifically asthmatics 
makes the present study unique and novel.  
Treatment of steroid-resistant airway structural cells in vitro with NCOA2 has 
been demonstrated to restore corticosteroid responsiveness (Bhandare et al. 2010). 
The same study noticed that NCOA2 depletion attenuated IRF-1 mRNA expression 
and reduced GR-mediated transactivation activities. This in turn restored steroid 
sensitivity to the cell line. These results suggest that NCOA2 plays a pivotal role in 
histone acetylation, and in steroid sensitivity. No related studies into asthma and 
NCOA3, HAT-1 and CREBBP with response to corticosteroid treatment currently 
exist. The present study is the first to examine the expression of these genes and the 
possible change associated with induced acute airway inflammation. 
Correlation Analysis 
Pearson’s product moment correlation coefficient was calculated to assess any 
association between inflammatory gene expression (TFFs and SCGBs) and histone 
acetylation gene expression (HDACs and HATs), as well as any association between 
neutrophil increase and change in TFF, SCGB, HAT or HDAC expression.  
The TFF1 gene had positive correlations with NCOA2, NCOA3 and HDAC5 in 
SI-2, and NCOA3 and CREBBP in SI-3. This indicates that with increased TFF1 
there was a corresponding increase in HAT (NCOA2-3) expression, which are all 
involved in the stimulation of inflammation. What was not expected was the positive 
correlations between TFF1 and HDAC4-5, which suggests up-regulation of HDACs 
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that would in turn affect control of the inflammation in the airway. This indicates that 
there are still defence mechanisms against the increased inflammation in asthmatics’ 
airways; however, further research is needed into how effective they are. The TFF3 
gene had positive correlations with CREBBP in SI-3, and positive correlations with 
HDAC3 in both SI-2 and SI-3, and HDAC5 in SI-2 only. Again, this suggests that 
both HAT and HDAC activity were up-regulated with TFF increase.  
Secretoglobin 1A1 had positive correlations with CREBBP, HDAC3 and 
HDAC5 in SI-2. The correlation between SCGB1A1 and HATs did not agree with our 
hypothesis, as it is believed that SCGB1A1 is primarily an anti-inflammatory peptide 
and HATs are known for stimulating inflammation through the initiation of 
inflammatory gene expression. The SCGB3A2 gene had a positive correlation with 
NCOA3 in SI-3. Results showed that the increases in HATs and HDACs were 
correlated with increases in TFFs and SCGBs, which does not agree with the original 
hypothesis. These results indicate that both HATs and HDACs are expressed in 
higher levels in inflammation. The activity of these individual HATs and HDACs in 
the airways of asthmatics still needs to be identified. 
Comparisons between neutrophil count and gene expressions had negative 
correlations between neutrophil increase and HDAC3 expression pre-inflammation 
and NCOA2 expression post-inflammation. The decrease in NCOA2 with neutrophil 
increase suggests that there is a response to airway inflammation that knocks down 
HATs expression in order to try to stabilise inflammation. However, this may not 
actually be enough to control inflammation. Positive correlation was seen between 
neutrophil increase and the difference in HDAC4 expression in SI-3 compared to SI-
2. This suggests that HDAC4 is increased in association with inflammation to try to 
stem the increased inflammation in the A-ST group. Positive correlations were seen 
when columnar epithelial counts were compared to NCOA2 SI-2 and SI-3 expression 
and HDAC1 SI-2 expression. This suggests that the amount of columnar epithelial 
cells in the A-ST samples affects the amount of NCOA2 and HDAC1 expression. 
5.6.4 Western Blotting of TFFs and SCGBs 
This study used western blot analysis to semi-quantify the protein expression 
of TFFs and SCGBs between the three sessions, within each participant in the A-ST 
group. Unfortunately, the inability to choose an appropriate loading control inhibited 
the extraction of significance from the data. Trends that reflect our original 
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hypothesis do exist. The SCGB1A1 protein showed a decrease in concentration in 11 
of the 13 samples in association with airway inflammation. For SCGB3A2, six of the 
nine samples interrogated showed a decrease in association with airway 
inflammation. 
Trefoil factors 1 and 3 both showed decreases in protein concentration in 
association with airway inflammation (in 6/9 and 9/12 participants respectively). 
This does not reflect our hypothesis or correspond with the gene expression results 
for the A-ST group, and suggests that there is an unknown process involved that is 
controlling the protein expression of TFF1 and TFF3, which is most likely linked 
with corticosteroid medication. 
This study is the first to our knowledge to compare the protein expression of 
TFFs and SCGBs in association with induced acute airway inflammation in A-ST 
participants. It has previously been shown that sputum induction causes airway 
inflammation (Holz et al. 1998; van der Vaart et al. 2006), but this study is the first 
to take advantage of this to compare the expression of genes and proteins. The 
presence of TFF1 and TFF3 proteins has been previously described in the asthmatic 
airway through immuno-histochemistry (Wiede et al. 1999; dos Santos Silva et al. 
2000). Secretoglobin expression has previously been identified in asthmatics. 
SCGB3A2 expression has been found to be increased in asthmatics compared to non-
asthmatics and an insignificant yet positively correlated increase in SCGB1A1 
expression has also been seen (de Burbure et al. 2007). The present data indicated a 
decrease in SCGB1A1 and SCGB3A2 protein expression, which occurred in the event 
of airway inflammation. 
Due to the nature of the secreted protein samples, it was hard to select a 
loading control or indicate equal loading by other methods. As extracellular samples 
contain no cell structure proteins or evenly expressed protein that can easily be used 
as a loading control, choosing such a protein was impossible. Coomassie and 
ponceau staining were used as alternatives to show equal loading, as well as 
Bradford assays to quantify protein concentration. Unfortunately, the secreted protein 
samples were very difficult to process as each sample contained a variable volume of 
saliva contamination. This changed the protein composition of each sample 
dramatically, which can be seen in the coomassie blots performed for the 
bronchodilator asthmatic samples (Appendix C). Another reason for the differing 
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protein expression patterns between samples seen in the coomassie stained gels is 
that different levels of inflammation change the concentration of the protein 
constituents of the sample, and therefore the expression patterns in the gel. Multiple 
Bradford quantification assays were performed on each sample to assure equal 
loading; therefore, it is believed that the differences in the appearance of some bands 
between the samples in the coomassie stain can be attributed to the dilution effect as 
a consequence of variable saliva contamination and/or the differences in 
inflammation in the different samples. The sputum plug selection method (Pin et al. 
1992) may have helped collect cleaner samples with less saliva contamination; 
however, this method also loses a substantial amount of the secreted proteins 
collected, which would raise major problems for the secreted protein analysis. 
In summary, the A-ST group showed that sputum induction does cause 
inflammation as presented by an increase in neutrophil counts in SI-3 compared to 
SI-2. Real-time PCR results showed that the HDAC2 gene is significantly decreased 
in association with induced acute airway inflammation. This may be due to the active 
up-regulation of the HDAC2 protein as it is known that HDAC2 plays an important 
role in the effectiveness of corticosteroid medication on airway inflammation. There 
were no other genes that displayed a change in association with induced acute airway 
inflammation. The western blots results indicated a decrease in both TFF and SCGB 
proteins in association with airway inflammation. This did not support the original 
hypothesis and indicates that corticosteroids may play a role in the control of the 
expression of TFF3 and SCGB proteins. Correlation analysis indicated that both 
HATs and HDACs correlate both positively and negatively with TFF and SCGB 
expression. This indicates that histone acetylation may only incorporate some of the 
HAT and HDAC genes chosen in this study in its control/exacerbation of airway 
inflammation, and that different HATs and HDACs may have higher or lower affinity 
to binding of histones. This needs to be researched further. 
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Chapter 6: Comparison of Non-asthmatic 
Individuals, Asthmatics 
Medicating with 
Bronchodilators and Asthmatics 
Medicating with Corticosteroids 
6.1 INTRODUCTION 
Asthma is a disease of the lower respiratory tract in which bronchoconstriction, 
airway inflammation and mucus hyper-secretion occur in response to a stimulus. 
There are two main forms of treatment for the symptoms of asthma: rescue 
medication and controller medication. Ventolin, a commonly used bronchodilator, is 
an example of rescue medication as it is taken when the sufferer feels the symptoms 
of asthma. Inhaled corticosteroids (ICSs) are controller medications as they are taken 
either at morning, night or both to prevent the symptoms of asthma. ICSs are very 
effective at controlling inflammation in the asthmatic airways. The majority of 
moderate to severe asthma sufferers treat their disease with inhaled corticosteroids, 
while mild intermittent sufferers generally are able to control their symptoms with 
bronchodilator medications. The different treatment methods of asthma may 
contribute to different gene expression patterns. Hence, we need to compare the 
results from the studies described in Chapters 3–5 to unveil the differences between 
the three groups (N-A, A-BD and A-ST).  
In the following analyses, the expression of TFFs, SCGBs, HATs and HDACs 
are compared between the N-A, A-BD and A-ST groups. It is expected that there will 
be differences at baseline in airway function, inflammation and the expression of the 
target genes due to the inherent components that control the different types of 
asthma. 
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6.2 HYPOTHESIS 
For this component of the project, it was hypothesised that there would be 
progressively larger differences in the changes in the mediators of airway 
inflammation as a function of group – N-A vs. A-BD vs. A-ST: 
9. the expression of TFF1 and TFF3 would be higher in the A-BD group than 
the N-A and A-ST groups, signifying increased inflammation as a result of 
asthma. The A-ST group would present with lower TFF expression 
indicating that corticosteroids combat inflammation directly by controlling 
TFF expression; 
10. the expression of SCGB1A1 and SCGB3A2 would be increased in the N-A 
and A-ST groups, signifying that induced airway inflammation is 
controlled by SCGBs and that corticosteroid medication controls 
inflammation via the up-regulation of SCGBs; 
11. HAT expression would be at its highest and HDAC expression at its lowest 
in the A-BD group, explaining the high inflammation through histone 
hyperacetylation. HDAC expression will be at its highest in the A-ST 
group, identifying corticosteroid treatment as directly controlling airway 
inflammation through histone deacetylation; 
12. the changes in TFF expression would be positively correlated with 
changes in neutrophil numbers, and that the changes in SCGB expression 
would be negatively correlated with changes in neutrophil numbers; 
13. the changes in HAT expression would be positively correlated with 
changes in TFF expression and negatively correlated with changes in 
SCGB expression, and that the changes in HDAC expression would be 
negatively correlated with changes in TFF expression and positively 
correlated with changes in SCGB expression. 
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6.3 DESIGN 
This study used a three group, repeated measures design to measure the 
inflammatory response in non-asthmatics (N-A), asthmatics medicating with 
bronchodilators (A-BD) and asthmatics medicating with corticosteroids (A-ST). The 
study included the recruitment and screening of 15 participants for each group. Each 
participant undertook three testing sessions from which sputum was collected for 
measurement of gene expression using qPCR, differential cell counts to gauge 
inflammation of each sample, and protein expression using immunological analysis. 
The results were directly compared between the three groups. 
6.4 RESULTS 
6.4.1 Session 1 (SI-1) 
Airway Function 
Session 1 (SI-1) airway function data for the three groups are presented in 
Table 6.1. Analysis revealed a significantly higher reversibility in the A-BD group 
compared to the N-A group. 
Airway Inflammation 
Session 1 (SI-1) differential leukocyte counts are presented for all three groups 
in Table 6.2. A significantly higher neutrophil count was seen in the A-ST group 
compared to the A-BD group. 
6.4.2 Session 2 (SI-2) 
Airway Function 
Session 2 (SI-2) airway function data for the three groups are presented in 
Table 6.3. Results showed a significantly higher reversibility in the A-BD group 
compared to the N-A group.  
Airway Inflammation 
Session 2 (SI-2) differential leukocyte counts are presented for all three groups 
in Table 6.4. No statistical differences were seen between the groups in session 2. 
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6.4.3 Session 3 (SI-3) 
Airway Function 
Session 3 (SI-3) airway function data for the three groups are presented in 
Table 6.5. A significantly higher reversibility was seen in the A-BD group compared 
to the N-A group. 
Airway Inflammation 
Session 3 (SI-3) differential leukocyte counts are presented for all three groups 
in Table 6.6. No significant differences in leukocyte distribution were seen between 
the three groups.  
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Table 6.1.  Airway function data comparing the three groups for session 1 (SI-1).   
SI-1 FEV1 (L) 
(Pre) 
FVC (L) 
(Pre) 
FEV1/FVC % 
(Pre) 
FEV1 
 % Pred. 
FEV1 (L) 
(Post) 
FVC (L) 
(Post) 
FEV1/FVC % 
(Post) 
Rev. (%) 
N-A 3.57 
(0.9) 
4.26 
(1.1) 
84.2 
(5) 
92.7 
(4) 
3.61 
(0.9) 
4.11 
(1.1) 
88.0 
(6) 
0.45 
(0.9) 
A-BD 3.64 
(0.8) 
4.67 
(1.1) 
78.6 
(10) 
81.9 
(6) 
3.95 
(0.9) 
4.89 
(1.2) 
81.1 
(7) 
7.1 
(1.5) 
A-ST 3.32 
(0.8) 
4.27 
(0.9) 
77.7 
(2) 
84.8 
(3) 
3.47 
(0.7) 
4.29 
(0.7) 
80.7 
(2) 
5.4 
(2.3) 
         
p (N-A ν A-BD) 1.00 1.00 0.35 0.72 1.00 0.86 0.07 0.003 
p (N-A ν A-ST) 0.99 1.00 0.33 0.87 1.00 1.00 0.10 0.35 
p (A-BD ν A-ST) 1.00 1.00 1.00 1.00 0.99 0.98 1.00 0.44 
Data are expressed as means ± SEM (in brackets). FEV1 (pre), FVC (pre), FEV1 (post) and FVC (post) represent forced expiratory volume in 1 second and forced 
vital capacity in litres both pre- and post-salbutamol treatment respectively. Rev. corresponds to airway reversibility due to salbutamol use and is measured as the 
difference between FEV1 (pre) and FEV1 (post). Statistical analysis was performed using ANOVA and Tukey’s post-hoc analysis. A  p≤0.05 was considered 
significant. 
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Table 6.2.  Cell count data for all three groups in session 1 (SI-1) 
SI-1 TCC (x 10
5
/mL) Mac (%) Lymp (%) Neut (%) Eos (%) *Col Epi *Squam Epi 
N-A 10.10  
(0.7) 
51.63  
(4.6) 
0.91  
(0.2) 
46.86  
(4.7) 
0.58  
(0.3) 
7.9  
(1.7) 
34  
(11.2) 
A-BD 10.50   
(0.9) 
51.06  
(4.5) 
0.68  
(0.2) 
41.05  
(3.7) 
7.19  
(7.2) 
4.3  
(1.4) 
29  
(9.1) 
A-ST 8.90  
(1.8) 
31.43  
(5.1) 
0.32  
(0.1) 
64.47  
(5.2) 
3.76  
(1.1) 
4.9  
(1.2) 
38  
(5.2) 
 
p (N-A ν A-BD) 0.83 1.00 1.00 0.99 0.60 0.26 0.35 
p (N-A ν A-ST) 0.67 0.07 0.95 0.24 0.99 0.48 0.52 
p (A-BD ν A-ST) 0.75 0.10 0.99 0.03 0.98 0.50 0.18 
Data expressed as means ± SEM. Values represent total cell count x 105/mL (TCC), and macrophages (Mac), lymphocytes (Lymp), neutrophils (Neut) and 
eosinophils (Eos) as a percentage of total leukocytes. Columnar epithelial cells (*Col Epi) and squamous epithelial cells (*Squam Epi) are represented as a 
percentage of all non-squamous cells. A  p≤0.05 was considered significant. 
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Table 6.3.  Airway function data comparing the three groups for session 2 (SI-2).   
SI-2 FEV1 (L) 
(Pre) 
FVC (L) 
(Pre) 
FEV1/FVC % 
(Pre) 
FEV1 
%Pred. 
FEV1 (L) 
(Post) 
FVC (L) 
(Post) 
FEV1/FVC % 
(Post) 
Rev. (%) 
N-A 3.54 
(0.2) 
4.21 
(0.3) 
85.2 
(8) 
91.1 
(3) 
3.66 
(0.2) 
4.22 
(0.2) 
87.4 
(6) 
3.4 
(0.8) 
A-BD 3.61 
(0.9) 
4.83 
(1.1) 
74.8 
(9) 
77.3 
(4) 
3.95 
(1.0) 
4.91 
(1.1) 
80.3 
(7) 
7.2 
(1.7) 
A-ST 3.41 
(0.9) 
4.26 
(1.0) 
79.5 
(2) 
89.5 
(3) 
3.6 
(0.9) 
4.28 
(0.9) 
83.8 
(2) 
5.0 
(1.4) 
         
p (N-A ν A-BD) 0.99 1.00 0.09 0.34 1.00 1.00 0.30 0.008 
p (N-A ν A-ST) 1.00 1.00 0.67 0.99 1.00 1.00 0.90 0.09 
p (A-BD ν A-ST) 1.00 1.00 0.97 0.79 1.00 1.00 0.98 0.47 
Data are expressed as means ± SEM (in brackets). FEV1 (pre), FVC (pre), FEV1 (post) and FVC (post) represent forced expiratory volume in 1 second and forced 
vital capacity in litres both pre- and post-salbutamol treatment respectively. Rev. corresponds to airway reversibility due to salbutamol use and is measured as the 
difference between FEV1 (pre) and FEV1 (post). Statistical analysis was performed using ANOVA and Tukey’s post-hoc analysis. A  p≤0.05 was considered 
significant. 
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Table 6.4.  Cell count data for all three groups in session 2 (SI-2). 
SI-2 TCC (x10
5
/mL) Mac (%) Lymp (%) Neut (%) Eos (%) *Col Epi *Squam Epi 
N-A 8.40 
(1.7) 
52.48 
(5.4) 
0.92 
(0.2) 
46.12 
(5.3) 
0.46 
(0.1) 
11.1 
(2.9) 
32.4 
(4.3) 
A-BD 8.80 
(2.1) 
47.17 
(5.8) 
1.75 
(0.7) 
43.62 
(5.3) 
7.43 
(3.6) 
5.5 
(1.0) 
31 
(4.3) 
A-ST 13.40 
(2.6) 
38.91 
(5.1) 
1.19 
(0.3) 
56.3 
(5.9) 
3.58 
(1.3) 
5.3 
(1.6) 
44.8 
(6.0) 
 
p (N-A ν A-BD) 0.70 0.99 0.77 1.00 0.56 0.50 0.54 
p (N-A ν A-ST) 0.13 0.56 1.00 0.88 0.99 0.19 0.19 
p (A-BD ν A-ST) 0.07 0.95 0.96 0.69 0.97 0.20 0.10 
Data expressed as means ± SEM. Values represent total cell count x 105/mL (TCC), and macrophages (Mac), lymphocytes (Lymp), neutrophils (Neut) and 
eosinophils (Eos) as a percentage of total leukocytes. Columnar epithelial cells (*Col Epi) and squamous epithelial cells (*Squam Epi) are represented as a 
percentage of all non-squamous cells. A  p≤0.05 was considered significant. 
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Table 6.5.  Airway function data comparing the three groups for session 3 (SI-3).   
SI-3 FEV1 (L)  
(Pre) 
FVC (L) 
(Pre) 
FEV1/FVC 
% (Pre) 
FEV1 %  
Pred. 
FEV1 (L)  
(Post) 
FVC (L)  
(Post) 
FEV1/FVC 
% (Post) 
Rev. 
(%) 
N-A 3.51  
(0.2) 
4.18  
(0.3) 
84.7  
(7) 
90  
(4) 
3.62  
(0.2) 
4.19  
(0.3) 
87.0  
(6) 
3.3  
(0.9) 
A-BD 3.5  
(0.9) 
4.58  
(1.1) 
77  
(8) 
77.7  
(4) 
3.87  
(0.9) 
4.75  
(1.1) 
82.2  
(6) 
9.5  
(2.2) 
A-ST 3.41  
(0.9) 
4.26  
(1.0) 
79.5  
(2) 
89.5  
(3) 
3.6  
(0.9) 
4.28  
(0.9) 
83.8  
(2) 
5.0  
(1.4) 
         
p (N-A ν A-BD) 0.99 1.00 0.30 0.43 1.00 1.00 0.63 0.02 
p (N-A ν A-ST) 1.00 1.00 0.82 0.99 1.00 1.00 0.94 0.26 
p (A-BD ν A-ST) 1.00 1.00 0.99 0.86 1.00 1.00 0.99 0.11 
Data are expressed as means ± SEM (in brackets). FEV1 (pre), FVC (pre), FEV1 (post) and FVC (post) represent forced expiratory volume in 1 second and forced 
vital capacity in litres both pre- and post-salbutamol treatment respectively. Rev. corresponds to airway reversibility due to salbutamol use and is measured as the 
difference between FEV1 (pre) and FEV1 (post). Statistical analysis was performed using ANOVA and Tukey’s post-hoc analysis. A  p≤0.05 was considered 
significant. 
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Table 6.6.  Cell count data for all three groups in session 3 (SI-3) 
SI-3 TCC (x 10
5
/mL) Mac (%) Lymp (%) Neut (%) Eos (%) *Col Epi *Squam Epi 
N-A 11.30  
(2.2) 
34.22  
(4.9) 
1.05  
(0.2) 
67.22  
(4.9) 
0.25  
(0.3) 
6.6 
(1.7) 
30.6 
(5.7) 
A-BD 7.80  
(3.0) 
25  
(3.8) 
0.38  
(0.2) 
70.73  
(6.0) 
0.25  
(5.0) 
6.3 
(1.4) 
40.1 
(4.8) 
A-ST 12.10  
(6.2) 
19.16  
(4.3) 
0.60  
(0.2) 
85.57  
(4.6) 
0.76  
(0.6) 
3.5 
(1.7) 
28.6 
(6.3) 
 
p (N-A ν A-BD) 0.17 0.92 0.99 1.00 0.60 0.89 0.21 
p (N-A ν A-ST) 0.84 0.23 0.77 0.31 1.00 0.36 0.94 
p (A-BD ν A-ST) 0.07 0.96 0.99 0.56 0.79 0.53 0.15 
Data expressed as means ± SEM. Values represent total cell count x 105/mL (TCC), and macrophages (Mac), lymphocytes (Lymp), neutrophils (Neut) and 
eosinophils (Eos) as a percentage of total leukocytes. Columnar epithelial cells (*Col Epi) and squamous epithelial cells (*Squam Epi) are represented as a 
percentage of all non-squamous cells. A  p≤0.05 was considered significant. 
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6.4.4 qRT-PCR of TFFs, SCGBs, HATs and HDACs 
Trefoil Factors (TFF1 and TFF3) 
TFF1 
Gene expression data comparing TFF1 expression in all three groups are 
presented in Figure 6.1. Results showed no significant changes in gene expression 
between the groups at either SI-2 or SI-3. 
TFF3 
Gene expression data comparing TFF3 expression in all three groups are 
presented in Figure 6.2. A 9-fold increase in expression was noted in A-BD 
compared to N-A in SI-3 (p=0.008). No significant changes were seen when 
comparing the A-ST group to the N-A or A-BD groups. 
Secretoglobins (SCGB1A1 and SCGB3A2) 
SCGB1A1 
Secretoglobin 1A1 gene expression for all three groups is presented in Figure 
6.3. A 34-fold increase was seen in the A-BD group in SI-3 when compared to N-A 
group (p=0.03). No significant changes were seen when comparing the A-ST group 
to the N-A or A-BD groups. 
SCGB3A2 
Gene expression for SCGB3A2 in all three groups is presented in Figure 6.4. 
No significant changes were noticed when comparing the three groups. 
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Figure 6.1.  TFF1 mRNA expression of non-asthmatics (N-A), asthmatics 
medicating with bronchodilators (A-BD) and asthmatics medicating with 
corticosteroids (A-ST) over three sessions.  
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Figure 6.2.  TFF3 mRNA expression of non-asthmatics (N-A), asthmatics 
medicating with bronchodilators (A-BD) and asthmatics medicating with 
corticosteroids (A-ST) over three sessions. Significance between groups is presented 
as * with a p-value <0.05. 
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Figure 6.3.  SCGB1A1 mRNA expression of non-asthmatics (N-A), asthmatics 
medicating with bronchodilators (A-BD) and asthmatics medicating with 
corticosteroids (A-ST) over three sessions. Significance between groups is presented 
as * with a p-value <0.05. 
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Figure 6.4.  SCGB3A2 mRNA expression of non-asthmatics (N-A), asthmatics 
medicating with bronchodilators (A-BD) and asthmatics medicating with 
corticosteroids (A-ST) over three sessions.  
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Histone Deacetylases (HDAC1-5) 
HDAC1 
Gene expression data comparing HDAC1 in all three groups are presented in 
Figure 6.5. Results revealed an increase in the A-ST group in SI-2 compared to the 
A-BD group (3.8-fold, p=0.03). Gene expression in SI-3 showed a 6.4-fold increase 
in the A-ST group compared to the N-A group (p=0.04). No significant changes were 
seen when comparing the A-BD group to the N-A group. 
HDAC2 
Gene expression data comparing HDAC2 in all three groups are presented in 
Figure 6.6. The A-ST group revealed a 41-fold decrease in SI-3 compared to the A-
BD group (p=0.008). No significant changes were seen when comparing the N-A 
group to the A-BD or A-ST groups. 
HDAC3 
Gene expression data comparing HDAC3 in all three groups are presented in 
Figure 6.7. No significant differences were seen between the groups or the three 
sessions. 
HDAC4 
Gene expression data comparing HDAC4 in all three groups are presented in 
Figure 6.8. No significant differences were seen between the groups or the three 
sessions. 
HDAC5 
Gene expression data comparing HDAC5 in all three groups are presented in 
Figure 6.9. Higher expression was found in the A-ST group compared to the N-A 
group in both SI-2 (3.6-fold, p=0.04) and SI-3 (5.2-fold, p=0.008). 
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Figure 6.5.  HDAC1 mRNA expression of non-asthmatics (N-A), asthmatics 
medicating with bronchodilators (A-BD) and asthmatics medicating with 
corticosteroids (A-ST) over three sessions. Significance between groups is presented 
as * with a p-value <0.05.   
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Figure 6.6.  HDAC2 mRNA expression of non-asthmatics (N-A), asthmatics 
medicating with bronchodilators (A-BD) and asthmatics medicating with 
corticosteroids (A-ST) over three sessions. Significance between groups is presented 
as * with a p-value <0.05. 
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Figure 6.7.  HDAC3 mRNA expression of non-asthmatics (N-A), asthmatics 
medicating with bronchodilators (A-BD) and asthmatics medicating with 
corticosteroids (A-ST) over three sessions.  
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Figure 6.8.  HDAC4 mRNA expression of non-asthmatics (N-A), asthmatics 
medicating with bronchodilators (A-BD) and asthmatics medicating with 
corticosteroids (A-ST) over three sessions.  
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Figure 6.9.  HDAC5 mRNA expression of non-asthmatics (N-A), asthmatics 
medicating with bronchodilators (A-BD) and asthmatics medicating with 
corticosteroids (A-ST) over three sessions. Significance between groups is presented 
as * with a p-value <0.05. 
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Histone Acetylases (NCOA1-3, HAT-1 and CREBBP) 
NCOA1 
Gene expression data comparing NCOA1 in all three groups are presented in 
Figure 6.10. Results showed no significant changes in either session across the three 
groups.  
NCOA2 
Gene expression data comparing NCOA2 in all three groups are presented in 
Figure 6.11. The A-ST group had significantly higher expression compared to the N-
A group in both SI-2 (8.5-fold, p=0.04) and SI-3 (9.6-fold, p=0.03). No significant 
gene expression changes were seen when comparing the A-BD group to the N-A or 
A-ST groups. 
NCOA3 
Gene expression data comparing NCOA3 in all three groups are presented in 
Figure 6.12. In SI-2, increased expression was seen in the A-ST group compared to 
the N-A group (17-fold, p=0.01) and the A-BD group (4.5-fold, p=0.03). Results 
showed a non-significant 16-fold increase (p=0.06) in expression in the A-ST group 
compared to the N-A group in SI-2.  
HAT-1 
Gene expression data comparing HAT-1 in all three groups are presented in 
Figure 6.13. Comparisons between the groups revealed the A-ST group had higher 
expression in both SI-2 and SI-3 compared to the N-A group (SI-2 36-fold, p=0.003; 
SI-3 41-fold, p<0.001) and the A-BD group (SI-2 5.3-fold, p=0.01; SI-3 4.3-fold, 
p=0.003). 
CREBBP 
Gene expression data comparing CREBBP in all three groups are presented in 
Figure 6.14. Comparisons between the groups revealed higher A-ST expression in 
both SI-2 and SI-3 compared to the N-A group (SI-2 13-fold, p=0.001; SI-3 31-fold, 
p=0.001) and the A-BD group (SI-2 23-fold, p=0.001; SI-3 40-fold, p=0.001). 
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Figure 6.10.  NCOA1 mRNA expression of non-asthmatics (N-A), asthmatics 
medicating with bronchodilators (A-BD) and asthmatics medicating with 
corticosteroids (A-ST) over three sessions.. 
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Figure 6.11.  NCOA2 mRNA expression of non-asthmatics (N-A), asthmatics 
medicating with bronchodilators (A-BD) and asthmatics medicating with 
corticosteroids (A-ST) over three sessions. Significance between groups is presented 
as * with a p-value <0.05. 
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Figure 6.12.  NCOA3 mRNA expression of non-asthmatics (N-A), asthmatics 
medicating with bronchodilators (A-BD) and asthmatics medicating with 
corticosteroids (A-ST) over three sessions. Significance between groups is presented 
as * with a p-value <0.05. 
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Figure 6.13.  HAT-1 mRNA expression of non-asthmatics (N-A), asthmatics 
medicating with bronchodilators (A-BD) and asthmatics medicating with 
corticosteroids (A-ST) over three sessions. Significance between groups is presented 
as * with a p-value <0.05. 
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Figure 6.14.  CREBBP mRNA expression of non-asthmatics (N-A), asthmatics 
medicating with bronchodilators (A-BD) and asthmatics medicating with 
corticosteroids (A-ST) over three sessions. Significance between groups is presented 
as * with a p-value <0.05. 
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6.5 DISCUSSION 
The aim of this study was to compare the gene expression of TFFs, SCGBs, 
HATs and HDACs in association with induced acute airway inflammation, between 
the N-A, A-BD and A-ST groups. Interesting results seen in the gene expression data 
for the three groups included a marked increase in TFF3 expression in the A-BD 
group in SI-3 compared to the N-A group, and a significantly higher expression of 
both HAT-1 and CREBBP in both sessions of the A-ST group compared to the N-A 
and A-BD group. The TFF3 increase suggests that TFF3 plays an active role in 
asthma and airway inflammation. The HAT-1 and CREBBP increases indicate that 
histone acetylation may play an active role in airway inflammation in asthma; 
however, they may be involved in more severe cases of asthma and not the mild 
intermittent variety. 
6.5.1 Airway Function 
It was expected that when comparing the pulmonary function of the three 
groups, the A-BD and A-ST groups would exhibit signs of asthma by way of higher 
airway reversibility. Comparisons of airway reversibility measurements between the 
groups identified a significantly higher reversibility in the A-BD group compared to 
the N-A group. The A-ST group did display airway reversibility; however, statistical 
analysis did not deem the result significant when compared to the N-A group. The A-
ST reversibility was not significantly different to the A-BD group either. It is 
apparent that the corticosteroid medications taken by the A-ST group are partially 
controlling the reversible obstruction in their airways. 
6.5.2 Airway Inflammation 
The aim of this project was to induce airway inflammation in all three groups, 
as measured by increased neutrophils in sputum samples. Results showed that 
significant increases in neutrophil count occurred in both the A-BD and A-ST 
groups, but not the N-A group. This presented a problem, although the N-A group 
still had a higher mean neutrophil count in SI-3 compared to SI-2. Omission of two 
samples from the N-A group (N-A1 and N-A6), resulted in a significant neutrophil 
increase in SI-3 (p=0.01). This is due to N-A1 showing a decrease in neutrophils in 
SI-3 and N-A6 having no neutrophil change in association with induced acute airway 
inflammation.  
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Comparisons of the leukocyte distribution between the three groups in SI-2 and 
SI-3 revealed no significant differences. It is also notable that SI-3 neutrophil counts 
displayed a small severity dependent neutrophil increase with A-ST having the 
highest SI-3 mean count, followed by A-BD and then N-A. 
The increase in neutrophilic inflammation seen in the three groups allows us to 
compare the baseline sample (SI-2) with the post-inflammation sample (SI-3) and 
attribute any changes in gene expression to the process of inflammation. This study 
is not the first to find inflammation as a result of sputum induction. Studies by Holz 
et al. (1998) and Nightingale et al. (1998) previously showed neutrophil increases 
due to sputum induction. This study was able to re-create the method, causing 
neutrophilic increase six hours post initial sputum induction.  
Asthma has traditionally been explained by the influx of eosinophils into the 
airways, which cause the exacerbation of asthma. Research has proven this not to be 
the case with findings of a large population of neutrophilic asthma. Fahy et al. (1995) 
showed that in the majority of asthmatics presenting at a clinic with acute 
exacerbations of asthma, neutrophils made up >75% of sputum cells. A more recent 
paper by McGrath et al. (2012) established that there is a large sub-group of mild to 
moderate asthmatics who have persistent non-eosinophilic airways (<2% 
eosinophils). They found that in a cohort of 995 asthmatics, 47% presented with no 
eosinophilia in multiple sputum collections. They also noted that after two weeks of 
combined anti-inflammatory therapy, significant improvements were achieved in the 
eosinophilic asthmatics but not in the persistent non-eosinophilic asthmatics. This 
suggests that there is a sub-population of persistent non-eosinophilic asthmatics who 
respond poorly to current anti-inflammatory medication.  
The mean eosinophil counts for the A-BD group were higher in SI-2 compared 
to the A-ST group, and both groups mean eosinophil counts reflected eosinophilia 
(>2%). The SI-3 results showed low mean eosinophil counts in both the A-BD and 
A-ST groups, diluted by the neutrophilic influx. The results also showed that in both 
asthmatic groups, neutrophils played a larger role than eosinophils in the 
inflammation of the airways, due to the induction method used. Review of the 
experimental literature indicated that at most 50% of asthma cases in studies are 
attributed to eosinophilic inflammation and that neutrophilic inflammation is just as 
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prevalent and important (Douwes et al. 2002). This is reflected in the present study in 
both the bronchodilator and corticosteroid groups. 
6.5.3 qRT-PCR of TFFs, SCGBs, HATs and HDACs 
Trefoil Factors (TFF1 and TFF3) 
It was expected that TFF1 and TFF3 gene expression would be highest in the 
A-BD group compared to the N-A and A-ST groups. In association with airway 
inflammation, it was also hypothesised that the largest increase would be seen in the 
A-BD group. Analysis of TFF1 had no changes in expression between the groups in 
SI-2 or SI-3. The TFF3 gene showed significantly higher expression in the A-BD 
group in SI-3 compared to the N-A group. 
Most of the published research into the expression of TFFs has been performed 
using murine models. One such study by Kouznetsova et al. (2007) using an 
established mouse ‘asthma’ model (i.e. exposure to Aspergillus fumigates antigens) 
showed elevated TFF1 gene levels in the challenged animals.  
TFF1 gene expression has been analysed in the human airway previously. A 
study by dos Santos Silva et al. (2000) compared the expression of TFF1 in cystic 
fibrosis lung tissue and nasal polyps, normal lung tissue, and stomach, colon and 
muscle tissue using multiplex RT-PCR. No deductions were made for the differences 
in expression between the tissue types, but the results confirmed that both TFF1 gene 
and protein were expressed in cystic fibrosis and normal human lungs. The present 
study is the first to compare TFF1 gene expression in A-BD, A-ST and N-A cohorts, 
in association with airway inflammation. Mean TFF1 expression results suggest that 
the gene is expressed in higher levels in the A-BD group, and to a lesser extent in the 
A-ST group, compared to the N-A group (Figure 6.1). Variability in the data resulted 
in no significance.  
This study is not the first to show higher TFF3 expression in asthmatics 
compared to non-asthmatics. The Hallstrand et al. (2010) study showed an increase 
in TFF3 post an exercise protocol in asthmatics who suffered from exercise-induced 
bronchoconstriction (EIB) and a small increase in asthmatics who didn’t suffer from 
EIB. Sputum induction was used to collect pre- and post-exercise samples. The 
current study used sputum induction as the technique to cause inflammation to 
compare TFF3 gene expression. It is highly possible that the Hallstrand study 
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confounded their data by the use of sputum induction. TFF3 was initially isolated in 
the human lower airways by Wiede et al. (1999) who found it to be a significant 
constituent of airway mucus of patients with chronic bronchitis. Dos Santos Silva et 
al. (2000) found TFF3 expression to be higher in cystic fibrosis sufferers than in 
normal healthy lungs, which provides further evidence that TFF3 is an important 
inflammatory peptide of the human airway and may play a role in the initiation and 
exacerbation of airway inflammation in many disease types, including asthma. 
Secretoglobins (SCGB1A1 and SCGB3A2) 
It was expected that in association with airway inflammation, the expression of 
SCGBs would decrease in the asthmatic groups. This response would indicate that 
there is a problem with the anti-inflammatory response due to the silencing of the 
SCGB genes. It was also hypothesised that SCGB expression would be higher in the 
N-A group, signifying a normal anti-inflammatory response. Neither SCGB1A1 nor 
SCGB3A2 results agreed with the hypothesis. SCGB1A1 showed higher expression in 
the A-BD group in SI-3 compared to the N-A group, and SCGB3A2 showed no 
significant change between the groups.  
Results suggest that in the A-BD group, SCGB1A1 expression is significantly 
up-regulated in order to combat airway inflammation, while the other two groups 
have low expression suggesting that it may not be needed. The SCGB3A2 gene 
expression results (Figure 6.4) suggest that the expression may be higher in the A-
BD group compared to the N-A group, although variability in the data resulted in no 
significance in the differences. 
A study by de Burbure et al. (2007) showed a significant increase in the protein 
level of SCGB3A2 and a non-significant but positive correlation to SCGB1A1 in 
sputum of asthmatics compared to non-asthmatics. In the study, 13 of the asthmatics 
were smokers and 19 were medicating with corticosteroids. A study by Chari et al. 
(2007) showed that tobacco smoke causes a decrease in SCGB1A1 expression in 
human airways, and the present study has shown low conserved SCGB1A1 gene 
expression in the A-ST group (Figure 6.3). This could explain the lack of 
significance in SCGB1A1 expression in the de Burbure study. Both the de Burbure 
study and this study demonstrate that SCGB gene and protein expression are higher 
in asthmatics, disproving the original hypothesis and indicating that SCGBs may be 
over-expressed in asthmatics in order to try to control airway inflammation. This 
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mechanism, however, may not be the primary response to controlling airway 
inflammation, as there seems to be less SCGB expression in N-A and A-ST groups.  
Histone Deacetylases 
The original hypothesis for HDAC expression was that there would be higher 
expression in the N-A and A-ST groups than the A-BD group, as HDACs are known 
to control the expression of inflammatory genes that control inflammation. It was 
also thought that in association with airway inflammation the expression of HDACs 
would be even lower in the A-BD group, suggesting that hyper-acetylation is 
responsible for the airway inflammation in asthma. 
HDAC1 
Gene expression of HDAC1 was higher in the A-ST group compared to the A-
BD group in SI-2. This supports the hypothesis and indicates that the corticosteroid 
therapy may increase HDAC1 expression as part of its effect on controlling 
inflammation of the airways in asthma. The A-ST group showed significant increases 
in HDAC1 gene expression in SI-3 compared to the N-A group. This does not 
support the original hypothesis but may indicate that histone acetylation is well 
controlled in the N-A group and therefore there is no need for extra HDAC 
expression.  
A study by Ito et al. (2002) looking at the expression and activity of HDACs 
showed a significant reduction in HDAC1 protein expression in asthmatics compared 
to non-asthmatics. The study also noticed that asthmatics medicating with 
corticosteroids had higher HDAC activity than untreated asthmatics, although still 
lower than non-asthmatic expression. This is similar to the HDAC1 gene expression 
results seen in the present study, suggesting that HDAC1 may play a role in raising 
HDAC activity in the corticosteroid population as noticed in the Ito study.   
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HDAC2 
Histone deacetylase 2 had significantly lower expression in the A-ST group in 
SI-3 compared to the A-BD group. This does not agree with the original hypothesis. 
However, it may indicate that a protein up-regulation stimulated by corticosteroid 
therapy is the reason for the lower gene expression in the A-ST group. 
A study by Ito et al. (2002) showed decreased HDAC2 protein in untreated 
asthmatics. The difference in expression was small and the cohort size was only six 
participants. Our study incorporates the gene expression of 15 participants in three 
groups, and depicted equally high yet variable expression in both the N-A and A-BD 
groups. The A-ST group in the Ito study showed similar protein expression to that of 
the non-asthmatic group. The gene expression in the present study depicted much 
lower expression in the corticosteroid group than the other two groups. It is known 
that corticosteroids bind to glucocorticoid receptors (GRs), which activates the GRs 
to interact with co-repressor molecules, mainly HDAC2, to attenuate NF-κB 
associated co-activator activity, effectively reducing histone acetylation 
(Rajendrasozhan et al. 2008).  
In our study, the gene expression of HDAC2 was low, and there are several 
possible hypotheses as to why this occurred. Firstly, the GRs may recruit HDAC2 for 
translation much quicker in A-ST than in the other groups due to the treatment with 
corticosteroids causing a need for an abundance of HDAC2 protein. As the sputum 
induction technique collects only a single moment in time and there is a six hour 
incubation time between sputum inductions, it is highly possible that an up-
regulation of HDAC2 protein has already occurred, resulting in the low HDAC2 gene 
levels seen in the SI-3 sample. Secondly, it has been previously described that 
HDAC2 protein expression is lower in more severe asthmatics (Bhavsar et al. 2008), 
and it has only been shown that HDAC2 expression can be restored in mild 
asthmatics with corticosteroids (Ito et al. 2002). Deficiency in HDAC2 protein has 
been linked with corticosteroid insensitivity in vitro (Hew et al. 2006). It is evident 
that HDAC2 gene expression was lower in the A-ST group; however, the protein 
expression is unknown and was beyond the scope of this project. 
HDAC3 
There were no significant differences in the gene expression of HDAC3 either 
within or between the three participant groups. This suggests that HDAC3 does not 
190 Chapter 6: Discussion 
play a role in asthma or in the control of inflammation in normal airways. A recent 
study comparing gene microarray data in resting neutrophils from eosinophilic and 
non-eosinophilic asthma phenotypes had a significant 2.7-fold increase in HDAC3 
expression in the non-eosinophilic asthma type (Baines et al. 2010). The present 
study did not characterise groups by eosinophil concentration, but if we had done so 
differences in expression may have been noted, rather than the non-significant 
variability noticed in the HDAC3 expression in the three groups. 
HDAC4 
Gene expression of HDAC4 saw no significant differences between the groups 
in association with induced acute airway inflammation. Histone deacetylase 4 has not 
been previously linked to asthma. However, studies have linked HDAC4 to TNF-α, 
which is an important cytokine in the control of airway inflammation (Keslacy et al. 
2007). A study by Ito et al. (2005) showed that in COPD, HDAC4 is expressed in 
higher amounts than in normal healthy participants. Asthma and COPD are different 
diseases but do share similarities. 
HDAC5 
The HDAC5 gene saw higher expression in A-ST in both SI-2 and SI-3 
compared to the N-A group. The A-BD group also had high expression; however, 
due to variability, the increase was not significant compared to the N-A group. This 
suggests that HDAC5 may play a role in asthma regardless of severity. This does not 
agree with the hypothesis as lower HDAC expression was theorised in the asthmatic 
groups, suggesting that the HATs have a controlling role in causing uncontrolled 
inflammation in the airways. 
A recent study comparing gene microarray data in resting neutrophils from 
eosinophilic and non-eosinophilic asthma phenotypes had a significant 2.5-fold 
increase in HDAC5 in the non-eosinophilic asthma phenotype (Baines et al. 2010). 
Our study characterised airway inflammation as an increase in sputum neutrophils. 
Both of our asthma groups revealed higher concentrations of neutrophils post-
inflammation and, more importantly, a higher expression of HDAC5, which concurs 
with the Baines study. A COPD study by Ito et al. (2005) saw a decrease in HDAC5 
expression. The Ito study also analysed samples from mild asthmatics for HDAC 
activity and saw a non-significant decrease compared to non-asthmatics. Although 
HDAC5 expression is higher in the asthmatic groups, which does not support the 
  
Chapter 6: Discussion 191 
initial hypothesis, it is highly possible that the expression of HDAC5 is increased in 
order to try to combat inflammation in asthma. 
Histone Acetyltransferases 
The original hypothesis for HAT expression was that there would be increased 
expression in the asthmatic groups compared to the non-asthmatic group, indicating 
that hyper-acetylation is controlling the increased inflammation in the asthmatic 
airways. It was also hypothesised that the expression would be lower in the A-ST 
group compared to the A-BD group, suggesting that corticosteroids control the over-
production of HATs. With induced inflammation, it was thought that HAT expression 
would be higher in the A-BD group than the other groups. 
NCOA1 
Results for NCOA1 gene expression showed no significant difference in 
expression between the groups in association with induced acute airway 
inflammation. Highly variable but increased NCOA1 expression was seen in the A-
ST group compared to the N-A group, but did not reach significance. 
To date, the actual expression of NCOA1, both gene and protein, has not been 
described in asthma. However, there is evidence that NCOA1 is involved with 
binding to STAT6 (Razeto et al. 2004). This is important as the STAT6 signalling 
pathway is a much studied target for the treatment of allergic disease, and it is also 
known that STAT6 is crucial for class switching IgE, a pivotal factor in asthma 
pathogenesis (Razeto et al. 2004). 
NCOA2 
The NCOA2 gene expression results indicated higher expression in the A-ST 
group both before and after induction of inflammation compared to the N-A group. 
These results do not support the original hypothesis, yet suggest that increased HAT 
expression in the airways of the A-ST group compared to the N-A group signifies 
hyper-acetylation and increased inflammation as a result. The significantly lower A-
BD expression was unexpected and indicates that histone acetylation may not play a 
significant modulating role in mild intermittent asthma.  
Nuclear receptor co-activator 2 has been studied for its interaction with steroid 
medications. Studies have shown that NCOA2 interacts with the glucocorticoid 
receptor (GR), which is the receptor responsible for interaction with corticosteroid 
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medication (Bhandare et al. 2010). Corticosteroids bind to GR and are internalised 
into the nucleus where they transactivate or transrepress responsive genes. Treatment 
of steroid-resistant airway structural cells in vitro with NCOA2 has been 
demonstrated to restore corticosteroid responsiveness. The study demonstrated this 
by firstly producing steroid-insensitive cells by treating with interferon regulatory 
factor-1 (IRF-1). They noticed that NCOA2 depletion attenuated IRF-1 mRNA 
expression and reduced GR-mediated transactivation activities. This in turn restored 
steroid sensitivity to the cell line. These results suggest that NCOA2 plays a pivotal 
role in histone acetylation, and in steroid sensitivity. The present study is the first to 
use clinical samples to analyse NCOA2 gene expression. It is clear that NCOA2 plays 
a role in more severe asthmatics (A-ST). However, it is not clear yet what level of 
expression causes steroid insensitivity, and this would be a good topic for further 
study.  
NCOA3 
This study showed marked increases in NCOA3 mRNA in the A-ST group in 
SI-2 compared to the N-A and A-BD groups. A non-significant increase was seen in 
the A-ST group in SI-3 compared to N-A (p=0.06). This again showed that HAT 
gene expression is at a higher level in the A-ST group, indicating that HATs are more 
active and may play a role in the increased inflammation in asthma.  
A recent study by Baines et al. (2010) found a 16-fold increase for the NCOA3 
gene in the neutrophils of non-eosinophilic asthmatics compared to the eosinophilic 
phenotype. The present study did not categorise the asthmatics as eosinophilic or 
non-eosinophilic. Further sub-classification of the asthma groups may be an 
important step. However, the difference in NCOA3 expression was still seen in this 
study without the further classification. 
HAT-1 
Histone acetyltransferase-1 gene expression demonstrated significant increases 
in the A-ST group for SI-2 and SI-3 compared to the N-A and A-BD groups. This 
again demonstrated the over-expression of HATs in the A-ST group. It is clear that 
HATs, including HAT-1, play a significant role in moderate to severe asthma, as they 
are clearly expressed in higher levels in asthmatics medicating with corticosteroids. 
Apart from the discovery of the HAT-1 mRNA sequence, which was isolated 
from the human airway, no work has been done to identify its expression in the 
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airways or to compare expression in different asthma phenotypes. Histone 
acetyltransferase-1 has been shown to play a pivotal role in histone acetylation in 
other tissue types (Verreault et al. 1998). HAT-1 may play a role in the airway 
inflammation in asthma, and its expression is positively correlated with disease 
severity. 
CREBBP 
The CREBBP gene showed the biggest expression differences of all the HAT 
genes. The gene expression in the A-ST group was higher in SI-2 and SI-3 compared 
to the N-A and A-BD groups. What was very interesting was that the expression in 
SI-2 and SI-3 for the N-A and A-BD groups were very low, indicating that the two 
groups have similar expression. It is clear from the high expression in the A-ST 
group that CREBBP plays a pivotal role in their airways. 
CREBBP was once thought to be unable to acetylate histones on its own and 
was simply an adaptor between DNA-binding factors and PCAF (Yang et al. 1996), 
or transcription initiation factors (Kwok et al. 1994). A study by Ogryzko et al. 
(1996) not only determined that CREBBP can acetylate histones on its own, but also 
showed that it was an extremely potent acetyltransferase, able to acetylate all four 
core histones in nucleosomes. This led us to believe that CREBBP is a very important 
acetyltransferase and could play a pivotal role in the prevalence of hyper-acetylation 
in inflammatory disease. The role of histone acetylation in asthma has been discussed 
at great length, yet solid studies are rare. We have been able to describe the 
expression of CREBBP in non-asthmatics and asthmatics medicating with 
bronchodilators and corticosteroids. Not only has CREBBP expression been 
compared between the groups, the association that induced acute airway 
inflammation has on its expression has been analysed. 
 Chapter 7: Results 195 
Chapter 7: Proteomic Analysis of Non-
asthmatic Individuals and 
Asthmatics Medicating with 
Bronchodilators  
7.1 INTRODUCTION 
Proteomic techniques have recently become very popular due to their ability to 
analyse mixed samples and build a list of the sample’s constituents. This is extremely 
effective for clinical samples where, with the right sample preparation, the sample 
can be interrogated for its entire protein make-up. There are some problems 
associated with some proteomic approaches, including protein masking when high 
abundant, high molecular weight proteins are present, and some techniques are also 
quite expensive. 
In this study, we used a proteomic approach called iTRAQ, which has been 
developed to quantitatively interrogate amounts of protein constituents in a sample. It 
does this by comparing samples to one another by differentially labelling each 
sample. The samples are then fractionated and analysed by tandem mass 
spectrometry. This allows the proteins in the sample to be identified by protein type 
and chemical label, which means the proteins can be differentiated by sample. This 
in turn allows comparisons of protein concentration between samples.  
It must be stressed that, in this study, iTRAQ was used solely as a discovery 
tool to find proteins that are differentially expressed when compared between N-A 
and A-BD groups. Any protein found must subsequently be validated by other 
methods (immunology). Antibody detection methods can be very expensive and 
laborious, especially when the targets are unknown and the method is being used for 
discovery. Using iTRAQ allows the comparison of eight samples in one reaction, 
which makes analysis faster and more efficient. A problem with the iTRAQ approach 
is that it can be set up to compare treatments or compare two groups, but not both in 
one reaction.  
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For the purpose of this study, comparison was made between SI-2 and SI-3 for 
the N-A group, and again for the A-BD group. This method was used to analyse both 
the extracellular protein and intracellular protein collections of the sputum samples. 
The protein collections from the A-ST group were not analysed using iTRAQ and 
compared with the other groups due to both financial and time constraints. 
7.2 ITRAQ PROTEOMICS TO COMPARE EXTRACELLULAR PROTEIN 
SAMPLES OF NON-ASTHMATICS AND ASTHMATICS 
MEDICATING WITH BRONCHODILATORS  
7.2.1 Design 
This study used extracellular protein collections from session 2 (SI-2) and 
session 3 (SI-3) samples of eight non-asthmatics and eight asthmatics medicating 
with bronchodilators. The experiment was designed to analyse the difference in 
expression pre- and post-inflammation in the non-asthmatics and bronchodilator-
treated asthmatics. This approach presented some challenges in interpretation. The 
results identified changes in protein expression within each group between SI-2 and 
SI-3, which is valuable information. However, this method made quantifying the 
changes impossible. The inability to quantify the protein concentration in SI-2 and 
SI-3 samples meant that direct comparison could not be made between the groups at 
each session. It must be stressed that the iTRAQ technique has been used only as a 
discovery tool to find candidates appropriate for further validation. 
7.2.2 Results 
The iTRAQ analysis of the extracellular protein of N-A and A-BD groups 
returned 31 peptide hits (Appendix A). This is a low return for such a sample type 
and suggests abundance and/or molecular weight protein masking, protein loss 
during the processing stages, inefficient iTRAQ label binding or a combination of all 
of these.  
One peptide showed a significant change in concentration. The SCGB1A1 
protein displayed a reduction post-inflammation in both groups, but a 5-fold higher 
reduction in the A-BD group (p=0.02) (Figure 7.1). Unfortunately, no conclusion can 
be made about the changes between the groups (i.e. SI-2 N-A vs. SI-2 A-BD), as the 
method did not provide a quantitative measure because no standard was used so that 
more participant samples could be analysed.  
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Mucin-5B was an important protein identified by iTRAQ. As part of the 
processing involved the removal of mucins, it would appear that the technique was 
not successful. No differences were seen in association with induced acute airway 
inflammation in either group. 
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Figure 7.1.  The ∆ SI-3 – SI-2 fold change in SCGB1A1 protein expression in non-
asthmatics (N-A) compared to asthmatics medicating with bronchodilators (A-BD). 
Significance is indicated by * at p-value <0.05. 
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7.3 ITRAQ PROTEOMICS TO COMPARE INTRACELLULAR PROTEIN 
SAMPLES FOR NON-ASTHMATICS AND ASTHMATICS 
MEDICATING WITH BRONCHODILATORS  
7.3.1 Design 
This study used nuclear protein collections from session 2 (SI-2) and session 3 
(SI-3) samples of eight N-A and eight A-BD participants only. The experiment was 
designed to analyse the difference in expression pre- and post-inflammation in the N-
A and A-BD groups. In this experiment, the intracellular protein of the sputum cells 
was used. No depletions were performed, so the whole intracellular collection was 
interrogated. It must be stressed that the iTRAQ technique has been used only as a 
discovery tool to find candidates appropriate for further validation. 
7.3.2 Results 
Over the 16 samples analysed, 665 protein hits were identified (Appendix B). 
The samples contained many nuclear and cytoplasmic proteins, which indicated that 
the initial fractionation from the cells was unsuccessful and therefore the samples 
should be considered intracellular protein samples rather than nuclear samples. 
Despite this, eight of the proteins were found to have significant differences in 
expression in the A-BD group compared to the N-A group (p<0.05), and these are 
mentioned below. 
Significant Intracellular Proteins 
Results from iTRAQ do not elucidate the initial concentration of proteins in the 
sputum samples. This means that the reported change only comments on the change 
in association with airway inflammation in each group and not the relative 
concentration of one group compared to the other.  
Chloride Intracellular Channel Protein 1 
The changes in concentration of chloride intracellular channel protein 1 in the 
N-A and A-BD groups in association with airway inflammation are presented in 
Figure 7.2 A. A significant 1.07-fold increase in expression in association with 
airway inflammation was seen in the A-BD group compared to a 0.62-fold decrease 
seen in the N-A group (p=0.04).  
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Cystatin-A  
The changes in concentration of cystatin-A in the N-A and A-BD groups in 
association with airway inflammation are presented in Figure 7.2 B. Results showed 
an increase in SI-3 compared to SI-2 in the N-A group (1.45-fold) and a decrease in 
the A-BD group (0.97-fold; p=0.003). 
Keratin Type One Cytoskeletal Protein 19 (Keratin-19) 
The changes in concentration of keratin-19 in the N-A and A-BD groups in 
association with airway inflammation are presented in Figure 7.2 C. Results showed 
a small increase post-inflammation in the A-BD group (0.36-fold) and a significant 
decrease in the N-A group (1.52-fold; p=0.016).  
Eosinophil Cationic Protein  
The changes in concentration of eosinophil cationic protein in the N-A and A-
BD groups in association with airway inflammation are presented in Figure 7.2 D. 
Data showed an increase due to inflammation in the A-BD group (1.47-fold) 
compared to a decrease in the N-A group (1.27-fold), displaying a significantly 
different response to inflammation (p=0.008).  
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Figure 7.2.  Change in concentration from SI-2 to SI-3 for A) Chloride intracellular 
protein 1, B) Cystatin-A, C) Keratin type 1 cytoskeletal protein 19, and D) 
Eosinophil cationic protein in N-A and A-BD groups. 
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Calnexin  
The changes in concentration of calnexin in the N-A and A-BD groups in 
association with airway inflammation are presented in Figure 7.3 A. Results showed 
an increase in the A-BD group (1.57-fold) and a decrease in the N-A group (0.66-
fold; p=0.029).  
Peroxiredoxin-5 
The changes in concentration of peroxiredoxin-5 in the N-A and A-BD groups 
in association with airway inflammation are presented in Figure 7.3 B. An increase 
was seen in the A-BD group (1.25-fold) and a decrease in the N-A group (0.4-fold) 
in association with airway inflammation (p=0.017).  
ATP Synthase Subunit Delta, Mitochondrial 
The changes in concentration of ATP synthase subunit delta, mitochondrial in 
the N-A and A-BD groups in association with airway inflammation are presented in 
Figure 7.3 C. A 1.64-fold increase was noted in the A-BD group, while a very small 
0.38-fold decrease was seen in the N-A group (p=0.011).  
Mucin-5AC 
The changes in concentration of mucin-5AC in the N-A and A-BD groups in 
association with airway inflammation are presented in Figure 7.3 D. Through 
proteomic analysis, it was shown that there was a decrease in expression in the A-BD 
group (1.09-fold) post-inflammation and a small increase in the N-A group (0.4-fold; 
p=0.036). 
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Figure 7.3.  Change in concentration from SI-2 to SI-3 for A) Calnexin, B) 
Peroxiredoxin-5, C) ATP synthase subunit delta, mitochondrial, and D) Mucin-5AC 
in N-A and A-BD groups. 
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7.4 DISCUSSION 
7.4.1 ITRAQ Proteomics to Compare Extracellular Protein Samples for Non-
Asthmatics and Asthmatics Medicating with Bronchodilators  
Through the use of the iTRAQ kit, we wanted to identify new secreted proteins 
that are differentially regulated as a consequence of inflammation in the A-BD 
group. A secondary aim was to identify the TFFs and SCGBs in the samples and 
compare the concentration in the N-A and A-BD groups in association with induced 
acute airway inflammation. This proteomic approach positively identified SCGB1A1, 
which showed a decrease in both groups; however, the decrease in the A-BD group 
was 5-fold greater. This result supported the hypothesis in part, showing the expected 
decrease in the A-BD group in association with induced acute airway inflammation. 
The iTRAQ proteomic approach identified only 31 peptides from the secreted 
samples of N-A and A-BD groups. No experimental literature currently exists in 
regard to the use of iTRAQ for sputum analysis. Results of this study indicate that 
the iTRAQ procedure is possible on sputum samples. However, due to the small 
return of peptide hits, a better processing and fractionation method is needed. The 
method successfully identified SCGB1A1 in both N-A and A-BD groups in both SI-2 
and SI-3, finding a large decrease in protein concentration in SI-3 of the A-BD 
group. Interestingly, this does not correlate with the SCGB1A1 gene expression in the 
A-BD group (Figure 4.3), which showed an increase in SI-3. However, the 
proteomic and western blot data are similar to a decrease in SI-3 (Figure 4.10). 
Western blot data were similar to the proteomic result for the N-A group, with a 
decrease seen in SI-3 (Figure 3.10). Results suggested that the expression of 
SCGB1A1 protein is being silenced by a mechanism other than at the transcription 
level, and its lack of protein expression may contribute to the uncontrolled nature of 
inflammation in the A-BD participants. Unfortunately, SCGB3A2 was not found in 
any of the samples; however, it is known to be expressed in much smaller amounts 
than the SCGB1A1 protein, so this could be expected (de Burbure et al. 2007).  
This study is the first known to have used iTRAQ proteomics to interrogate 
sputum. Few previous studies have used a proteomic approach to identify the protein 
content of sputum and have highlighted the problem of mucin glycoproteins 
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interfering with iso-electric focusing in 2D-gel based proteomics and column 
fractionation (Nicholas et al. 2006).  
Mucin-5B was another protein found in all the samples. The processing of the 
extracellular protein samples included fractionation to pull off the high molecular 
weight mucin glycoproteins. Some contamination was to be expected, and no 
comparisons should be made due to the active removal of these proteins. Mucin-5B 
is the principal gel-forming mucin in the small airways of humans and is likely to 
perform most of the homeostatic clearance functions. A study by Evans et al. (2009) 
found that mucin-5AC production is up-regulated in asthma, whereas no differences 
were seen in mucin-5B production. This study found that mucins were abundant 
proteins that formed gels within the samples, making processing hard as most of the 
other proteins were attracted to these glycoproteins. 
In conclusion, performing the iTRAQ procedure on secreted protein samples 
revealed that this approach is possibly a very potent discovery tool for detecting 
proteins in sputum that may be of interest for further study. The method allows the 
detection of the proteins within a sample, and comparisons can be made between the 
expression of the proteins across groups or treatment types. The most significant 
result to date was the identification of SCGB1A1 protein, depicting a much greater 
decrease in expression post-inflammation in the A-BD group compared to the N-A 
group. These results are only preliminary data and need to be further validated. 
7.4.2 ITRAQ Proteomics to Compare Intracellular Protein Samples for Non-
Asthmatics and Asthmatics Medicating with Bronchodilators  
The primary focus of using iTRAQ to compare protein concentrations in 
association with airway inflammation in N-A and A-BD intracellular protein samples 
was to identify possible inflammatory targets that were up/down-regulated in the A-
BD group compared to the N-A group. The technique found differential expression 
of eight proteins, with the A-BD group displaying increased expression of chloride 
intracellular channel protein 1, eosinophil cationic protein, calnexin, peroxiredoxin-5 
(mitochondrial), ATP synthase subunit delta (mitochondrial) and cystatin-A, and 
decreases in keratin type 1 cytoskeletal protein 19 and mucin-5AC. 
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Significant Proteins 
Chloride intracellular channel protein 1 has previously been implicated in 
inflammation. A study by Gage et al. (2009) using proteomics to analyse the 
recruitment of proteins in mast cells upon stimulation showed that, upon activation of 
mast cells, chloride intracellular channel protein 1 is recruited to the nuclear 
membrane, suggesting it may play a role in airway inflammation. This is because 
mast cells are effector cells of the immune system that are well known for their 
presence and involvement in ongoing mediator release in bronchial asthma (Quesada 
et al. 2001).  
Cystatin is another protein that has been previously implicated in asthma, albeit 
analysed in the serum only. The present study was able to establish that, in 
association with airway inflammation, cystatin-A has an increased concentration in 
the non-asthmatic group and a decreased concentration in the bronchodilator group. 
These results reflect those of a study by Cimerman et al. (2001), which noted, 
through the use of ELISAs and serum samples, that cystatin-A levels of asthmatics 
were lower than non-asthmatics, and in response to methacholine challenge in the 
asthma group, levels decreased again, showing that the down-regulation is associated 
with induced bronchoconstriction and inflammation. Interestingly, they analysed 
corticosteroid-dependent asthmatics both before and after corticosteroid treatment 
(methylprednisolone), which showed a significantly higher expression of cystatin-A 
pre-treatment compared to the non-asthmatic group, and a similar expression to the 
non-asthmatics post-treatment. This shows that cystatin-A may play a role in asthma 
and is controllable through the use of corticosteroid medication. 
The small increase in keratin-19 concentration in the A-BD group may simply 
be explained by looking at the cell count data for each group. Columnar epithelial 
cells (bronchial epithelial cells) were counted both pre- and post-inflammation in the 
two groups. The N-A group displayed a SI-3 count half that of the SI-2 count. The 
A-BD SI-3 count showed an increase compared to SI-2. This demonstrates a 
correlation between keratin-19 concentration and bronchial epithelial cell 
concentration in the sputum samples, and may not be due to increased inflammation. 
However, there is reported evidence of differential expression of keratin-19 in 
asthma. A study by Choi et al. (2010) looked at the effect of toluene diisocyanate-
induced (TDI) exposure on bronchial epithelial cells in vitro in asthmatics and non-
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asthmatics. They found an increase in keratin-19 gene expression in the bronchial 
epithelial cells after exposure and a corresponding increase in the serum keratin-19 
protein. They concluded that TDI exposure augments keratin-19 expression from the 
bronchial epithelial cells, which may involve immune response as an auto-antigen to 
induce airway inflammation in asthmatics. Interestingly, a Kicic et al. (2006) study 
using airway epithelial cells obtained from mild intermittent allergic asthmatic 
children and a group of atopic non-asthmatics found that keratin-19 expression 
reduced with disease phenotype, with greatest expression in non-asthmatics and 
lowest in the asthmatics. It must be stressed that both studies, although using primary 
cells from humans, use multiple passages during the cell culture of the cells, and 
therefore may not mimic that of the same cell in its natural environment where it 
interacts with mediators from multiple cell types and responds accordingly. This 
means that the expression of keratin-19 may be very different in a true clinical 
sample.  
The finding and expression levels of eosinophil cationic protein (ECP) were of 
most interest from the iTRAQ data. Data suggested that in association with airway 
inflammation, ECP expression increases in A-BD and decreases in N-A. Eosinophil 
cationic protein has been measured previously in serum, plasma, saliva, broncho-
alveolar lavage and most importantly sputum (Escudero Pastor and Hernandez 
Garcia 1993). ECP is well correlated with airway inflammation, and it has been 
widely discussed as a marker of asthma. In a study that compared serum and sputum 
ECP levels with asthma severity using symptom scoring, sputum eosinophils and 
spirometry (FEV1 and FEV1/FVC), sputum ECP was found to be a much more 
sensitive marker of airway inflammation and asthma severity than serum ECP, and 
ECP levels were positively correlated with severity (Pizzichini et al. 1997). More 
recently, however, sputum ECP has been shown to be unacceptable as a marker of 
asthma as it is also raised in diseases such as allergic rhinitis, and nasal lavage fluids 
of sufferers of rhinovirus infection and bacterial sinusitis (Grunberg et al. 1997; 
Niehaus et al. 2000; Ahlstrom-Emanuelsson et al. 2004). Both serum and sputum 
ECP have been shown to correlate with severity of asthma as classified by the STEP 
classification of the National Heart, Lung and Blood Institute (NHLBI) (Badar et al. 
2004; Bartoli et al. 2004). Bartoli et al. (2004) showed that there is little difference in 
sputum ECP between mild and moderate asthmatics, suggesting it is more useful in 
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distinguishing between mild and severe asthmatics. The primary conclusion from this 
is that ECP concentration increase in SI-3 of the A-BD group is added evidence, 
other than the cell count data, that sputum induction performed in SI-2 caused acute 
airway inflammation for collection in SI-3. 
Calnexin is an important protein of the endoplasmic reticulum. It acts as a 
chaperone molecule assisting in protein folding and quality control. The endoplasmic 
reticulum is highly specialised for protein folding, with approximately one-third of 
proteins in eukaryotic cells translocated to the endoplasmic reticulum (Anfinsen 
1973). It is possible that an increase in inflammation in SI-3 of the A-BD group 
causes an increase in cellular activity and the production of proteins. Higher levels of 
calnexin are produced to help with the increased need for protein folding. 
The iTRAQ data also identified mitochondrial proteins. Mitochondrial 
peroxiredoxin-5 and ATP synthase subunit delta both showed increased protein 
levels in the bronchodilator group in the SI-3 samples. Peroxiredoxin-5 (PRDX-5) is 
an antioxidant enzyme produced by the mitochondria in human cells. During airway 
inflammation, the release of pro-inflammatory mediators recruits inflammatory cells 
(leukocytes) (Wood et al. 2003). The inflammatory cells release various free radicals 
such as superoxide anions, hydroxyl radicals, hydrogen peroxide and nitric oxide, 
which damage the epithelial cells in the airway. The asthmatic epithelium has 
previously been shown to be abnormally sensitive to apoptosis induced by oxidants, 
which is speculated as being due to a lack of protective factors (Fahn et al. 1998; 
Servais et al. 2005). Our results show that PRDX-5 is up-regulated in association 
with airway inflammation in asthmatics. This may be due to an increased presence of 
free radicals in the A-BD airways as a result of the increased inflammation. A study 
by Yuan et al. (2004) showed that in tendon cells, PRDX-5 expression is increased in 
hydrogen peroxide treated cells, indicating that it plays a protective role in human 
tendon cells against oxidative stress. A mouse asthma model study has also shown an 
increase in PRDX-5 expression compared to ‘non-asthmatic’ mice (Liu et al. 2008). 
Peroxiredoxin-5 increase in association with inflammation does not seem to be 
asthma specific or cell specific. The increase in expression in our asthma group does 
correlate with an increase in airway inflammation.  
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ATP synthase is a critical protein of the mitochondria, responsible for 
producing ATP from ADP, which is critical for producing energy that is usable for 
cells to perform their tasks. There is some evidence that the mitochondria play a role 
in the activity and pathogenesis of asthma. Roth and Black (2009) showed that in 
asthmatic airway smooth-muscle cells, there is a higher basal energy turnover due to 
an increased number and activity of mitochondria. The ATP synthase protein is 
expressed in higher amounts in the samples from the asthmatics possibly due to a 
combination of the airway cells having more mitochondria and also the need for 
energy to combat the higher amount of inflammation, which increases the activity of 
the mitochondria and in turn the proteins involved in creating the energy. 
Mucin-5AC was found to have increased protein levels in the non-asthmatic 
group and decreased levels in the bronchodilator group, in association with airway 
inflammation. These changes were quite small (<1-fold) and may be considered 
insignificant. The main issue with the iTRAQ procedure we used is that the baseline 
expression (SI-2) for each group could not be identified. This meant that the method 
was not quantitative as the quantities could not be compared between the groups at 
SI-2 and SI-3. The results extrapolated from the data are the amount of change in 
protein concentration in SI-3 compared to SI-2 within each group. It is highly 
possible that the concentration of mucin-5AC in the bronchodilator group is 10-fold 
higher than in the non-asthmatic group, yet we cannot tell from the information we 
retrieve from the data. Other studies have shown increases in mucin-5AC in 
asthmatics being responsible for mucus hyper-secretion, which is prevalent in 
asthma. A study by Ordonez et al. (2001) showed a 3-fold higher gene expression of 
mucin-5AC in airways of asthmatics than non-asthmatics. The study also showed 
that compared to non-asthmatics, mild asthmatics had increased stored mucins, while 
moderate asthmatics had increased stored and secreted mucins. The current study 
suggests that if we were able to identify the difference in concentration between the 
two groups, an increase would be seen in the A-BD group as mild asthmatics have 
increased stored mucin compared to the N-A group. 
In summary, interrogation of the non-asthmatic and bronchodilator 
intracellular protein samples found some very interesting proteins to be studied in the 
future to improve the knowledge of asthma. Unfortunately, the present iTRAQ 
procedure did not allow for direct comparison of pre-inflammation expression levels 
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of the proteins, which, when achieved, may elucidate many more proteins with 
significant differences in concentration between the N-A and A-BD group. Another 
possible future study will be to perform the same experiment and analysis on the 
samples collected from the A-ST group to compare the protein expression levels to 
N-A and A-BD groups. The iTRAQ kit is a worthwhile first step for revealing 
proteins that may be differentially expressed in a disease state for further 
experimentation. 
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Chapter 8: General Discussion 
8.1 INTRODUCTION 
The aim of this project was to analyse the gene expression of TFFs, SCGBs, 
HATs and HDACs in non-asthmatics (N-A), asthmatics medicating with 
bronchodilators (A-BD) and asthmatics medicating with corticosteroids (A-ST). The 
expression of the target genes was compared between the groups and in association 
with induced acute airway inflammation within the groups. The primary hypothesis 
was that induced acute airway inflammation would increase TFF and HAT 
expression, explaining the increase in inflammation, and decreases would be seen in 
SCGB and HDAC expression.  
However, when comparing the groups, it was hypothesised that TFF 
expression would be highest in the A-BD group, with low expression in the N-A 
group, signifying lower response to induced acute airway inflammation. Low 
expression was expected in the A-ST group also, signifying that corticosteroid 
medication controls the expression of TFFs, in-turn controlling airway inflammation. 
In regards to SCGB expression, the lowest expression was proposed to be in the A-
BD group, suggesting that a lack of SCGBs is in part responsible for the uncontrolled 
airway inflammation in asthmatics. For HAT and HDAC expression, it was 
hypothesised that the highest HAT and lowest HDAC expression would be found in 
the A-BD group, suggesting high histone acetylation, responsible for the increased 
inflammation. Low HAT and high HDAC expression would be seen in the N-A 
group, signifying well controlled airways, and high HDAC expression would be seen 
in the A-ST group, suggesting that corticosteroids up-regulated HDAC expression in 
order to combat HAT expression and lower airway inflammation. The protein 
expressions of TFF1, TFF3, SCGB1A1 and SCGB3A2 were analysed using a western 
blotting technique. It was expected that the same trend as expected in the gene 
expression would be seen. 
As a discovery tool, a proteomic approach called iTRAQ was used to 
interrogate both intra- and extra-cellular protein collections from pre- and post-
inflammation samples to identify regulation of proteins in the N-A and A-BD groups. 
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This technique was used to find candidate proteins for further validation and as a 
starting point for new avenues of research.  
The results from these studies, which were outlined in Chapter 3 to Chapter 7, 
contributed to new knowledge in the field of asthma and the expression of 
inflammatory proteins, epigenetic modification and its role in asthma, and a novel 
proteomic approach to interrogate sputum samples (iTRAQ). 
8.2 INFLAMMATION 
The principal aim of the project was to use sputum induction as a protocol to 
induce inflammation. Previous studies have shown that this technique is highly 
effective in both non-asthmatic and asthmatic airways (Holz et al. 1998; Nightingale 
et al. 1998). Significant increases in neutrophil counts in SI-3 samples compared to 
SI-2 samples were seen in both the A-BD and A-ST groups. The N-A group 
presented an increase in neutrophils, but this increase did not reach significance. The 
lack of significance was due to the neutrophil counts of two participants (N-A1 and 
N-A6). Removal of these outliers resulted in a significant increase in neutrophil 
counts in association with induced acute airway inflammation. The proteomics data 
in Chapter 7 identified an increase in eosinophil cationic protein (ECP) in association 
with induced acute airway inflammation in the intracellular protein from the A-BD 
group. An increase in ECP has previously been shown to be positively correlated 
with asthma severity (Pizzichini et al. 1997). This result may be used to validate the 
increase in inflammation in the A-BD group and therefore may be a candidate for 
assessing airway inflammation in asthmatics only. 
8.3 TREFOIL FACTORS (TFF1 AND TFF3) 
The data presented in this thesis is the first report of the differences in TFF1 
and TFF3 gene expression in association with induced acute airway inflammation in 
non–asthmatics (N-A), asthmatics medicating with bronchodilators (A-BD) and 
asthmatics medicating with corticosteroids (A-ST). Through the use of real-time 
PCR, this study found that when comparing TFF3 gene expression in SI-2 and SI-3, 
the A-BD group had a 7.3-fold increase in SI-3 (p=0.05). Comparisons of TFF3 
between the groups identified a 9-fold increase in the A-BD group compared to the 
N-A group in SI-3 (p=0.008). This result confirmed the hypothesis that TFF 
expression is higher in the A-BD group than the N-A group, identifying TFFs as 
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contributing to airway inflammation in asthma. Gene expression in the A-ST group 
was higher than the N-A group, however it was not deemed significant. 
Due to the inability to provide an effective loading control, and the variability 
of the protein constituents of the samples, no significant results were taken from the 
protein analyses. However, general analysis of the results did show some interesting 
yet non-significant changes. Western blot analysis of both TFF1 and TFF3 had 
varying increases in association with induced acute airway inflammation in the N-A 
and A-BD group.  A decrease was seen for both in the A-ST group and may be due 
to the corticosteroid treatment. This is further evidence that corticosteroid medication 
may control the expression of these pro-inflammatory proteins, contributing to the 
control of inflammation in asthma. The gene and protein expression of TFF3 in the 
A-BD group both showed an increase in association with induced acute airway 
inflammation. This is most likely because TFF3 plays a pivotal role in the induction 
of inflammation in asthmatics. No correlations were seen in the N-A group, with 
increases in TFF1 and TFF3 protein and no change in gene expression. No change in 
gene expression was seen in the A-ST group; however, decreases in the TFF1 and 
TFF3 proteins were seen. This may indicate a down-regulatory effect produced by 
the corticosteroid medication. 
This study is the first to compare the expression of TFF1 and TFF3 in 
association with induced acute airway inflammation through the use of sputum 
induction. A recent study by Hallstrand et al. (2010) showed an increase in TFF3 
mRNA levels in asthmatics in response to induced bronchoconstriction. The increase 
was seen in a subset of asthmatics with exercise-induced bronchoconstriction (EIB). 
The Hallstrand study used sputum induction to collect the samples. Through the 
induction of neutrophilic inflammation, the present study was able to identify 
significant TFF3 increases in the A-BD group. In the Hallstrand study, there was no 
mention of the possibility that the sputum induction may in fact play a part in the up-
regulation of TFF3 in asthmatics. This is made clearer by the smaller increase in 
TFF3 expression seen in a group of EIB-insensitive asthmatics in the Hallstrand 
study. This either proves that both phenotypes (EIB+ and EIB−) are susceptible to 
bronchoconstriction by their exercise protocol or, more likely, the sputum induction 
is inducing inflammation which is contributing to an increase in TFF3 gene 
expression. 
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Trefoil factors have been researched in other airway diseases. TFF3 was 
previously isolated in the human lower airways and found to be a significant 
constituent of airway mucus in patients with chronic bronchitis (Wiede et al. 1999). 
Dos Santos Silva et al. (2000) found TFF3 expression to be higher in cystic fibrosis 
sufferers than in normal healthy lungs. Chronic bronchitis and cystic fibrosis are both 
chronic inflammatory conditions. Asthma is effectively an inflammatory disease, and 
TFF3 may also play a major role. The present study is the first to compare TFF gene 
expression in non-asthmatic and asthmatic cohorts, and compare the effect 
bronchodilator and corticosteroid medication has on TFF expression. It is also the 
first study to analyse the differences in expression in association with induced acute 
airway inflammation, both within and between each of the three groups.  
Most experimental asthma research with TFFs has been performed using 
murine models. One such study by Kouznetsova et al. (2007) used an established 
mouse ‘asthma’ model (i.e. exposure to Aspergillus fumigates antigens) and showed, 
through the use of real-time PCR, elevated TFF1 levels in the challenged animals. 
The present study is a clinically relevant project, analysing the expression of TFFs in 
humans and human asthma. 
8.4 SECRETOGLOBINS (SCGB1A1 AND SCGB3A2) 
The expression of SCGB1A1 and SCGB3A2 was expected to be down-
regulated in the A-BD group compared to the N-A group, explaining the inherent 
uncontrolled nature of inflammation in asthma. We also expected the expression in 
the A-ST group to be higher than the A-BD group, suggesting corticosteroid control 
over the expression of the SCGBs in order to combat inflammation. Results 
suggested a marked SCGB1A1 increase in the A-BD group compared to the N-A 
group in the SI-3 sample. This was not as expected, but did suggest that SCGB1A1 is 
expressed in higher amounts in the A-BD group for use in combating inflammation. 
The A-ST group SCGB1A1 expression had similar low expression to the N-A group. 
This suggests that corticosteroids may play a role in the control of the SCGB1A1 
gene. The SCGB3A2 gene expression displayed an increase in the A-BD group pre-
inflammation compared to the N-A group. This again identifies the SCGBs as being 
up-regulated in the A-BD group. This suggests that the SCGB genes may be 
functioning as they should in defending the airways from inflammation. 
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Due to the inability to provide an effective loading control, and the variability 
of the protein constituents of the samples, no significant results were taken from the 
protein analyses.  However, general analysis of the results did show some interesting 
yet non-significant changes. Western blot analysis of the SCGB proteins in secreted 
samples suggested that SCGB1A1 is down-regulated in association with airway 
inflammation in all three groups. SCGB3A2 is down-regulated in the asthma groups 
and up-regulated in the N-A group. The gene and protein data did not match. There 
are multiple possible reasons for this finding. Collecting clinical samples such as 
sputum only provides a ‘snapshot’ of the levels of inflammatory cells, genes and 
proteins at the time of collection. The SI-3 collection was six hours post the initial 
induction. This may not have been the optimal time to collect a sample showing both 
gene and protein change. In the case of the N-A group with a protein increase in 
SCGB3A2 and low gene expression, it is possible that the protein translation had 
already occurred, resulting in depleted gene levels and increased protein levels. 
The proteomic analysis of the extracellular protein identified the presence of 
SCGB1A1 in both the N-A and A-BD groups. Comparison saw a decrease in both 
groups, which concurs with the western blot data. The decrease in the A-BD group, 
however, was greater, suggesting that there may be a far less abundance of SCGB1A1 
in the A-BD group than the N-A group, which could have a serious effect on the 
ability of the asthmatic airways to combat inflammation.  
A study by de Burbure et al. (2007) showed a significant increase in SCGB3A2 
expression and a non-significant but positive increase in SCGB1A1 in sputum of 
asthmatics compared to non-asthmatics. In the study, 13 of the asthmatics were 
smokers. A study by Chari et al. (2007) showed that tobacco smoke caused a 
decrease in SCGB1A1 expression in human airways. The pre-inflammatory gene 
expression figures in our study do reflect the de Burbure study. However, we have 
provided the first evidence of the change in gene expression as a result of induced 
acute airway inflammation and have shown an increase in A-BD group SCGB1A1 
expression that is significantly higher than the N-A and A-ST groups. The A-ST 
group’s results reflect those of the non-asthmatic group for SCGB1A1. This is 
evidence that the treatment of asthma with corticosteroids controls the expression of 
SCGB1A1 either directly or indirectly by the control of inflammatory pathways. A 
study by Inoue et al. (2008) looked at SCGB3A2 plasma levels in non-asthmatics, 
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mild asthmatics, moderate asthmatics and severe asthmatics. It found a small 
increase in expression in mild asthmatics compared to non-asthmatics, and a 
decrease in order of asthma severity. However, when the severe asthma group was 
split into corticosteroid-treated and untreated groups, the treated group showed 
significantly higher SCGB3A2 expression. These results directly reflect the result 
seen in the present study but in gene expression rather than protein. These results 
indicated that SCGB3A2 expression is similar in the airways as seen in the peripheral 
blood. 
8.5 HISTONE DEACETYLASES (HDAC1-5) 
We initially hypothesised that in the A-BD group, expression of HDAC1-5 
would be lower than in the N-A group. We also hypothesised that HDAC expression 
would be higher in the A-ST group than the A-BD group, suggesting that the 
corticosteroid treatment up-regulated the HDACs to control histone acetylation and 
stop the up-regulation of inflammatory genes. Results for HDAC1 confirmed the 
hypothesis, displaying higher expression pre-inflammation in the N-A and A-ST 
groups than the A-BD group. The A-ST group showed increased expression 
compared to the A-BD group in SI-2 and the N-A group in SI-3. Results suggested 
that HDAC1 plays an important role in corticosteroid treatment of asthma perhaps by 
controlling airway inflammation.  
The HDAC2 gene showed a different expression profile. The A-BD group 
exhibited increased expression post-inflammation compared to the A-ST group. This 
result suggested that HDAC2 may be more active in the A-BD group. Within the A-
ST group, a significant decrease in HDAC2 was seen in SI-3 compared to SI-2. It is 
known that HDAC2 plays a very important role in the anti-inflammatory pathway 
initiated by inhaled corticosteroids (Barnes 2010). This means that it is possible that 
an up-regulation of HDAC2 protein occurred in the A-ST group, resulting in lower 
gene abundance. The HDAC5 gene expression results showed increased SI-2 and SI-
3 expression in the A-ST group compared to the N-A group. This result again 
demonstrates that histone acetylation must play a role in asthma and quite possibly is 
positively linked with disease severity.  
A study by Ito et al. (2002) looking at the expression and activity of HDACs 
showed a significant reduction in HDAC1 protein expression in asthmatics compared 
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to non-asthmatics. The study also noticed that asthmatics medicating with 
corticosteroids had higher HDAC activity than untreated asthmatics, although still 
lower than non-asthmatic expression. This is similar to the HDAC1 gene expression 
results seen in the present study, and HDAC1 may play a role in pushing the higher 
HDAC activity in the A-ST population noticed in the Ito study. The Ito study also 
noticed a decrease in HDAC2 protein in untreated asthmatics. The difference in 
expression was small and the cohorts had only six participants. Our study 
incorporated the gene expression of 15 participants in each group, and depicted 
equally high yet variable expression in both the N-A and A-BD groups. The A-ST 
group in the Ito study showed similar protein expression to the N-A group.  
The gene expression in the present study depicted much lower gene expression 
in the A-ST group than the other two groups. Corticosteroids are known to bind to 
glucocorticoid receptors (GRs), which activates the GRs to interact with co-repressor 
molecules, mainly HDAC2, to attenuate NF-κB associated co-activator activity, 
effectively reducing histone acetylation (Rajendrasozhan et al. 2008). In this study, 
the gene expression of HDAC2 was lower in the A-ST group; there are multiple 
possible reasons for this. Firstly, the GRs may be recruiting the transcribed HDAC2 
genes for translation to be used due to the treatment with corticosteroids. Secondly, it 
has been previously described that HDAC2 protein expression is lower in more 
severe asthmatics (Bhavsar et al. 2008), and it has been shown that HDAC2 
expression can only be restored with corticosteroids in mild asthmatics (Ito et al. 
2002). The A-ST cohort in this study are not classified with severe asthma, so the 
first reason is most likely, but it would need to be verified by analysing the 
concentration of intracellular HDAC2 protein.  
A recent study comparing gene microarray data in resting neutrophils from 
eosinophilic and non-eosinophilic asthma phenotypes had a significant 2.5-fold 
increase in HDAC5 in the non-eosinophilic asthmatics (Baines et al. 2010). This 
study characterised airway inflammation as an increase in sputum neutrophils. The 
A-ST group revealed a higher concentration of neutrophils post-inflammation and, 
more importantly, a high expression of HDAC5, which concurs with the Baines 
study. A COPD study by Ito et al. (2005) saw a decrease in HDAC5 expression. The 
study also analysed samples from mild asthmatics for HDAC activity and saw a 
decrease, but it was not considered significant compared to non-asthmatics. Another 
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theory developed by Wang et al. (2002), believe that HDACs play a role in reseting 
chromatin modification states on effected genes and maintain an adequate level of 
histone acetylation, after the activities of polymerase II and HATs.  This is an 
interesting idea and reflects the idea of histone acetylation being a homeostatic 
process, with constant changes in HAT and HDAC activity. 
 
8.6 HISTONE ACETYLTRANSFERASES (NCOA1-3, HAT-1 AND 
CREBBP) 
The initial hypothesis for the gene expression of HATs was that their 
expression would be higher after the induction of inflammation. We further 
hypothesised higher expression levels in the A-BD group than the N-A group, and 
that the expression in the A-ST group would be lower than in the A-BD group, 
signifying a controlling effect by corticosteroid treatment. Results displayed that, for 
the most part, the expression of the HATs was low and conserved in the N-A and A-
BD group both pre- and post-induction of airway inflammation, with higher 
expression shown by the A-ST group. The NCOA2 gene displayed higher expression 
in the A-ST group than the N-A group in SI-2 and SI-3. The NCOA3 gene showed 
higher expression in the A-ST group compared to both N-A and A-BD groups in SI-
2 and a non-significant higher expression in SI-3 compared to N-A, with a p-value of 
0.06 indicating that there was almost significance in the data. Gene expression results 
for HAT-1 and CREBBP genes demonstrated higher expression in the A-ST group 
compared to the others both pre- and post-inflammation. All of the HAT results 
strongly suggested that histone acetylation plays a significant role in more severe 
asthma (A-ST group) as indicated by the increases compared to N-A and A-BD 
groups in some of the HATs analysed. 
Nuclear receptor co-activator 2 has been studied mainly for its interaction with 
steroid medications. Studies have shown NCOA2 to interact with the glucocorticoid 
receptor (GR), which is the receptor responsible for interaction with corticosteroid 
medication. Corticosteroids bind to GR and are internalised into the nucleus where 
they transactivate or transrepress responsive genes. Treatment of steroid-resistant 
airway structural cells with NCOA2 in vitro has demonstrated restored corticosteroid 
responsiveness (Bhandare et al. 2010). This was demonstrated by firstly producing 
steroid-insensitive cells by treating with interferon regulatory factor-1 (IRF-1). 
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NCOA-2 depletion was seen to attenuate IRF-1 mRNA expression and reduce GR-
mediated transactivation activities. These results suggest that NCOA2 plays a pivotal 
role in histone acetylation and in steroid sensitivity. The present study is the first to 
use clinical samples to analyse NCOA2 gene expression. It is clear that NCOA2 plays 
a role in more severe asthmatics (A-ST); however, it is not yet clear what level of 
expression causes steroid insensitivity, and this would be a good topic for further 
study.  
A recent study by Baines et al. (2010) found a 16-fold increase of the NCOA3 
gene in the neutrophils of non-eosinophilic asthmatics compared to the eosinophilic 
phenotype. The present study did not further sub-classify the participants by 
inflammatory cell phenotype.  
No current studies have analysed HAT-1 expression in the airways of humans. 
Histone acetyltransferase 1 has been studied for its role in histone acetylation in other 
human tissue types and has been shown to play a pivotal role (Verreault et al. 1998). 
It may be proposed that HAT-1 plays a role in airway inflammation in asthma, and its 
expression is positively correlated with disease severity.  
It was once commonly thought that CREBBP was unable to acetylate histones 
on its own and was simply an adaptor between DNA-binding factors and PCAF 
(Yang et al. 1996), or transcription initiation factors (Kwok et al. 1994). A study by 
Ogryzko et al. (1996) not only determined that CREBBP could acetylate histones on 
its own, but that it was also an extremely potent acetyltransferase, able to acetylate 
all four core histones in nucleosomes. The CREBBP gene was present in very high 
levels in the A-ST group. This leads us to believe that CREBBP is a very important 
acetyltransferase and could play a pivotal role in the prevalence of hyper-acetylation 
in inflammatory diseases, including asthma, where symptoms need corticosteroid 
treatment. The presence and activity of histone acetylation in asthma has been 
discussed at great length, yet solid studies are rare. This study provides new research 
into the gene expression of HATs in N-A, A-BD and A-ST cohorts. 
8.7 PROTEOMICS 
To provide future direction for this study, proteomics was employed to identify 
possible new proteins, both extracellular and intracellular, from the sputum of the N-
A and A-BD groups that may be involved with or modulated by the induction of 
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inflammation. The extracellular (secreted) protein and intracellular protein from the 
sputum of N-A and A-BD participants’ SI-2 and SI-3 collections were interrogated 
using a proteomic approach called iTRAQ. iTRAQ allowed the identification of the 
protein constituents of the samples as well as semi-quantifying the relative 
concentrations in SI-3 compared to SI-2. This allowed the detection of the up/down-
regulation of proteins associated with airway inflammation. This approach was a first 
step only, with further validation needed. 
Extracellular Protein Analysis 
A total of 41 peptides were identified from the proteomic analysis. The 
identification of the SCGB1A1 protein linked this study with the other studies in this 
project. The SCGB1A1 protein was identified in both N-A and A-BD groups, with 
results indicating a down-regulation of the protein in SI-3 compared to SI-2. The A-
BD group exhibited a much greater decrease in response to inflammation. These 
results corresponded to the western blot data for SCGB1A1 described previously.  
The iTRAQ procedure did not identify the SCGB3A2 protein, or the TFF1 and 
TFF3 proteins. Studies have shown SCGB1A1 protein to be expressed at much 
higher levels than SCGB3A2, which suggests that SCGB3A2 may be in low 
abundance and  this procedure wasn’t sensitive enough to pick it up  (de Burbure et 
al. 2007).  
The mucin proteins were extracted as part of sample processing. Studies have 
shown that TFFs interact with mucins, and they are known to be bound together 
(Wiede et al. 2001). Reduction and fractionation caused the high molecular weight 
mucins to release any of the proteins as visualised by PAGE gel with silver stain and 
alcian blue staining. We believe that the TFFs were not removed with the mucin 
proteins, however 100% separation cannot be guaranteed. The mucin proteins had to 
be removed as previous experiments performed without mucin removal blocked the 
filter columns during HPLC and mass spec analysis, causing expensive damage to 
the machines.  
This study is the first known to use iTRAQ proteomics to interrogate sputum. 
Few previous studies have used a proteomic approach to identify the protein content 
of sputum and have highlighted the problem of mucin glycoproteins interfering with 
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iso-electric focusing in 2D-gel based proteomics and column fractionation (Nicholas 
et al. 2006). 
In conclusion, performing the iTRAQ procedure on secreted protein samples 
revealed that it is possibly a very potent analysis tool for detecting proteins in sputum 
that may be of interest for further study. iTRAQ identified information about the 
proteins within the sample, as well as whether the expression of the proteins was 
modulated according to disease type and inflammatory status. One positive result 
was the identification of the expression of SCGB1A1 protein, which showed a much 
greater decrease in expression post-inflammation in the A-BD group than the N-A 
group.  
Intracellular Protein Analysis 
The primary focus of using iTRAQ to compare protein concentration in 
association with airway inflammation in N-A and A-BD intracellular protein samples 
was to identify possible inflammatory targets that were up/down-regulated in the A-
BD group compared to the N-A group. The technique found 665 peptides, with 
differential expression found in eight proteins. The A-BD group saw significant 
increases in association with airway inflammation for chloride intracellular channel 
protein 1, keratin type I cytoskeletal 19, eosinophil cationic protein, calnexin, 
peroxiredoxin-5 (mitochondrial) and ATP synthase subunit delta (mitochondrial), 
and decreases in cystatin-A and mucin-5AC, compared to the N-A group. 
In conclusion, interrogation of the N-A and A-BD intracellular protein samples 
found some very interesting proteins to be used in the future to study their 
involvement and capabilities as asthma markers and/or targets for treatment. The 
results of this study must be validated immunologically to assure true results from 
the iTRAQ procedure. The present iTRAQ procedure did not allow for quantitative 
comparison of pre-inflammation expression levels of the proteins, which would be a 
better method to use with iTRAQ. When a quantitative method is achieved, the 
results will identify all the differential expression between the two groups both pre- 
and post-inflammation, adding another dimension to the data and many more 
positive results. 
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8.8 LIMITATIONS 
This project was not without its limitations. A lot of problems were 
encountered that involved having to change direction or make a compromise. 
The first limitation, and probably the most important, was the use of clinical 
samples as the biological material on which all further experimentation was based. 
The use of sputum meant that individual samples varied greatly in quality and 
quantity. Sputum induction is an effort based test and not all participants were able to 
produce an acceptable sample. Drop-out rate was also high. Each participant needed 
to participate in three sputum inductions, so if someone dropped out after the first 
session or a participant was not able to produce a sample for one of the sessions, it 
meant the recruitment of a new participant, which cost time, money and effort. 
Another limitation in this study was the variability of volume and 
concentration of the sputum samples. Concentration of cells in the individual 
samples varied greatly, which resulted in high variability in subsequent RNA and 
protein concentrations extracted from the samples. This posed a problem with some 
samples not containing enough material to perform all the planned experiments.  
The use of a mixed cell population to analyse the expression of genes did 
present limitations. For instance, the expression of certain genes may have been 
affected differently by the presence of neutrophils and macrophages. An example 
may be that the increase of neutrophils stimulates the increase in expression of a 
certain gene, while the decrease of macrophages stimulates a decrease in that same 
gene. This may negate the effects of each stimulus and result in no change in the 
expression of this gene. We would argue that for this reason, investigating gene 
expression in the total cell population of a sputum collection reflects a real analysis 
of what is happening in the airways, not what is being stimulated by different 
mediators.  It would have been interesting to analyse the expression of the target 
genes by the individual cells of the sputum samples. This would have resulted in 
identifying which genes are stimulated by which cells. 
The extracellular protein samples were complex and took a lot of processing to 
clean up for the experiments. They contained DTT, which is a potent reducing agent, 
to break bonds between the mucins and other proteins in the sample. The DTT made 
quantifying the protein levels difficult as the DTT concentrations were higher than 
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normal BCA assays were capable of handling. The use of the Bradford assay enabled 
quantification of sample protein concentrations; however, the Bradford assay is 
known to be less accurate. The processing of the extracellular protein samples for 
iTRAQ analysis resulted in the extraction of DTT from the samples and allowed the 
use of BCA assay for protein concentration analysis. Mucin proteins were a major 
constituent of the extracellular protein samples, as they are the main secreted protein 
of the airways. All samples contained mucins and during the processing of the 
extracellular protein samples, large gel plugs formed. These ‘plugs’ were the mucins 
binding to each other and other proteins to form a clot-like structure. This problem 
was rectified in the proteomic processing by trypsin digest and fractionation; 
however, we cannot be 100% confident that concentrations of the other proteins were 
not affected, and the effectiveness of this may be displayed by the fact that our 
proteomic results only identified 31 peptides. 
Cytokine measurement was performed using a Biorad Bioplex assay as another 
method to measure the inflammation in the sputum samples. This was a flow 
cytometric method to analyse the concentration of bound cytokines to immuno-
beads. The analysis of TNF-α and IL-10 was performed; however, all experiments 
failed and were not reported in the project. The highest possible concentration that 
allowed equal loading was used (1 mg/mL), with almost all samples falling under the 
lowest standard or not registering at all, which suggested degradation of the samples. 
No protease inhibitors were used when initially processing the samples. This 
highlights the need for the addition of a protease inhibitor, preferably added at the 
end of the sputum induction to assure no degradation of the proteins during the 
processing steps performed at room temperature. The proteomics and western blot 
procedures worked; however, it is unknown whether the addition of a protease 
inhibitor may have influenced the results. The Bioplex system was used to further 
prove the induction of inflammation in SI-3 samples in terms of cytokine expression. 
This system was chosen over conventional ELISAs as it was more cost effective due 
to the ability to perform multiple cytokine analysis per sample, within a kit. It was 
more efficient in terms of sample usage which was vital considering the small 
amount of sample collected which was needed to western blot and proteomic work. 
The failure of the experiment restricted us to the use of neutrophil counts only to 
indicate inflammation in the group’s samples. 
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Another problem was encountered when performing the western blots. The 
extracellular protein samples represented the secreted proteins in the airways of the 
participants. This type of protein sample does not contain any measurable structural 
proteins for use as an internal loading control. Other studies have used coomassie 
and ponceau staining to get around this. Coomassie staining of 1D gels was 
performed to indicate equal loading of the samples (Appendix C). Results showed 
variable expression profiles between the samples. The most probable reason for this 
is varying levels of saliva contamination. This not only changes the dilution of the 
sample, but it also adds saliva proteins to the mix, which change the type and amount 
of proteins in the samples. As part of the sputum induction, inflammation is induced, 
which is expected to change the expression of a myriad of proteins and result in 
different staining patterns within each sample. To limit saliva contamination, we had 
the participants spit any saliva directly before they expectorated sputum. Other 
studies have used the sputum plug selection technique to obtain high quality sputum 
samples from the collection. This eliminates saliva contamination completely. 
However, it may also eliminate a lot of the secreted proteins from the sample, which 
we needed to collect for experimentation. 
The design of this project involved relying on three samples of high quality 
from each participant. It was noticed with most of the real-time data that there was 
quite a bit of variability between SI-1 and SI-2 sessions. Having no influence on the 
participants outside of the testing sessions, it is quite possible that environmental 
factors played a part in causing the variability. The way around this was to discount 
SI-1 and count SI-2 as the better example of a pre-inflammation sample to compare 
to SI-3 as they were collected on the same day. Another problem with using one 
sample as a post-inflammation sample is the time after the initial sputum induction 
that it was collected. The response rate of the expression of any of the target genes 
and proteins in association with airway inflammation in the three groups is not 
known. It is highly possible that each of the dependent variables are transcribed and 
translated at different speeds, and that those speeds may differ between the groups. 
This is unavoidable, and so we only comment on what we found at six hours after the 
induction of inflammation. Collecting multiple samples at varying time points (i.e. 
every hour for six hours) would not have been acceptable in terms of participant 
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comfort, specimen processing and time management as it would increase the number 
of samples for experimentation more than 2-fold. 
The iTRAQ procedure proved to be a potential powerful tool to discover 
differentially expressed proteins in sputum samples. An issue with the iTRAQ 
method used in this study was that the baseline concentration (SI-2) for each group 
could not be quantified. This made quantitative comparison between the two groups 
impossible. The method identified a relative change in association with airway 
inflammation within each group. A procedure must be designed to quantify baseline 
expression in the two groups as this will identify differences in protein 
concentrations between the groups, and find many more proteins of interest due to 
their differential expression both between and within the groups in association with 
induced acute airway inflammation. This improved method is possible and would 
include the addition of a protein standard, which would allow the quantities of the 
peptides identified in each sample to be determined, resulting in a fully quantitative 
analysis. The iTRAQ procedure is only a discovery tool to identify potential 
candidates for further research. It is important to validate the proteins identified 
before the data can truly be trusted. This study has not performed the validation; 
however, this would be the first step in further study. 
8.9 FUTURE DIRECTIONS 
The current project reported the gene expression of TFFs, SCGBs, HDACs and 
HATs in association with induced acute airway inflammation in non-asthmatics, 
asthmatics medicating with bronchodilators and asthmatics medicating with 
corticosteroids. A future direction for this project would be to better quantify the 
protein expression of all the targets in the three groups. It would be interesting to use 
a proteomic approach due to the high number of samples and proteins to be analysed. 
Selected reaction monitoring (SRM) is a proteomic tool that can be used to 
selectively interrogate a sample using a mass spectrometry approach. The procedure 
allows both the identification and quantification of chosen targets, and it is known 
for its high sensitivity and specificity. To better determine the activity of histone 
acetylation in the samples from the three groups, HAT and HDAC activity needs to 
be measured, which is possible with commercially available kits. It would also be 
advantageous to analyse the protein expression of the HATs and HDACs chosen to 
identify their protein expression in response to treatment in asthma. The proteomic 
226 Chapter 8: General Discussion 
approach used in this project was highly successful in interrogating intracellular 
protein from sputum induction. The same process needs to be performed for the A-
ST samples and a method needs to be adopted allowing better comparison of 
concentration of proteins between the groups. This will identify an inflammatory 
protein profile that can be validated and further explored for possible biomarker 
discovery, eventually leading to clinical use as well as possible treatment strategies. 
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The following chapter outlines the primary results of the entire project. A 
number of significant findings were identified through the analysis of airway cells of 
non-asthmatics (N-A), asthmatics medicating with bronchodilators (A-BD) and 
asthmatics medicating with corticosteroids (A-ST). 
The primary purpose was to analyse the gene expression of TFF1, TFF3, 
SCGB1A1, SCGB3A2, HDAC1-5, NCOA1-3, HAT-1 and CREBBP in N-A, A-BD 
and A-ST groups. This project used sputum induction for both the collection and 
induction of airway inflammation. This was achieved by performing an initial 
sputum induction to collect a baseline sample and stimulate acute airway 
inflammation, followed by a second sputum induction six hours later to collect an 
inflamed sample. Sputum induction creates a mechanical induction of inflammation 
that consequently causes a neutrophilic influx. Airway inflammation was induced so 
the expression of the aforementioned target genes could be compared both within 
and between the groups, to identify any changes in expression in association with 
induced acute airway inflammation. 
The analysis of induced inflammation was conducted using differential cell 
counts. This method allowed the comparison of the distribution of leukocytes in the 
pre- and post-inflammation samples. The cell counts for each group are presented in 
Figure 9.1. Of the 15 N-A participants, only 14 had appropriate sample for further 
analysis. Cell counts of the N-A group initially showed no significant change in 
neutrophil counts between the samples. This result was due to two outliers (N-A1 
and N-A6), and when the outliers were removed, a significant 21% units increase 
was seen (p=0.01). The A-BD group displayed a 27% unit increase in SI-3 compared 
to SI-2 (p=0.04) with a full cohort of 15 participants. The A-ST group also had a 
significant increase in neutrophils of 29% units (p=0.01) in a full cohort of 15. These 
results showed that the sputum induction protocol induced inflammation in the 
samples, which allowed the comparison of gene expression between SI-2 and SI-3 
samples to be associated with induced acute airway inflammation.  
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Analysis of the expression of the target genes within each group identified few 
significant differences in association with induced acute airway inflammation 
(Figure 9.1). In the N-A group, a 5.5-fold decrease was seen in HDAC1 expression 
in SI-3 compared to SI-2 (p=0.03). The A-BD group displayed a 7.3-fold increase in 
TFF3 (p=0.05) and a 2.8-fold increase in SCGB1A1 (p=0.03) in SI-3 compared to SI-
2. The A-ST group had a 7.6-fold decrease in HDAC2 expression in SI-3 compared 
to SI-2 (p=0.001).  
The expression of all the target genes was compared between the N-A, A-BD 
and A-ST groups, which identified changes in the target genes as associated with 
asthma and medication type. Comparisons between the N-A and A-BD groups had a 
9-fold higher TFF3 and 34-fold higher SCGB1A1 expression in the A-BD group in 
SI-3. This result indicated that induced acute airway inflammation has an up-
regulating effect on TFF3 and SCGB1A1 in the A-BD group compared to the N-A 
group. Comparisons of the A-ST group to the N-A group had higher expression in 
the A-ST group for HDAC1, HDAC5, NCOA2, NCOA3, HAT-1 and CREBBP 
(Figure 9.1). These results indicated that histone acetylation is much more active in 
the A-ST group than in the N-A group. Comparisons of the A-ST and A-BD groups 
showed increased expression in the A-ST group of HDAC1, HDAC2, NCOA3, HAT-
1 and CREBBP, which indicated that histone acetylation is more active in the A-ST 
group than in the A-BD group. 
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Figure 9.1.  Cell counts and real-time PCR data for the non-asthmatics (N-A), asthmatics medicating with bronchodilators (A-BD) and 
asthmatics medicating with corticosteroids (A-ST). 
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The protein expression of TFF1, TFF3, SCGB1A1 and SCGB3A2 were 
compared within the groups in the SI-2 and SI-3 samples. Problems with low 
concentrations of the extracellular protein samples resulted in smaller cohort sizes in 
all the groups for some of the proteins analysed. Densitometry results showed that in 
the N-A group, TFF1 protein was increased in SI-3 in 9 of the 13 participants 
analysed; TFF3 was increased in 10 of 12; SCGB1A1 was decreased in 9 of 13; and 
SCGB3A2 was increased in 8 of 11. These changes were as initially hypothesised 
with the exception of SCGB3A2 showing an increase in association with induced 
acute airway inflammation. It is clear now that in non-asthmatics, better control of 
airway inflammation exists and the increased production of SCGB3A2 may be part of 
this. The A-BD group showed that TFF1 protein was increased in 8 of 14 
participants in SI-3; TFF3 was increased in 8 of 14 analysed; and that 7 participants 
showed an increase in both. The A-BD group displayed decreases in SCGB1A1 in 11 
of 14 participants, and SCGB3A2 in 8 of 14 participants. The A-ST group displayed 
different results for TFF levels than the A-BD group, with a decrease in a TFF1 in 6 
of 9 participants, and a decrease in TFF3 in 10 of 12 participants. The A-ST group 
had decreases in SCGB1A1 expression in 11 of 13, and SCGB3A2 in 6 of 9 
participants. 
Lastly, as a discovery measure, a proteomic approach called iTRAQ was used 
to interrogate the SI-2 and SI-3 extracellular and intracellular protein samples of the 
N-A and A-BD groups. The main purpose of this was to develop a proteomic method 
to quickly interrogate the samples to find proteins that are regulated in association 
with induced acute airway inflammation. This method was used as a first step only. 
Further validation is needed to prove that the changes seen exist. However, this 
method is a good screening tool, much like microarray for gene analysis. Figure 9.2 
shows the proteins identified and the changes that were seen in expression. The eight 
proteins seen need further validation, using western blot analysis to prove that the 
changes in the intracellular proteins are in association with induced acute airway 
inflammation. However, these results do provide a reason to perform further analysis 
on these proteins. The proteins that showed differential expression in the A-BD 
group are candidates for further research. 
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Figure 9.2.  Flow diagram presenting the western blot data for non-asthmatics (N-A), asthmatics medicating with bronchodilators (A-BD) and 
asthmatics medicating with corticosteroids (A-ST). Proteomic iTRAQ data presented for the extracellular and intracellular protein collections 
from the N-A and A-BD groups. 
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Appendix A Extracellular Protein Identification from ITRAQ Proteomic Analysis 
N Accession Name 
1 sp|Q8TDL5|LPLC1_HUMAN Long palate, lung and nasal epithelium carcinoma-associated protein 1 OS=Homo sapiens GN=LPLUNC1 PE=2 
SV=1 
2 sp|P02768|ALBU_HUMAN Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 
3 sp|Q9HC84|MUC5B_HUMAN Mucin-5B OS=Homo sapiens GN=MUC5B PE=1 SV=2 
4 sp|P04745|AMY1_HUMAN Alpha-amylase 1 OS=Homo sapiens GN=AMY1A PE=1 SV=2 
5 sp|P01833|PIGR_HUMAN Polymeric immunoglobulin receptor OS=Homo sapiens GN=PIGR PE=1 SV=4 
6 sp|P01876|IGHA1_HUMAN Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2 
7 sp|P25311|ZA2G_HUMAN Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 PE=1 SV=1 
8 sp|Q9NP55|PLUNC_HUMAN Protein Plunc OS=Homo sapiens GN=PLUNC PE=1 SV=1 
9 sp|P31025|LCN1_HUMAN Lipocalin-1 OS=Homo sapiens GN=LCN1 PE=1 SV=1 
10 sp|P12273|PIP_HUMAN Prolactin-inducible protein OS=Homo sapiens GN=PIP PE=1 SV=1 
11 sp|P11684|UTER_HUMAN Uteroglobin OS=Homo sapiens GN=SCGB1A1 PE=1 SV=1 
12 sp|P98088|MUC5A_HUMAN Mucin-5AC (Fragments) OS=Homo sapiens GN=MUC5AC PE=1 SV=3 
13 sp|Q9UGM3|DMBT1_HUMAN Deleted in malignant brain tumors 1 protein OS=Homo sapiens GN=DMBT1 PE=1 SV=2 
14 sp|P01834|IGKC_HUMAN Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1 
15 sp|P61626|LYSC_HUMAN Lysozyme C OS=Homo sapiens GN=LYZ PE=1 SV=1 
16 sp|P01842|LAC_HUMAN Ig lambda chain C regions OS=Homo sapiens GN=IGLC1 PE=1 SV=1 
246 Appendices 
17 sp|Q96QR1|SG3A1_HUMAN Secretoglobin family 3A member 1 OS=Homo sapiens GN=SCGB3A1 PE=1 SV=2 
18 sp|Q6P5S2|CF058_HUMAN Uncharacterized protein C6orf58 OS=Homo sapiens GN=C6orf58 PE=1 SV=2 
19 sp|Q16378|PROL4_HUMAN Proline-rich protein 4 OS=Homo sapiens GN=PRR4 PE=1 SV=2 
20 sp|P07988|PSPB_HUMAN Pulmonary surfactant-associated protein B OS=Homo sapiens GN=SFTPB PE=1 SV=3 
21 sp|P01591|IGJ_HUMAN Immunoglobulin J chain OS=Homo sapiens GN=IGJ PE=1 SV=4 
22 sp|P23280|CAH6_HUMAN Carbonic anhydrase 6 OS=Homo sapiens GN=CA6 PE=1 SV=3 
23 sp|Q8TAX7|MUC7_HUMAN Mucin-7 OS=Homo sapiens GN=MUC7 PE=1 SV=1 
24 sp|P09228|CYTT_HUMAN Cystatin-SA OS=Homo sapiens GN=CST2 PE=1 SV=1 
25 sp|P02788|TRFL_HUMAN Lactotransferrin OS=Homo sapiens GN=LTF PE=1 SV=6 
26 sp|P10909|CLUS_HUMAN Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 
27 sp|P04080|CYTB_HUMAN Cystatin-B OS=Homo sapiens GN=CSTB PE=1 SV=2 
28 sp|Q14508|WFDC2_HUMAN WAP four-disulfide core domain protein 2 OS=Homo sapiens GN=WFDC2 PE=1 SV=2 
29 sp|Q96HU1|SGSM3_HUMAN Small G protein signaling modulator 3 OS=Homo sapiens GN=SGSM3 PE=1 SV=1 
30 RRRRRsp|Q7Z3J2|CP062_HUMAN REVERSED UPF0505 protein C16orf62 OS=Homo sapiens GN=C16orf62 PE=1 SV=2 
31 sp|Q562R1|ACTBL_HUMAN Beta-actin-like protein 2 OS=Homo sapiens GN=ACTBL2 PE=1 SV=2 
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N Accession Name 
1 sp|A0M8Q6|LAC7_HUMAN Ig lambda-7 chain C region OS=Homo sapiens GN=IGLC7 PE=1 SV=2 
2 sp|A6NI72|NCF1B_HUMAN Putative neutrophil cytosol factor 1B OS=Homo sapiens GN=NCF1B PE=5 SV=2 
3 sp|A6NL28|TPM3L_HUMAN Putative tropomyosin alpha-3 chain-like protein OS=Homo sapiens PE=5 SV=2 
4 sp|A8K2U0|A2ML1_HUMAN Alpha-2-macroglobulin-like protein 1 OS=Homo sapiens GN=A2ML1 PE=1 SV=3 
5 sp|A8K7I4|CLCA1_HUMAN Calcium-activated chloride channel regulator 1 OS=Homo sapiens GN=CLCA1 PE=1 SV=3 
6 sp|O00299|CLIC1_HUMAN Chloride intracellular channel protein 1 OS=Homo sapiens GN=CLIC1 PE=1 SV=4 
7 sp|O00602|FCN1_HUMAN Ficolin-1 OS=Homo sapiens GN=FCN1 PE=1 SV=2 
8 sp|O00748|EST2_HUMAN Carboxylesterase 2 OS=Homo sapiens GN=CES2 PE=1 SV=1 
9 sp|O00764|PDXK_HUMAN Pyridoxal kinase OS=Homo sapiens GN=PDXK PE=1 SV=1 
10 sp|O14745|NHRF1_HUMAN Na(+)/H(+) exchange regulatory cofactor NHE-RF1 OS=Homo sapiens GN=SLC9A3R1 PE=1 SV=4 
11 sp|O14773|TPP1_HUMAN Tripeptidyl-peptidase 1 OS=Homo sapiens GN=TPP1 PE=1 SV=2 
12 sp|O14880|MGST3_HUMAN Microsomal glutathione S-transferase 3 OS=Homo sapiens GN=MGST3 PE=1 SV=1 
13 sp|O15144|ARPC2_HUMAN Actin-related protein 2/3 complex subunit 2 OS=Homo sapiens GN=ARPC2 PE=1 SV=1 
14 sp|O15145|ARPC3_HUMAN Actin-related protein 2/3 complex subunit 3 OS=Homo sapiens GN=ARPC3 PE=1 SV=3 
15 sp|O15511|ARPC5_HUMAN Actin-related protein 2/3 complex subunit 5 OS=Homo sapiens GN=ARPC5 PE=1 SV=3 
16 sp|O15533|TPSN_HUMAN Tapasin OS=Homo sapiens GN=TAPBP PE=1 SV=1 
17 sp|O43169|CYB5B_HUMAN Cytochrome b5 type B OS=Homo sapiens GN=CYB5B PE=1 SV=2 
18 sp|O43653|PSCA_HUMAN Prostate stem cell antigen OS=Homo sapiens GN=PSCA PE=1 SV=1 
19 sp|O43707|ACTN4_HUMAN Alpha-actinin-4 OS=Homo sapiens GN=ACTN4 PE=1 SV=2 
20 sp|O60218|AK1BA_HUMAN Aldo-keto reductase family 1 member B10 OS=Homo sapiens GN=AKR1B10 PE=1 SV=1 
21 sp|O60437|PEPL_HUMAN Periplakin OS=Homo sapiens GN=PPL PE=1 SV=3 
22 sp|O60664|PLIN3_HUMAN Perilipin-3 OS=Homo sapiens GN=PLIN3 PE=1 SV=2 
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23 sp|O75083|WDR1_HUMAN WD repeat-containing protein 1 OS=Homo sapiens GN=WDR1 PE=1 SV=4 
24 sp|O75347|TBCA_HUMAN Tubulin-specific chaperone A OS=Homo sapiens GN=TBCA PE=1 SV=3 
25 sp|O75348|VATG1_HUMAN V-type proton ATPase subunit G 1 OS=Homo sapiens GN=ATP6V1G1 PE=1 SV=3 
26 sp|O75367|H2AY_HUMAN Core histone macro-H2A.1 OS=Homo sapiens GN=H2AFY PE=1 SV=4 
27 sp|O75368|SH3L1_HUMAN SH3 domain-binding glutamic acid-rich-like protein OS=Homo sapiens GN=SH3BGRL PE=1 SV=1 
28 sp|O75390|CISY_HUMAN Citrate synthase, mitochondrial OS=Homo sapiens GN=CS PE=1 SV=2 
29 sp|O75531|BAF_HUMAN Barrier-to-autointegration factor OS=Homo sapiens GN=BANF1 PE=1 SV=1 
30 sp|O75556|SG2A1_HUMAN Mammaglobin-B OS=Homo sapiens GN=SCGB2A1 PE=1 SV=1 
31 sp|O75874|IDHC_HUMAN Isocitrate dehydrogenase [NADP] cytoplasmic OS=Homo sapiens GN=IDH1 PE=1 SV=2 
32 sp|O75874|IDHC_HUMAN Isocitrate dehydrogenase [NADP] cytoplasmic OS=Homo sapiens GN=IDH1 PE=1 SV=2 
33 sp|O75915|PRAF3_HUMAN PRA1 family protein 3 OS=Homo sapiens GN=ARL6IP5 PE=1 SV=1 
34 sp|O75964|ATP5L_HUMAN ATP synthase subunit g, mitochondrial OS=Homo sapiens GN=ATP5L PE=1 SV=3 
35 sp|O94905|ERLN2_HUMAN Erlin-2 OS=Homo sapiens GN=ERLIN2 PE=1 SV=1 
36 sp|O95197|RTN3_HUMAN Reticulon-3 OS=Homo sapiens GN=RTN3 PE=1 SV=2 
37 sp|O95571|ETHE1_HUMAN Protein ETHE1, mitochondrial OS=Homo sapiens GN=ETHE1 PE=1 SV=2 
38 sp|O95833|CLIC3_HUMAN Chloride intracellular channel protein 3 OS=Homo sapiens GN=CLIC3 PE=1 SV=2 
39 sp|O95994|AGR2_HUMAN Anterior gradient protein 2 homolog OS=Homo sapiens GN=AGR2 PE=1 SV=1 
40 sp|O96009|NAPSA_HUMAN Napsin-A OS=Homo sapiens GN=NAPSA PE=1 SV=1 
41 sp|P00167|CYB5_HUMAN Cytochrome b5 OS=Homo sapiens GN=CYB5A PE=1 SV=2 
42 sp|P00338|LDHA_HUMAN L-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=2 
43 sp|P00352|AL1A1_HUMAN Retinal dehydrogenase 1 OS=Homo sapiens GN=ALDH1A1 PE=1 SV=2 
44 sp|P00367|DHE3_HUMAN Glutamate dehydrogenase 1, mitochondrial OS=Homo sapiens GN=GLUD1 PE=1 SV=2 
45 sp|P00387|NB5R3_HUMAN NADH-cytochrome b5 reductase 3 OS=Homo sapiens GN=CYB5R3 PE=1 SV=3 
46 sp|P00403|COX2_HUMAN Cytochrome c oxidase subunit 2 OS=Homo sapiens GN=MT-CO2 PE=1 SV=1 
47 sp|P00441|SODC_HUMAN Superoxide dismutase [Cu-Zn] OS=Homo sapiens GN=SOD1 PE=1 SV=2 
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48 sp|P00450|CERU_HUMAN Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 
49 sp|P00491|PNPH_HUMAN Purine nucleoside phosphorylase OS=Homo sapiens GN=PNP PE=1 SV=2 
50 sp|P00505|AATM_HUMAN Aspartate aminotransferase, mitochondrial OS=Homo sapiens GN=GOT2 PE=1 SV=3 
51 sp|P00558|PGK1_HUMAN Phosphoglycerate kinase 1 OS=Homo sapiens GN=PGK1 PE=1 SV=3 
52 sp|P00738|HPT_HUMAN Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 
53 sp|P00751|CFAB_HUMAN Complement factor B OS=Homo sapiens GN=CFB PE=1 SV=2 
54 sp|P01009|A1AT_HUMAN Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 
55 sp|P01023|A2MG_HUMAN Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 
56 sp|P01024|CO3_HUMAN Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 
57 sp|P01033|TIMP1_HUMAN Metalloproteinase inhibitor 1 OS=Homo sapiens GN=TIMP1 PE=1 SV=1 
58 sp|P01034|CYTC_HUMAN Cystatin-C OS=Homo sapiens GN=CST3 PE=1 SV=1 
59 sp|P01036|CYTS_HUMAN Cystatin-S OS=Homo sapiens GN=CST4 PE=1 SV=3 
60 sp|P01037|CYTN_HUMAN Cystatin-SN OS=Homo sapiens GN=CST1 PE=1 SV=3 
61 sp|P01040|CYTA_HUMAN Cystatin-A OS=Homo sapiens GN=CSTA PE=1 SV=1 
62 sp|P01591|IGJ_HUMAN Immunoglobulin J chain OS=Homo sapiens GN=IGJ PE=1 SV=4 
63 sp|P01593|KV101_HUMAN Ig kappa chain V-I region AG OS=Homo sapiens PE=1 SV=1 
64 sp|P01601|KV109_HUMAN Ig kappa chain V-I region HK101 (Fragment) OS=Homo sapiens PE=4 SV=1 
65 sp|P01602|KV110_HUMAN Ig kappa chain V-I region HK102 (Fragment) OS=Homo sapiens GN=IGKV1-5 PE=4 SV=1 
66 sp|P01614|KV201_HUMAN Ig kappa chain V-II region Cum OS=Homo sapiens PE=1 SV=1 
67 sp|P01614|KV201_HUMAN Ig kappa chain V-II region Cum OS=Homo sapiens PE=1 SV=1 
68 sp|P01703|LV105_HUMAN Ig lambda chain V-I region NEWM OS=Homo sapiens PE=1 SV=1 
69 sp|P01761|HV106_HUMAN Ig heavy chain V-I region SIE OS=Homo sapiens PE=1 SV=1 
70 sp|P01764|HV303_HUMAN Ig heavy chain V-III region VH26 OS=Homo sapiens PE=1 SV=1 
71 sp|P01766|HV305_HUMAN Ig heavy chain V-III region BRO OS=Homo sapiens PE=1 SV=1 
72 sp|P01766|HV305_HUMAN Ig heavy chain V-III region BRO OS=Homo sapiens PE=1 SV=1 
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73 sp|P01768|HV307_HUMAN Ig heavy chain V-III region CAM OS=Homo sapiens PE=1 SV=1 
74 sp|P01772|HV311_HUMAN Ig heavy chain V-III region KOL OS=Homo sapiens PE=1 SV=1 
75 sp|P01772|HV311_HUMAN Ig heavy chain V-III region KOL OS=Homo sapiens PE=1 SV=1 
76 sp|P01781|HV320_HUMAN Ig heavy chain V-III region GAL OS=Homo sapiens PE=1 SV=1 
77 sp|P01833|PIGR_HUMAN Polymeric immunoglobulin receptor OS=Homo sapiens GN=PIGR PE=1 SV=4 
78 sp|P01834|IGKC_HUMAN Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1 
79 sp|P01857|IGHG1_HUMAN Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 PE=1 SV=1 
80 sp|P01859|IGHG2_HUMAN Ig gamma-2 chain C region OS=Homo sapiens GN=IGHG2 PE=1 SV=2 
81 sp|P01860|IGHG3_HUMAN Ig gamma-3 chain C region OS=Homo sapiens GN=IGHG3 PE=1 SV=2 
82 sp|P01861|IGHG4_HUMAN Ig gamma-4 chain C region OS=Homo sapiens GN=IGHG4 PE=1 SV=1 
83 sp|P01871|IGHM_HUMAN Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 
84 sp|P01876|IGHA1_HUMAN Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2 
85 sp|P01877|IGHA2_HUMAN Ig alpha-2 chain C region OS=Homo sapiens GN=IGHA2 PE=1 SV=3 
86 sp|P01903|DRA_HUMAN HLA class II histocompatibility antigen, DR alpha chain OS=Homo sapiens GN=HLA-DRA PE=1 SV=1 
87 sp|P01911|2B1F_HUMAN HLA class II histocompatibility antigen, DRB1-15 beta chain OS=Homo sapiens GN=HLA-DRB1 PE=1 SV=2 
88 sp|P01911|2B1F_HUMAN HLA class II histocompatibility antigen, DRB1-15 beta chain OS=Homo sapiens GN=HLA-DRB1 PE=1 SV=2 
89 sp|P02533|K1C14_HUMAN Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 
90 sp|P02538|K2C6A_HUMAN Keratin, type II cytoskeletal 6A OS=Homo sapiens GN=KRT6A PE=1 SV=3 
91 sp|P02545|LMNA_HUMAN Prelamin-A/C OS=Homo sapiens GN=LMNA PE=1 SV=1 
92 sp|P02647|APOA1_HUMAN Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 
93 sp|P02652|APOA2_HUMAN Apolipoprotein A-II OS=Homo sapiens GN=APOA2 PE=1 SV=1 
94 sp|P02671|FIBA_HUMAN Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 
95 sp|P02679|FIBG_HUMAN Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1 SV=3 
96 sp|P02763|A1AG1_HUMAN Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1 
97 sp|P02765|FETUA_HUMAN Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=1 
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98 sp|P02766|TTHY_HUMAN Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1 
99 sp|P02768|ALBU_HUMAN Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 
100 sp|P02774|VTDB_HUMAN Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 
101 sp|P02786|TFR1_HUMAN Transferrin receptor protein 1 OS=Homo sapiens GN=TFRC PE=1 SV=2 
102 sp|P02787|TRFE_HUMAN Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 
103 sp|P02788|TRFL_HUMAN Lactotransferrin OS=Homo sapiens GN=LTF PE=1 SV=6 
104 sp|P02790|HEMO_HUMAN Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 
105 sp|P04040|CATA_HUMAN Catalase OS=Homo sapiens GN=CAT PE=1 SV=3 
106 sp|P04075|ALDOA_HUMAN Fructose-bisphosphate aldolase A OS=Homo sapiens GN=ALDOA PE=1 SV=2 
107 sp|P04080|CYTB_HUMAN Cystatin-B OS=Homo sapiens GN=CSTB PE=1 SV=2 
108 sp|P04083|ANXA1_HUMAN Annexin A1 OS=Homo sapiens GN=ANXA1 PE=1 SV=2 
109 sp|P04114|APOB_HUMAN Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=2 
110 sp|P04179|SODM_HUMAN Superoxide dismutase [Mn], mitochondrial OS=Homo sapiens GN=SOD2 PE=1 SV=2 
111 sp|P04196|HRG_HUMAN Histidine-rich glycoprotein OS=Homo sapiens GN=HRG PE=1 SV=1 
112 sp|P04206|KV307_HUMAN Ig kappa chain V-III region GOL OS=Homo sapiens PE=1 SV=1 
113 sp|P04207|KV308_HUMAN Ig kappa chain V-III region CLL OS=Homo sapiens PE=1 SV=2 
114 sp|P04208|LV106_HUMAN Ig lambda chain V-I region WAH OS=Homo sapiens PE=1 SV=1 
115 sp|P04233|HG2A_HUMAN HLA class II histocompatibility antigen gamma chain OS=Homo sapiens GN=CD74 PE=1 SV=3 
116 sp|P04264|K2C1_HUMAN Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 
117 sp|P04406|G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 
118 sp|P04432|KV124_HUMAN Ig kappa chain V-I region Daudi OS=Homo sapiens PE=4 SV=1 
119 sp|P04433|KV309_HUMAN Ig kappa chain V-III region VG (Fragment) OS=Homo sapiens PE=1 SV=1 
120 sp|P04632|CPNS1_HUMAN Calpain small subunit 1 OS=Homo sapiens GN=CAPNS1 PE=1 SV=1 
121 sp|P04745|AMY1_HUMAN Alpha-amylase 1 OS=Homo sapiens GN=AMY1A PE=1 SV=2 
122 sp|P04792|HSPB1_HUMAN Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 PE=1 SV=2 
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123 sp|P04839|CY24B_HUMAN Cytochrome b-245 heavy chain OS=Homo sapiens GN=CYBB PE=1 SV=2 
124 sp|P04843|RPN1_HUMAN Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 OS=Homo sapiens GN=RPN1 PE=1 SV=1 
125 sp|P04844|RPN2_HUMAN Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 OS=Homo sapiens GN=RPN2 PE=1 SV=3 
126 sp|P04899|GNAI2_HUMAN Guanine nucleotide-binding protein G(i) subunit alpha-2 OS=Homo sapiens GN=GNAI2 PE=1 SV=3 
127 sp|P04899|GNAI2_HUMAN Guanine nucleotide-binding protein G(i) subunit alpha-2 OS=Homo sapiens GN=GNAI2 PE=1 SV=3 
128 sp|P05091|ALDH2_HUMAN Aldehyde dehydrogenase, mitochondrial OS=Homo sapiens GN=ALDH2 PE=1 SV=2 
129 sp|P05107|ITB2_HUMAN Integrin beta-2 OS=Homo sapiens GN=ITGB2 PE=1 SV=2 
130 sp|P05109|S10A8_HUMAN Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 
131 sp|P05114|HMGN1_HUMAN Non-histone chromosomal protein HMG-14 OS=Homo sapiens GN=HMGN1 PE=1 SV=3 
132 sp|P05141|ADT2_HUMAN ADP/ATP translocase 2 OS=Homo sapiens GN=SLC25A5 PE=1 SV=6 
133 sp|P05164|PERM_HUMAN Myeloperoxidase OS=Homo sapiens GN=MPO PE=1 SV=1 
134 sp|P05204|HMGN2_HUMAN Non-histone chromosomal protein HMG-17 OS=Homo sapiens GN=HMGN2 PE=1 SV=3 
135 sp|P05204|HMGN2_HUMAN Non-histone chromosomal protein HMG-17 OS=Homo sapiens GN=HMGN2 PE=1 SV=3 
136 sp|P05386|RLA1_HUMAN 60S acidic ribosomal protein P1 OS=Homo sapiens GN=RPLP1 PE=1 SV=1 
137 sp|P05387|RLA2_HUMAN 60S acidic ribosomal protein P2 OS=Homo sapiens GN=RPLP2 PE=1 SV=1 
138 sp|P05388|RLA0_HUMAN 60S acidic ribosomal protein P0 OS=Homo sapiens GN=RPLP0 PE=1 SV=1 
139 sp|P05787|K2C8_HUMAN Keratin, type II cytoskeletal 8 OS=Homo sapiens GN=KRT8 PE=1 SV=7 
140 sp|P06314|KV404_HUMAN Ig kappa chain V-IV region B17 OS=Homo sapiens PE=2 SV=1 
141 sp|P06326|HV107_HUMAN Ig heavy chain V-I region Mot OS=Homo sapiens PE=1 SV=1 
142 sp|P06331|HV209_HUMAN Ig heavy chain V-II region ARH-77 OS=Homo sapiens PE=4 SV=1 
143 sp|P06396|GELS_HUMAN Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1 
144 sp|P06454|PTMA_HUMAN Prothymosin alpha OS=Homo sapiens GN=PTMA PE=1 SV=2 
145 sp|P06576|ATPB_HUMAN ATP synthase subunit beta, mitochondrial OS=Homo sapiens GN=ATP5B PE=1 SV=3 
146 sp|P06702|S10A9_HUMAN Protein S100-A9 OS=Homo sapiens GN=S100A9 PE=1 SV=1 
147 sp|P06703|S10A6_HUMAN Protein S100-A6 OS=Homo sapiens GN=S100A6 PE=1 SV=1 
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148 sp|P06731|CEAM5_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 5 OS=Homo sapiens GN=CEACAM5 PE=1 SV=2 
149 sp|P06733|ENOA_HUMAN Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 
150 sp|P06737|PYGL_HUMAN Glycogen phosphorylase, liver form OS=Homo sapiens GN=PYGL PE=1 SV=4 
151 sp|P06744|G6PI_HUMAN Glucose-6-phosphate isomerase OS=Homo sapiens GN=GPI PE=1 SV=4 
152 sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens GN=NPM1 PE=1 SV=2 
153 sp|P06753|TPM3_HUMAN Tropomyosin alpha-3 chain OS=Homo sapiens GN=TPM3 PE=1 SV=1 
154 sp|P06870|KLK1_HUMAN Kallikrein-1 OS=Homo sapiens GN=KLK1 PE=1 SV=2 
155 sp|P07099|HYEP_HUMAN Epoxide hydrolase 1 OS=Homo sapiens GN=EPHX1 PE=1 SV=1 
156 sp|P07108|ACBP_HUMAN Acyl-CoA-binding protein OS=Homo sapiens GN=DBI PE=1 SV=2 
157 sp|P07195|LDHB_HUMAN L-lactate dehydrogenase B chain OS=Homo sapiens GN=LDHB PE=1 SV=2 
158 sp|P07203|GPX1_HUMAN Glutathione peroxidase 1 OS=Homo sapiens GN=GPX1 PE=1 SV=4 
159 sp|P07237|PDIA1_HUMAN Protein disulfide-isomerase OS=Homo sapiens GN=P4HB PE=1 SV=3 
160 sp|P07305|H10_HUMAN Histone H1.0 OS=Homo sapiens GN=H1F0 PE=1 SV=3 
161 sp|P07339|CATD_HUMAN Cathepsin D OS=Homo sapiens GN=CTSD PE=1 SV=1 
162 sp|P07355|ANXA2_HUMAN Annexin A2 OS=Homo sapiens GN=ANXA2 PE=1 SV=2 
163 sp|P07384|CAN1_HUMAN Calpain-1 catalytic subunit OS=Homo sapiens GN=CAPN1 PE=1 SV=1 
164 sp|P07437|TBB5_HUMAN Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 
165 sp|P07476|INVO_HUMAN Involucrin OS=Homo sapiens GN=IVL PE=1 SV=2 
166 sp|P07477|TRY1_HUMAN Trypsin-1 OS=Homo sapiens GN=PRSS1 PE=1 SV=1 
167 sp|P07602|SAP_HUMAN Proactivator polypeptide OS=Homo sapiens GN=PSAP PE=1 SV=2 
168 sp|P07686|HEXB_HUMAN Beta-hexosaminidase subunit beta OS=Homo sapiens GN=HEXB PE=1 SV=3 
169 sp|P07686|HEXB_HUMAN Beta-hexosaminidase subunit beta OS=Homo sapiens GN=HEXB PE=1 SV=3 
170 sp|P07737|PROF1_HUMAN Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 
171 sp|P07858|CATB_HUMAN Cathepsin B OS=Homo sapiens GN=CTSB PE=1 SV=3 
172 sp|P07900|HS90A_HUMAN Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP90AA1 PE=1 SV=5 
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173 sp|P07910|HNRPC_HUMAN Heterogeneous nuclear ribonucleoproteins C1/C2 OS=Homo sapiens GN=HNRNPC PE=1 SV=4 
174 sp|P07988|PSPB_HUMAN Pulmonary surfactant-associated protein B OS=Homo sapiens GN=SFTPB PE=1 SV=3 
175 sp|P08107|HSP71_HUMAN Heat shock 70 kDa protein 1A/1B OS=Homo sapiens GN=HSPA1A PE=1 SV=5 
176 sp|P08133|ANXA6_HUMAN Annexin A6 OS=Homo sapiens GN=ANXA6 PE=1 SV=3 
177 sp|P08238|HS90B_HUMAN Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 
178 sp|P08246|ELNE_HUMAN Neutrophil elastase OS=Homo sapiens GN=ELANE PE=1 SV=1 
179 sp|P08263|GSTA1_HUMAN Glutathione S-transferase A1 OS=Homo sapiens GN=GSTA1 PE=1 SV=3 
180 sp|P08311|CATG_HUMAN Cathepsin G OS=Homo sapiens GN=CTSG PE=1 SV=2 
181 sp|P08575|PTPRC_HUMAN Receptor-type tyrosine-protein phosphatase C OS=Homo sapiens GN=PTPRC PE=1 SV=2 
182 sp|P08670|VIME_HUMAN Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4 
183 sp|P08727|K1C19_HUMAN Keratin, type I cytoskeletal 19 OS=Homo sapiens GN=KRT19 PE=1 SV=4 
184 sp|P08758|ANXA5_HUMAN Annexin A5 OS=Homo sapiens GN=ANXA5 PE=1 SV=2 
185 sp|P08779|K1C16_HUMAN Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 
186 sp|P08865|RSSA_HUMAN 40S ribosomal protein SA OS=Homo sapiens GN=RPSA PE=1 SV=4 
187 sp|P08962|CD63_HUMAN CD63 antigen OS=Homo sapiens GN=CD63 PE=1 SV=2 
188 sp|P09211|GSTP1_HUMAN Glutathione S-transferase P OS=Homo sapiens GN=GSTP1 PE=1 SV=2 
189 sp|P09228|CYTT_HUMAN Cystatin-SA OS=Homo sapiens GN=CST2 PE=1 SV=1 
190 sp|P09429|HMGB1_HUMAN High mobility group protein B1 OS=Homo sapiens GN=HMGB1 PE=1 SV=3 
191 sp|P09467|F16P1_HUMAN Fructose-1,6-bisphosphatase 1 OS=Homo sapiens GN=FBP1 PE=1 SV=5 
192 sp|P09525|ANXA4_HUMAN Annexin A4 OS=Homo sapiens GN=ANXA4 PE=1 SV=4 
193 sp|P09622|DLDH_HUMAN Dihydrolipoyl dehydrogenase, mitochondrial OS=Homo sapiens GN=DLD PE=1 SV=2 
194 sp|P09668|CATH_HUMAN Cathepsin H OS=Homo sapiens GN=CTSH PE=1 SV=4 
195 sp|P09669|COX6C_HUMAN Cytochrome c oxidase subunit 6C OS=Homo sapiens GN=COX6C PE=1 SV=2 
196 sp|P09758|TACD2_HUMAN Tumor-associated calcium signal transducer 2 OS=Homo sapiens GN=TACSTD2 PE=1 SV=3 
197 sp|P09917|LOX5_HUMAN Arachidonate 5-lipoxygenase OS=Homo sapiens GN=ALOX5 PE=1 SV=2 
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198 sp|P09960|LKHA4_HUMAN Leukotriene A-4 hydrolase OS=Homo sapiens GN=LTA4H PE=1 SV=2 
199 sp|P0CG04|LAC1_HUMAN Ig lambda-1 chain C regions OS=Homo sapiens GN=IGLC1 PE=1 SV=1 
200 sp|P0CG04|LAC1_HUMAN Ig lambda-1 chain C regions OS=Homo sapiens GN=IGLC1 PE=1 SV=1 
201 sp|P0CG05|LAC2_HUMAN Ig lambda-2 chain C regions OS=Homo sapiens GN=IGLC2 PE=1 SV=1 
202 sp|P0CG05|LAC2_HUMAN Ig lambda-2 chain C regions OS=Homo sapiens GN=IGLC2 PE=1 SV=1 
203 sp|P0CG06|LAC3_HUMAN Ig lambda-3 chain C regions OS=Homo sapiens GN=IGLC3 PE=1 SV=1 
204 sp|P0CG06|LAC3_HUMAN Ig lambda-3 chain C regions OS=Homo sapiens GN=IGLC3 PE=1 SV=1 
205 sp|P0CG38|POTEI_HUMAN POTE ankyrin domain family member I OS=Homo sapiens GN=POTEI PE=3 SV=1 
206 sp|P10153|RNAS2_HUMAN Non-secretory ribonuclease OS=Homo sapiens GN=RNASE2 PE=1 SV=2 
207 sp|P10253|LYAG_HUMAN Lysosomal alpha-glucosidase OS=Homo sapiens GN=GAA PE=1 SV=3 
208 sp|P10412|H14_HUMAN Histone H1.4 OS=Homo sapiens GN=HIST1H1E PE=1 SV=2 
209 sp|P10412|H14_HUMAN Histone H1.4 OS=Homo sapiens GN=HIST1H1E PE=1 SV=2 
210 sp|P10412|H14_HUMAN Histone H1.4 OS=Homo sapiens GN=HIST1H1E PE=1 SV=2 
211 sp|P10599|THIO_HUMAN Thioredoxin OS=Homo sapiens GN=TXN PE=1 SV=3 
212 sp|P10606|COX5B_HUMAN Cytochrome c oxidase subunit 5B, mitochondrial OS=Homo sapiens GN=COX5B PE=1 SV=2 
213 sp|P10809|CH60_HUMAN 60 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPD1 PE=1 SV=2 
214 sp|P10909|CLUS_HUMAN Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 
215 sp|P11021|GRP78_HUMAN 78 kDa glucose-regulated protein OS=Homo sapiens GN=HSPA5 PE=1 SV=2 
216 sp|P11142|HSP7C_HUMAN Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 
217 sp|P11215|ITAM_HUMAN Integrin alpha-M OS=Homo sapiens GN=ITGAM PE=1 SV=2 
218 sp|P11233|RALA_HUMAN Ras-related protein Ral-A OS=Homo sapiens GN=RALA PE=1 SV=1 
219 sp|P11279|LAMP1_HUMAN Lysosome-associated membrane glycoprotein 1 OS=Homo sapiens GN=LAMP1 PE=1 SV=3 
220 sp|P11413|G6PD_HUMAN Glucose-6-phosphate 1-dehydrogenase OS=Homo sapiens GN=G6PD PE=1 SV=4 
221 sp|P11678|PERE_HUMAN Eosinophil peroxidase OS=Homo sapiens GN=EPX PE=1 SV=2 
222 sp|P11684|UTER_HUMAN Uteroglobin OS=Homo sapiens GN=SCGB1A1 PE=1 SV=1 
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223 sp|P12236|ADT3_HUMAN ADP/ATP translocase 3 OS=Homo sapiens GN=SLC25A6 PE=1 SV=4 
224 sp|P12236|ADT3_HUMAN ADP/ATP translocase 3 OS=Homo sapiens GN=SLC25A6 PE=1 SV=4 
225 sp|P12273|PIP_HUMAN Prolactin-inducible protein OS=Homo sapiens GN=PIP PE=1 SV=1 
226 sp|P12429|ANXA3_HUMAN Annexin A3 OS=Homo sapiens GN=ANXA3 PE=1 SV=3 
227 sp|P12532|KCRU_HUMAN Creatine kinase U-type, mitochondrial OS=Homo sapiens GN=CKMT1A PE=1 SV=1 
228 sp|P12724|ECP_HUMAN Eosinophil cationic protein OS=Homo sapiens GN=RNASE3 PE=1 SV=2 
229 sp|P12814|ACTN1_HUMAN Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 SV=2 
230 sp|P13073|COX41_HUMAN Cytochrome c oxidase subunit 4 isoform 1, mitochondrial OS=Homo sapiens GN=COX4I1 PE=1 SV=1 
231 sp|P13473|LAMP2_HUMAN Lysosome-associated membrane glycoprotein 2 OS=Homo sapiens GN=LAMP2 PE=1 SV=2 
232 sp|P13489|RINI_HUMAN Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 
233 sp|P13639|EF2_HUMAN Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4 
234 sp|P13645|K1C10_HUMAN Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 
235 sp|P13646|K1C13_HUMAN Keratin, type I cytoskeletal 13 OS=Homo sapiens GN=KRT13 PE=1 SV=4 
236 sp|P13647|K2C5_HUMAN Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 
237 sp|P13667|PDIA4_HUMAN Protein disulfide-isomerase A4 OS=Homo sapiens GN=PDIA4 PE=1 SV=2 
238 sp|P13686|PPA5_HUMAN Tartrate-resistant acid phosphatase type 5 OS=Homo sapiens GN=ACP5 PE=1 SV=3 
239 sp|P13688|CEAM1_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 1 OS=Homo sapiens GN=CEACAM1 PE=1 SV=2 
240 sp|P13693|TCTP_HUMAN Translationally-controlled tumor protein OS=Homo sapiens GN=TPT1 PE=1 SV=1 
241 sp|P13760|2B14_HUMAN HLA class II histocompatibility antigen, DRB1-4 beta chain OS=Homo sapiens GN=HLA-DRB1 PE=1 SV=1 
242 sp|P13796|PLSL_HUMAN Plastin-2 OS=Homo sapiens GN=LCP1 PE=1 SV=6 
243 sp|P13797|PLST_HUMAN Plastin-3 OS=Homo sapiens GN=PLS3 PE=1 SV=4 
244 sp|P13804|ETFA_HUMAN Electron transfer flavoprotein subunit alpha, mitochondrial OS=Homo sapiens GN=ETFA PE=1 SV=1 
245 sp|P14314|GLU2B_HUMAN Glucosidase 2 subunit beta OS=Homo sapiens GN=PRKCSH PE=1 SV=2 
246 sp|P14406|CX7A2_HUMAN Cytochrome c oxidase subunit 7A2, mitochondrial OS=Homo sapiens GN=COX7A2 PE=1 SV=1 
247 sp|P14550|AK1A1_HUMAN Alcohol dehydrogenase [NADP+] OS=Homo sapiens GN=AKR1A1 PE=1 SV=3 
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248 sp|P14618|KPYM_HUMAN Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM2 PE=1 SV=4 
249 sp|P14625|ENPL_HUMAN Endoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=1 
250 sp|P14780|MMP9_HUMAN Matrix metalloproteinase-9 OS=Homo sapiens GN=MMP9 PE=1 SV=3 
251 sp|P14923|PLAK_HUMAN Junction plakoglobin OS=Homo sapiens GN=JUP PE=1 SV=3 
252 sp|P14927|QCR7_HUMAN Cytochrome b-c1 complex subunit 7 OS=Homo sapiens GN=UQCRB PE=1 SV=2 
253 sp|P15090|FABP4_HUMAN Fatty acid-binding protein, adipocyte OS=Homo sapiens GN=FABP4 PE=1 SV=3 
254 sp|P15153|RAC2_HUMAN Ras-related C3 botulinum toxin substrate 2 OS=Homo sapiens GN=RAC2 PE=1 SV=1 
255 sp|P15311|EZRI_HUMAN Ezrin OS=Homo sapiens GN=EZR PE=1 SV=4 
256 sp|P15515|HIS1_HUMAN Histatin-1 OS=Homo sapiens GN=HTN1 PE=1 SV=2 
257 sp|P15924|DESP_HUMAN Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 
258 sp|P15941|MUC1_HUMAN Mucin-1 OS=Homo sapiens GN=MUC1 PE=1 SV=3 
259 sp|P16104|H2AX_HUMAN Histone H2A.x OS=Homo sapiens GN=H2AFX PE=1 SV=2 
260 sp|P16152|CBR1_HUMAN Carbonyl reductase [NADPH] 1 OS=Homo sapiens GN=CBR1 PE=1 SV=3 
261 sp|P16401|H15_HUMAN Histone H1.5 OS=Homo sapiens GN=HIST1H1B PE=1 SV=3 
262 sp|P16402|H13_HUMAN Histone H1.3 OS=Homo sapiens GN=HIST1H1D PE=1 SV=2 
263 sp|P16403|H12_HUMAN Histone H1.2 OS=Homo sapiens GN=HIST1H1C PE=1 SV=2 
264 sp|P16435|NCPR_HUMAN NADPH--cytochrome P450 reductase OS=Homo sapiens GN=POR PE=1 SV=2 
265 sp|P17096|HMGA1_HUMAN High mobility group protein HMG-I/HMG-Y OS=Homo sapiens GN=HMGA1 PE=1 SV=3 
266 sp|P17213|BPI_HUMAN Bactericidal permeability-increasing protein OS=Homo sapiens GN=BPI PE=1 SV=4 
267 sp|P17931|LEG3_HUMAN Galectin-3 OS=Homo sapiens GN=LGALS3 PE=1 SV=5 
268 sp|P18085|ARF4_HUMAN ADP-ribosylation factor 4 OS=Homo sapiens GN=ARF4 PE=1 SV=3 
269 sp|P18124|RL7_HUMAN 60S ribosomal protein L7 OS=Homo sapiens GN=RPL7 PE=1 SV=1 
270 sp|P18136|KV313_HUMAN Ig kappa chain V-III region HIC OS=Homo sapiens PE=2 SV=1 
271 sp|P18510|IL1RA_HUMAN Interleukin-1 receptor antagonist protein OS=Homo sapiens GN=IL1RN PE=1 SV=1 
272 sp|P18669|PGAM1_HUMAN Phosphoglycerate mutase 1 OS=Homo sapiens GN=PGAM1 PE=1 SV=2 
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273 sp|P18859|ATP5J_HUMAN ATP synthase-coupling factor 6, mitochondrial OS=Homo sapiens GN=ATP5J PE=1 SV=1 
274 sp|P19013|K2C4_HUMAN Keratin, type II cytoskeletal 4 OS=Homo sapiens GN=KRT4 PE=1 SV=4 
275 sp|P19105|ML12A_HUMAN Myosin regulatory light chain 12A OS=Homo sapiens GN=MYL12A PE=1 SV=2 
276 sp|P19338|NUCL_HUMAN Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 
277 sp|P19367|HXK1_HUMAN Hexokinase-1 OS=Homo sapiens GN=HK1 PE=1 SV=3 
278 sp|P19971|TYPH_HUMAN Thymidine phosphorylase OS=Homo sapiens GN=TYMP PE=1 SV=2 
279 sp|P20039|2B1B_HUMAN HLA class II histocompatibility antigen, DRB1-11 beta chain OS=Homo sapiens GN=HLA-DRB1 PE=1 SV=1 
280 sp|P20073|ANXA7_HUMAN Annexin A7 OS=Homo sapiens GN=ANXA7 PE=1 SV=3 
281 sp|P20160|CAP7_HUMAN Azurocidin OS=Homo sapiens GN=AZU1 PE=1 SV=3 
282 sp|P20292|AL5AP_HUMAN Arachidonate 5-lipoxygenase-activating protein OS=Homo sapiens GN=ALOX5AP PE=1 SV=2 
283 sp|P20340|RAB6A_HUMAN Ras-related protein Rab-6A OS=Homo sapiens GN=RAB6A PE=1 SV=3 
284 sp|P20674|COX5A_HUMAN Cytochrome c oxidase subunit 5A, mitochondrial OS=Homo sapiens GN=COX5A PE=1 SV=2 
285 sp|P20700|LMNB1_HUMAN Lamin-B1 OS=Homo sapiens GN=LMNB1 PE=1 SV=2 
286 sp|P20810|ICAL_HUMAN Calpastatin OS=Homo sapiens GN=CAST PE=1 SV=4 
287 sp|P21128|ENDOU_HUMAN Poly(U)-specific endoribonuclease OS=Homo sapiens GN=ENDOU PE=1 SV=2 
288 sp|P21333|FLNA_HUMAN Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 
289 sp|P21796|VDAC1_HUMAN Voltage-dependent anion-selective channel protein 1 OS=Homo sapiens GN=VDAC1 PE=1 SV=2 
290 sp|P21926|CD9_HUMAN CD9 antigen OS=Homo sapiens GN=CD9 PE=1 SV=4 
291 sp|P21964|COMT_HUMAN Catechol O-methyltransferase OS=Homo sapiens GN=COMT PE=1 SV=2 
292 sp|P21980|TGM2_HUMAN Protein-glutamine gamma-glutamyltransferase 2 OS=Homo sapiens GN=TGM2 PE=1 SV=2 
293 sp|P22079|PERL_HUMAN Lactoperoxidase OS=Homo sapiens GN=LPO PE=1 SV=2 
294 sp|P22314|UBA1_HUMAN Ubiquitin-like modifier-activating enzyme 1 OS=Homo sapiens GN=UBA1 PE=1 SV=3 
295 sp|P22392|NDKB_HUMAN Nucleoside diphosphate kinase B OS=Homo sapiens GN=NME2 PE=1 SV=1 
296 sp|P22626|ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens GN=HNRNPA2B1 PE=1 SV=2 
297 sp|P22735|TGM1_HUMAN Protein-glutamine gamma-glutamyltransferase K OS=Homo sapiens GN=TGM1 PE=1 SV=4 
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298 sp|P23083|HV103_HUMAN Ig heavy chain V-I region V35 OS=Homo sapiens PE=1 SV=1 
299 sp|P23141|EST1_HUMAN Liver carboxylesterase 1 OS=Homo sapiens GN=CES1 PE=1 SV=2 
300 sp|P23280|CAH6_HUMAN Carbonic anhydrase 6 OS=Homo sapiens GN=CA6 PE=1 SV=3 
301 sp|P23284|PPIB_HUMAN Peptidyl-prolyl cis-trans isomerase B OS=Homo sapiens GN=PPIB PE=1 SV=2 
302 sp|P23381|SYWC_HUMAN Tryptophanyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=WARS PE=1 SV=2 
303 sp|P23528|COF1_HUMAN Cofilin-1 OS=Homo sapiens GN=CFL1 PE=1 SV=3 
304 sp|P24158|PRTN3_HUMAN Myeloblastin OS=Homo sapiens GN=PRTN3 PE=1 SV=3 
305 sp|P24534|EF1B_HUMAN Elongation factor 1-beta OS=Homo sapiens GN=EEF1B2 PE=1 SV=3 
306 sp|P24752|THIL_HUMAN Acetyl-CoA acetyltransferase, mitochondrial OS=Homo sapiens GN=ACAT1 PE=1 SV=1 
307 sp|P25311|ZA2G_HUMAN Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 PE=1 SV=2 
308 sp|P25398|RS12_HUMAN 40S ribosomal protein S12 OS=Homo sapiens GN=RPS12 PE=1 SV=3 
309 sp|P25705|ATPA_HUMAN ATP synthase subunit alpha, mitochondrial OS=Homo sapiens GN=ATP5A1 PE=1 SV=1 
310 sp|P25787|PSA2_HUMAN Proteasome subunit alpha type-2 OS=Homo sapiens GN=PSMA2 PE=1 SV=2 
311 sp|P25815|S100P_HUMAN Protein S100-P OS=Homo sapiens GN=S100P PE=1 SV=2 
312 sp|P26038|MOES_HUMAN Moesin OS=Homo sapiens GN=MSN PE=1 SV=3 
313 sp|P26373|RL13_HUMAN 60S ribosomal protein L13 OS=Homo sapiens GN=RPL13 PE=1 SV=4 
314 sp|P26447|S10A4_HUMAN Protein S100-A4 OS=Homo sapiens GN=S100A4 PE=1 SV=1 
315 sp|P26583|HMGB2_HUMAN High mobility group protein B2 OS=Homo sapiens GN=HMGB2 PE=1 SV=2 
316 sp|P26641|EF1G_HUMAN Elongation factor 1-gamma OS=Homo sapiens GN=EEF1G PE=1 SV=3 
317 sp|P27105|STOM_HUMAN Erythrocyte band 7 integral membrane protein OS=Homo sapiens GN=STOM PE=1 SV=3 
318 sp|P27348|1433T_HUMAN 14-3-3 protein theta OS=Homo sapiens GN=YWHAQ PE=1 SV=1 
319 sp|P27482|CALL3_HUMAN Calmodulin-like protein 3 OS=Homo sapiens GN=CALML3 PE=1 SV=2 
320 sp|P27797|CALR_HUMAN Calreticulin OS=Homo sapiens GN=CALR PE=1 SV=1 
321 sp|P27824|CALX_HUMAN Calnexin OS=Homo sapiens GN=CANX PE=1 SV=2 
322 sp|P28066|PSA5_HUMAN Proteasome subunit alpha type-5 OS=Homo sapiens GN=PSMA5 PE=1 SV=3 
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323 sp|P28676|GRAN_HUMAN Grancalcin OS=Homo sapiens GN=GCA PE=1 SV=2 
324 sp|P28838|AMPL_HUMAN Cytosol aminopeptidase OS=Homo sapiens GN=LAP3 PE=1 SV=3 
325 sp|P29034|S10A2_HUMAN Protein S100-A2 OS=Homo sapiens GN=S100A2 PE=1 SV=3 
326 sp|P29350|PTN6_HUMAN Tyrosine-protein phosphatase non-receptor type 6 OS=Homo sapiens GN=PTPN6 PE=1 SV=1 
327 sp|P29401|TKT_HUMAN Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 
328 sp|P29508|SPB3_HUMAN Serpin B3 OS=Homo sapiens GN=SERPINB3 PE=1 SV=2 
329 sp|P29966|MARCS_HUMAN Myristoylated alanine-rich C-kinase substrate OS=Homo sapiens GN=MARCKS PE=1 SV=4 
330 sp|P30040|ERP29_HUMAN Endoplasmic reticulum resident protein 29 OS=Homo sapiens GN=ERP29 PE=1 SV=4 
331 sp|P30041|PRDX6_HUMAN Peroxiredoxin-6 OS=Homo sapiens GN=PRDX6 PE=1 SV=3 
332 sp|P30042|ES1_HUMAN ES1 protein homolog, mitochondrial OS=Homo sapiens GN=C21orf33 PE=1 SV=3 
333 sp|P30044|PRDX5_HUMAN Peroxiredoxin-5, mitochondrial OS=Homo sapiens GN=PRDX5 PE=1 SV=3 
334 sp|P30048|PRDX3_HUMAN Thioredoxin-dependent peroxide reductase, mitochondrial OS=Homo sapiens GN=PRDX3 PE=1 SV=3 
335 sp|P30049|ATPD_HUMAN ATP synthase subunit delta, mitochondrial OS=Homo sapiens GN=ATP5D PE=1 SV=2 
336 sp|P30050|RL12_HUMAN 60S ribosomal protein L12 OS=Homo sapiens GN=RPL12 PE=1 SV=1 
337 sp|P30085|KCY_HUMAN UMP-CMP kinase OS=Homo sapiens GN=CMPK1 PE=1 SV=3 
338 sp|P30086|PEBP1_HUMAN Phosphatidylethanolamine-binding protein 1 OS=Homo sapiens GN=PEBP1 PE=1 SV=3 
339 sp|P30101|PDIA3_HUMAN Protein disulfide-isomerase A3 OS=Homo sapiens GN=PDIA3 PE=1 SV=4 
340 sp|P30533|AMRP_HUMAN Alpha-2-macroglobulin receptor-associated protein OS=Homo sapiens GN=LRPAP1 PE=1 SV=1 
341 sp|P30536|TSPOA_HUMAN Translocator protein OS=Homo sapiens GN=TSPO PE=1 SV=3 
342 sp|P30740|ILEU_HUMAN Leukocyte elastase inhibitor OS=Homo sapiens GN=SERPINB1 PE=1 SV=1 
343 sp|P30837|AL1B1_HUMAN Aldehyde dehydrogenase X, mitochondrial OS=Homo sapiens GN=ALDH1B1 PE=1 SV=3 
344 sp|P30838|AL3A1_HUMAN Aldehyde dehydrogenase, dimeric NADP-preferring OS=Homo sapiens GN=ALDH3A1 PE=1 SV=3 
345 sp|P31025|LCN1_HUMAN Lipocalin-1 OS=Homo sapiens GN=LCN1 PE=1 SV=1 
346 sp|P31146|COR1A_HUMAN Coronin-1A OS=Homo sapiens GN=CORO1A PE=1 SV=4 
347 sp|P31151|S10A7_HUMAN Protein S100-A7 OS=Homo sapiens GN=S100A7 PE=1 SV=4 
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348 sp|P31930|QCR1_HUMAN Cytochrome b-c1 complex subunit 1, mitochondrial OS=Homo sapiens GN=UQCRC1 PE=1 SV=3 
349 sp|P31946|1433B_HUMAN 14-3-3 protein beta/alpha OS=Homo sapiens GN=YWHAB PE=1 SV=3 
350 sp|P31947|1433S_HUMAN 14-3-3 protein sigma OS=Homo sapiens GN=SFN PE=1 SV=1 
351 sp|P31949|S10AB_HUMAN Protein S100-A11 OS=Homo sapiens GN=S100A11 PE=1 SV=2 
352 sp|P32119|PRDX2_HUMAN Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2 PE=1 SV=5 
353 sp|P33241|LSP1_HUMAN Lymphocyte-specific protein 1 OS=Homo sapiens GN=LSP1 PE=1 SV=1 
354 sp|P35232|PHB_HUMAN Prohibitin OS=Homo sapiens GN=PHB PE=1 SV=1 
355 sp|P35527|K1C9_HUMAN Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 
356 sp|P35542|SAA4_HUMAN Serum amyloid A-4 protein OS=Homo sapiens GN=SAA4 PE=1 SV=2 
357 sp|P35579|MYH9_HUMAN Myosin-9 OS=Homo sapiens GN=MYH9 PE=1 SV=4 
358 sp|P35908|K22E_HUMAN Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 
359 sp|P35914|HMGCL_HUMAN Hydroxymethylglutaryl-CoA lyase, mitochondrial OS=Homo sapiens GN=HMGCL PE=1 SV=2 
360 sp|P36406|TRI23_HUMAN E3 ubiquitin-protein ligase TRIM23 OS=Homo sapiens GN=TRIM23 PE=1 SV=1 
361 sp|P36542|ATPG_HUMAN ATP synthase subunit gamma, mitochondrial OS=Homo sapiens GN=ATP5C1 PE=1 SV=1 
362 sp|P36543|VATE1_HUMAN V-type proton ATPase subunit E 1 OS=Homo sapiens GN=ATP6V1E1 PE=1 SV=1 
363 sp|P36578|RL4_HUMAN 60S ribosomal protein L4 OS=Homo sapiens GN=RPL4 PE=1 SV=5 
364 sp|P36952|SPB5_HUMAN Serpin B5 OS=Homo sapiens GN=SERPINB5 PE=1 SV=2 
365 sp|P37802|TAGL2_HUMAN Transgelin-2 OS=Homo sapiens GN=TAGLN2 PE=1 SV=3 
366 sp|P37837|TALDO_HUMAN Transaldolase OS=Homo sapiens GN=TALDO1 PE=1 SV=2 
367 sp|P38117|ETFB_HUMAN Electron transfer flavoprotein subunit beta OS=Homo sapiens GN=ETFB PE=1 SV=3 
368 sp|P38571|LICH_HUMAN Lysosomal acid lipase/cholesteryl ester hydrolase OS=Homo sapiens GN=LIPA PE=1 SV=2 
369 sp|P38646|GRP75_HUMAN Stress-70 protein, mitochondrial OS=Homo sapiens GN=HSPA9 PE=1 SV=2 
370 sp|P39656|OST48_HUMAN Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit OS=Homo sapiens GN=DDOST PE=1 SV=4 
371 sp|P40121|CAPG_HUMAN Macrophage-capping protein OS=Homo sapiens GN=CAPG PE=1 SV=2 
372 sp|P40925|MDHC_HUMAN Malate dehydrogenase, cytoplasmic OS=Homo sapiens GN=MDH1 PE=1 SV=4 
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373 sp|P40926|MDHM_HUMAN Malate dehydrogenase, mitochondrial OS=Homo sapiens GN=MDH2 PE=1 SV=3 
374 sp|P40939|ECHA_HUMAN Trifunctional enzyme subunit alpha, mitochondrial OS=Homo sapiens GN=HADHA PE=1 SV=2 
375 sp|P41218|MNDA_HUMAN Myeloid cell nuclear differentiation antigen OS=Homo sapiens GN=MNDA PE=1 SV=1 
376 sp|P42765|THIM_HUMAN 3-ketoacyl-CoA thiolase, mitochondrial OS=Homo sapiens GN=ACAA2 PE=1 SV=2 
377 sp|P43304|GPDM_HUMAN Glycerol-3-phosphate dehydrogenase, mitochondrial OS=Homo sapiens GN=GPD2 PE=1 SV=3 
378 sp|P43307|SSRA_HUMAN Translocon-associated protein subunit alpha OS=Homo sapiens GN=SSR1 PE=1 SV=3 
379 sp|P43353|AL3B1_HUMAN Aldehyde dehydrogenase family 3 member B1 OS=Homo sapiens GN=ALDH3B1 PE=1 SV=1 
380 sp|P43490|NAMPT_HUMAN Nicotinamide phosphoribosyltransferase OS=Homo sapiens GN=NAMPT PE=1 SV=1 
381 sp|P45880|VDAC2_HUMAN Voltage-dependent anion-selective channel protein 2 OS=Homo sapiens GN=VDAC2 PE=1 SV=2 
382 sp|P46940|IQGA1_HUMAN Ras GTPase-activating-like protein IQGAP1 OS=Homo sapiens GN=IQGAP1 PE=1 SV=1 
383 sp|P47755|CAZA2_HUMAN F-actin-capping protein subunit alpha-2 OS=Homo sapiens GN=CAPZA2 PE=1 SV=3 
384 sp|P47756|CAPZB_HUMAN F-actin-capping protein subunit beta OS=Homo sapiens GN=CAPZB PE=1 SV=4 
385 sp|P47929|LEG7_HUMAN Galectin-7 OS=Homo sapiens GN=LGALS7 PE=1 SV=2 
386 sp|P47985|UCRI_HUMAN Cytochrome b-c1 complex subunit Rieske, mitochondrial OS=Homo sapiens GN=UQCRFS1 PE=1 SV=2 
387 sp|P48047|ATPO_HUMAN ATP synthase subunit O, mitochondrial OS=Homo sapiens GN=ATP5O PE=1 SV=1 
388 sp|P48594|SPB4_HUMAN Serpin B4 OS=Homo sapiens GN=SERPINB4 PE=1 SV=2 
389 sp|P48668|K2C6C_HUMAN Keratin, type II cytoskeletal 6C OS=Homo sapiens GN=KRT6C PE=1 SV=3 
390 sp|P48735|IDHP_HUMAN Isocitrate dehydrogenase [NADP], mitochondrial OS=Homo sapiens GN=IDH2 PE=1 SV=2 
391 sp|P49189|AL9A1_HUMAN 4-trimethylaminobutyraldehyde dehydrogenase OS=Homo sapiens GN=ALDH9A1 PE=1 SV=3 
392 sp|P49411|EFTU_HUMAN Elongation factor Tu, mitochondrial OS=Homo sapiens GN=TUFM PE=1 SV=2 
393 sp|P49748|ACADV_HUMAN Very long-chain specific acyl-CoA dehydrogenase, mitochondrial OS=Homo sapiens GN=ACADVL PE=1 SV=1 
394 sp|P49755|TMEDA_HUMAN Transmembrane emp24 domain-containing protein 10 OS=Homo sapiens GN=TMED10 PE=1 SV=2 
395 sp|P49913|CAMP_HUMAN Cathelicidin antimicrobial peptide OS=Homo sapiens GN=CAMP PE=1 SV=1 
396 sp|P50395|GDIB_HUMAN Rab GDP dissociation inhibitor beta OS=Homo sapiens GN=GDI2 PE=1 SV=2 
397 sp|P50552|VASP_HUMAN Vasodilator-stimulated phosphoprotein OS=Homo sapiens GN=VASP PE=1 SV=3 
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398 sp|P50914|RL14_HUMAN 60S ribosomal protein L14 OS=Homo sapiens GN=RPL14 PE=1 SV=4 
399 sp|P50995|ANX11_HUMAN Annexin A11 OS=Homo sapiens GN=ANXA11 PE=1 SV=1 
400 sp|P51148|RAB5C_HUMAN Ras-related protein Rab-5C OS=Homo sapiens GN=RAB5C PE=1 SV=2 
401 sp|P51149|RAB7A_HUMAN Ras-related protein Rab-7a OS=Homo sapiens GN=RAB7A PE=1 SV=1 
402 sp|P51149|RAB7A_HUMAN Ras-related protein Rab-7a OS=Homo sapiens GN=RAB7A PE=1 SV=1 
403 sp|P51572|BAP31_HUMAN B-cell receptor-associated protein 31 OS=Homo sapiens GN=BCAP31 PE=1 SV=3 
404 sp|P51648|AL3A2_HUMAN Fatty aldehyde dehydrogenase OS=Homo sapiens GN=ALDH3A2 PE=1 SV=1 
405 sp|P51659|DHB4_HUMAN Peroxisomal multifunctional enzyme type 2 OS=Homo sapiens GN=HSD17B4 PE=1 SV=3 
406 sp|P51858|HDGF_HUMAN Hepatoma-derived growth factor OS=Homo sapiens GN=HDGF PE=1 SV=1 
407 sp|P52209|6PGD_HUMAN 6-phosphogluconate dehydrogenase, decarboxylating OS=Homo sapiens GN=PGD PE=1 SV=3 
408 sp|P52565|GDIR1_HUMAN Rho GDP-dissociation inhibitor 1 OS=Homo sapiens GN=ARHGDIA PE=1 SV=3 
409 sp|P52790|HXK3_HUMAN Hexokinase-3 OS=Homo sapiens GN=HK3 PE=1 SV=2 
410 sp|P52907|CAZA1_HUMAN F-actin-capping protein subunit alpha-1 OS=Homo sapiens GN=CAPZA1 PE=1 SV=3 
411 sp|P53634|CATC_HUMAN Dipeptidyl peptidase 1 OS=Homo sapiens GN=CTSC PE=1 SV=1 
412 sp|P53999|TCP4_HUMAN Activated RNA polymerase II transcriptional coactivator p15 OS=Homo sapiens GN=SUB1 PE=1 SV=3 
413 sp|P54819|KAD2_HUMAN Adenylate kinase 2, mitochondrial OS=Homo sapiens GN=AK2 PE=1 SV=2 
414 sp|P55008|AIF1_HUMAN Allograft inflammatory factor 1 OS=Homo sapiens GN=AIF1 PE=1 SV=1 
415 sp|P55058|PLTP_HUMAN Phospholipid transfer protein OS=Homo sapiens GN=PLTP PE=1 SV=1 
416 sp|P55072|TERA_HUMAN Transitional endoplasmic reticulum ATPase OS=Homo sapiens GN=VCP PE=1 SV=4 
417 sp|P55084|ECHB_HUMAN Trifunctional enzyme subunit beta, mitochondrial OS=Homo sapiens GN=HADHB PE=1 SV=3 
418 sp|P55786|PSA_HUMAN Puromycin-sensitive aminopeptidase OS=Homo sapiens GN=NPEPPS PE=1 SV=2 
419 sp|P56385|ATP5I_HUMAN ATP synthase subunit e, mitochondrial OS=Homo sapiens GN=ATP5I PE=1 SV=2 
420 sp|P59998|ARPC4_HUMAN Actin-related protein 2/3 complex subunit 4 OS=Homo sapiens GN=ARPC4 PE=1 SV=3 
421 sp|P60174|TPIS_HUMAN Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=2 
422 sp|P60660|MYL6_HUMAN Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 
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423 sp|P60709|ACTB_HUMAN Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 
424 sp|P60763|RAC3_HUMAN Ras-related C3 botulinum toxin substrate 3 OS=Homo sapiens GN=RAC3 PE=1 SV=1 
425 sp|P60903|S10AA_HUMAN Protein S100-A10 OS=Homo sapiens GN=S100A10 PE=1 SV=2 
426 sp|P60953|CDC42_HUMAN Cell division control protein 42 homolog OS=Homo sapiens GN=CDC42 PE=1 SV=1 
427 sp|P60981|DEST_HUMAN Destrin OS=Homo sapiens GN=DSTN PE=1 SV=3 
428 sp|P61019|RAB2A_HUMAN Ras-related protein Rab-2A OS=Homo sapiens GN=RAB2A PE=1 SV=1 
429 sp|P61020|RAB5B_HUMAN Ras-related protein Rab-5B OS=Homo sapiens GN=RAB5B PE=1 SV=1 
430 sp|P61026|RAB10_HUMAN Ras-related protein Rab-10 OS=Homo sapiens GN=RAB10 PE=1 SV=1 
431 sp|P61088|UBE2N_HUMAN Ubiquitin-conjugating enzyme E2 N OS=Homo sapiens GN=UBE2N PE=1 SV=1 
432 sp|P61106|RAB14_HUMAN Ras-related protein Rab-14 OS=Homo sapiens GN=RAB14 PE=1 SV=4 
433 sp|P61158|ARP3_HUMAN Actin-related protein 3 OS=Homo sapiens GN=ACTR3 PE=1 SV=3 
434 sp|P61160|ARP2_HUMAN Actin-related protein 2 OS=Homo sapiens GN=ACTR2 PE=1 SV=1 
435 sp|P61204|ARF3_HUMAN ADP-ribosylation factor 3 OS=Homo sapiens GN=ARF3 PE=1 SV=2 
436 sp|P61224|RAP1B_HUMAN Ras-related protein Rap-1b OS=Homo sapiens GN=RAP1B PE=1 SV=1 
437 sp|P61225|RAP2B_HUMAN Ras-related protein Rap-2b OS=Homo sapiens GN=RAP2B PE=1 SV=1 
438 sp|P61247|RS3A_HUMAN 40S ribosomal protein S3a OS=Homo sapiens GN=RPS3A PE=1 SV=2 
439 sp|P61586|RHOA_HUMAN Transforming protein RhoA OS=Homo sapiens GN=RHOA PE=1 SV=1 
440 sp|P61604|CH10_HUMAN 10 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPE1 PE=1 SV=2 
441 sp|P61626|LYSC_HUMAN Lysozyme C OS=Homo sapiens GN=LYZ PE=1 SV=1 
442 sp|P61769|B2MG_HUMAN Beta-2-microglobulin OS=Homo sapiens GN=B2M PE=1 SV=1 
443 sp|P61978|HNRPK_HUMAN Heterogeneous nuclear ribonucleoprotein K OS=Homo sapiens GN=HNRNPK PE=1 SV=1 
444 sp|P61981|1433G_HUMAN 14-3-3 protein gamma OS=Homo sapiens GN=YWHAG PE=1 SV=2 
445 sp|P62081|RS7_HUMAN 40S ribosomal protein S7 OS=Homo sapiens GN=RPS7 PE=1 SV=1 
446 sp|P62140|PP1B_HUMAN Serine/threonine-protein phosphatase PP1-beta catalytic subunit OS=Homo sapiens GN=PPP1CB PE=1 SV=3 
447 sp|P62158|CALM_HUMAN Calmodulin OS=Homo sapiens GN=CALM1 PE=1 SV=2 
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448 sp|P62249|RS16_HUMAN 40S ribosomal protein S16 OS=Homo sapiens GN=RPS16 PE=1 SV=2 
449 sp|P62258|1433E_HUMAN 14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1 SV=1 
450 sp|P62263|RS14_HUMAN 40S ribosomal protein S14 OS=Homo sapiens GN=RPS14 PE=1 SV=3 
451 sp|P62328|TYB4_HUMAN Thymosin beta-4 OS=Homo sapiens GN=TMSB4X PE=1 SV=2 
452 sp|P62330|ARF6_HUMAN ADP-ribosylation factor 6 OS=Homo sapiens GN=ARF6 PE=1 SV=2 
453 sp|P62424|RL7A_HUMAN 60S ribosomal protein L7a OS=Homo sapiens GN=RPL7A PE=1 SV=2 
454 sp|P62701|RS4X_HUMAN 40S ribosomal protein S4, X isoform OS=Homo sapiens GN=RPS4X PE=1 SV=2 
455 sp|P62750|RL23A_HUMAN 60S ribosomal protein L23a OS=Homo sapiens GN=RPL23A PE=1 SV=1 
456 sp|P62805|H4_HUMAN Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 
457 sp|P62820|RAB1A_HUMAN Ras-related protein Rab-1A OS=Homo sapiens GN=RAB1A PE=1 SV=3 
458 sp|P62841|RS15_HUMAN 40S ribosomal protein S15 OS=Homo sapiens GN=RPS15 PE=1 SV=2 
459 sp|P62851|RS25_HUMAN 40S ribosomal protein S25 OS=Homo sapiens GN=RPS25 PE=1 SV=1 
460 sp|P62857|RS28_HUMAN 40S ribosomal protein S28 OS=Homo sapiens GN=RPS28 PE=1 SV=1 
461 sp|P62879|GBB2_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 OS=Homo sapiens GN=GNB2 PE=1 SV=3 
462 sp|P62906|RL10A_HUMAN 60S ribosomal protein L10a OS=Homo sapiens GN=RPL10A PE=1 SV=2 
463 sp|P62913|RL11_HUMAN 60S ribosomal protein L11 OS=Homo sapiens GN=RPL11 PE=1 SV=2 
464 sp|P62937|PPIA_HUMAN Peptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 SV=2 
465 sp|P62979|RS27A_HUMAN Ubiquitin-40S ribosomal protein S27a OS=Homo sapiens GN=RPS27A PE=1 SV=2 
466 sp|P62987|RL40_HUMAN Ubiquitin-60S ribosomal protein L40 OS=Homo sapiens GN=UBA52 PE=1 SV=2 
467 sp|P63104|1433Z_HUMAN 14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 
468 sp|P63241|IF5A1_HUMAN Eukaryotic translation initiation factor 5A-1 OS=Homo sapiens GN=EIF5A PE=1 SV=2 
469 sp|P63244|GBLP_HUMAN Guanine nucleotide-binding protein subunit beta-2-like 1 OS=Homo sapiens GN=GNB2L1 PE=1 SV=3 
470 sp|P63261|ACTG_HUMAN Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1 
471 sp|P63313|TYB10_HUMAN Thymosin beta-10 OS=Homo sapiens GN=TMSB10 PE=1 SV=2 
472 sp|P67936|TPM4_HUMAN Tropomyosin alpha-4 chain OS=Homo sapiens GN=TPM4 PE=1 SV=3 
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473 sp|P68032|ACTC_HUMAN Actin, alpha cardiac muscle 1 OS=Homo sapiens GN=ACTC1 PE=1 SV=1 
474 sp|P68363|TBA1B_HUMAN Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 
475 sp|P68402|PA1B2_HUMAN Platelet-activating factor acetylhydrolase IB subunit beta OS=Homo sapiens GN=PAFAH1B2 PE=1 SV=1 
476 sp|P68871|HBB_HUMAN Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 
477 sp|P69905|HBA_HUMAN Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 
478 sp|P78417|GSTO1_HUMAN Glutathione S-transferase omega-1 OS=Homo sapiens GN=GSTO1 PE=1 SV=2 
479 sp|P79483|DRB3_HUMAN HLA class II histocompatibility antigen, DR beta 3 chain OS=Homo sapiens GN=HLA-DRB3 PE=1 SV=1 
480 sp|P80188|NGAL_HUMAN Neutrophil gelatinase-associated lipocalin OS=Homo sapiens GN=LCN2 PE=1 SV=2 
481 sp|P80303|NUCB2_HUMAN Nucleobindin-2 OS=Homo sapiens GN=NUCB2 PE=1 SV=2 
482 sp|P80511|S10AC_HUMAN Protein S100-A12 OS=Homo sapiens GN=S100A12 PE=1 SV=2 
483 sp|P80723|BASP1_HUMAN Brain acid soluble protein 1 OS=Homo sapiens GN=BASP1 PE=1 SV=2 
484 sp|P80748|LV302_HUMAN Ig lambda chain V-III region LOI OS=Homo sapiens PE=1 SV=1 
485 sp|P84077|ARF1_HUMAN ADP-ribosylation factor 1 OS=Homo sapiens GN=ARF1 PE=1 SV=2 
486 sp|P84095|RHOG_HUMAN Rho-related GTP-binding protein RhoG OS=Homo sapiens GN=RHOG PE=1 SV=1 
487 sp|P98088|MUC5A_HUMAN Mucin-5AC (Fragments) OS=Homo sapiens GN=MUC5AC PE=1 SV=3 
488 sp|P99999|CYC_HUMAN Cytochrome c OS=Homo sapiens GN=CYCS PE=1 SV=2 
489 sp|Q00325|MPCP_HUMAN Phosphate carrier protein, mitochondrial OS=Homo sapiens GN=SLC25A3 PE=1 SV=2 
490 sp|Q00610|CLH1_HUMAN Clathrin heavy chain 1 OS=Homo sapiens GN=CLTC PE=1 SV=5 
491 sp|Q00688|FKBP3_HUMAN Peptidyl-prolyl cis-trans isomerase FKBP3 OS=Homo sapiens GN=FKBP3 PE=1 SV=1 
492 sp|Q00839|HNRPU_HUMAN Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens GN=HNRNPU PE=1 SV=6 
493 sp|Q01105|SET_HUMAN Protein SET OS=Homo sapiens GN=SET PE=1 SV=3 
494 sp|Q01469|FABP5_HUMAN Fatty acid-binding protein, epidermal OS=Homo sapiens GN=FABP5 PE=1 SV=3 
495 sp|Q01518|CAP1_HUMAN Adenylyl cyclase-associated protein 1 OS=Homo sapiens GN=CAP1 PE=1 SV=5 
496 sp|Q02218|ODO1_HUMAN 2-oxoglutarate dehydrogenase, mitochondrial OS=Homo sapiens GN=OGDH PE=1 SV=3 
497 sp|Q02817|MUC2_HUMAN Mucin-2 OS=Homo sapiens GN=MUC2 PE=1 SV=2 
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498 sp|Q02818|NUCB1_HUMAN Nucleobindin-1 OS=Homo sapiens GN=NUCB1 PE=1 SV=4 
499 sp|Q02878|RL6_HUMAN 60S ribosomal protein L6 OS=Homo sapiens GN=RPL6 PE=1 SV=3 
500 sp|Q02978|M2OM_HUMAN Mitochondrial 2-oxoglutarate/malate carrier protein OS=Homo sapiens GN=SLC25A11 PE=1 SV=3 
501 sp|Q04941|PLP2_HUMAN Proteolipid protein 2 OS=Homo sapiens GN=PLP2 PE=1 SV=1 
502 sp|Q06323|PSME1_HUMAN Proteasome activator complex subunit 1 OS=Homo sapiens GN=PSME1 PE=1 SV=1 
503 sp|Q06830|PRDX1_HUMAN Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 
504 sp|Q07020|RL18_HUMAN 60S ribosomal protein L18 OS=Homo sapiens GN=RPL18 PE=1 SV=2 
505 sp|Q07021|C1QBP_HUMAN Complement component 1 Q subcomponent-binding protein, mitochondrial OS=Homo sapiens GN=C1QBP PE=1 SV=1 
506 sp|Q07955|SRSF1_HUMAN Serine/arginine-rich splicing factor 1 OS=Homo sapiens GN=SRSF1 PE=1 SV=2 
507 sp|Q08188|TGM3_HUMAN Protein-glutamine gamma-glutamyltransferase E OS=Homo sapiens GN=TGM3 PE=1 SV=4 
508 sp|Q08380|LG3BP_HUMAN Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP PE=1 SV=1 
509 sp|Q08722|CD47_HUMAN Leukocyte surface antigen CD47 OS=Homo sapiens GN=CD47 PE=1 SV=1 
511 sp|Q09666|AHNK_HUMAN Neuroblast differentiation-associated protein AHNAK OS=Homo sapiens GN=AHNAK PE=1 SV=2 
512 sp|Q12905|ILF2_HUMAN Interleukin enhancer-binding factor 2 OS=Homo sapiens GN=ILF2 PE=1 SV=2 
513 sp|Q12907|LMAN2_HUMAN Vesicular integral-membrane protein VIP36 OS=Homo sapiens GN=LMAN2 PE=1 SV=1 
514 sp|Q13011|ECH1_HUMAN Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial OS=Homo sapiens GN=ECH1 PE=1 SV=2 
515 sp|Q13162|PRDX4_HUMAN Peroxiredoxin-4 OS=Homo sapiens GN=PRDX4 PE=1 SV=1 
516 sp|Q13228|SBP1_HUMAN Selenium-binding protein 1 OS=Homo sapiens GN=SELENBP1 PE=1 SV=2 
517 sp|Q13510|ASAH1_HUMAN Acid ceramidase OS=Homo sapiens GN=ASAH1 PE=1 SV=5 
518 sp|Q13835|PKP1_HUMAN Plakophilin-1 OS=Homo sapiens GN=PKP1 PE=1 SV=2 
519 sp|Q13938|CAYP1_HUMAN Calcyphosin OS=Homo sapiens GN=CAPS PE=1 SV=1 
520 sp|Q14019|COTL1_HUMAN Coactosin-like protein OS=Homo sapiens GN=COTL1 PE=1 SV=3 
521 sp|Q14103|HNRPD_HUMAN Heterogeneous nuclear ribonucleoprotein D0 OS=Homo sapiens GN=HNRNPD PE=1 SV=1 
522 sp|Q14108|SCRB2_HUMAN Lysosome membrane protein 2 OS=Homo sapiens GN=SCARB2 PE=1 SV=2 
523 sp|Q14240|IF4A2_HUMAN Eukaryotic initiation factor 4A-II OS=Homo sapiens GN=EIF4A2 PE=1 SV=2 
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524 sp|Q14696|MESD_HUMAN LDLR chaperone MESD OS=Homo sapiens GN=MESDC2 PE=1 SV=2 
525 sp|Q14697|GANAB_HUMAN Neutral alpha-glucosidase AB OS=Homo sapiens GN=GANAB PE=1 SV=3 
526 sp|Q14956|GPNMB_HUMAN Transmembrane glycoprotein NMB OS=Homo sapiens GN=GPNMB PE=1 SV=2 
527 sp|Q14974|IMB1_HUMAN Importin subunit beta-1 OS=Homo sapiens GN=KPNB1 PE=1 SV=2 
528 sp|Q14CN2|CLCA4_HUMAN Calcium-activated chloride channel regulator 4 OS=Homo sapiens GN=CLCA4 PE=1 SV=2 
529 sp|Q15084|PDIA6_HUMAN Protein disulfide-isomerase A6 OS=Homo sapiens GN=PDIA6 PE=1 SV=1 
530 sp|Q15121|PEA15_HUMAN Astrocytic phosphoprotein PEA-15 OS=Homo sapiens GN=PEA15 PE=1 SV=2 
531 sp|Q15363|TMED2_HUMAN Transmembrane emp24 domain-containing protein 2 OS=Homo sapiens GN=TMED2 PE=1 SV=1 
532 sp|Q15363|TMED2_HUMAN Transmembrane emp24 domain-containing protein 2 OS=Homo sapiens GN=TMED2 PE=1 SV=1 
533 sp|Q15366|PCBP2_HUMAN Poly(rC)-binding protein 2 OS=Homo sapiens GN=PCBP2 PE=1 SV=1 
534 sp|Q15833|STXB2_HUMAN Syntaxin-binding protein 2 OS=Homo sapiens GN=STXBP2 PE=1 SV=2 
535 sp|Q15907|RB11B_HUMAN Ras-related protein Rab-11B OS=Homo sapiens GN=RAB11B PE=1 SV=4 
536 sp|Q16378|PROL4_HUMAN Proline-rich protein 4 OS=Homo sapiens GN=PRR4 PE=1 SV=2 
537 sp|Q16563|SYPL1_HUMAN Synaptophysin-like protein 1 OS=Homo sapiens GN=SYPL1 PE=1 SV=1 
538 sp|Q16610|ECM1_HUMAN Extracellular matrix protein 1 OS=Homo sapiens GN=ECM1 PE=1 SV=2 
539 sp|Q16629|SRSF7_HUMAN Serine/arginine-rich splicing factor 7 OS=Homo sapiens GN=SRSF7 PE=1 SV=1 
540 sp|Q16698|DECR_HUMAN 2,4-dienoyl-CoA reductase, mitochondrial OS=Homo sapiens GN=DECR1 PE=1 SV=1 
541 sp|Q16772|GSTA3_HUMAN Glutathione S-transferase A3 OS=Homo sapiens GN=GSTA3 PE=1 SV=3 
542 sp|Q16822|PCKGM_HUMAN Phosphoenolpyruvate carboxykinase [GTP], mitochondrial OS=Homo sapiens GN=PCK2 PE=1 SV=3 
543 sp|Q16851|UGPA_HUMAN UTP--glucose-1-phosphate uridylyltransferase OS=Homo sapiens GN=UGP2 PE=1 SV=5 
544 sp|Q16891|IMMT_HUMAN Mitochondrial inner membrane protein OS=Homo sapiens GN=IMMT PE=1 SV=1 
545 sp|Q32P51|RA1L2_HUMAN Heterogeneous nuclear ribonucleoprotein A1-like 2 OS=Homo sapiens GN=HNRNPA1L2 PE=2 SV=2 
546 sp|Q53GD3|CTL4_HUMAN Choline transporter-like protein 4 OS=Homo sapiens GN=SLC44A4 PE=2 SV=2 
547 sp|Q53GQ0|DHB12_HUMAN Estradiol 17-beta-dehydrogenase 12 OS=Homo sapiens GN=HSD17B12 PE=1 SV=2 
548 sp|Q562R1|ACTBL_HUMAN Beta-actin-like protein 2 OS=Homo sapiens GN=ACTBL2 PE=1 SV=2 
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549 sp|Q58FG1|HS904_HUMAN Putative heat shock protein HSP 90-alpha A4 OS=Homo sapiens GN=HSP90AA4P PE=5 SV=1 
550 sp|Q5K4L6|S27A3_HUMAN Long-chain fatty acid transport protein 3 OS=Homo sapiens GN=SLC27A3 PE=2 SV=3 
551 sp|Q5T2P8|AXA81_HUMAN Annexin A8-like protein 1 OS=Homo sapiens GN=ANXA8L1 PE=2 SV=1 
552 sp|Q5VSK2|MRC1L_HUMAN Macrophage mannose receptor 1-like protein 1 OS=Homo sapiens GN=MRC1L1 PE=2 SV=1 
553 sp|Q5VT79|AXA82_HUMAN Annexin A8-like protein 2 OS=Homo sapiens GN=ANXA8L2 PE=2 SV=1 
554 sp|Q5VTE0|EF1A3_HUMAN Putative elongation factor 1-alpha-like 3 OS=Homo sapiens GN=EEF1AL3 PE=5 SV=1 
555 sp|Q5VTM1|FAM25_HUMAN Protein FAM25 OS=Homo sapiens GN=FAM25A PE=2 SV=2 
556 sp|Q5Y7A7|2B1D_HUMAN HLA class II histocompatibility antigen, DRB1-13 beta chain OS=Homo sapiens GN=HLA-DRB1 PE=1 SV=1 
557 sp|Q6DD88|ATLA3_HUMAN Atlastin-3 OS=Homo sapiens GN=ATL3 PE=1 SV=1 
558 sp|Q6IS14|IF5AL_HUMAN Eukaryotic translation initiation factor 5A-1-like OS=Homo sapiens GN=EIF5AL1 PE=1 SV=2 
559 sp|Q6MZM9|CD040_HUMAN Uncharacterized protein C4orf40 OS=Homo sapiens GN=C4orf40 PE=1 SV=1 
560 sp|Q6NUK1|SCMC1_HUMAN Calcium-binding mitochondrial carrier protein SCaMC-1 OS=Homo sapiens GN=SLC25A24 PE=1 SV=2 
561 sp|Q6P5S2|CF058_HUMAN UPF0762 protein C6orf58 OS=Homo sapiens GN=C6orf58 PE=1 SV=2 
562 sp|Q6PIU2|NCEH1_HUMAN Neutral cholesterol ester hydrolase 1 OS=Homo sapiens GN=NCEH1 PE=1 SV=3 
563 sp|Q6UW68|TM205_HUMAN Transmembrane protein 205 OS=Homo sapiens GN=TMEM205 PE=1 SV=1 
564 sp|Q6UWP8|SBSN_HUMAN Suprabasin OS=Homo sapiens GN=SBSN PE=2 SV=1 
565 sp|Q6UWV6|ENPP7_HUMAN Ectonucleotide pyrophosphatase/phosphodiesterase family member 7 OS=Homo sapiens GN=ENPP7 PE=1 SV=3 
566 sp|Q6YN16|HSDL2_HUMAN Hydroxysteroid dehydrogenase-like protein 2 OS=Homo sapiens GN=HSDL2 PE=1 SV=1 
567 sp|Q6ZVX7|NCRP1_HUMAN Non-specific cytotoxic cell receptor protein 1 homolog OS=Homo sapiens GN=NCCRP1 PE=1 SV=1 
568 sp|Q71DI3|H32_HUMAN Histone H3.2 OS=Homo sapiens GN=HIST2H3A PE=1 SV=3 
569 sp|Q71U36|TBA1A_HUMAN Tubulin alpha-1A chain OS=Homo sapiens GN=TUBA1A PE=1 SV=1 
570 sp|Q71UI9|H2AV_HUMAN Histone H2A.V OS=Homo sapiens GN=H2AFV PE=1 SV=3 
571 sp|Q7Z4W1|DCXR_HUMAN L-xylulose reductase OS=Homo sapiens GN=DCXR PE=1 SV=2 
572 sp|Q7Z5L0|VMO1_HUMAN Vitelline membrane outer layer protein 1 homolog OS=Homo sapiens GN=VMO1 PE=1 SV=1 
573 sp|Q86T26|TM11B_HUMAN Transmembrane protease serine 11B OS=Homo sapiens GN=TMPRSS11B PE=2 SV=2 
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574 sp|Q8IUE6|H2A2B_HUMAN Histone H2A type 2-B OS=Homo sapiens GN=HIST2H2AB PE=1 SV=3 
575 sp|Q8IWL1|SFPA2_HUMAN Pulmonary surfactant-associated protein A2 OS=Homo sapiens GN=SFTPA2 PE=1 SV=1 
576 sp|Q8N0Y7|PGAM4_HUMAN Probable phosphoglycerate mutase 4 OS=Homo sapiens GN=PGAM4 PE=1 SV=1 
577 sp|Q8N1N0|CLC4F_HUMAN C-type lectin domain family 4 member F OS=Homo sapiens GN=CLEC4F PE=2 SV=2 
578 sp|Q8N4F0|BPIL1_HUMAN Bactericidal/permeability-increasing protein-like 1 OS=Homo sapiens GN=BPIL1 PE=1 SV=2 
579 sp|Q8NAP3|ZBT38_HUMAN Zinc finger and BTB domain-containing protein 38 OS=Homo sapiens GN=ZBTB38 PE=1 SV=2 
580 sp|Q8NBJ5|GT251_HUMAN Procollagen galactosyltransferase 1 OS=Homo sapiens GN=GLT25D1 PE=1 SV=1 
581 sp|Q8NBQ5|DHB11_HUMAN Estradiol 17-beta-dehydrogenase 11 OS=Homo sapiens GN=HSD17B11 PE=1 SV=3 
582 sp|Q8NC51|PAIRB_HUMAN Plasminogen activator inhibitor 1 RNA-binding protein OS=Homo sapiens GN=SERBP1 PE=1 SV=2 
583 sp|Q8NC51|PAIRB_HUMAN Plasminogen activator inhibitor 1 RNA-binding protein OS=Homo sapiens GN=SERBP1 PE=1 SV=2 
584 sp|Q8TAX7|MUC7_HUMAN Mucin-7 OS=Homo sapiens GN=MUC7 PE=1 SV=2 
585 sp|Q8TDL5|LPLC1_HUMAN Long palate, lung and nasal epithelium carcinoma-associated protein 1 OS=Homo sapiens GN=LPLUNC1 PE=2 SV=1 
586 sp|Q8TE68|ES8L1_HUMAN Epidermal growth factor receptor kinase substrate 8-like protein 1 OS=Homo sapiens GN=EPS8L1 PE=1 SV=3 
587 sp|Q8WUM4|PDC6I_HUMAN Programmed cell death 6-interacting protein OS=Homo sapiens GN=PDCD6IP PE=1 SV=1 
588 sp|Q92522|H1X_HUMAN Histone H1x OS=Homo sapiens GN=H1FX PE=1 SV=1 
589 sp|Q92688|AN32B_HUMAN Acidic leucine-rich nuclear phosphoprotein 32 family member B OS=Homo sapiens GN=ANP32B PE=1 SV=1 
590 sp|Q92743|HTRA1_HUMAN Serine protease HTRA1 OS=Homo sapiens GN=HTRA1 PE=1 SV=1 
591 sp|Q92817|EVPL_HUMAN Envoplakin OS=Homo sapiens GN=EVPL PE=1 SV=3 
592 sp|Q92882|OSTF1_HUMAN Osteoclast-stimulating factor 1 OS=Homo sapiens GN=OSTF1 PE=1 SV=2 
593 sp|Q96BQ1|FAM3D_HUMAN Protein FAM3D OS=Homo sapiens GN=FAM3D PE=1 SV=1 
594 sp|Q96C19|EFHD2_HUMAN EF-hand domain-containing protein D2 OS=Homo sapiens GN=EFHD2 PE=1 SV=1 
595 sp|Q96DA0|ZG16B_HUMAN Zymogen granule protein 16 homolog B OS=Homo sapiens GN=ZG16B PE=1 SV=3 
596 sp|Q96DR5|SPLC2_HUMAN Short palate, lung and nasal epithelium carcinoma-associated protein 2 OS=Homo sapiens GN=SPLUNC2 PE=1 SV=2 
597 sp|Q96FQ6|S10AG_HUMAN Protein S100-A16 OS=Homo sapiens GN=S100A16 PE=1 SV=1 
598 sp|Q96G03|PGM2_HUMAN Phosphoglucomutase-2 OS=Homo sapiens GN=PGM2 PE=1 SV=4 
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599 sp|Q96HE7|ERO1A_HUMAN ERO1-like protein alpha OS=Homo sapiens GN=ERO1L PE=1 SV=2 
600 sp|Q96I99|SUCB2_HUMAN Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial OS=Homo sapiens GN=SUCLG2 PE=1 SV=2 
601 sp|Q96KP4|CNDP2_HUMAN Cytosolic non-specific dipeptidase OS=Homo sapiens GN=CNDP2 PE=1 SV=2 
602 sp|Q96PL1|SG3A2_HUMAN Secretoglobin family 3A member 2 OS=Homo sapiens GN=SCGB3A2 PE=1 SV=1 
603 sp|Q96QR1|SG3A1_HUMAN Secretoglobin family 3A member 1 OS=Homo sapiens GN=SCGB3A1 PE=1 SV=2 
604 sp|Q96QV6|H2A1A_HUMAN Histone H2A type 1-A OS=Homo sapiens GN=HIST1H2AA PE=1 SV=3 
605 sp|Q96TA1|NIBL1_HUMAN Niban-like protein 1 OS=Homo sapiens GN=FAM129B PE=1 SV=2 
606 sp|Q96TC7|RMD3_HUMAN Regulator of microtubule dynamics protein 3 OS=Homo sapiens GN=FAM82A2 PE=1 SV=2 
607 sp|Q99497|PARK7_HUMAN Protein DJ-1 OS=Homo sapiens GN=PARK7 PE=1 SV=2 
608 sp|Q99536|VAT1_HUMAN Synaptic vesicle membrane protein VAT-1 homolog OS=Homo sapiens GN=VAT1 PE=1 SV=2 
609 sp|Q99536|VAT1_HUMAN Synaptic vesicle membrane protein VAT-1 homolog OS=Homo sapiens GN=VAT1 PE=1 SV=2 
610 sp|Q99623|PHB2_HUMAN Prohibitin-2 OS=Homo sapiens GN=PHB2 PE=1 SV=2 
611 sp|Q99714|HCD2_HUMAN 3-hydroxyacyl-CoA dehydrogenase type-2 OS=Homo sapiens GN=HSD17B10 PE=1 SV=3 
612 sp|Q99798|ACON_HUMAN Aconitate hydratase, mitochondrial OS=Homo sapiens GN=ACO2 PE=1 SV=2 
613 sp|Q99877|H2B1N_HUMAN Histone H2B type 1-N OS=Homo sapiens GN=HIST1H2BN PE=1 SV=3 
614 sp|Q99879|H2B1M_HUMAN Histone H2B type 1-M OS=Homo sapiens GN=HIST1H2BM PE=1 SV=3 
615 sp|Q99880|H2B1L_HUMAN Histone H2B type 1-L OS=Homo sapiens GN=HIST1H2BL PE=1 SV=3 
616 sp|Q99935|PROL1_HUMAN Proline-rich protein 1 OS=Homo sapiens GN=PROL1 PE=1 SV=2 
617 sp|Q9BRF8|CPPED_HUMAN Calcineurin-like phosphoesterase domain-containing protein 1 OS=Homo sapiens GN=CPPED1 PE=1 SV=2 
618 sp|Q9BS26|ERP44_HUMAN Endoplasmic reticulum resident protein 44 OS=Homo sapiens GN=ERP44 PE=1 SV=1 
619 sp|Q9BSJ8|ESYT1_HUMAN Extended synaptotagmin-1 OS=Homo sapiens GN=ESYT1 PE=1 SV=1 
620 sp|Q9BVC6|TM109_HUMAN Transmembrane protein 109 OS=Homo sapiens GN=TMEM109 PE=1 SV=1 
621 sp|Q9BW30|TPPP3_HUMAN Tubulin polymerization-promoting protein family member 3 OS=Homo sapiens GN=TPPP3 PE=1 SV=1 
622 sp|Q9BWD1|THIC_HUMAN Acetyl-CoA acetyltransferase, cytosolic OS=Homo sapiens GN=ACAT2 PE=1 SV=2 
623 sp|Q9GZZ8|LACRT_HUMAN Extracellular glycoprotein lacritin OS=Homo sapiens GN=LACRT PE=1 SV=1 
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624 sp|Q9H0U4|RAB1B_HUMAN Ras-related protein Rab-1B OS=Homo sapiens GN=RAB1B PE=1 SV=1 
625 sp|Q9H299|SH3L3_HUMAN SH3 domain-binding glutamic acid-rich-like protein 3 OS=Homo sapiens GN=SH3BGRL3 PE=1 SV=1 
626 sp|Q9H2U2|IPYR2_HUMAN Inorganic pyrophosphatase 2, mitochondrial OS=Homo sapiens GN=PPA2 PE=1 SV=2 
627 sp|Q9H3Z4|DNJC5_HUMAN DnaJ homolog subfamily C member 5 OS=Homo sapiens GN=DNAJC5 PE=1 SV=1 
628 sp|Q9H4G4|GAPR1_HUMAN Golgi-associated plant pathogenesis-related protein 1 OS=Homo sapiens GN=GLIPR2 PE=1 SV=3 
629 sp|Q9HC84|MUC5B_HUMAN Mucin-5B OS=Homo sapiens GN=MUC5B PE=1 SV=3 
630 sp|Q9HCY8|S10AE_HUMAN Protein S100-A14 OS=Homo sapiens GN=S100A14 PE=1 SV=1 
631 sp|Q9HD89|RETN_HUMAN Resistin OS=Homo sapiens GN=RETN PE=2 SV=1 
632 sp|Q9HDC9|APMAP_HUMAN Adipocyte plasma membrane-associated protein OS=Homo sapiens GN=APMAP PE=1 SV=2 
633 sp|Q9NP55|PLUNC_HUMAN Protein Plunc OS=Homo sapiens GN=PLUNC PE=1 SV=1 
634 sp|Q9NQC3|RTN4_HUMAN Reticulon-4 OS=Homo sapiens GN=RTN4 PE=1 SV=2 
635 sp|Q9NRW1|RAB6B_HUMAN Ras-related protein Rab-6B OS=Homo sapiens GN=RAB6B PE=1 SV=1 
636 sp|Q9NVJ2|ARL8B_HUMAN ADP-ribosylation factor-like protein 8B OS=Homo sapiens GN=ARL8B PE=1 SV=1 
637 sp|Q9NYL9|TMOD3_HUMAN Tropomodulin-3 OS=Homo sapiens GN=TMOD3 PE=1 SV=1 
638 sp|Q9NZ01|TECR_HUMAN Trans-2,3-enoyl-CoA reductase OS=Homo sapiens GN=TECR PE=1 SV=1 
639 sp|Q9NZT1|CALL5_HUMAN Calmodulin-like protein 5 OS=Homo sapiens GN=CALML5 PE=1 SV=2 
640 sp|Q9P0L0|VAPA_HUMAN Vesicle-associated membrane protein-associated protein A OS=Homo sapiens GN=VAPA PE=1 SV=3 
641 sp|Q9P0M6|H2AW_HUMAN Core histone macro-H2A.2 OS=Homo sapiens GN=H2AFY2 PE=1 SV=3 
642 sp|Q9UBC9|SPRR3_HUMAN Small proline-rich protein 3 OS=Homo sapiens GN=SPRR3 PE=1 SV=2 
643 sp|Q9UBG3|CRNN_HUMAN Cornulin OS=Homo sapiens GN=CRNN PE=1 SV=1 
644 sp|Q9UGM3|DMBT1_HUMAN Deleted in malignant brain tumors 1 protein OS=Homo sapiens GN=DMBT1 PE=1 SV=2 
645 sp|Q9UHA7|IL1F6_HUMAN Interleukin-1 family member 6 OS=Homo sapiens GN=IL1F6 PE=1 SV=1 
646 sp|Q9UHG3|PCYOX_HUMAN Prenylcysteine oxidase 1 OS=Homo sapiens GN=PCYOX1 PE=1 SV=3 
647 sp|Q9UHL4|DPP2_HUMAN Dipeptidyl peptidase 2 OS=Homo sapiens GN=DPP7 PE=1 SV=3 
648 sp|Q9UIV8|SPB13_HUMAN Serpin B13 OS=Homo sapiens GN=SERPINB13 PE=2 SV=2 
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649 sp|Q9UJ70|NAGK_HUMAN N-acetyl-D-glucosamine kinase OS=Homo sapiens GN=NAGK PE=1 SV=4 
650 sp|Q9UJC5|SH3L2_HUMAN SH3 domain-binding glutamic acid-rich-like protein 2 OS=Homo sapiens GN=SH3BGRL2 PE=1 SV=2 
651 sp|Q9UL46|PSME2_HUMAN Proteasome activator complex subunit 2 OS=Homo sapiens GN=PSME2 PE=1 SV=4 
652 sp|Q9ULC6|PADI1_HUMAN Protein-arginine deiminase type-1 OS=Homo sapiens GN=PADI1 PE=1 SV=2 
653 sp|Q9ULV4|COR1C_HUMAN Coronin-1C OS=Homo sapiens GN=CORO1C PE=1 SV=1 
654 sp|Q9ULZ3|ASC_HUMAN Apoptosis-associated speck-like protein containing a CARD OS=Homo sapiens GN=PYCARD PE=1 SV=2 
655 sp|Q9UM07|PADI4_HUMAN Protein-arginine deiminase type-4 OS=Homo sapiens GN=PADI4 PE=1 SV=2 
656 sp|Q9UNM6|PSD13_HUMAN 26S proteasome non-ATPase regulatory subunit 13 OS=Homo sapiens GN=PSMD13 PE=1 SV=1 
657 sp|Q9Y277|VDAC3_HUMAN Voltage-dependent anion-selective channel protein 3 OS=Homo sapiens GN=VDAC3 PE=1 SV=1 
658 sp|Q9Y2Q3|GSTK1_HUMAN Glutathione S-transferase kappa 1 OS=Homo sapiens GN=GSTK1 PE=1 SV=3 
659 sp|Q9Y2V2|CHSP1_HUMAN Calcium-regulated heat stable protein 1 OS=Homo sapiens GN=CARHSP1 PE=1 SV=2 
660 sp|Q9Y3D6|FIS1_HUMAN Mitochondrial fission 1 protein OS=Homo sapiens GN=FIS1 PE=1 SV=2 
661 sp|Q9Y3Z3|SAMH1_HUMAN SAM domain and HD domain-containing protein 1 OS=Homo sapiens GN=SAMHD1 PE=1 SV=2 
662 sp|Q9Y490|TLN1_HUMAN Talin-1 OS=Homo sapiens GN=TLN1 PE=1 SV=3 
663 sp|Q9Y6C9|MTCH2_HUMAN Mitochondrial carrier homolog 2 OS=Homo sapiens GN=MTCH2 PE=1 SV=1 
664 sp|Q9Y6N5|SQRD_HUMAN Sulfide:quinone oxidoreductase, mitochondrial OS=Homo sapiens GN=SQRDL PE=1 SV=1 
665 sp|Q9Y6R7|FCGBP_HUMAN IgGFc-binding protein OS=Homo sapiens GN=FCGBP PE=1 SV=3 
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Appendix C Coomassie gel stains for extracellular protein samples 
Gel1 
 
Gel2 
 
Gel3 
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Gel4 
 
Gel 5 
 
Gel 6 
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Gel7 
 
Gel8 
 
Gel 9 
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Gel Lane Sample Gel Lane Sample Gel Lane Sample 
1 1 N1 2 1 3N5 3 1 2N10 
2 2N1 2 N6 2 3N10 
3 3N1 3 2N6 3 N11 
4 N2 4 3N6 4 2N11 
5 2N2 5 N7 5 3N11 
6 3N2 6 2N7 6 N12 
7 N3 7 3N7 7 2N12 
8 2N3 8 N8 8 3N12 
9 3N3 9 2N8 9 A1 
10 N4 10 3N8 10 2A1 
11 2N4 11 N9 11 3A1 
12 3N4 12 2N9 12 A2 
13 N5 13 3N9 13 2A2 
14 2N5 14 N10 14 3A2 
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Gel Lane Sample Gel Lane Sample Gel Lane Sample 
4 1 A3 5 1 A8 6 1 A112 
2 2A3  2 2A8  2 2A112 
3 3A3  3 3A8  3 3A112 
4 A4  4 A9  4 A113 
5 2A4  5 2A9  5 2A113 
6 3A4  6 3A9  6 3A113 
7 A5  7 A10  7 A114 
8 2A5  8 2A10  8 2A114 
9 3A5  9 3A10  9 3A114 
10 A6  10 A11  10 ST1 
11 2A6  11 2A11  11 2ST1 
12 A7  12 3A11  12 3ST1 
13 2A7       
14 3A7       
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Gel Lane Sample Gel Lane Sample Gel Lane Sample 
7 1 ST2 8 1 ST6 9 1 ST10 
2 2ST2 2 2ST6 2 2ST10 
3 3ST2 3 3ST6 3 3ST10 
4 ST3 4 ST7 4 ST11 
5 2ST3 5 2ST7 5 2ST11 
6 3ST3 6 3ST7 6 3ST11 
7 ST4 7 ST8 7 ST12 
8 2ST4 8 2ST8 8 2ST12 
9 3ST4 9 3ST8 9 3ST12 
10 ST5 10 ST9 10 ST13 
11 2ST5 11 2ST8 11 2ST13 
12 3ST5 12 3ST9 12 3ST13 
 
